<SEC-DOCUMENT>0001019056-22-000478.txt : 20220628
<SEC-HEADER>0001019056-22-000478.hdr.sgml : 20220628
<ACCEPTANCE-DATETIME>20220628155648
ACCESSION NUMBER:		0001019056-22-000478
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220628
DATE AS OF CHANGE:		20220628

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Modular Medical, Inc.
		CENTRAL INDEX KEY:			0001074871
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870620495
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41277
		FILM NUMBER:		221049909

	BUSINESS ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-800-3500

	MAIL ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEAR LAKE RECREATION INC
		DATE OF NAME CHANGE:	19981208
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>modular_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:modd="http://modular-medical.com/20220331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_modd_modular%2Dmedical.com_20220331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20210401_20220331 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001074871 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wMy0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityCentralIndexKey">0001074871</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:CurrentFiscalYearEndDate">--03-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:UnsecuredDebtCurrent" contextRef="AsOf2022-03-31" id="xdx2ixbrl0093" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2022-03-31" id="xdx2ixbrl0096" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2022-03-31" id="xdx2ixbrl0105" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-03-31" id="xdx2ixbrl0117" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-03-31" id="xdx2ixbrl0118" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0173" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0207" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0214" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0223" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0228" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0242" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0250" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0259" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:SharesIssuedForReverseStockSplit" contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:SharesIssuedForReverseStockSplit" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:SharesIssuedForReverseStockSplit" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:GainOnPPPNoteForgiveness" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:AccruedInterest" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:ProceedsFromIssuanceOfPromissoryNote" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:RepaymentOfPromissoryNote" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2021-03-31" id="xdx2ixbrl0469" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:AccruedPlacementFees" contextRef="AsOf2022-03-31" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:AccruedInterests" contextRef="AsOf2022-03-31" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2020-04-02" name="us-gaap:LesseeOperatingLeaseTermOfContract">P39M</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P5Y9M</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0553" decimals="INF" unitRef="Pure">0</ix:nonFraction>
  <ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">P2Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-012022-03-31_srt_MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-012022-03-31_srt_MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P6Y2M12D</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2020-04-012021-03-31_srt_MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2020-04-012021-03-31_srt_MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P6Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P8Y4D</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0646" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0647" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesRegulatoryAssets" contextRef="AsOf2021-03-31" id="xdx2ixbrl0725" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2021-03-31" id="xdx2ixbrl0728" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-03-31" id="xdx2ixbrl0733" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-03-31" id="xdx2ixbrl0734" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="modd-20220331.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-04-01to2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_OtherMachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_OtherMachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">modd:SecuredPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-272021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">modd:SecuredPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-27</xbrli:startDate>
        <xbrli:endDate>2021-10-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-092022-02-10_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-09</xbrli:startDate>
        <xbrli:endDate>2022-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_CommonStockMember_us-gaap_EmployeeStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_StockOptionMember_us-gaap_EmployeeStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_StockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_StockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-14</xbrli:startDate>
        <xbrli:endDate>2022-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-14</xbrli:startDate>
        <xbrli:endDate>2022-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-14</xbrli:startDate>
        <xbrli:endDate>2022-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-14</xbrli:startDate>
        <xbrli:endDate>2022-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_custom_MemberOfBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-14_custom_MemberOfBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-142022-02-14_custom_MemberOfBoardMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-14</xbrli:startDate>
        <xbrli:endDate>2022-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-142022-02-14_custom_MemberOfBoardMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-14</xbrli:startDate>
        <xbrli:endDate>2022-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_DaughterOfPresidentCFOTreasurerAndChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:DaughterOfPresidentCFOTreasurerAndChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-bottom: Black 1pt solid; font-size: 1pt; width: 100%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt"><b>UNITED STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 18pt"><b>FORM</b>&#160;<b><span id="xdx_908_edei--DocumentType_c20210401__20220331_zuq7zTYoq999"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">(Mark One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 45.8pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><span style="font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_901_edei--DocumentAnnualReport_c20210401__20220331_zxfTkJXJE3Aa"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">x</ix:nonNumeric></span></span><b>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font: 10pt Times New Roman, Times, Serif">For the
    fiscal year ended:</span></td>
    <td style="border-bottom: windowtext 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 75%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--DocumentPeriodEndDate_c20210401__20220331_zDDBtYFWFri4"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 31,  2022</ix:nonNumeric></span></b></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><span style="font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_908_edei--DocumentTransitionReport_c20210401__20220331_zxcRA6r91O91"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">o</ix:nonNumeric></span></span><b>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; padding-bottom: 1pt"><span style="font-size: 10pt">For the
    transition period from</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">to</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font: 10pt Times New Roman, Times, Serif">Commission file number:</span></td>
    <td style="border-bottom: windowtext 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 75%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityFileNumber_c20210401__20220331_zEWtgyqRMesf"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityFileNumber">001-41277</ix:nonNumeric></span></b></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%; padding-bottom: 1pt; text-align: center"><span style="font-size: 24pt"><b><span id="xdx_90B_edei--EntityRegistrantName_c20210401__20220331_zL0R9jDr6q38"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityRegistrantName">MODULAR MEDICAL, INC.</ix:nonNumeric></span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Exact name of registrant as specified in its charter)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 48%; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20210401__20220331_zbzPpc1FX9Dj"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 4%; padding-right: 3pt; padding-left: 3pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 48%; padding-right: 3pt; padding-left: 3pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20210401__20220331_z7OXGIEHXrDa"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityTaxIdentificationNumber">87-0620495</ix:nonNumeric></span></b></span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or Other Jurisdiction of<br />Incorporation
    or Organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer<br />Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 48%; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20210401__20220331_zL6FXsxdphPk"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityAddressAddressLine1">16772 W. Bernardo Drive</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressCityOrTown_c20210401__20220331_z2howCiHa49b"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20210401__20220331_zEU3Yk2VYsLb"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 4%; padding-right: 3pt; padding-left: 3pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 48%; padding-right: 3pt; padding-left: 3pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressPostalZipCode_c20210401__20220331_zf8RrigiLCvl"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityAddressPostalZipCode">92127</ix:nonNumeric></span></b></span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 3pt; padding-left: 3pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Zip
    Code)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%">Registrant&#8217;s telephone number, including area code:&#160;&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 99%"><b><span id="xdx_902_edei--CityAreaCode_c20210401__20220331_zELhxbKgUved"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:CityAreaCode">(858)</ix:nonNumeric></span> <span id="xdx_902_edei--LocalPhoneNumber_c20210401__20220331_zxXz1DBsxQQh"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:LocalPhoneNumber">800-3500</ix:nonNumeric></span></b></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-size: 10pt">Securities registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: center"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 19%; text-align: center"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20210401__20220331_zrm4HBEo6kI9"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20210401__20220331_zJE7lJjNHE5b"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:TradingSymbol">MODD</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">The <span id="xdx_908_edei--SecurityExchangeName_c20210401__20220331_zKiZCTuoGE51"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market, LLC</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Securities registered pursuant to
Section 12(g) of the Act:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Title of class)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Indicate by
check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-size: 10pt">Yes&#160;<span style="font-family: Wingdings">o</span>&#160;<span id="xdx_90C_edei--EntityWellKnownSeasonedIssuer_c20210401__20220331_zirxHtleiqP2"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>&#160;<span style="font-family: Wingdings">x</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Indicate by
check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-size: 10pt">Yes&#160;<span style="font-family: Wingdings">o</span>&#160;<span id="xdx_906_edei--EntityVoluntaryFilers_c20210401__20220331_zTey8mchgqA5"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>&#160;<span style="font-family: Wingdings">x</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Indicate by
check mark if the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_edei--EntityCurrentReportingStatus_c20210401__20220331_zt0dqQnFMln2"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Wingdings">x</span>&#160;No&#160;<span style="font-family: Wingdings">o</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Indicate by
check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-size: 10pt">Yes&#160;<span style="font-family: Wingdings">o</span>&#160;<span id="xdx_90F_edei--EntityInteractiveDataCurrent_c20210401__20220331_z0NY7JWniAWd"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityInteractiveDataCurrent">No</ix:nonNumeric></span>&#160;<span style="font-family: Wingdings">x</span></span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 54%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 22%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Large accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Wingdings">o</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Wingdings">o</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><span id="xdx_90E_edei--EntityFilerCategory_c20210401__20220331_zh6Oi2q1jeub"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric></span>
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Wingdings">x</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Smaller reporting
    company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Wingdings"><span id="xdx_900_edei--EntitySmallBusiness_c20210401__20220331_zjBEkiuFRTI4"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">x</ix:nonNumeric></span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Wingdings"><span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20210401__20220331_zyGSXm83wUM9"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">x</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings"><span id="xdx_908_edei--EntityExTransitionPeriod_c20210401__20220331_zqahDeG9dsK9"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">o</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;<span style="font-family: Wingdings">o</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Indicate by
check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-size: 10pt">Yes&#160;<span style="font-family: Wingdings">o</span>&#160;<span id="xdx_905_edei--EntityShellCompany_c20210401__20220331_zi2CxIDiqkP6"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span>&#160;<span style="font-family: Wingdings">x</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The aggregate market value of the voting and non-voting common stock held by non-affiliates of the Registrant, based on the average of the bid and asked price of the common stock on the OTC Pink Open Market of $9.51 per share, was $<span id="xdx_90B_edei--EntityPublicFloat_iI_c20210930_zxBY6zhcxs11"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,862,263</ix:nonFraction></span> as of September 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The number of shares of the registrant&#8217;s common stock outstanding, par value $0.001 per share, as of June 24, 2022, was <span id="xdx_901_edei--EntityCommonStockSharesOutstanding_iI_c20220624_zHU6i0x4xSNg"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-06-24" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,911,684</ix:nonFraction></span>.</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<!-- Field: Page; Sequence: 2 -->
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
REPORT ON FORM&#160;10-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEAR ENDED MARCH&#160;31, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Part&#160;I</span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 85%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara001"><span style="font-size: 10pt">Item&#160;1.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara001"><span style="font-size: 10pt">Business</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">4</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara002"><span style="font-size: 10pt">Item&#160;1A.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara002"><span style="font-size: 10pt">Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">23</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara003"><span style="font-size: 10pt">Item&#160;1B.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara003"><span style="font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">37</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara004"><span style="font-size: 10pt">Item&#160;2.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara004"><span style="font-size: 10pt">Properties</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">37</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara005"><span style="font-size: 10pt">Item&#160;3.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara005"><span style="font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">37</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara006"><span style="font-size: 10pt">Item&#160;4.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara006"><span style="font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">37</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Part&#160;II</span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara007"><span style="font-size: 10pt">Item&#160;5.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara007"><span style="font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">38</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara008"><span style="font-size: 10pt">Item 6.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara008"><span style="font-size: 10pt">Reserved</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">39</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara009"><span style="font-size: 10pt">Item&#160;7.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara009"><span style="font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">39</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara010"><span style="font-size: 10pt">Item 7A.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara010"><span style="font-size: 10pt">Quantitative and Qualitative Disclosures about Market Risk</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">43</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara011"><span style="font-size: 10pt">Item&#160;8.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara011"><span style="font-size: 10pt">Financial Statements and Supplementary Data</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">44</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara012"><span style="font-size: 10pt">Item&#160;9.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara012"><span style="font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">62</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara013"><span style="font-size: 10pt">Item&#160;9A.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara013"><span style="font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">62</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara014"><span style="font-size: 10pt">Item&#160;9B.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara014"><span style="font-size: 10pt">Other Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">63</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara015"><span style="font-size: 10pt">Item 9C.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara015"><span style="font-size: 10pt; background-color: white">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">63</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Part&#160;III</span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara016"><span style="font-size: 10pt">Item&#160;10.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara016"><span style="font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">64</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara017"><span style="font-size: 10pt">Item&#160;11.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara017"><span style="font-size: 10pt">Executive Compensation</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">71</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara018"><span style="font-size: 10pt">Item&#160;12.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara018"><span style="font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">74</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara019"><span style="font-size: 10pt">Item&#160;13.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara019"><span style="font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">76</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara020"><span style="font-size: 10pt">Item&#160;14.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara020"><span style="font-size: 10pt">Principal Accountant Fees and Services</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">76</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Part&#160;IV</span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara021"><span style="font-size: 10pt">Item&#160;15.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara021"><span style="font-size: 10pt">Exhibits</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">77</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara022"><span style="font-size: 10pt">Item 16.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara022"><span style="font-size: 10pt">Form 10K Summary</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">78</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modulara023"><span style="font-size: 10pt">Signatures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">79</td></tr>
</table>



<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORWARD-LOOKING
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This Annual Report
on Form 10-K (this &#8220;Report&#8221;) contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;), that relate to future events or to our future operations or financial performance. Any forward-looking statement involves
known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements
to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking
statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Words such as, but
not limited to, &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221;
&#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;targets,&#8221;
&#8220;likely,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;scheduled&#8221;
and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words. Although we believe that we have a reasonable basis for
each forward-looking statement contained in this report, we caution you that these statements are based on our estimates or projections
of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our actual results,
level of activity, performance, experience or achievements to differ materially from those expressed or implied by any forward-looking
statement. Actual results, level of activity, performance, experience or achievements may differ materially from those expressed or implied
by any forward-looking statement as a result of various important factors, including our critical accounting policies and risks and uncertainties
relating, to:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            strategies, prospects, plans, expectations, forecasts or objectives;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to achieve a marketable product (i.e., our insulin pump) and the costs and timing
                                            thereof;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
                                            of our product candidate by our target market and our ability to compete in such market;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to raise additional financing when needed and the terms and timing thereof;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to expand, protect and maintain our intellectual property rights;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            future operations, financial position, revenues, costs, expenses, uses of cash, capital requirements,
                                            our need for additional financing or the period for which our existing cash resources will
                                            be sufficient to meet our operating requirements;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            analysis of the target market for our insulin pump;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            impact of COVID-19 and other adverse public health developments on our operations and our
                                            industry:</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain all regulatory approvals and clearances relating to our insulin pump including
                                            those of the United States Food and Drug Administration, or FDA;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            developments in the United States and other countries;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing and costs of our obtaining all regulatory approvals and clearances identified immediately
                                            above;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            compliance with all applicable laws, rules and regulations, including those of the Securities
                                            and Exchange Commission, or SEC, and the FDA;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to compete in the diabetes marketplace with larger and more substantial medical device
                                            companies;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                            economic, business, political and social conditions;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            reliance on and our ability to retain (and if necessary, timely recruit and replace) our
                                            officers, directors and key employees and their ability to timely and competently perform
                                            at levels expected of them;&#160;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to generate significant revenues and achieve profitability;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to manage the growth of our business;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            commercialization, marketing and manufacturing capabilities and strategies;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to expand, protect and maintain our intellectual property position;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            success of competing third-party products;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to comply with regulatory requirements relating to our business, and the costs of
                                            compliance with those requirements, including those on data privacy and security;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            specific risk factors discussed under the heading &#8220;Risk Factors&#8221; set forth in
                                            this report; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">various
                                            other matters, many of which are beyond our control.</span></td></tr></table>
<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara001"></span>ITEM
1. BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our fiscal year ends
on March 31 of each calendar year. Each reference to a fiscal year in this Report, refers to the fiscal year ended March 31 of the calendar
year indicated (for example, fiscal 2022 refers to the fiscal year ended March&#160;31, 2022). Unless the context requires otherwise,
references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to Modular Medical, Inc. and
its consolidated subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are a development
stage medical device company focused on the design, development, and commercialization of an innovative insulin pump using modernized
technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, our MODD1 product
candidate, or MODD1, we seek to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of
care that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription,
reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated
&#8220;super users&#8221; and expand the category into the mass market. The product candidate seeks to serve both the Type 1 and the
rapidly growing especially in terms of device adoption, type 2 diabetes markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Differentiation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe that there
are a number of shortcomings and issues with currently available insulin pumps that prevent a substantial number of people who require
insulin on a daily basis from choosing an insulin pump to treat their diabetes. We believe, that by tailoring our insulin pump to address
such factors, we can expand the scope and adoption rate of insulin pump usage. We believe that to achieve broader market acceptance,
an insulin pump must be easier to learn to use, be less time consuming to operate, more intuitive to both patients and physicians, and
meet the standards for coverage by insurance providers so that co-payments required from patients are affordable and the hurdles to insurance
coverage are significantly reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Among the more
prominent issues are:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Complexity</i>:
                                            Many existing pumps are highly complex and require significant technical expertise to use
                                            effectively. We believe such pumps were designed for &#8220;super users,&#8221; who have
                                            high levels of motivation and technical competence. The complexity of pumps proves daunting
                                            to less technically inclined users.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cumbersome</i>:
                                            We believe that a majority of existing pumps are bulky and difficult to manage, in many cases
                                            requiring additional equipment to introduce a catheter to the patient&#8217;s body and up
                                            to 48 inches of tubing, which must be replaced frequently, to connect the catheter to a pump.
                                            This requires users to carry spare parts and other equipment adding to the difficulty of
                                            using the pump.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Costs:
                                            </i>Costs associated with insulin pump therapy are high and can be prohibitive, especially
                                            for those on fixed or limited incomes. These costs vary by pump, but multi-thousand-dollar
                                            upfront payments, often with substantial co-payments in addition to possible daily co-payments
                                            on consumables, can easily place current pumps out of reach for patients. This makes insurance
                                            providers hesitant to pay for them, leading to limited or absent reimbursement/coverage and
                                            high hurdles for patients to gain access.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Outdated
                                            style</i>: Consumer electronics devices have evolved in both form and function. Diabetes
                                            pumps have not experienced similar progress. We believe that consumers will be more receptive
                                            of products designed with the user experience in mind and that many have low tolerance for
                                            complex, difficult procedures for use and maintenance of products.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pump
                                            mechanism limitations</i>: Traditional pumps generally utilize a syringe and plunger mechanism
                                            to deliver insulin. We believe this design limits the ability to reduce the size of the pump,
                                            and also potentially exposes the user to the unintended delivery of the full volume of insulin
                                            within the pump, which can cause hypoglycemia or death. We believe that the fear of adverse
                                            health events due to technical malfunctions related to traditional pump mechanism limitations
                                            deters the adoption of insulin pump therapy.</span></td></tr></table>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our team has substantial
knowledge of the diabetes industry and experience in developing, obtaining regulatory authorization for, and bringing insulin pumps to
market. Based on this experience, we believe that our innovative insulin pump, using a new and proprietary method of pumping insulin,
can address most or all of these shortcomings. It provides a state-of-the-art insulin pump capable of both basal (steady flow) and bolus
(mealtime dosing) insulin disbursement. It also has been designed considering a natural migration path to multi-chamber/multi-liquid
pumps, potentially offering an exciting array of new therapies to patients with diabetes and other conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our goal is to become
the leader in expanding access to insulin pump technology to a wider portion of diabetes sufferers and provide not just care for the
super users, but &#8220;diabetes care for the rest of us.&#8221; We believe there is a substantial opportunity to penetrate the type
2 MDI marketplace, whether through this new insulin pump or further simplification of pumps for the type 2 marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The MODD1 is a high-precision,
first-line pump that we believe represents the best choice for new pump patients because it is easy to afford, easy to learn, easy to
use, and has a revolutionary design and technology that enable precision with low-cost manufacture and high reproducibility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Key features include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43.8pt"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
                                            parts - one reusable, one disposable - snap together to form the working system;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
                                            button interface, easy to learn and use;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90-day
                                            reusable, 3-day disposable;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Removable
                                            at any time from an adhesive bracket;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            external controller required, no charging, no battery replacement; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Slim
                                            profile, lighter weight.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">A proprietary survey
of American healthcare payors representing 50 million covered lives (approximately one-third of U.S. covered lives) performed for us
by industry leading survey firm ISA has demonstrated that payors are willing to grant equivalent or preferential coverage for a product
with this feature set at launch in exchange for rebates of approximately 20%. These costs are built into all of our models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Diabetes
Classifications and Therapies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Diabetes is typically
classified as either type 1 or type 2:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    1 diabetes is an auto-immune condition characterized by the body&#8217;s nearly complete inability to produce insulin. It is frequently
    diagnosed during childhood or adolescence. Individuals with type 1 diabetes require daily insulin therapy to survive.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    2 diabetes represents over 90% of all individuals diagnosed with diabetes and is characterized by the body&#8217;s inability to either
    properly utilize insulin or produce sufficient insulin. Initially, many people with type 2 diabetes attempt to manage their condition
    with improvements in diet and exercise and/or the use of oral medications and/or injection of glucagon-like peptide-1 (GLP-1) drugs.
    However, as their diabetes advances, patients often progress to require insulin therapies such as once-daily long-acting insulin
    and ultimately to intensified mealtime rapid-acting insulin therapy.&#160;&#160;This represents an important portion of the diabetes
    market with an estimated 1.6 million type 2 individuals with diabetes intensively treated with insulin currently in the United States</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Glucose,
the primary source of energy for cells, must be maintained at certain levels in the blood in order to permit optimal cell function and
health. In people with diabetes, blood glucose levels are not well controlled and frequently become very high, a condition known as hyperglycemia,
and very low, a condition called hypoglycemia. Hyperglycemia can lead to serious long-term complications, including blindness, kidney
disease, nervous system disease, occlusive vascular diseases, lower-limb amputation, stroke, cardiovascular disease, and death. Hypoglycemia
can lead to confusion or loss of consciousness, often requiring a visit to the emergency room or, in certain cases, result in seizures,
coma, and/or death.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All people with type
1 diabetes, which is our primary market, require daily insulin. According to the Seagrove 2021 Diabetes Blue Book, approximately 18%
of people with type 2 diabetes in the United States, or 4.7 million people, require insulin (basal alone represent 3.1 million and basal
plus mealtime represent 1.6 million) to manage their diabetes. In this Report, we refer to people with type 1 diabetes and people with
type 2 diabetes who require mealtime insulin as &#8220;insulin-requiring people with diabetes.&#8221;</span></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently, there are two primary therapies
available for insulin-requiring people with diabetes: multiple daily insulin injections directly into the body through syringes or insulin
pens, referred to as Multiple Daily Injection, or MDI therapy, or the use of an insulin pump to deliver mealtime insulin boluses (single
dose) to help with glucose absorption after carbohydrate consumption and a continuous subcutaneous insulin infusion, or CSII therapy,
into the body. Generally, CSII therapy is considered to provide a number of advantages over MDI therapy, primarily an improvement in
glycemic control, as measured by certain diabetes management tests such as hemoglobin A1c (HbA1c) measure and more recently Time in Range
(TIR) where a continuous glucose measuring device is used to calculate this test. Among other medical benefits, it has been demonstrated
that insulin pump use can decrease glucose variability, reduce the number of hypoglycemia, decrease the daily doses of insulin and reduce
the fear of hypoglycemia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><img src="modular001.jpg" alt="(Graphic)" style="margin-bottom: 10pt; float: right; margin-left: 20pt" /></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 94.5pt 0pt 0; text-align: justify"><span style="font-size: 10pt">Notwithstanding
these advantages, the difficulty in use resulting from the complexity and cumbersome design of available insulin pumps as well as high
and often prohibitive costs for both the patient and insurance provider has resulted not only in dissatisfaction among many existing
pump users (fewer than half purchase a new pump after warranty expires per Seagrove Partners (estimate), but also has severely limited
the adoption rate of insulin pumps by a large segment of the MDI diabetes population, who we refer to in this Report as &#8220;Almost
Pumpers.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We define Almost Pumpers
as insulin-requiring people with diabetes who are aware of pumps and their potential benefits but, because of past experience, pump shortcomings,
cost, complexity and time and learning required to adopt and utilize available insulin pumps, continue to receive their daily insulin
through MDI therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our initial focus for
our insulin pump is the almost pumper segment population located in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our research, along
with marketplace data, estimates that 32% of Americans with type 1 diabetes use insulin pump therapy and 28% of Americans with type 1
diabetes (44% of those who currently utilize MDI) can be classified as having an interest in pump adoption and meeting the American Diabetes
Association guidelines of glucose control if their objections to the currently available suite of products can be overcome. They do not
want to closely manage their glucose levels and incur the associated time and effort involved. They are the Almost Pumpers. We have developed
what we believe to be the most technologically advanced delivery system overcome the objections and provided motivation for this market.
We believe that there are four addressable hurdles to adoption:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Usability:
                                            the device needs to be easy to learn and to operate;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Affordability:
                                            we will focus on overcoming copay and insurance hurdles rather than leaving the &#8220;insurance
                                            journey&#8221; to the clinician and patient;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accessibility
                                            and Education: we will seek to engage patients to sample this new technology by supplying
                                            clinicians with free samples and simple training to allow people to see first-hand the typical
                                            barriers to adoption that have been overcome; and </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service
                                            and Support: where we will answer their questions and concerns during this diabetes experience.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe this conversion
process, engaging people to try and thereby receive the benefits of our technology will substantially increase adoption of insulin pumps
among both those with type 1 diabetes and type 2 diabetes who remain reliant upon multiple daily injections. Diabetes is a disease that
appears throughout the world. Therefore, we cannot segment the market by socioeconomics, education or level of care. We intend to create
an insulin pump that appeals to all Almost Pumpers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The International Diabetes
Federation, or IDF, estimates that, in 2019, approximately 460 million people were living with diabetes worldwide and, that by 2045,
this number will increase to approximately 700 million people.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">An estimated 34 million
people in the United States live with diabetes. Within this group, type 1 diabetes accounts for approximately 1.8 million people (7%
of total) with the remainder being type 2 diabetes. However, of the people with type 2 diabetes about 1.6 million of them require intensive
insulin treatments to manage their diabetes. This represents a large and growing market with the effects of diabetes accounting for roughly
25% of all healthcare dollars spent annually in the United States.</span></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">According to
the National Diabetes Health Care Provider Survey conducted by Seagrove Partners, approximately 25% of the 1.6 million highly insulin intensive type 2
diabetes have considered going &#8220;on pump.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Insulin pumps have
been shown to provide a higher level of care for insulin dependent people with diabetes and result in better glycemic control, fewer
comorbidities, fewer trips to the emergency room, and higher overall quality of life. They also result in lower overall costs to the
healthcare system, reducing typical expense per patient year from $27,195 to $16,992.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Despite these
benefits, only 1 in 3 (33%) of the 1.8 million Americans with type 1 diabetes and very few of the 1.6 million type 2 diabetes intensively
treated with insulin currently use an insulin pump, for a total of approximately 670,000 current users, with only a slow increase of
insulin pump use. The remaining 68% of type 1 diabetes&#8217; and virtually all of the type 2 diabetes&#8217; rely on multiple daily
injections (MDI) for glucose control. Decades of advances in technology advances have left these non-pumpers at a significant disadvantage
from a control perspective versus their &#8220;pumping&#8221; counterparts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have identified
a large segment of the market that we refer to as &#8220;Almost Pumpers.&#8221; Almost Pumpers are those insulin-requiring people with
diabetes (type 1 diabetes and type 2 diabetes) who feel that they would adopt the pump if it were less expensive, less time consuming,
less technically intimidating, and if there was no separate controller. They represent approximately 32% of the type 1 diabetes market
correlating to a $1.9 billion growth opportunity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">Insulin pumps on the
market today require a substantial amount of time to manage the therapy, have high out of pocket costs that place these technologies
out of reach for a large part of the population, and are feature-heavy with complex systems that have hampered adoption and intimidated
many users. The most commonly used insulin pumps today require extensive training and hours of daily management. The average pump user
must go through 42 steps of setup and refill process every 72 hours to &#8220;stay on track.&#8221;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><img src="modular002.jpg" alt="(Graphic)" style="margin-bottom: 10pt; float: left; margin-right: 25pt" />&#160;<span style="font: 10pt Times New Roman, Times, Serif">The
current reluctance to adopt the insulin pump has had serious consequences on the healthcare system. In the United States, people
living with type 1 diabetes have struggled to attain glycemic targets. A 2019 analysis of the large type 1 diabetes Exchange clinical
registry found that only 21% of U.S. adults with type 1 diabetes achieved the ADA A1c goal (&lt;7.0%). Further, according to a
study published in JAMA Internal Medicine, researchers found no significant improvements in diabetes care between 2005 and 2016,
with persistent gaps in care related to socioeconomic status.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The recent introduction
and rapid adoption of Abbott Labs&#8217; Freestyle Libre, or the Libre, has made continuous glucose monitoring, or CGM, easier and more
affordable, expanding the product category, and doubling its size. Now for the first time, there is an easy, less painful (i.e., no more
finger sticks) way for patients to have the data they need to understand more about their glucose levels and their insulin requirements.
Access to such data has motivated patients to ask their diabetes clinician how they can achieve better glycemic control and made them
more comfortable with using technology and wearables to treat their diabetes. Pumps offer a clear pathway to better control and better
overall care. We believe that the insulin pump market is ready for a similar transition as that experienced in the CGM space. We believe our MODD1 pump
represents a new and better offering to assist and induce a wide variety of patients to make the transition and bridge the void to superior
control by becoming a &#8220;pumper.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe the present
pump marketplace is approximately a $1.9 billion market, comprising approximately 33% of type 1 diabetes pumpers and a small group of
type 2 diabetes pumpers. Seagrove Partners estimates that 28% of type 1 diabetes patients and 25% of type 2 diabetes patients would adopt
technology that was easier to use, access and pay for. We believe the total addressable market approximates $3 billion, assuming revenue
of $4,128 per patient, per year. We expect to spend approximately 15% of our total revenue on discounts and free samples to encourage
adoption of our pump product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are dedicated to
helping all people with diabetes gain access to high quality care. We aim to help people with diabetes, especially Almost Pumpers and
the historically underserved communities, gain access to insulin pump technology by making it affordable and easy to use.</span></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Diabetes
Care is at an Inflection Point</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">We believe that
the insulin pump market stands at a crossroads as a confluence of events makes the timing for a new product introduction ideal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">2020 was a very
difficult year in diabetes. Between COVID-19 and a loss of glycemic control during quarantines and isolation, deaths from diabetes rose
by 17% in 2020 versus the prior year. This was sharpest among the young who saw deaths rise 29% in the 25 to 44 year-old demographic.
This has created a pain point and a desire to find new and better solutions and has raised awareness among patients, caregivers, payors,
and policy makers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">COVID-19 also
encouraged (and required) trial and adoption of telehealth models and a great many people have found them to their liking with a high
proportion of patients and of health care providers, or HCPs, that want to continue to use these technologies. We expect much of this
shift and newfound comfort with distance care models to persist and believes that this can provide a patient acquisition and engagement
model for insulin pumps and diabetes care, especially for pumps optimized for free trial and easy learning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">At the same
time, reimbursement for patch pumps has been increasingly moving to a pharmacy benefits manager, or PBM, model, which simplifies reimbursement
which will further aid in a &#8220;frictionless launch.&#8221; This represents a fundamental shift in the insulin pump market, making
onboarding rapid and simplifying a previously complex and time-consuming &#8220;insurance journey.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The CGM space
(wearable devices that monitor blood glucose levels) has been experiencing explosive growth largely driven by the Libre. This product
was a more affordable, easier to use version of the popular Dexcom CGM product. Not only is it now a larger (by revenues) product than
Dexcom, but it accomplished this without seeming to slow Dexcom&#8217;s growth but rather by growing a new category with a new type of
user.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">These users
are increasingly interested in adopting technology and wearables to manage their diabetes. We believe they are a natural market for a
new type of pump if it can meet their needs and address their objections and that the conjunction of the above trends represents a unique
opportunity in the insulin pump market&#8217;s history.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Diabetes technology
companies understand that we are at a turning point with new markets. This can be seen with increased discussion around this topic during
recent national diabetes conferences, as well as but also an increase in marketing promotion. For example, Dexcom aired a $5.5 million
30-second commercial during the 2021 Super Bowl.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All these recent changes
support the high proportion of type 1 diabetes and type 2 diabetes intensively treated with insulin that are considered as Almost Pumpers,
number that may grow in the next years and that may be more reachable with adequate marketing strategies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Insulin Pump</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Instead of building
complex, bespoke, and difficult to manufacture and maintain pumping and control systems, we began with the technology and the user in
mind. Using proprietary and patented methods of insulin measurement, we were able to eschew complex mechanisms and instead built a product
candidate using only parts from high volume consumer electronics manufacturing lines, breaking the cost vs functionality curve that has
existed in the insulin pump space and representing the first truly modern insulin pump design. This is a new kind of product for a new
kind of patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The pre-production
models of our low-cost insulin pump are now undergoing the testing required to submit to the FDA for clearance to market them in the
United States. We continue to devote, substantial time and resources to better understand the needs and preferences of Almost Pumpers
and the specific patent/provider/payor requirements to motivate change from MDI.</span></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">MODD1 has several distinguishing
features:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;<img src="modular003.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">1 - The pump has a
simple button to press to deliver insulin as the patient requires it. The electronic pump uses a simple motor and rotating cam to motivate
the insulin into the patient along with a low power Bluetooth and near field communication chips to allow the patient to communicate
with their smart phone, tablet, or other mobile computing platform, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">2 - The pump snaps
together with a three-day disposable cartridge that is patient filled with insulin for delivery. It includes the power source and a simple
coin cell that allows it to run through the 80-hour life of the cartridge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">3 - There is a set
(not shown) that contains a soft 6 millimeter cannula and an introducer for insertion into the skin and removal of the needle used to
transfer insulin to the body.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">4 - MODD1 comes with
a variety of methods for the patient to wear the pump. Options include: a base plate with adhesive (shown) for attaching to the body
that has features for holding the pump to the patient; overwraps to hold the product candidate to the patient; and a velcro strap with
a base plate suitable for wrapping around the arm or leg of the patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The system will deliver
a small continuous rate called a basal that will provide approximately 50% of the total daily dose required and the user will use the
on-pump button to administer boluses, typically before and after meals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The objective is to
make the product candidate simple to acquire and take home, simple to learn and most importantly, simple to use to expand the pump market,
drive adoption and ultimately better clinical outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Technological
Advantages</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The adoption of new
ultra-high volume technologies will result in far easier manufacturing scale up as parts sourcing and assembly processes are far easier.
The MODD1 was designed from the beginning for mass manufacturing processes and &#8220;lights out&#8221; or near lights out production
assembly lines. This advantage is compounded by the high availability and already optimized cost reduction in its components. This has
resulted in a cost of goods, estimated on the competitors&#8217; announced margins and sales, 50% lower than our closest patch pump competitor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The adoption of modern,
miniaturized technologies has led to numerous other advantages as well. The MODD1 pump is smaller in overall volume than Insulet&#8217;s
popular Omnipod product, or the Omnipod, and has a lower profile to the skin. Despite this, it holds a full 3mL (300 units) of insulin
in line with full sized pumps such as Tandem and Medtronic, 50% more than the 2mL reservoir in the Omnipod. We believe that this volume
advantage over other patch pumps will be significant as 24% of type 1 and over 50% of the rapidly growing type 2 market require more
than 2mL of insulin every three days (the expected wear time of patch pumps).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition, our new
and patented pumping modality will provide what we believe is the most even (and thus closest to the function of a healthy pancreas)
delivery of basal insulin in the industry. Basal rate can be delivered almost continuously while other pumps are delivering micro-boluses
every 5 minutes for the Omnipod and Tandem and Medtronic pumps. We plan to demonstrate the impact of our system on glycemic control in
a future clinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The technology allows
the patient to simply add insulin and operate. The battery is included in each cartridge and the device is operated without a controller.
Nothing needs charging. MODD1 has been made push button simple to appeal to a wider audience of users.</span></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This new technology
has also made the MODD1 lighter than existing offerings. Compared to the Omnipod, MODD1 weighs 20 grams (vs. 26 grams) empty and 23 grams
(vs. 28 grams) fully filled (despite carrying 50% more insulin), a reduction of 23% and 18%, respectively. Also, unlike existing patch
pumps, the MODD1 can be removed from the needle and taken off and replaced later if the user desires. This avoids loss of insulin in
a pump due to accidental dislodging of the soft canula, an issue that users have expressed considerable dissatisfaction with on other
patch pumps.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This technology is
also uniquely suited to dual (or more) chamber pumps. We believe that such pumps will be integral to the realization of high time in
range artificial pancreas solutions that require no human intervention, the next step forward from the cumbersome and awkward solutions
today that require the user to announce meals, count and input carbs, and adjust delivery for exercise and sleep. The advantages of cost
and miniaturization are multiplied in a multi-chamber setup and we expect to be able to reach price points, ease of use, and form factor
unlike anything seen in the industry thus far. We believe that a prefilled, multi-hormone peel and stick patch pump able to function
in a fully autonomous closed loop system with CGM&#8217;s represents the next generation of diabetes care. We believe that we have demonstrated
our technology and are securing intellectual property protection on our approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe this technology,
especially in dual chamber, will open up numerous applications outside of diabetes where medication compliance of complex therapy regimes
is difficult addressing such spaces as weight loss, fertility, and simplifying complex delivery of multi-drug cocktails, especially those
with diverse and challenging dosing schedules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Solution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our proposed pump is
being designed and developed to address the aforementioned shortcomings of the existing pump market and to appeal to: (i) the substantial
group of &#8220;Almost-Pumpers&#8221; who are currently interested in using an insulin pump, but have not done so because of the complexity,
cost or cumbersome nature of existing products, and (ii) people who are using one of the currently available insulin pumps but are dissatisfied
with such products. We believe that, owing to our new proprietary technology, our proposed insulin pump will be the simplest and least
expensive product on the market and the easiest for providers to prescribe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our current pump prototype
of our proposed pump has been built to test what we believe to be our novel approach to insulin pumps. By providing a pump that we believe
will establish industry standards in terms of technology, simplicity to understand, ease of use and price, we believe our proposed pump
will offer the vast majority of benefits afforded by more expensive and complex pumps but remain accessible to a substantially greater
percentage of diabetes sufferers requiring daily insulin therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe people generally
will not use technology that intimidates them and physicians are hesitant to prescribe such technology. We believe mass market products,
such as is intended for our proposed pump, must be &#8220;user friendly&#8221; and affordable. We believe this approach is fundamentally
different from that applied to the existing pump market today where most pumps are continuously adding complex features and are &#8220;user
friendly&#8221; to only the most technically astute.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our current goal is
to successfully design, develop and obtain all required regulatory approvals for our proposed insulin pump, and, thereafter, commercialize
the finished product. Our long-term goal is to become a leading provider of insulin pump therapy by focusing on both consumer and clinical
needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To achieve our above
stated immediate and current goals, we intend to pursue the following business strategies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
                                            of innovative proprietary technology.</i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Based upon the substantial
experience of Paul DiPerna, our president, chief financial officer, treasurer and chairman of our board of directors, in engineering
design and innovative technology in the medical device industry and, in particular, with insulin pumps, we have generated proprietary
technology that has been incorporated into our proposed insulin pump. Generally, this technology is involved in the delivery of insulin
to the user at the appropriate and necessary times. We believe this technology will greatly assist us in creating a simpler, user-friendly
pump. We believe the proposed design, engineering and technology being incorporated into our proposed pump will make it substantially
simpler and more affordable than those currently available. These features, together with the safety and reliability of our proposed
pump, are designed to create the next generation of insulin pumps that will feature important and well-differentiated attributes compared
to those currently available and make it available to consumers across mostly all socioeconomic groups in the United States and around
the world.</span></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Keep
                                            costs low during our design and development process.</i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To attempt to ensure
that we have sufficient funds to design, develop, and obtain all required regulatory approvals for our proposed insulin pump without
having to sacrifice quality and efficiency, we intend to maintain a tight budget and limit expenditures where possible. We believe this
will be possible because of the extensive knowledge and experience of Mr. DiPerna, not only in the diabetes industry and more specifically
in the insulin pump device market, but also his experience in designing and developing insulin pumps and other medical devices and his
ability to manage a small, focused development team. We currently expect that various other expenses, such as product scale up, and sales
and marketing costs, will not be incurred until such time as development work is completed and regulatory approvals obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employ
                                            experienced engineers selected, supervised, and led by Mr. DiPerna, a highly experienced
                                            and respected engineer and executive in the insulin pump industry.</i></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To attempt to ensure
our proposed insulin pump is &#8220;state of the art,&#8221; functional, and efficient, as well as to conserve funds, substantially all
of our employees will initially be hand-picked engineers under the leadership of Mr. DiPerna. We believe that there is a strong pool
of engineers with significant applicable experience and knowledge who we will be able to initially employ on a contract and/or outsource
basis to help us design and develop our proposed insulin pump. We believe by hiring such persons on an out-source basis, we will save
substantial resources and by having Mr. DiPerna lead and focus the team on technological and mechanical aspects of our proposed insulin
pump, we believe our team will be well guided, focused, cost efficient, and able to efficiently design and develop our product candidate
that we believe can eventually be a competitive and popular choice for people with insulin requiring diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commercialization
Strategy: Overcoming the Insurance Hurdles</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our goal is to establish
MODD1 as the best option for new pump patients as we expand the market into the Almost Pumpers (Type 1 and Type 2) and the newly motivated
CGM users. We seek to grow the market by providing first-line insulin pump therapy that is well suited to meet the needs of both diabetes
patients requiring insulin and their clinicians.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MODD1
                                            is approximately 50% less expensive to manufacture than the Omnipod. This low cost allows
                                            us to spend more on patients and sampling. This will save money for payers. We can offer
                                            the pump with no upfront cost to patients. Benefits of MODD1 include:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20%
                                            discount vs Insulet will drive preferred status;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            to use PBM codes as a disposable;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            new code needed to be reimbursed at launch; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saves
                                            provider an estimated $1,062/patient/year vs the Omnipod.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            MODD1 will be sampled and given to patients by the doctor or diabetes nurse educator at the
                                            time of the patient visit. When a patient is motivated to make change, our starter kit will
                                            make it easy for the clinician to initiate the new therapy that same day. We seek to eliminate
                                            the currently challenging &#8220;insurance journey&#8221; and product acquisition timeline
                                            and significantly reduce training time for the busy clinician, all major hurdles to pump
                                            adoption. We intend to add telehealth support to help the patient throughout adoption and
                                            use and to facilitate greater collaboration between patients and their physicians.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Europe represents
another large potential market for MODD1. Approximately 60 million people in Europe live with diabetes, and approximately $161
billion is spent annually in diabetes healthcare costs in Europe. At present, cost containment is restricting pump uptake across
Europe. Current pump usage hovers between 10% and 20% in many markets. Single payor healthcare systems across the Europe traditionally
attempt to contain costs in the short term and seek low price technologies with moderate medical benefits. MODD1 will offer a
rebalance of this risk/reward strategy in that payors will incur only minor incremental short-term costs with the benefit of longer
-term cost savings associated with reliable pump use. We intend to employ a partnership strategy across Europe following in-house
managed regulatory and pricing activities in the major markets (e.g., the United Kingdom) and more cost receptive markets (e.g.,
the Nordic countries). We are targeting European and United Kingdom approval towards early 2023. Our initial target market for
our insulin pump is the Almost Pumper population located in the United States followed quickly by an effort to obtain <i>Conformit&#232;
Europ&#235;enne</i>, or CE, mark approval for distribution throughout Europe.</span></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketing
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">MODD1 tackles the most
significant barriers to pump use-access and affordability-and makes it easier for clinicians, caregivers and individuals to manage diabetes
care. Our commercialization plan will drive adoption and is designed to expand the market and is intended to do the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximize
                                            adoption with a comprehensive frictionless launch program. </b>We will seek to decrease the
                                            level of reimbursement effort and cost to encourage HCPs to offer our pumps and encourage
                                            patient trials. Our product candidate reduces the technical hurdles to widen appeal, new
                                            starts and increase adherence. We will encourage MDI patients who want or need more control
                                            to make the switch to the pump earlier in their treatment-ideally right at diagnosis.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leverage
                                            technology to support sales and new patient acquisition</b>. We intend to set up tech enabled
                                            sales teams backed with a full omnichannel program to drive awareness and trial with HCPs
                                            and patients. We will focus on educating providers that our product candidate is simple to
                                            teach and easy to support making it an ideal front line offering.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Facilitate
                                            patient trials. To facilitate patient trials, we intend to:</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
                                            a free pump and a 30-day supply of cartridges, insurance verification, co-pay coupons and
                                            telehealth support to patients thereby reducing outlay of time and money</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partner
                                            with connected care companies to provide superb support of patients from trial through the
                                            first year</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">We believe
that MODD1 will be the only insulin pump that patients can take home immediately from the doctor&#8217;s office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leverage
                                            MODD1 300-unit chamber to increase adoption with Type 2 patients</b>. MODD1 has a major advantage
                                            over existing patch pumps in that the chamber carries enough insulin to meet the high doses
                                            many type 2 patients need. We intend to promote this advantage and capture a significant
                                            share of the existing type 2 pump users as well as new starts.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Work
                                            with key organizations and policy makers to pave the way for greater access to pumps. </b>We
                                            will<b>&#160;</b>promote MODD1 technology among the underserved, who are typically low users
                                            of health technology. We will identify individuals, patient organizations, professional societies,
                                            and policy and DEI organizations that are critically important to the adoption of new technologies
                                            in the diabetes space and build relationships with these influential stakeholders.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Initiate
                                            a clinical study program (with key diabetes centers</b>) to provide additional clinical support
                                            for MODD1 in special patient types and clinical setting. After obtaining 510(k) clearance,
                                            we intend to conduct a soft launch and clinical research program in major markets to pave
                                            the way for the full launch in late 2022. We will work with our advisors and key diabetes
                                            associations to educate the community about the MODD1. In addition, we will conduct clinical
                                            studies to develop competitive claims and market expansion.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Work
                                            with major health plans to establish MODD1 as the first line pump for Type 2 patients</b>.
                                            We believe MODD1 will be payor preferred for both type 1 and type 2 patients. It was designed
                                            to attain preferential reimbursement and avoid the coverage pitfalls many other pumps have
                                            experienced.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payors
                                            want a simple product that is less expensive. We will launch with a discount program for
                                            payers of 20% less than Omnipod to drive uptake.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            to use existing PBM codes as a disposable</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            new code: Reimbursed at launch</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tie-in
with the massive movement to telehealth. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">2020 saw personal telehealth
go from beta test to mainstream. Customers and providers have become comfortable with it. There are only 4,000 patient-facing endocrinologists
in the United States. The treatment of diabetes will be significantly enhanced with telehealth to drive more volume and clinical enhancements
through their practices. Telemedicine is a force multiplier for a small group of doctors to better serve a large market. MODD1 was designed
to be affordable enough for free sampling and trial, and simple enough for self-guided user training. We believe that by combining telehealth
support with MODD1, we will decrease the burden of diabetes care and improve the lives of people with diabetes.</span></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Launch/Trial</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We intend to initiate
a &#8220;soft launch&#8221; following FDA clearance of the MODD1 device. Our plan is to select a group of clinicians who are well trained,
experienced and have the support infrastructure to take on initial patients and monitor them carefully to provide clinical feedback on
our performance to further refine our product candidate and support infrastructure prior to full commercial launch. Many of these clinicians
will have been those who assisted in the development of the MODD1 offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We intend to continue
to modify, refine and finalize our system to best meet:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            general needs and preferences of our almost pumper target market based upon our knowledge
                                            of the diabetes industry and information available and/or obtained by us from Almost Pumpers
                                            and their caregivers; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            general guidelines of third-party payors, private and public insurance companies, preferred
                                            provider organizations and other managed care providers with particular focus on the guidelines
                                            established by the Center for Medicare and Medicaid Services, or CMS, which administrates
                                            the United States Medicare program, or Medicare. To assist us in making such modifications
                                            and refinements, we have retained independent consultants to focus on ensuring that our product
                                            candidate satisfies the existing coverage and reimbursement criteria of such third-party
                                            payors.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Manufacturing requires
the production of pumps, cartridges, and baseplates as well as assembly with sets. In connection therewith:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            plan to build an automation machine for implementation in Southern California, close to the
                                            design engineers, that will be capable of assembling the cassettes at a rate sufficient to
                                            supply 50,000 patients in a single shift (500,000 per month). This equipment will require
                                            nine months to design and build and three months to verify and validate into our manufacturing
                                            process.</span></td></tr><tr style="font: 9pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 9pt Times New Roman, Times, Serif"><span style="font-size: 9pt">&#160;</span></td><td style="font: 9pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 9pt">&#160;</span></td></tr>
                                                                     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            packaging equipment and boxing will start as manual operations while the automation is refined.
                                            This equipment will be purchased and implemented as the second phase of automation of the
                                            cassette.</span></td></tr></table>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            sets will be purchased through third party suppliers with expertise in the product to time
                                            and cost-effectively introduce the product and focus on our core expertise.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            standard cost of the cartridge is estimated to be $7.68 at the point we are manufacturing
                                            for 3,000 users or more. The pump is estimated to cost $34.00 at similar volumes.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            internal estimates project potential gross margins as high as 78% and a 20% operating margin,
                                            approximately 30 months after launch.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The pumps will be built
and tested in our San Diego facility while we build volume and expertise. When the production methodology has matured and the volumes
have risen, we will consider a transition to outside and offshore manufacturing, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FDA
Clearance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The FDA requires us
to meet all applicable regulations for insulin pumps, a subcategory of infusion pumps, which are generally considered Class 2 devices.
The design of the MODD1 pump has been completed, units have been built and testing is underway to verify that the design meets all FDA
requirements. There are 17 specific tests required to submit for 510(k) clearance. We break these required tests into four testing categories:
wetted surface, electrical safety, usability and internal. Appropriate design control and standard operating procedures have been implemented
to allow us, when testing is completed, to submit for clearance under the premarket notification (or 510(k)) process. To achieve this,
we will continue to work closely with our regulatory consultants to complete, finalize and file our submission to the FDA for 510(k)
clearance and all other documentation necessary to obtain marketing authorization of our insulin pump.</span></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have engaged the FDA in two pre-submission conferences to ensure that we understand and meet
                                            the FDA&#8217;s requirements, expectations and standards with regard to clearance of our
                                            product candidate. At these meetings, our team, including our FDA regulatory consultant,
                                            received FDA comments and guidance regarding our proposed submission during the pre-market
                                            notification period for 510(k) clearance (including any suggested modifications to the device
                                            description, indications for use or summary of supporting data contained in the notification);</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                                                                                                                           </table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are currently preparing and ensuring that our premarket notification, which will be part
                                            of our FDA submission in order to demonstrate that our insulin pump is substantially equivalent
                                            to an insulin pump previously cleared by the FDA and legally marketed to the public and generally
                                            safe and effective for its intended use. We are also preparing our submission to the FDA,
                                            which will include the relevant results of our performance and human factor tests (relating
                                            to, among other things, user effectiveness, sterility, pump efficiency and shipping compatibility)
                                            demonstrating the accuracy and usability of our insulin pump, which we believe will satisfy
                                            the mandates of the FDCA and any applicable performance standards.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commercialization
Steps</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">While we have substantially
completed the general engineering and mechanical aspects of our insulin pump prototype, prior to commercializing, we still must successfully
complete a number of material steps including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continue
                                            to modify, refine and finalize our prototype so that it meets:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            general needs and preferences of our almost-pumper target market based upon our knowledge
                                            of the diabetes industry and information available and/or obtained by us from Almost Pumpers
                                            and their caregivers; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            general guidelines of third-party payors, private and public insurance companies, preferred
                                            provider organizations and other managed care providers with particular focus on the guidelines
                                            established by CMS, which administers Medicare. To assist us in making such modifications
                                            and refinements, we have retained independent consultants to focus on ensuring that our product
                                            candidate satisfies the existing coverage and reimbursement criteria of such third-party
                                            payors.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refine
                                            our manufacturing process during the submission process to identify and select a manufacturer
                                            of our insulin pump through a competitive bidding process, as we prepare for our product
                                            introduction;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Take
                                            such actions, if any, as may be required by the FDA as a condition to granting approval and
                                            providing 510(k) clearance for our insulin pump; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hire
                                            and retain appropriate sales and marketing personnel to develop, implement and launch a promotional
                                            campaign for our insulin pump substantially focused on our target market.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As with any medical
device attempting to enter and successfully compete with existing products in an established and competitive marketplace, we will face
significant hurdles to accomplish the above steps to commercialization including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
                                            FDA 510(k) clearance to market and sell our insulin pump to the public;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
                                            any other FDA-required authorizations with regard to our product candidate, as required by
                                            the FDCA;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Educating
                                            endocrinologists, physician&#8217;s assistants, nurse practitioners and nurse educators,
                                            who typically prescribe pump usage, and certified diabetes educators and dieticians, who
                                            provide education and guidance to diabetes patients, as to what we believe to be the superior
                                            qualities of our product candidate;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Demonstrating
                                            to select general practitioners, who have historically been skeptical of the heightened support
                                            inherent in insulin pumps, our product candidate&#8217;s ease of use and convenience;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
                                            that our final product does, in fact, meet the needs of Almost-Pumpers;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overcoming
                                            the historic obstacles and reluctance of Almost-Pumpers to using insulin pumps to treat their
                                            diabetes; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
                                            that third party payors agree to cover all or a substantial portion of the purchase price
                                            and recurring costs of the use of our insulin pump.</span></td></tr></table>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Looking
Forward</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Going forward, we expect
to continue to evolve the MODD1 pumps and their capabilities and functionality, both in response to patient needs and as part of our
current platform roadmap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            our next generation product, or MODD2, we will seek to add phone-based control and alternate
                                            controller enabled, or ACE, and automated insulin delivery, or AID, capability to allow integration
                                            with popular continuous glucose monitors. This will expand our available market to include
                                            many existing pumpers. The new model has the same modular design and low-cost components
                                            as MODD1 and provides a much desired breakthrough for patients - two-factor command authentication
                                            that allows the wearer to use his/her own cell phone as the controller.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
                                            adds AID control functionality via an ACE designation</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            approved algorithm controller can drive insulin delivery in &#8220;auto&#8221; mode</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CGM
                                            integration allows the controller to potentially adjust basal insulin rate for meals and
                                            exercise with an approved algorithm.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
                                            MODD2, we will seek to move to a full featured multi chamber pump optimized for high time
                                            in range fully autonomous close loop insulin delivery utilizing the form factor and cost
                                            advantages of its pumping designs to create an affordable, easy to use drug delivery system
                                            to realize the aspiration of true &#8220;artificial pancreas&#8221; systems. We envision
                                            moving to a drug prefill model such that cartridges can be filled with therapeutics and shipped
                                            cold chain to patients, further simplifying the use process.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our operations are
subject to comprehensive federal, state, and local laws and regulations in the jurisdictions in which we or our research and development
partners do business. The laws and regulations governing our business and interpretations of those laws and regulations and are subject
to frequent change. Our ability to operate profitably will depend in part upon our ability, and that of our research and development
partners and affiliates, to operate in compliance with applicable laws and regulations. The laws and regulations relating to medical
products and healthcare services that apply to our business and that of our partners and affiliates continue to evolve, and we must,
therefore, devote significant resources to monitoring developments in legislation, enforcement, and regulation in such areas. As the
applicable laws and regulations change, we are likely to make conforming modifications in our business processes from time to time. We
cannot provide assurance that a review of our business by courts or regulatory authorities will not result in determinations that could
adversely affect our operations or that the regulatory environment will not change in a way that restricts our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FDA
Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the United States,
medical devices are strictly regulated by the FDA. Under the FDCA, a medical device is defined as &#8220;an instrument, apparatus, implement,
machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component, part or accessory which
is, among other things: intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention
of disease, in man or other animals; or intended to affect the structure or any function of the body of man or other animals, and which
does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not
dependent upon being metabolized for the achievement of any of its primary intended purposes.&#8221; This definition provides a clear
distinction between a medical device and other FDA regulated products such as drugs. If the primary intended use of a medical product
is achieved through chemical action or by being metabolized by the body, the product is usually a drug or biologic. If not, it is generally
a medical device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are currently developing
an insulin pump delivery system, which is regulated by the FDA as a medical device under the FDCA, as implemented and enforced by the
FDA. The FDA regulates the development, testing, manufacturing, labeling, packaging, storage, installation, servicing, advertising, promotion,
marketing, distribution, import, export, and market surveillance of our medical devices.</span></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Device
Premarket Regulatory Requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Before being introduced
into the U.S. market, each medical device must obtain marketing clearance or approval from the FDA through the premarket notification
(or 510(k)) process, the <span style="font-family: Times New Roman, Times, Serif"><i>de novo</i></span> classification process, or the
premarket approval, or PMA, process, unless they are determined to be Class I devices or to otherwise qualify for an exemption from one
of these available forms of premarket review and authorization by the FDA. Under the FDCA, medical devices are classified into one of
three classes - Class I, Class II or Class III - depending on the degree of risk associated with each medical device and the extent of
control needed to provide reasonable assurance of safety and effectiveness. Classification of a device is important because the class
to which a device is assigned determines, among other things, the necessity and type of FDA review required prior to marketing the device.
Class I devices are those for which reasonable assurance of safety and effectiveness can be maintained through adherence to general controls
which include compliance with the applicable portions of the FDA&#8217;s Quality System Regulation, or the QSR, as well as regulations
requiring facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading
labeling, advertising, and promotional materials. The Class I designation also applies to devices for which there is insufficient information
to determine that general controls are sufficient to provide reasonable assurance of the safety and effectiveness of the device or to
establish special controls to provide such assurance, but that are not life-supporting or life-sustaining or for a use which is of substantial
importance in preventing impairment of human health, and that do not present a potential, unreasonable risk of illness or injury.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Class II devices are
those for which general controls alone are insufficient to provide reasonable assurance of safety and effectiveness and there is sufficient
information to establish &#8220;special controls.&#8221; These special controls can include performance standards, post-market surveillance
requirements, patient registries and FDA guidance documents describing device-specific special controls. While most Class I devices are
exempt from the premarket notification requirement, most Class II devices require a premarket notification prior to commercialization
in the United States; however, the FDA has the authority to exempt Class II devices from the premarket notification requirement under
certain circumstances. As a result, manufacturers of most Class II devices must submit premarket notifications to the FDA under Section
510(k) of the FDCA (21 U.S.C. &#167; 360(k)) in order to obtain the necessary clearance to market or commercially distribute such devices.
To obtain 510(k) clearance, manufacturers must submit to the FDA adequate information demonstrating that the proposed device is &#8220;substantially
equivalent&#8221; to a &#8220;predicate device&#8221; that is already on the market. A predicate device is a legally marketed device
that is not subject to PMA, meaning, (i) a device that was legally marketed prior to May 28, 1976 (&#8220;pre-amendments device&#8221;)
and for which a PMA is not required, (ii) a device that has been reclassified from Class III to Class II or I or (iii) a device that
was found substantially equivalent through the 510(k) process. If the FDA agrees that the device is substantially equivalent to the predicate
device identified by the applicant in a premarket notification submission, the agency will grant 510(k) clearance for the new device,
permitting the applicant to commercialize the device. Premarket notifications are subject to user fees, unless a specific exemption applies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If there is no adequate
predicate to which a manufacturer can compare its proposed device, the proposed device is automatically classified as a Class III device.
In such cases, a device manufacturer must then fulfill the more rigorous PMA requirements or can request a risk-based classification
determination for its device in accordance with the de novo classification process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Devices that are intended
to be life sustaining or life supporting, devices that are implantable, devices that present a potential unreasonable risk of harm or
are of substantial importance in preventing impairment of health, and devices that are not substantially equivalent to a predicate device
and for which safety and effectiveness cannot be assured solely by the general controls and special controls are placed in Class III.
Such devices generally require FDA approval through the PMA process, unless the device is a pre-amendments device not yet subject to
a regulation requiring premarket approval. The PMA process is more demanding than the 510(k) process. For a PMA, the manufacturer must
demonstrate through extensive data, including data from preclinical studies and one or more clinical trials, that the device is safe
and effective for its proposed indication. The PMA must also contain a full description of the device and its components, a full description
of the methods, facilities and controls used for manufacturing, and proposed labeling. Following receipt of a PMA submission, the FDA
determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the application for review,
it has 180 days under the FDCA to complete its review and determine whether the proposed device can be approved for commercialization,
although in practice, PMA reviews often take significantly longer, and it can take up to several years for the FDA to issue a final decision.
Before approving a PMA, the FDA generally also performs an on-site inspection of manufacturing facilities for the product to ensure compliance
with the QSR.</span></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The <span style="font-family: Times New Roman, Times, Serif"><i>de
novo</i></span> classification process allows a manufacturer whose novel device is automatically classified into Class III to request
down-classification of its device to Class I or Class II, on the basis that the device presents low or moderate risk, as an alternative
to following the typical Class III device pathway requiring the submission and approval of a PMA application. Under the Food and Drug
Administration Safety and Innovation Act of 2012, the FDA is required to classify a device within 120 days following receipt of the <span style="font-family: Times New Roman, Times, Serif"><i>de
novo</i></span> classification request from an applicant; however, the most recent FDA premarket review goals state that in fiscal year
2021, FDA will attempt to issue a decision within 150 days of receipt on 65% of all <span style="font-family: Times New Roman, Times, Serif"><i>de
novo </i></span>classification requests received during the year and on 70% of <span style="font-family: Times New Roman, Times, Serif"><i>de
novo</i></span> requests received during fiscal year 2022. If the manufacturer seeks reclassification into Class II, the classification
request must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness
of the medical device. The FDA may reject the classification request if it identifies a legally marketed predicate device that would
be appropriate for a 510(k) notification or determines that the device is not low to moderate risk or that general controls would be
inadequate to control the risks and special controls cannot be developed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Clinical trials are
almost always required to support PMAs and are sometimes required to support 510(k) and de novo classification submissions. All clinical
investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s investigational
device exemption, or IDE, regulations that govern investigational device labeling, prohibit promotion of investigational devices, and
specify recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a
&#8220;significant risk,&#8221; as defined by the FDA, the agency requires the study sponsor to submit an IDE application to the FDA,
which must become effective prior to commencing human clinical trials. The IDE will automatically become effective 30 days after receipt
by the FDA, unless the FDA denies the application or notifies the sponsor that the investigation is on hold and may not begin until the
sponsor provides supplemental information about the investigation that satisfies the agency&#8217;s concerns. If the FDA determines that
there are deficiencies or other concerns with an IDE that require modification of the study, the FDA may permit a clinical trial to proceed
under a conditional approval. The FDA may also notify the sponsor that the study is approved as proposed or approved with specific requested
modification. Furthermore, the agency may withdraw approval of an IDE under certain circumstances. In addition, the study must be approved
by, and conducted under the oversight of, an institutional review board, or IRB, for each clinical site. If the device presents a non-significant
risk to the patient according to criteria established by the FDA as part of the IDE regulations, a sponsor may begin the clinical trial
after obtaining approval for the trial by one or more IRBs without separate authorization from the FDA, but must still comply with abbreviated
IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping
requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Post-Marketing
Restrictions and Enforcement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">After a device is placed
on the market, numerous regulatory requirements apply. These include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submitting
                                            and updating establishment registration and device listings with the FDA;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
                                            with the QSR, which requires manufacturers to follow stringent design, testing, control,
                                            documentation, record maintenance, including maintenance of complaint and related investigation
                                            files, and other quality assurance controls during the manufacturing process;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unannounced
                                            routine or for-cause device facility inspections by the FDA, which may include our suppliers&#8217;
                                            facilities;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">labeling
                                            regulations, which prohibit the promotion of products for uncleared or unapproved (or &#8220;off-label&#8221;)
                                            uses and impose other restrictions relating to promotional activities;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">corrections
                                            and removal reporting regulations, which require that manufacturers report to the FDA field
                                            corrections or removals if undertaken to reduce a risk to health posed by a device or to
                                            remedy a violation of the FDCA that may present a risk to health; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-market
                                            surveillance regulations, which apply to certain Class II or III devices when necessary to
                                            protect the public health or to provide additional safety and effectiveness data for the
                                            device.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition, under
the FDA medical device reporting, or MDR, regulations, medical device manufacturers are required to report to the FDA information that
a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or
contribute to death or serious injury if the malfunction of the device or a similar device of such manufacturer were to recur. The decision
to file an MDR involves a judgment by the manufacturer. If the FDA disagrees with the manufacturer&#8217;s determination, the FDA can
take enforcement action.</span></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The MDR
requirements also extend to health care facilities that use medical devices in providing care to patients, or &#8220;device user
facilities,&#8221; which include hospitals, ambulatory surgical facilities, nursing homes, outpatient diagnostic facilities, or
outpatient treatment facilities, but not physician offices. A device user facility must report any device-related death to both the
FDA and the device manufacturer, or any device-related serious injury to the manufacturer (or, if the manufacturer is unknown, to
the FDA) within 10 days of the event. Device user facilities are not required to report device malfunctions that would likely cause
or contribute to death or serious injury if the malfunction were to recur but may voluntarily report such malfunctions through
MedWatch, the FDA&#8217;s Safety Information and Adverse Event Reporting Program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The FDA also has the
authority to require the recall of commercialized medical device products in the event of material deficiencies or defects in design
or manufacture. The authority to require a recall must be based on an FDA finding that there is a reasonable probability that the device
would cause serious adverse health consequences or death. Manufacturers may, under their own initiative, recall a product if any distributed
devices fail to meet established specifications, are otherwise misbranded or adulterated under the Federal Food, Drug, and Cosmetic Act, or the FDCA, or if any other material deficiency
is found. The FDA requires that certain classifications of recalls be reported to the FDA within ten working days after the recall is
initiated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The failure to comply
with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
                                            letters, fines, injunctions or civil penalties;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls,
                                            detentions or seizures of products;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
                                            restrictions;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            in the introduction of products into the market;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">total
                                            or partial suspension of production;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
                                            or refusal of the FDA or other regulators to grant 510(k) clearance, PMA approvals, or other
                                            marketing authorization to new products;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawals
                                            of marketing authorizations; or</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the most serious cases, criminal prosecution.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To ensure compliance
with regulatory requirements, medical device manufacturers are subject to market surveillance and periodic, pre-scheduled and unannounced
inspections by the FDA, and these inspections may include the manufacturing facilities of subcontractors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Federal
Trade Commission Regulatory Oversight</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our advertising for
our products and services is subject to federal truth-in-advertising laws enforced by the Federal Trade Commission, or the FTC, as well
as comparable state consumer protection laws. Under the Federal Trade Commission Act, or FTC Act, the FTC is empowered, among other things,
to (a) prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b) seek monetary redress
and other relief for conduct injurious to consumers; and (c) gather and compile information and conduct investigations relating to the
organization, business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority, and
failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or judicial
penalties, including civil penalties, injunctions affecting the manner in which we would be able to market services or products in the
future, or criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Law and Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>United
States</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If our MODD1 product
candidate or our other future product candidates are approved in the United States, we will have to comply with various U.S. federal
and state laws, rules and regulations pertaining to healthcare fraud and abuse, including anti-kickback laws and physician self-referral
laws, rules and regulations. Violations of the fraud and abuse laws are punishable by criminal and civil sanctions, including, in some
instances, exclusion from participation in federal and state healthcare programs, including Medicare and Medicaid. These laws include
the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully
                                            soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash
                                            or in kind, to induce or reward either the referral of an individual for, or the purchase,
                                            order or recommendation of, any good or service, for which payment may be made, in whole
                                            or in part, under a federal healthcare program such as Medicare and Medicaid;</span></td></tr></table>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal False Claims Act imposes civil penalties, and provides for civil whistleblower or
                                            qui tam actions, against individuals or entities for knowingly presenting, or causing to
                                            be presented, to the federal government, claims for payment that are false or fraudulent
                                            or making a false statement to avoid, decrease or conceal an obligation to pay money to the
                                            federal government;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal
                                            and civil liability for executing a scheme to defraud any healthcare benefit program or making
                                            false statements relating to healthcare matters;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
                                            as amended by the Health Information Technology for Economic and Clinical Health Act and
                                            its implementing regulations, also imposes obligations, including mandatory contractual terms,
                                            with respect to safeguarding the privacy, security and transmission of individually identifiable
                                            health information;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal false statements statute prohibits knowingly and willfully falsifying, concealing
                                            or covering up a material fact or making any materially false statement in connection with
                                            the delivery of or payment for healthcare benefits, items or services;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal transparency requirements under the Physician Payments Sunshine Act require manufacturers
                                            of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid
                                            to report, on an annual basis, to the Department of Health and Human Services information
                                            related to payments and other transfers of value to physicians, teaching hospitals, and certain
                                            advanced non-physician health care practitioners and physician ownership and investment interests;
                                            and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
                                            state and foreign laws and regulations, such as state anti-kickback and false claims laws,
                                            may apply to sales or marketing arrangements and claims involving healthcare items or services
                                            reimbursed by nongovernmental third-party payors, including private insurers.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Some state laws require
pharmaceutical or medical device companies to comply with the relevant industry&#8217;s voluntary compliance guidelines and the relevant
compliance guidance promulgated by the federal government in addition to requiring drug and device manufacturers to report information
related to payments to physicians and other health care providers or marketing expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">State and foreign laws
also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant
ways and often are not preempted by HIPAA, thus complicating compliance efforts. We also may be subject to, or may in the future become
subject to, U.S. federal and state, and foreign laws and regulations imposing obligations on how we collect, use, disclose, store and
process personal information. Our actual or perceived failure to comply with such obligations could result in liability or reputational
harm and could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our customer
base and thereby decrease our future revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The European Union, or EU,
approves the use of medical devices in a very different way. They have similar regulations and requirements to adhere to, however a Notified
Body, in the form of a private company, will represent their interests and is required to have sufficient expertise to review all applications
and the company&#8217;s internal processes to ensure the safety of the product for which approval is being requested. We are in the process
of identifying a Notified Body to represent us, and we will follow our FDA submission process with regard to preparing the materials
and processes required to meet the regulations and gain clearance.</span></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>European
Union</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">European
Economic Area</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the European Economic
Area (which is comprised of the 27 member states of the European Union plus Norway, Iceland and Liechtenstein), or the EEA, manufacturers
of medical devices need to comply with the Essential Requirements laid out in Annex I to the EU Medical Devices Directive (Council Directive
93/42/EEC) or with the General Safety and Performance Requirements (GSPR) of the new EU Medical Devices Regulation (EU 2017/745). Compliance
with these requirements is a prerequisite to be able to affix the CE mark to medical devices, without which they cannot be marketed or
sold in the EEA. To demonstrate compliance with the Essential Requirements and the GSPR and obtain the right to affix the CE Mark, manufacturers
of medical devices must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification.
Except for low-risk medical devices (Class I with no measuring function and which are not sterile), where the manufacturer can issue
an EC Declaration of Conformity based on a self-assessment of the conformity of its products with the Essential Requirements and the
GSPR, a conformity assessment procedure requires the intervention of a Notified Body, which is an organization designated by a competent
authority of an EEA country to conduct conformity assessments. Depending on the relevant conformity assessment procedure, the Notified
Body would audit and examine the Technical File and the quality system for the manufacture, design and final inspection of the devices.
The Notified Body issues a CE Certificate of Conformity following successful completion of a conformity assessment procedure conducted
in relation to the medical device and its manufacturer and their conformity with the Essential Requirements and GSPR. This Certificate
entitles the manufacturer to affix the CE mark to its medical devices after having prepared and signed a related EC Declaration of Conformity.
As a general rule, demonstration of conformity of medical devices and their manufacturers with the Essential Requirements and GSPR must
be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal
conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions
of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits
of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All manufacturers placing
medical devices into the market in the EEA must comply with the EU Medical Device Vigilance System. Under this system, incidents must
be reported to the relevant authorities of the member states of the EEA, and manufacturers are required to take Field Safety Corrective
Actions, or FSCAs, to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device
that is already placed on the market. An incident is defined as any malfunction or deterioration in the characteristics and/or performance
of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might
have led to the death of a patient or user or of other persons or to a serious deterioration in their state of health. An FSCA may include
the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its
legal representative to its customers and/or to the end users of the device through Field Safety Notices. Where appropriate, our products
commercialized in Europe are CE marked and classified as either Class I or Class II.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In 2017, the European
Parliament passed the Medical Devices Regulation, which repeals and replaces the EU Medical Devices Directive. Unlike directives, which
must be implemented into the national laws of the EEA member states, the regulations would be directly applicable (i.e., without the
need for adoption of EEA member State laws implementing them) in all EEA member states and are intended to eliminate current differences
in the regulation of medical devices among EEA member States. The Medical Devices Regulation, among other things, is intended to establish
a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and in vitro diagnostic devices
and ensure a high level of safety and health while supporting innovation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Medical Device
Regulation was meant to become applicable three years after publication (in May 2020). However, in April 2020, to allow EEA national
authorities, notified bodies, manufacturers and other actors to focus fully on urgent priorities related to the COVID-19 pandemic, the
European Council and Parliament adopted Regulation 2020/561, postponing the date of application of the Medical Device Regulation by one
year. The Medical Device Regulation became applicable on May 26, 2021. Devices lawfully placed on the market pursuant to the EU Medical
Devices Directive prior to May 26, 2021 may generally continue to be made available on the market or put into service until May 26, 2025.
The Medical Devices Regulation, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthens
                                            the rules on placing devices on the market and reinforces surveillance once they are available;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishes
                                            explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality,
                                            performance and safety of devices placed on the market;</span></td></tr></table>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improves
                                            the traceability of medical devices throughout the supply chain to the end-user or patient
                                            through a unique identification number;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sets
                                            up a central database to provide patients, healthcare professionals and the public with comprehensive
                                            information on products available in the EU; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strengthens
                                            rules for the assessment of certain high-risk devices, such as implants, which may have to
                                            undergo an additional check by experts before they are placed on the market.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Today, in the United
States, only three companies are commercializing insulin pumps to type 1 diabetes patients and insulin treated type 2 diabetes patients:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medtronic
                                            - commercializes the durable Minimed 770G also offering older durable pumps still in use
                                            (e.g., the 670G, 630G etc.). In 2020, they held approximately 51% of the US insulin pump
                                            market.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tandem
                                            - commercializes the durable t:slim X2 pump (with or without algorithms - Basal-IQ and Control-IQ).
                                            In 2020, they held approximately 28% of the US insulin pump market.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insulet
                                            - commercializes the disposable Omnipod patch pump with about 19% of the US market in 2020.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Older insulin pumps
are also still being used by a minority of patients previously provided by Roche or Animas, though these pumps are not commercialized
any longer. To a lesser extent, the pumps described below are also used in small numbers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">These three insulin
pump offerings are vying for the attention of the most motivated and well insured in hope of converting them away from their reliance
on multi-day insulin injections. The t:slim X2 and Minimed 770G each have a ~$5,000 list price that is covered through Durable Medical
Equipment (DME) reimbursement; daily consumables and insulin are also required to complete these offerings. These products have controllers
integrated into the pump, making them cumbersome and bulky, along with long (&gt;20 inch) tubing between the pump and the cannular site.
The Omnipod is the third offering, a patch pump that attaches to the body for 72 hours and uses a separate controller to manage the insulin
delivery process. Insurance coverage can be provided via DME but also via Pharmacy Benefit (PB). The Omnipod patch pump is more expensive
per day and less accurate than other insulin pumps. Around 32% of people living with T1D are currently using insulin pumps; of these,
the vast majority are using one of these three offerings, a statistic that has not changed significantly over the last 5+ years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All of these pump products
require extensive training to initiate and two to four hours per day to use and manage on an ongoing basis. This level of sophistication
and effort along with the cost and awkwardness of these products contribute to the limited uptake.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Although there are
purely mechanical pumps available to patients with a small percentage of T2D patients are using the Zealand V-Go patch pump, a fixed
basal rate and a button to deliver small boluses. This pump is simple to use though gives little performance decision to the user (no
possibility to change the basal rate, no possibility to stop bolus doses, small reservoir, pump that needs to be changed every day, etc.).
The last available patch pump is provided by Cequr, called Simplicity, a bolus-only delivery option without basal delivery that is yet
to be available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the future, Medtronic
intends to launch a new version of their insulin pump, the Minimed 780G, already available in some European countries with an advanced
algorithm, but no obvious change in hardware. Tandem is currently developing a patch pump called t:sport, coupled with an algorithm with
potential launch expected in summer 2022. The t:sport should have a small 2mL reservoir and would be controlled by a separate unit as
is the current Omnipod. Insulet should launch in the coming quarters the Omnipod 5, a similar patch pump to their offering today, that
includes an algorithm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Approximately 71% of
the people who rely upon MDI choose to not administer a shot outside of their house, which creates a poorly controlled group. Our MODD1
product is designed to focus upon a segment of these people and mobilize them via a simple, easy to use, affordable product.</span></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our success depends
in part on our ability to obtain patents and trademarks, maintain trade secret and know-how protection, enforce our proprietary rights
against infringers, and operate without infringing on the proprietary rights of third parties. Because of the length of time and expense
associated with developing new products and bringing them through the regulatory approval process, the health care industry places considerable
emphasis on obtaining patent protection and maintaining trade secret protection for new technologies, products, processes, know-how,
and methods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of March 31, 2022,
we had one issued U.S. utility patent, five published U.S. utility patents, two pending foreign patent applications, and two pending
international PCT patent applications covering various aspects of our technology, including our proprietary fluid movement technology.
There can be no assurance that the pending patent applications will result in the issuance of patents, that patents issued to or licensed
by us will not be challenged or circumvented by competitors, or that these patents will be found to be valid or sufficiently broad to
protect our technology or provide us with a competitive advantage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our annual reports
on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to such reports filed or furnished pursuant
to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as well as section 16 reports on Form 3, 4, or 5, are available free
of charge on our website at www.modular-medical.com. as soon as it is reasonably practicable after they are filed or furnished with the
SEC. Our Code of Business Conduct and Ethics and the charters for the Audit Committee, Compensation Committee and Nominating and Governance
Committee are also available on our website. The Code of Business Conduct and charters are also available in print to any shareholder
upon request without charge. Requests for such documents should be directed to Corporate Secretary, at Modular Medical, Inc., 16772 W.
Bernardo Drive, San Diego CA 92127. Our Internet website and the information contained on it or connected to it are not part of, or incorporated
by, reference into this prospectus. Our filings with the SEC are also available on the SEC&#8217;s website at http://www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
History and Background</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We were formed as a
corporation under the laws of the State of Nevada in October 1998 under the name Bear Lake Recreation Inc. We had no material business
operations from 2002 until July 2017, when we acquired Quasuras, Inc., a Delaware corporation, in the Control Block Acquisition (as defined
below). Prior to the Control Block Acquisition, we were a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange
Act of 1934 (the &#8220;Exchange Act&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Control Block Acquisition.</i></b><i>&#160;</i></span><span style="font-size: 10pt">On April 26, 2017, pursuant to a Common Stock Purchase
Agreement, dated as of April 5, 2017, by and among Manchester Explorer, LP, a Delaware limited partnership, we and certain persons named
therein, Manchester Explorer, LP purchased from us 966,667 shares of our Common Stock representing in excess of a majority of our then
issued and outstanding Common Stock, for a purchase price of $375,000 (the &#8220;Control Block Acquisition&#8221;), resulting in a change
in control of the Company. In connection with the Control Block Acquisition, James E. Besser was appointed president and a director and
Morgan C. Frank was appointed the chief executive officer, chief financial officer, secretary, treasurer and a director of ours and immediately
following such appointments, our then officers and directors resigned. Mr. Besser is the managing member of and Mr. Frank is the portfolio
manager and a consultant to Manchester Management Company, LLC, a Delaware limited liability company also referred to herein as MMC.
MMC is the general partner of Manchester Explorer, LP and Jeb Partners, L.P. (Jeb Partners, and together with Manchester Explorer, LP,
collectively, the Purchasing Funds).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Acquisition. </i></b></span><span style="font-size: 10pt">On July 24, 2017, pursuant to a Reorganization and Share Exchange Agreement,
by and among us, Paul M. DiPerna, the sole officer, director and a controlling stockholder of Quasuras, Messrs. Besser and Frank (Messrs.
Besser, Frank and DiPerna, collectively, the &#8220;3 Quasuras Shareholders&#8221;), and Quasuras, Inc. (the &#8220;Share Exchange Agreement&#8221;),
we acquired all of the issued and outstanding shares of Quasuras, Inc. owned by the 3 Quasuras Shareholders, resulting in Quasuras, Inc.
becoming our wholly-owned subsidiary (the &#8220;Acquisition&#8221;). Simultaneously with the closing of the Acquisition, Manchester
Explorer, LP cancelled the 2,900,000 shares of our Common Stock purchased in the Control Block Acquisition, Mr. Besser resigned as our
president and a director and Mr. Frank resigned as our chief executive officer, chief financial officer, secretary, and treasurer, but
remained a director, and Mr. DiPerna was appointed our chairman of the board of directors, chief executive officer, chief financial officer,
president, secretary and treasurer. Mr. DiPerna served as our chief executive officer until August 2021 and as our secretary until October
2021.</span></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Quasuras, Inc., a Delaware
corporation, is our only subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of March&#160;31,
2022, we had 25 employees all of whom are located in the United States, consisting of 23 in research and development
and manufacturing operations and 2 in general and administrative functions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Properties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our corporate facility
is leased and located at 16772 West Bernardo Drive, San Diego, CA 92127. The 39-month lease term commenced April 1, 2020, and provides
for an initial monthly rent of approximately $12,400 with annual rent increases of approximately 3%. In addition to the minimum lease
payments, we are responsible for property taxes, insurance and certain other operating costs. We believe that our existing facility is
adequate to meet our current needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are a Nevada corporation.
Our corporate headquarters and operating facilities are located at 16772 West Bernardo Drive, San Diego, CA 92127 Our telephone number
is (858) 800-3500. We maintain a website at www.modular-medical.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Medtronic, Inc., Tandem
Diabetes Care, Inc. and Insulet Corporation are all much larger companies with substantially greater resources than us that make similar
products for the more sophisticated, technically capable person with diabetes.&#160; We do not intend to directly compete for those individuals
with diabetes, instead we intend to offer a simple to use more cost-effective solution to attract the more mainstream patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Smaller
Reporting Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are subject to the
reporting requirements of Section 13 of the Exchange Act and to the disclosure requirements of Regulation S-K of the SEC, as a &#8220;smaller
reporting company.&#8221; Such designation relieves us of some of the disclosure requirements of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara002"></span>ITEM
1A. RISK FACTORS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a developmental stage medical device company and have a history of significant operating losses; we expect to continue to incur operating
losses, and we may never achieve or maintain profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a development-stage
enterprise, we do not currently have revenues to generate cash flows to cover operating expenses. Since our inception, we have incurred
operating losses in each year due to costs incurred in connection with research and development activities and general and administrative
expenses associated with our operations. For the years ended March 31, 2022 and 2021, we incurred net losses of approximately $18.6 million
and $7.4 million, respectively. At March 31, 2022, we had an accumulated deficit of approximately $34.6 million. As a result, we will
need to raise additional capital in the future, which may or may not be available to us at all or only on unfavorable terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We expect to incur
losses for the foreseeable future, as we continue the development of, and seek regulatory clearance and approvals for, our insulin pump.
As our prototype insulin pump is currently our only product, if it fails to gain regulatory approval and market acceptance, we will not
be able to generate any revenue, or explore other opportunities to enhance shareholder value, such as through a sale. If we fail to generate
revenue and eventually become profitable, or if we are unable to fund our continuing losses, our shareholders could lose all or a substantial
part of their investment.</span></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
full effects of COVID-19 and other potential future public health crises, epidemics, pandemics or similar events are uncertain and could
have a material and adverse effect on our business, financial condition, operating results and cash flows.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The global outbreak
of the coronavirus disease 2019, or COVID-19, was declared a pandemic by the World Health Organization and a national emergency by the
U.S. government in March 2020. This has negatively affected the world economy, disrupted global supply chains, significantly restricted
travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221; and created significant disruption
of the financial markets. The extent of the impact on our operational and financial performance will depend on future developments, including
the duration and spread of the pandemic and related actions taken by&#160;&#160;U.S. and foreign&#160;government agencies to prevent
disease spread, all of which are uncertain, out of our control and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">We have been
complying with county and state orders and, until May 2021, had implemented a teleworking policy for our employees and contractors and
significantly minimized the number of employees who visit our office. However, a facility closure, work slowdowns or temporary stoppage
at one of our suppliers could occur, which could have a longer-term impact and could delay our prototype production and ability to conduct
business.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">If our workforce
is unable to work effectively, including because of illness, quarantines, absenteeism, government actions, facility closures, travel
restrictions or other restrictions in connection with the COVID-19 pandemic, our operations will be negatively impacted. We may be unable
to develop our product candidate, and our costs may increase as a result of the COVID-19 outbreak. The impacts could worsen if there
is an extended duration of any COVID-19 outbreak or a resurgence of COVID-19 infection in affected regions after they have begun to experience
improvement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">We rely on other
companies to provide components and to perform services for us. An extended period of supply chain disruption caused by the response
to COVID-19 could impact our ability to produce our initial product quantities, and, if we are not able to implement alternatives or
other mitigations, product deliveries would be adversely impacted and negatively impact our business, financial condition, operating
results and cash flows. Limitations on government operations can also impact regulatory approvals that are necessary for us to operate
our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The continued
spread of COVID-19 has also led to disruption and volatility in the global capital markets. We were recently able to raise additional
capital through equity offerings in February 2022 and May 2022, however, we will need to raise additional capital to support our operations
in the future. We may be unable to access the capital markets, and additional capital may only be available to us on terms that could
be significantly detrimental to our existing stockholders and to our business.&#160;</span></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need substantial additional funding to complete subsequent phases of our insulin pump product and to operate our business and such
funding may not be available or, if it is available, such financing is likely to substantially dilute our existing shareholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The discovery, development,
and commercialization of new medical devices, such as our insulin pump, entails significant costs. While we believe that we have generally
completed the engineering and mechanical aspects of our insulin pump prototype, we still must modify, refine and finalize our insulin
pump to, among other things, meet the general needs and preferences of the almost pumper marketplace and the guidelines of third-party
payors. To enable us to accomplish these and other related items and continue to operate our business, we will need to raise substantial
additional capital and/or enter into strategic partnerships or joint ventures to enable us to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fund
                                            clinical studies and seek regulatory approvals;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">build
                                            or access manufacturing and commercialization capabilities;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop,
                                            test, and, if approved, market our product candidate;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire
                                            or license additional internal systems and other infrastructure; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
                                            and support additional management, engineering and scientific personnel.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Until we can generate
a sufficient amount of product revenue to finance our cash requirements, which we may never achieve, we expect to finance our cash needs
primarily through public or private equity offerings, debt financings or through the establishment of possible strategic alliances. We
may in the future seek additional capital from public or private offerings of our capital stock or borrow additional amounts under new
credit lines or from other sources. If we issue equity or debt securities to raise additional funds, our existing stockholders may experience
dilution, we may incur significant financing costs, and the new equity or debt securities may have rights, preferences and privileges
senior to those of our existing stockholders. In addition, if we raise additional funds through collaborations, licensing, joint ventures,
strategic alliances, partnership arrangements or other similar arrangements, it may be necessary to relinquish valuable rights to our
potential future products or proprietary technologies or grant licenses on terms that are not favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We cannot be certain
that additional funding will be available on acceptable terms, or at all. If we are not able to secure additional equity funding when
needed, we may have to delay, reduce the scope of, or eliminate one or more of our clinical studies, development programs or future commercialization
initiatives. In addition, any additional equity funding that we do obtain will dilute the ownership held by our existing equity holders.
The amount of this dilution may be substantially increased if the trading price of our common stock is lower at the time of any financing.
Regardless, the economic dilution to shareholders will be significant if our stock price does not increase significantly, or if the effective
price of any sale is below the price paid by a particular shareholder. Any debt financing that we obtain in the future could involve
substantial restrictions on activities and creditors could seek a pledge of some or all of our assets. We have not identified potential
sources for such financing that we will require, and we do not have commitments from any third parties to provide any future debt financing.
If we fail to obtain funding as needed, we may be forced to cease or scale back operations, and our results, financial condition and
stock price would be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history and historical financial information upon which you may evaluate our performance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">You should consider,
among other factors, our prospects for success in light of the risks and uncertainties encountered by companies that, like us, are in
their early stages of development. We may not successfully address these risks and uncertainties or successfully complete our studies
and/or implement our existing and new products. If we fail to do so, it could materially harm our business and impair the value of our
common stock. Unanticipated problems, expenses and delays are frequently encountered in establishing a new business, conducting research,
and developing new products. These include, but are not limited to, inadequate funding, failure to obtain regulatory approval, unforeseen
research issues, lack of consumer acceptance, competition, sluggish product development, and inadequate sales and marketing. The failure
by us to meet any of these conditions would have a materially adverse effect upon us and may force us to reduce or curtail operations.
No assurance can be given that we can or will ever operate profitably.</span></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
amount of financing we require will depend on a number of factors, many of which are beyond our control. Our results of operations, financial
condition and stock price are likely to be adversely affected if our funding requirements increase or are otherwise greater than we expect.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our future funding
requirements will depend on many factors, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            testing costs for our insulin pump product and other development activities conducted by
                                            us directly, and our ability to successfully conclude the studies and activities and achieve
                                            favorable results;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to attract future strategic partners to pay for or share costs related to our product
                                            development efforts;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs and timing of seeking and obtaining regulatory clearance and approvals for our product
                                            candidate;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of filing, prosecuting, maintaining and enforcing any patents and other intellectual
                                            property rights that we may have and defending against potential claims of infringement;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decisions
                                            to hire additional scientific, engineering or administrative personnel or consultants;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to manage administrative and other costs of our operations; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            presence or absence of adverse developments in our research program.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If any of these factors
cause our funding needs to be greater than expected, our operations, financial condition, ability to continue operations and stock price
may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future cash requirements may differ significantly from our current estimates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our cash requirements
may differ significantly from our estimates from time to time, depending on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs and results of our clinical studies regarding our insulin pump product candidate;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            time and costs involved in obtaining regulatory clearance and approvals;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            we are able to obtain funding under future licensing agreements, strategic partnerships,
                                            or other collaborative relationships, if any;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of compliance with laws, regulations, or judicial decisions applicable to us; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of general and administrative infrastructure required to manage our business and protect
                                            corporate assets and shareholder interests.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If we fail to raise
additional funds on a timely basis, we will need to scale back our business plans, which would adversely affect our business, financial
condition, and stock price, and we may even be forced to discontinue our operations and liquidate our assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Technological
breakthroughs in diabetes monitoring, treatment or prevention could render our insulin pump obsolete.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The diabetes treatment
market is subject to rapid technological change and product innovation. Our insulin pump is based on our proprietary technology, but
a number of companies, medical researchers and existing pharmaceutical companies are pursuing new delivery devices, delivery technologies,
sensing technologies, procedures, drugs and other therapeutics for the monitoring, treatment and/or prevention of insulin-dependent diabetes.
Any technological breakthroughs in diabetes monitoring, treatment or prevention could render our insulin pump obsolete, which, since
our insulin pump is our only product, would have a material adverse effect on our business, financial condition and results of operations
and could result in shareholders losing their entire investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
failure to attract and retain skilled directors, executives, employees and consultants could impair our product development and commercialization
activities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our business depends
on the skills, performance, and dedication of our directors, executive officers and key engineering, scientific and technical advisors.
Many of our current engineering or scientific advisors are independent contractors and are either self-employed or employed by other
organizations. As a result, they may have conflicts of interest or other commitments, such as consulting or advisory contracts with other
organizations, which may affect their ability to provide services to us in a timely manner. We will need to recruit additional directors,
executive management employees, and advisers, particularly engineering, scientific and technical personnel, which will require additional
financial resources. In addition, there is currently intense competition for skilled directors, executives and employees with relevant
engineering, scientific and technical expertise, and this competition is likely to continue. If we are unable to attract and retain persons
with sufficient engineering, scientific, technical and managerial experience, we may be forced to limit or delay our product development
activities or may experience difficulties in successfully conducting our business, which would adversely affect our operations and financial
condition.</span></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited internal research and development personnel, making us dependent on consulting relationships.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We consider research
and development to be an important part of the process of designing, developing, obtaining regulatory required approvals and the eventual
commercialization of our insulin pump. We continue to incur increased research and development expenditures, which are attributable to
effort and expenses incurred in designing and developing our innovative insulin pump. We expect to continue to incur substantial costs
related to research and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to outsource and rely on third parties for various aspects relating to the development, manufacture, sales and marketing of
our insulin pump as well as in connection with assisting us in the preparation and filing of our FDA submission, and our future success
will be dependent on the timeliness and effectiveness of the efforts of these third parties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are dependent on
consultants for important aspects of our product development strategy. We do not have the required financial resources and personnel
to carry out independently the development of our product candidate, and do not have the capability or resources to manufacture, market
or sell our current product candidate. As a result, we contract with and rely on third parties for important functions, including in
connection with the development and finalization of our insulin pump, the preparation and filing of our FDA submission and eventual manufacturing
and commercialization of our product candidate. We have recently entered into several agreements with third parties for such services.
If problems develop in our relationships with third parties, or if such parties fail to perform as expected, it could lead to delays
or lack of progress in obtaining FDA clearance, significant cost increases, changes in our strategies, and even failure of our product
initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to identify, negotiate and maintain the strategic alliances necessary to develop and commercialize our products and technologies,
and we will be dependent on our corporate partners if we do.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We may seek to enter
into a strategic alliance with a diabetes related service providing company for the further development and approval of our insulin pump
product candidate. At this time, we have not entered into any such strategic alliance. Strategic alliances, if entered into, could potentially
provide us with additional funds, expertise, access, and other resources in exchange for exclusive or non-exclusive licenses or other
rights to the product that we are currently developing or a product we may explore in the future. We cannot give any assurance that we
will be able to enter into strategic relationships with a diabetes related service providing company or others in the near future or
at all. In addition, we cannot assure you that any agreements that we do reach will achieve our goals or be on terms that prove to be
economically beneficial to us. When we do enter into strategic or contractual relationships, we become dependent on the successful performance
of our partners or counter-parties. If they fail to perform as expected, such failure could adversely affect our financial condition,
lead to increases in our capital needs, or hinder or delay our development efforts. &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not receive the necessary regulatory clearance or approvals for our insulin pump, and failure to timely obtain necessary clearances
and/or approvals could harm our then operations, including our ability to commercialize our product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Before we can market
a new medical device, such as our insulin pump, we must first receive clearance under Section 510(k) of the Federal Food, Drug, and Cosmetic
Act, or the FDCA. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that such proposed device
is &#8220;substantially equivalent&#8221; to a legally-marketed &#8220;predicate&#8221; device, which includes a device that has been
previously cleared through the 510(k) process, a device that was legally marketed prior to May 28, 1976 (pre-amendments device), a device
that was originally on the U.S. market pursuant to an approved pre-market approval (PMA) and later down-classified, or a 510(k)-exempt
device. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and
either have the same technological characteristics as the predicate device or have different technological characteristics and not raise
different questions of safety or effectiveness than the predicate device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Certain future modifications
made to our product, which we currently expect to be cleared through 510(k), may require a new 510(k) clearance. The 510(k) clearance
process can be expensive, lengthy and uncertain. The FDA&#8217;s 510(k) clearance process usually takes from three to 12 months, but
can last longer. Despite the time, effort and cost, a device may not be approved or cleared by the FDA. Any delay or failure to obtain
necessary regulatory authorizations could harm our business, including our ability to commercialize our product candidate and our shareholders
could lose their entire investment. Furthermore, even if we are granted the required regulatory authorizations, such authorizations may
be subject to significant limitations on the indicated uses for the device, which may limit the market for our product candidate.</span></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the FDA requires
us to go through a lengthier, more rigorous examination for our product candidate than we had expected, product introductions or modifications
could be delayed or canceled, which could adversely affect our ability to grow our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The FDA can delay,
limit or deny clearance or approval for our insulin pump medical device for many reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            inability to demonstrate to the satisfaction of the FDA that our product candidate is substantially
                                            equivalent to the proposed predicate device;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            disagreement of the FDA with the design or implementation of our performance testing protocols
                                            or the interpretation of data from our performance testing;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            data from performance testing may be insufficient to support a determination of substantial
                                            equivalence or that our device meets required special controls or applicable performance
                                            standards;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            inability to demonstrate that the benefits of our pump outweigh the risks;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            manufacturing process or facilities we intend to use may not meet applicable requirements;
                                            and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            potential for approval policies or regulations of the FDA to change significantly in a manner
                                            rendering our data or regulatory filings insufficient for clearance or approval.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition, the FDA
may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which
may prevent or delay approval or clearance of our product candidate or impact our ability to modify our product candidate after clearance
on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain
clearance for our pump, increase the costs of compliance or restrict our ability to maintain our current approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a general rule,
demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based, among other things,
on the evaluation of data supporting the safety and performance of the product candidates during normal conditions of use. Specifically,
a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and
foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance,
and that any claims made about the performance and safety of the device are supported by suitable evidence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
marketing authorization in the United States will not obviate the need to obtain marketing authorization in other jurisdictions We must
obtain approval from foreign regulatory authorities before we can market and sell any of our product candidates in countries outside
the United States. We will incur additional costs in seeking such approvals, may experience delays in obtaining such approvals and cannot
be certain that such approvals will be granted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The development, manufacture,
and marketing of our product candidates outside the United States is subject to government regulation. In most foreign countries, we
must complete rigorous pre-clinical testing and extensive human clinical trials that demonstrate the safety and efficacy of a product
in order to apply for regulatory approval to market the product. If foreign regulatory authorities grant regulatory approval of a product,
the approval may be limited to specific indications or limited with respect to its distribution. Expanded or additional indications for
approved devices may not be approved, which could limit our potential revenues. Foreign regulatory authorities may refuse to grant any
approval. Consequently, even if we believe that pre-clinical and clinical data are sufficient to support regulatory approval for our
products, foreign regulatory authorities may not ultimately grant approval for commercial sale in any jurisdiction. If our product candidates
are not approved in such jurisdictions, our ability to generate revenues will be limited and our business will be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
competitors may develop products that are more effective, safer and less expensive than ours.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Existing insulin pumps
are expensive, with the more popular models having purchase prices exceeding $4,000 for individuals without health insurance and often
require significant patient copays. Others have daily use costs that exceed the reimbursement rates of many health insurance plans, forcing
some users to spend thousands of dollars a year in copays. We believe this makes insurers hesitant to pay for any pumps and places pumps
out of reach for many patients whom cannot afford such out of pocket expenses.</span></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are engaged in the
diabetes treatment sector of the healthcare marketplace, which is intensely competitive. There are current products that are quite effective
at addressing the effects of diabetes, and we expect that new developments by other companies and academic institutions in the areas
of diabetes treatment will continue. If approved for marketing by the FDA, depending on the approved clinical indication, our product
will be competing with existing and future products related to treatments for diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our competitors may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
                                            product candidates and market products that increase the levels of safety or efficacy that
                                            our product candidates will need to show in order to obtain regulatory approval;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
                                            product candidates and market products that are less expensive or more effective than ours;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercialize
                                            competing products before we can launch any products we are working to develop;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hold
                                            or obtain proprietary rights that could prevent us from commercializing our products; or</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduce
                                            therapies or market medical products that render our potential product candidates obsolete.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">We expect to
compete against large medical device companies, such as Medtronic, Inc., Tandem Diabetes Care, Inc. and Insulet Corporation and smaller
companies that are collaborating with larger medical device companies, new companies, academic institutions, government agencies and
other public and private research organizations. These competitors, in nearly all cases, produce similar products relative to the treatment
of diabetes that have substantially greater financial resources than we do. Our competitors also have significantly greater experience
in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
                                            medical device and other product candidates;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">undertaking
                                            testing and clinical studies;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">building
                                            relationships with key customers and opinion-leading physicians;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            and maintaining FDA and other regulatory approvals;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">formulating
                                            and manufacturing medical devices;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching,
                                            marketing and selling medical devices; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing
                                            management oversight for all of the above-listed operational functions.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If we fail to achieve
superiority over other existing or newly developed products, we may be unable to obtain regulatory approval. If our competitors&#8217;
market medical devices that are less expensive, safer or more effective than our insulin pump, or that gain or maintain greater market
acceptance, we may not be able to compete effectively. See &#8220;Our Business &#8211; Competition&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to rely on third-party manufacturers and will be dependent on their quality and effectiveness.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our insulin pump requires
precise, high-quality manufacturing. The failure to achieve and maintain high manufacturing standards, including failure to detect or
control anticipated or unanticipated manufacturing errors or the frequent occurrence of such errors, could result in patient injury or
death, discontinuance or delay of ongoing or planned clinical studies, delays or failures in product testing or delivery, cost overruns,
product recalls or withdrawals and other problems that could seriously hurt our business. Contract medical device manufacturers often
encounter difficulties involving production yields, quality control and quality assurance and shortages of qualified personnel. These
manufacturers are subject to stringent regulatory requirements, including the FDA&#8217;s current good-manufacturing-practices regulations.
If our contract manufacturers fail to maintain ongoing compliance at any time, the production of our product could be interrupted, resulting
in delays or discontinuance of our clinical studies, additional costs and loss of potential revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to successfully scale-up manufacturing of our product candidate in sufficient quality and quantity, which would delay
or prevent us from developing our product candidate and commercializing our product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In order to conduct
larger-scale or late-stage clinical studies and for commercialization of our insulin pump, if 510(k) clearance is granted, we will need
to manufacture it in larger quantities. We may not be able to successfully increase the manufacturing capacity for our product in a timely
or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we are unable to successfully
scale up the manufacture of our product in sufficient quality and quantity, the development and testing of our product candidate and
regulatory approval or commercial launch may be delayed, which could significantly harm our business.</span></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to potential product liability and other claims that could materially impact our business and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The development and
sale of our insulin pump exposes us to the risk of significant damages from product liability and other claims, and the use of our product
candidate in clinical studies may result in adverse effects. We cannot predict all the possible harms or adverse effects that may result.
We maintain a modest amount of product liability insurance to provide some protection from claims. Nonetheless, we may not have sufficient
resources to pay for any liabilities resulting from a personal injury or other claim, even if it is partially covered by insurance. In
addition to the possibility of direct claims, we may be required to indemnify third parties against damages and other liabilities arising
out of our development, commercialization and other business activities, which would increase our liability exposure. If third parties
that have agreed to indemnify us fail to do so, we may be held responsible for those damages and other liabilities as well.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legislative,
regulatory, or medical cost reimbursement changes may adversely impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">New laws, regulations
and judicial decisions, or new interpretations of existing laws, regulations and decisions, that relate to the health care system in
the U.S. and in other jurisdictions may change the nature of and regulatory requirements relating to innovations in medical devices,
testing and regulatory approvals, limit or eliminate payments for medical procedures and treatments, or subject the pricing of medical
devices to government control. In addition, third-party payors in the U.S. are increasingly attempting to contain health care costs by
limiting both coverage and the level of reimbursement of new products. Consequently, significant uncertainty exists as to the reimbursement
status of newly approved health care products. Significant changes in the health care system in the U.S. or elsewhere, including changes
resulting from adverse trends in third-party reimbursement programs, could have a material adverse effect on our projected future operating
results and our ability to raise capital, commercialize products, and remain in business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to extensive regulation by the FDA, which could restrict the sales and marketing of our insulin pump and could cause us to
incur significant costs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our insulin pump is
subject to extensive regulation by the FDA. These regulations relate to manufacturing, labeling, sale, promotion, distribution and shipping.
Before a new medical device, or a new intended use of a legally marketed device, can be marketed in the United States, it must be cleared
or approved by FDA through the applicable premarket review process (510(k), PMA, or <span style="font-family: Times New Roman, Times, Serif"><i>de
novo</i></span> classification), unless an exemption applies. If we receive 510(k) clearance for our insulin pump, we may be required
to obtain a new 510(k) clearance for significant post-market modifications to the pump. Each premarket submission and review process
can be expensive and lengthy, and entail significant user fees, unless exempt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Medical devices may
be marketed only for the indications for which they are approved or cleared. Further, 510(k) clearances can be revoked if safety or effectiveness
problems develop once the device is on the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The current regulatory
requirements to which we are subject may change in the future in a way that adversely affects us. If we fail to comply with present or
future regulatory requirements that are applicable to us, we may be subject to enforcement action by the FDA, which may include any of
the following sanctions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled
                                            letters, warning letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer
                                            notification, or orders for repair, replacement or refunds</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary
                                            or mandatory recall or seizure of our current or future products;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administrative
                                            detention by the FDA of medical devices believed to be adulterated or misbranded;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposing
                                            operating restrictions, suspension or shutdown of production;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing
                                            our requests for 510(k) clearance, PMA, or <i>de </i>novo classification any new products,
                                            new intended uses or modifications to our insulin pump;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">rescinding
                                            510(k) clearance that has already been granted; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
                                            prosecution.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The occurrence of any
of these events would have a material adverse effect on our business, financial condition and results of operations and could result
in shareholders losing their entire investment.</span></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Although
our system does not presently require clinical trials to apply to the FDA for clearance and even if a clinical trial is completed, the
results of our clinical testing may not demonstrate the safety and efficacy of the device or may be equivocal or otherwise not be sufficient
for us to obtain approval of our product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Clinical trials are
almost always required to support a PMA application and may also be required to support 510(k) submissions although at this time ours
does not require a PMA. If the device presents a &#8220;significant risk&#8221; to human health as defined by the FDA, the FDA requires
the study sponsor to submit an investigational device exemption (&#8220;IDE&#8221;) application and obtain IDE approval prior to commencing
human clinical trials. The IDE must be supported by appropriate data, such as animal and laboratory testing results, showing that it
is safe to test the device in humans and that the testing protocol is scientifically sound. An IDE will automatically become effective
30 days after receipt by the FDA, unless the FDA denies the application or notifies the sponsor that the investigation is on hold and
may not begin until the sponsor provides supplemental information about the investigation that satisfies the agency&#8217;s concerns.
The FDA may also notify the sponsor that the study is approved as proposed. If the FDA determines that there are deficiencies or other
concerns with an IDE that require modification of the study, the FDA may permit a clinical trial to proceed under a conditional approval.
Furthermore, the agency may withdraw approval of an IDE under certain circumstances. Clinical trials for a significant risk device may
begin once an IDE is approved by the FDA and the appropriate Institutional Review Board (&#8220;IRB&#8221;) at each clinical trial site.
If the product is deemed a &#8220;non-significant risk&#8221; device, IDE approval from the FDA would not be required, but the clinical
trial would need to meet other requirements including IRB approval. Our clinical trials must be conducted in accordance with FDA regulations
and federal and state regulations concerning human subject protection, including informed consent and healthcare privacy. A clinical
trial may be suspended by the FDA or at a specific site by the relevant IRB at any time for various reasons, including a determination
that the risks to the trial participants outweigh the benefits of participation in the clinical trial. Even if a clinical trial is completed,
the results of our clinical testing may not demonstrate the safety and efficacy of the device or may be equivocal or otherwise not be
sufficient for us to obtain approval of our product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success depends substantially upon our ability to obtain and maintain intellectual property protection relating to our product and research
technologies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have applied to
the U.S. Patent and Trademark Office for patents on our proprietary fluid movement technology and the configuration of our insulin pump.
There is no assurance that these patents will be issued, and no assurance that they will prevent other companies from competing with
us. We will continue to attempt to patent our innovations as appropriate to help ensure a sustainable competitive advantage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to evolving legal
standards relating to the patentability, validity and enforceability of patents covering health care product inventions, our ability
to enforce our existing patents and to obtain and enforce patents that may issue from any pending or future patent applications is uncertain
and involves complex legal, scientific and factual questions. To date, no consistent policy has emerged regarding the breadth of claims
allowed in medical device patents. Thus, we cannot be sure that any patents will issue from any pending or future patent applications
owned by or licensed to us. Even if patents do issue, we cannot be sure that the claims of these patents will be held valid or enforceable
by a court of law, will provide us with any significant protection against competing products, or will afford us a commercial advantage
over competitive products. If, at some point in the future, one or more products resulting from our product candidates is approved for
sale by the FDA and we do not have adequate intellectual property protection for those products, competitors could duplicate them for
approval and sale in the United States without repeating the extensive testing required of us to obtain FDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are sued for infringing on third-party intellectual property rights, it will be costly and time-consuming, and an unfavorable outcome
would have a significant adverse effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our ability to commercialize
our product candidate depends on our ability to use, manufacture and sell our product candidate without infringing the patents or other
proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties
exist in the diabetes medical device area. There may be existing patents, unknown to us, on which our activities with our insulin pump
candidate could infringe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If a third-party claims
that our actions infringe on its patents or other proprietary rights, we could face a number of issues that could seriously harm our
competitive position, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">infringement
                                            and other intellectual property claims that, even if meritless, can be costly and time-consuming,
                                            delay the regulatory approval process and divert management&#8217;s attention from our core
                                            business operations;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
                                            damages for infringement, including consequential damages for lost of profits or market share,
                                            if a court determines that our products or technologies infringe on a third party&#8217;s
                                            patent or other proprietary rights;</span></td></tr></table>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            court prohibiting us from selling or licensing our products or technologies unless the holder
                                            licenses the patent or other proprietary rights to us, which it is not required to do; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even
                                            if a license is available from a holder, we may have to pay substantial royalties or grant
                                            cross-licenses to our patents or other proprietary rights.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If any of these events
occur, it could significantly harm our operations and financial condition and negatively affect our stock price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely
affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition to patented
technology, we rely on our unpatented technology, trade secrets and know-how. We generally seek to protect this information by confidentiality,
non-disclosure and assignment of invention agreements with our officers, employees, contractors and other service providers and with
parties with which we do business. These agreements may be breached, which breach may result in the misappropriation of such information,
and we may not have adequate remedies for any such breach. We cannot be certain that the steps we have taken will prevent unauthorized
use or reverse engineering of our technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Moreover, our trade
secrets may be disclosed to or otherwise become known or be independently developed by competitors. To the extent that our officers,
employees, contractors, other service providers, or other third parties with whom we do business use intellectual property owned by others
in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. If, for any of the above reasons,
our intellectual property is disclosed or misappropriated, it would harm our ability to protect our rights and have a material adverse
effect on our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights do not necessarily address all potential threats to our competitive advantage.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The degree of future
protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not
adequately protect our business, or permit us to gain and maintain a competitive advantage. The following examples are illustrative:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
                                            may be able to make devices that are similar to our insulin pump but that are not covered
                                            by the claims of the patents that we own;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            or any collaborators might not have been the first to make the inventions covered by the
                                            issued patents or pending patent applications that we own;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            might not have been the first to file patent applications covering certain of our inventions;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
                                            may independently develop similar or alternative technologies or duplicate any of our technologies
                                            without infringing our intellectual property rights;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
                                            is possible that our pending patent applications will not lead to issued patents;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued
                                            patents that we own may not provide us with any competitive advantages, or may be held invalid
                                            or unenforceable as a result of legal challenges;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            competitors might conduct research and development activities in the U.S. and other countries
                                            that provide a safe harbor from patent infringement claims for certain research and development
                                            activities, as well as in countries where we do not have patent rights, and then use the
                                            information learned from such activities to develop competitive products for sale in our
                                            major commercial markets; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may not develop additional proprietary technologies that are patentable.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
reform laws could adversely affect our product candidate and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the United States,
there have been, and continue to be, a number of legislative initiatives to contain healthcare costs. In March 2010, the Patient Protection
and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (ACA), was enacted in the United
States, which made a number of substantial changes in the way healthcare is financed by both governmental and private insurers. Among
other ways in which it may affect our business, the ACA implemented payment system reforms, including a national pilot program on payment
bundling to encourage hospitals, physicians, and other providers to improve the coordination, quality, and efficiency of certain healthcare
services through bundled payment models and expanded the eligibility criteria for Medicaid programs.</span></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Since its enactment,
there have been judicial, executive, and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court
dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the
Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021
through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed
certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among
others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary
barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures
of the Biden administration or other efforts, if any, to challenge, repeal, or replace the ACA will impact the ACA or our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition, other
legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed
into law, which, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April 1, 2013 and, due
to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension
implemented under various COVID-19 relief legislation from May 1, 2020 through the end of 2021, unless additional Congressional action
is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced
Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover
overpayments to providers from three to five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Further, the Bipartisan
Budget Act of 2018 among other things, amended the Medicare statute, effective January 1, 2019, to reduce the coverage gap in most Medicare
drug plans, commonly known as the &#8220;donut hole,&#8221; by raising the manufacturer discount under the Medicare Part D coverage gap
discount program to 70%. It is unclear how the ACA and its implementation, as well as efforts to repeal or replace, or invalidate, the
ACA, or portions thereof, will affect our insulin pump or our business. Additional legislative changes, regulatory changes, and judicial
challenges related to the ACA remain possible. It is possible that the ACA, as currently enacted or as it may be amended in the future,
and other healthcare reform measures that may be adopted in the future, could have an adverse effect on our industry generally and on
our ability to commercialize our insulin pump and achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we are able to obtain all regulatory approvals and have completed all other steps needed to be taken to commercialize our insulin
pump, if we or any contract manufacturers we select fails to comply with the FDA&#8217;s quality system regulations, the manufacturing
and distribution of our product candidate could be interrupted, and our product sales and operating results could suffer.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">A material step in
the process of the commercialization of our product candidate will involve selecting a manufacturer or manufacturers for our pump. We
and any future contract manufacturers of our insulin pump will be required to comply with the FDA&#8217;s quality system regulations,
which impose a complex regulatory framework that covers the procedures and documentation of the design, testing, production, control,
quality assurance, labeling, packaging, sterilization, storage and shipping of medical devices. The FDA enforces its quality system regulations
through periodic unannounced inspections. We cannot assure you that, in the future, any manufacturing facilities owned by us or any contract
manufacturer will pass any quality system inspection. In the event that our or any contract manufacturer&#8217;s facilities fails a quality
system inspection, the manufacturing or distribution of our product candidate could be interrupted and our operations disrupted. Failure
to take adequate and timely corrective action in response to an adverse quality system inspection could force a suspension or shutdown
of any packaging and labeling operations or then manufacturing operations of any contract manufacturers, or a recall of our insulin pump.
If any of these events were to occur, we at such time would not be able to provide our customers with the quantity of insulin pumps that
they require on a timely basis, our reputation could be harmed and we could lose any customers we then have, any or all of which could
have a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may undertake infringement or other legal proceedings against third parties, causing us to spend substantial resources on litigation
and exposing our own intellectual property portfolio to challenge.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We may come to believe
that third parties are infringing on our patents or other proprietary rights. To prevent infringement or unauthorized use, we may need
to file infringement and/or misappropriation suits, which are very expensive and time-consuming, could result in meritorious counterclaims
against us and would distract management&#8217;s attention. Also, in an infringement or misappropriation proceeding, a court may decide
that one or more of our patents is invalid, unenforceable, or both, in which case third parties may be able to use our technology without
paying license fees or royalties. Even if the validity of our patents is upheld, a court may refuse to stop the other party from using
the technology at issue on the grounds that the other party&#8217;s activities are not covered by our patents. See &#8220;Our Business
&#8211; Patents,&#8221; below.</span></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may become involved in disputes with our present or future contract partners over intellectual property ownership or other matters, which
would have a significant effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Inventions discovered
in the course of performance of contracts with third parties or contractors may become jointly owned by such third party contractors
and us, in some cases, and the exclusive property of one of us, in other cases. Under some circumstances, it may be difficult to determine
who owns a particular invention or whether it is jointly owned, and disputes could arise regarding ownership or use of those inventions
or jointly developed improvements thereto. Other disputes may also arise relating to the performance or alleged breach of our agreements
with third parties. Any disputes could be costly and time-consuming, and an unfavorable outcome could have a significant adverse effect
on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Assuming
our insulin pump receives FDA clearance or approval, our insulin pump will still be subject to recalls, which would harm our reputation,
business operations and financial results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Even assuming we obtain
FDA approval or clearance with regard to our insulin pump, the FDA has the authority to require the recall of our pump if we commence
manufacturing of our insulin pump and we or any contract manufacturers we retain fail to comply with relevant regulations pertaining
to manufacturing practices, labeling, advertising or promotional activities, or if new information is obtained concerning the safety
or efficacy of the device. A government-mandated recall could occur if the FDA finds that there is a reasonable probability that our
device would cause serious, adverse health consequences or death. A voluntary recall by us could occur as a result of manufacturing defects,
labeling deficiencies, packaging defects or other failures to comply with applicable regulations. Any recall would divert management&#8217;s
attention and financial resources and harm our reputation with customers. A recall involving our insulin pump would be particularly harmful
to our business, financial condition and results of operations because it is currently our only product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
disruption and/or instability in economic conditions and capital markets could adversely affect our ability to access the capital markets,
and thus adversely affect our business and liquidity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Negative economic conditions
and issues with regard to the financial markets, could have a negative impact on our ability to access the capital markets, and thus
have a negative impact on our then operations and liquidity. A general shortage of liquidity and credit combined with the substantial
losses in worldwide equity markets could lead to an extended worldwide recession in the future. If such occurred, we would face significant
challenges if conditions in the capital markets did not improve. Our ability to access the capital markets under such circumstances could
be severely restricted at a time when we need to access such markets, which could have a negative impact on our business plans. Even
if we are able to raise capital under such circumstances, it may not be at a price or on terms that are favorable to us. We cannot predict
the occurrence of future disruptions or how long such negative conditions might continue.</span></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
our current insulin pump prototype is still in the development stage, it does not have reimbursement and is not approved for insurance
coverage. If in the future we are approved for and are otherwise able to commercialize our insulin pump, but are unable to obtain adequate
reimbursement or insurance coverage for such product from third-party payors, we will be unable to generate significant revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Because our current
insulin pump prototype is still in the development stage, it does not have reimbursement and is not approved for insurance coverage.
The future availability of insurance coverage and reimbursement for newly approved medical devices is highly uncertain. In the United
States, patients using insulin pumps are generally reimbursed for all or part of the product cost by Medicare or other third-party payors.
Any future commercial success of our insulin pump will be substantially dependent on whether third-party coverage and reimbursement is
available for future customers. Medicare, Medicaid, health maintenance organizations and other third-party payors are increasingly attempting
to contain healthcare costs by limiting both coverage and the level of reimbursement of new medical devices, and, as a result, they may
not cover or provide adequate reimbursement for our insulin pump, assuming we are able to fully develop and obtain all regulatory approval
to market it in the United States. In addition, in certain countries, no uniform policy of coverage and reimbursement for medical device
products and services exists among third-party payors. Therefore, coverage and reimbursement for medical device products and services
can differ significantly from payor to payor. In addition, payors continually review new technologies for possible coverage and can,
without notice, deny coverage for these new products and procedures. As a result, the coverage determination process is often a time-consuming
and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately,
with no assurance that coverage and adequate reimbursement will be obtained, or maintained if obtained. Reimbursement systems in international
markets vary significantly by country and by region within some countries, and reimbursement approvals must be obtained on a country-by-country
basis. In many international markets, a product must be approved for reimbursement before it can be approved for sale in that country.
Further, many international markets have government-managed healthcare systems that control reimbursement for new devices and procedures.
Accordingly, unless government and other third-party payors provide coverage and reimbursement for our insulin pump, patients may not
use it, which would cause investors to lose their entire investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to the oversight of the SEC and other regulatory agencies. Investigations by those agencies could divert management&#8217;s
focus and could have a material adverse effect on our reputation and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are subject to the
regulation and oversight of the SEC and state regulatory agencies, in addition to the FDA. As a result, we may face legal or administrative
proceedings by these agencies. We are unable to predict the effect of any investigations on our business, financial condition or reputation.
In addition, publicity surrounding any investigation, even if ultimately resolved in our favor, could have a material adverse effect
on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a &#8220;smaller reporting company&#8221; and, as a result of the reduced disclosure and governance requirements applicable to smaller
reporting companies, our Common Stock may be less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are a &#8220;smaller
reporting company,&#8221; and are subject to lesser disclosure obligations in our SEC filings compared to other issuers. Specifically,
&#8220;smaller reporting companies&#8221; are able to provide simplified executive compensation disclosures in their filings, are exempt
from the provisions of Section&#160;404(b) of the Sarbanes-Oxley Act requiring that independent registered public accounting firms provide
an attestation report on the effectiveness of internal control over financial reporting and have certain other decreased disclosure obligations
in their SEC filings, including, among other things, only being required to provide two years of audited financial statements in annual
reports. Decreased disclosures in our SEC filings due to our status as a &#8220;smaller reporting company&#8221; may make it harder for
investors to analyze our operating results and financial prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not expect any cash dividends to be paid on our shares of Common Stock for the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have never declared
or paid a cash dividend and we do not anticipate declaring or paying dividends on our Common Stock for the foreseeable future. We expect
to use future financing proceeds and earnings, if any, to fund operating expenses. Consequently, shareholders&#8217; only opportunity
to achieve a return on their investment is if the price of our stock appreciates and they sell their shares at a profit. We cannot assure
shareholders of a positive return on their investment when they sell their shares or that shareholders will not lose the entire amount
of their investment.</span></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the beneficial ownership of our Common Stock continues to be highly concentrated, it may prevent our shareholders from influencing significant
corporate decisions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of March 31, 2022,
our executive officers, directors and certain persons who may be deemed affiliates beneficially own in excess of 50.1% of our issued
and outstanding Common Stock. As a result, such persons may exercise substantial influence over the outcome of corporate actions requiring
shareholder approval including, without limitation, the election of directors, certain mergers, consolidations and sales of all or substantially
all of our assets or any other significant corporate transactions. Such persons may also vote against a change of control, even if such
a change of control would benefit our other shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sale
of our Common Stock by shareholders could encourage short sales by third parties, which could contribute to the further decline of our
stock price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The significant downward
pressure on the price of our Common Stock that would be caused by the sale of material amounts of our Common Stock could encourage short
sales by third parties. Such an event could place further downward pressure on the price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies
will make our Common Stock less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are an &#8220;emerging
growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). For as long as we continue to be
an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public
companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of
Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this prospectus and our periodic
reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and
stockholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier
of (i) the last day of the fiscal year (a) following the fifth anniversary of the completion of the first sale of shares covered by this
prospectus, (b) in which we have total annual gross revenue of at least $1.07 billion or (c) in which we are deemed to be a large accelerated
filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700.0 million as of the prior September
30<span style="font-family: Times New Roman, Times, Serif"><sup>th</sup></span>, and (ii) the date on which we have issued more than
$1.0 billion in non-convertible debt during the prior three-year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales of our securities could adversely affect the market price of our Common Stock and our future capital-raising activities could involve
the issuance of equity securities, which would dilute your investment and could result in a decline in the trading price of our Common
Stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We may sell securities
in the public or private equity markets at prices per share below the current market price of our Common Stock, even if we do not have
an immediate need for additional capital at that time. Sales of substantial amounts of shares of our Common Stock, or the perception
that such sales could occur, could adversely affect the prevailing market price of our shares and our ability to raise capital. We may
issue additional shares of Common Stock in future financing transactions or as incentive compensation for our executive management and
other key personnel, consultants and advisors. Issuing any equity securities would be dilutive to the equity interests represented by
our then-outstanding shares of Common Stock. Moreover, sales of substantial amounts of shares in the public market, or the perception
that such sales could occur, may adversely affect the prevailing market price of our Common Stock and make it more difficult for us to
raise additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
articles of incorporation allows for our board of directors to create new series of preferred stock without further approval by our shareholders,
which could adversely affect the rights of the holders of our Common Stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our board of directors
has the authority to fix and determine the relative rights and preferences of preferred stock. Currently, our board of directors has
the authority to designate and issue up to 5,000,000 shares of our preferred stock without further shareholder approval. In the future,
our board of directors could authorize the issuance of one or more series of preferred stock that would grant to holders, among other
rights, the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to
the holders of Common Stock and the right to the redemption of our preferred shares acquired by such persons, together with a premium,
prior to the redemption of our Common Stock. In addition, our board of directors could authorize the issuance of a series of preferred
stock that has greater voting power than our Common Stock or that is convertible into our Common Stock, which could decrease the relative
voting power of our Common Stock or result in dilution to our existing shareholders.</span></p>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to establish and maintain an effective system of internal controls, we may not be able to report our financial results accurately
or prevent fraud. Any inability to report and file our financial results accurately and timely could harm our reputation and adversely
affect the trading price of our Common Stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Effective
internal controls are necessary for us to provide reliable financial reports and prevent fraud. If we cannot provide reliable financial
reports or prevent fraud, we may not be able to manage our business as effectively as we would if an effective control environment existed,
and our business and reputation with investors may be harmed. If we are unable to maintain effective internal controls, we may not have
adequate, accurate or timely financial information, and we may be unable to meet our reporting obligations as a public company, including
the requirements of the&#160;Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act). In addition, we may be unable to accurately report
our financial results in future periods, or report them within the timeframes required by the requirements of the SEC or the&#160;Sarbanes-Oxley
Act. Failure to comply with the&#160;Sarbanes-Oxley Act, when and as applicable, could also potentially subject us to sanctions or investigations
by the SEC or other regulatory authorities. Any failure to maintain or implement required new or improved controls, or any difficulties
we encounter in their implementation, could result in identification of additional material weaknesses or significant deficiencies, cause
us to fail to meet our reporting obligations or result in material misstatements in our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Furthermore,
Section 404 of the Sarbanes-Oxley Act and related regulations require our management to evaluate the effectiveness of our internal control
over financial reporting as of the end of each fiscal year. Based on its evaluation, our management concluded that our internal controls
over financial reporting were effective as of March 31, 2022. We cannot provide assurance that, in the future, a material weakness or
significant deficiency will not exist or otherwise be discovered. If that were to happen, it could harm our operating results and cause
shareholders to lose confidence in our reported financial information. Any such loss of confidence would have a negative effect on the
trading price of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
board of directors is able to adopt recapitalizations through forward or reverse splits of our outstanding shares of Common Stock without
shareholder approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Pursuant to our amended
and restated articles of incorporation, our board of directors has the power, without obtaining shareholder approval, to effectuate recapitalizations
of us through forward or reverse splits of our outstanding Common Stock. As a result of such provision, our board of directors can implement
recapitalizations of us by effectuating a forward or reverse stock split of our outstanding Common Stock, which would increase or decrease
each of our shareholder&#8217;s number of shares owned, and our shareholders will have no right to approve or disapprove any such action
even if such actions have a material adverse effect on them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara003"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara004"></span>ITEM
2: PROPERTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our principal administrative
and research and development functions are located in a leased facility in San Diego, California. We currently occupy approximately 7,300
square feet of space in the San Diego facility, and the lease extends through June 2023. We believe that our existing facility is adequate
to meet our current needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara005"></span>ITEM
3: LEGAL PROCEEDINGS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are not a party
to any pending legal proceeding. To the knowledge of our management, no federal, state or local governmental agency is presently contemplating
any proceeding against us. No director, executive officer or affiliate of ours or owner of record or beneficially of more than five percent
of our common stock is a party adverse to us or has a material interest adverse to us in any proceeding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara006"></span>ITEM
4: MINE SAFETY DISCLOSURES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Not applicable</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara007"></span>ITEM
5: MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our common stock is
currently listed on the Nasdaq Capital Market under the symbol &#8220;MODD.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders
of Record</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On May 31, 2022, we had approximately 80
stockholders of record. <span style="font-family: Times New Roman, Times, Serif; background-color: white">The actual number of stockholders
is greater than this number of stockholders of record and includes stockholders who are beneficial owners but whose shares are held in
street name by brokers and other nominees. This number of stockholders of record also does not include stockholders whose shares may
be held in trust by other entities.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have never declared
or paid any cash dividend on our capital stock. We do not anticipate paying any cash dividends in the foreseeable future and we intend
to retain all of our earnings, if any, to finance our growth and operations and to fund the expansion of our business. Payment of any
dividends will be made in the discretion of our board of directors, after its taking into account various factors, including our financial
condition, operating results, current and anticipated cash needs and plans for expansion. Any dividends that may be declared or paid
on our common stock, must also be paid in the same consideration or manner, as the case may be, on our shares of preferred stock, if
any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Set
forth below is information regarding shares of Common Stock, convertible notes and warrants issued, and options granted, by us within
the past three years that were not registered under the Securities Act. Also included is the consideration, if any, received by us for
such shares, convertible notes, warrants and options, and information relating to the section of the Securities Act, or rule of the Securities
and Exchange Commission, under which exemption from registration was claimed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Director
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">On
March 31, 2022, we issued 15,250 shares of our Common Stock to non-employee members of our board of directors for service as directors
in accordance with our Outside Director Compensation Plan (the &#8220;Director Plan&#8221;). On December 31, 2021, we issued 5,775 shares
of our Common Stock to non-employee members of our board of directors for service as directors in accordance with the Director Plan.
On September 30, 2021, we issued 3,636 shares of our Common Stock to non-employee members of our board of directors for service as directors
in accordance with the Director Plan. On June 30, 2021, we issued 1,836 shares of our Common Stock to non-employee members of our board
of directors for service as directors in accordance with our Outside Director Compensation Plan the Director Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Service
Providers</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
March 23, 2022 we issued 45,000 shares of our Common Stock to a service provider. On January 5, 2022, we issued 16,666 shares of our
Common Stock to service providers. </span><span style="font-size: 10pt">In 2021, we issued a total of 52,834 shares of our Common Stock
to five service providers in exchange for services rendered. In 2019, we issued 10,000 shares of our Common Stock for cash to a service
provider.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Officer
Purchases of Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">On
October 28, 2021, we sold to two of our executive officers a total of 30,865 shares of our Common Stock at a purchase price of $8.10
per share, which resulted in gross proceeds to us of approximately $250,000.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021
Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Between
February and May 2021, we issued to accredited investors in a private placement $6,610,550 aggregate principal amount of our 12% unsecured
convertible promissory notes, due 12 months from each respective issuance date, at par and warrants to purchase in the aggregate 767,796
shares of our Common Stock at an exercise price of $24.00 per share, exercisable for a 5-year period, as provided in such warrants.</span></p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2020
Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Between
March and December 2020, we sold to accredited investors in a private placement a total of 320,796 shares of our Common Stock at a purchase
price of $8.61 per share. The 2020 Placement resulted in gross proceeds to us of $2,762,054.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2018
Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Between
November 2018 and March 2019, we sold to accredited investors in a private placement a total of 618,996 shares of our Common Stock at
a purchase price of $6.75 per share, resulting in gross proceeds to us of $4,142,666.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The above sales
of our securities were made pursuant to exemptions from registration pursuant to Section 4(2) and/or Rule 506 of Regulation D of the
Securities Act. We made such determinations based upon representations by the purchasers of such securities including, without limitation,
that such purchasers were &#8220;accredited investors&#8221; as defined in the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara008"></span>ITEM
6: RESERVED</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara009"></span>ITEM
7: MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following discussion
of our financial condition and results of operations should be read in conjunction with the financial statements and related notes included
in this Annual Report on Form 10-K. <span style="font-family: Times New Roman, Times, Serif"><i>Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations may contains statements that are forward-looking. These statements are based on current
expectations and assumptions that are subject to risk, uncertainties and other factors. These statements are often identified by the
use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221;
&#8220;could,&#8221; &#8220;estimate,&#8221; or &#8220;continue,&#8221; and similar expressions or variations. Actual results could differ
materially because of the factors discussed in Part I, Item 1A, </i></span>These risks and uncertainties may cause actual results to
differ materially from those discussed in the forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Our
fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in this Report, refers to the fiscal year ended March
31 of the calendar year indicated (for example, fiscal 2022 refers to the fiscal year ending March 31, 2022). Unless the context requires
otherwise, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to Modular Medical,
Inc. and its consolidated subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">We
are a development-stage medical device company focused on the design, development and commercialization of an innovative insulin pump
using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump,
our MODD1 product, we seek to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care
that presently-available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription,
reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated
&#8220;super users&#8221; and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing,
especially in terms of device adoption, type 2 diabetes markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Historically,
we have financed our operations principally through private placements and public offerings of our common stock and sales of convertible
promissory notes. Based on our current operating plan, we believe we have adequate cash for at least the next 12 months.
Our long-term ability to continue as a going concern depends on our ability to raise additional capital, through the sale
of equity or debt securities, to support our future operations. If we are unable to secure additional capital, we will be required
to curtail our research and development initiatives and take additional measures to reduce costs. We have provided additional
disclosure in Note 1 to the consolidated financial statements in Item 1 of this Report and under&#160;<span style="font-family: Times New Roman, Times, Serif"><i>Liquidity</i></span>&#160;below.</span></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impacts
of COVID-19</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The global outbreak
of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S.
government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221; and created significant
disruption of the financial markets. The full extent of the COVID-19 impact on our operational and financial performance will depend
on future developments, including, without limitation, the duration and spread of the pandemic and related actions taken by U.S. and
foreign government agencies to prevent disease spread, all of which are uncertain, out of our control, and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In March 2020, Santa
Diego County in California, where we are based, and the state of California issued &#8220;shelter-in-place&#8221; orders (the Orders).
We complied with the Orders and minimized business activities at our San Diego facility since March 2020 until May 2021. During that
time, we implemented a teleworking policy for our employees and contractors to reduce on-site activity at our facility. In May 2021,
our employees and certain contractors returned to work in our office. We have and continue to experience longer lead times for certain
components used to manufacture initial quantities of our products for our submission to the FDA. We remain diligent in continuing to
identify and manage risks to our business given the changing uncertainties related to COVID-19. While we believe that our operations
personnel are currently in a position to build an adequate supply of products for our FDA submission, we recognize that unpredictable
events could create difficulties in the months ahead. We may not be able to address these difficulties in a timely manner, which could
delay our submission to the FDA and negatively impact our business, results of operations, financial condition and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. We were recently able to raise
additional capital through equity offerings in February 2022 and May 2022, however, we will need to raise additional capital to commercialize
our pump product candidate and support our operations in the future. We may be unable to access the capital markets, and additional capital
may only be available to us on terms that could be significantly detrimental to our existing stockholders and to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">For additional information
on risks that could impact our future results, please refer to &#8220;Risk Factors&#8221; in Part I, Item 1A of this Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following discussion
should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; white-space: nowrap; font-weight: bold; text-align: center">Years ended March 31,</td><td style="white-space: nowrap; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; white-space: nowrap; font-weight: bold; text-align: center">Year-over-Year Change</td><td style="white-space: nowrap; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; white-space: nowrap; font-weight: bold; text-align: center">2022&#160;to&#160;2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 48%; text-align: left">Research and development</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">7,729,240</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4,083,303</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,645,937</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">89.3</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our research and development
expenses include personnel, materials and supplies and other costs associated with the development of our insulin pump product candidate.
We expense research and development costs as they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Research and
development, or R&amp;D, expenses increased in fiscal 2022 compared with fiscal 2021 primarily due to increased consulting costs,
engineering and operations personnel, stock compensation expense and materials and supplies expenditures. Our R&amp;D employee
headcount increased to 23 at March 31, 2022, from 17 at March 31, 2021.&#160;R&amp;D expenses included stock-based compensation
expenses of $758,938 and $390,045 for fiscal 2022 and fiscal 2021, respectively.&#160;We expect R&amp;D expenses to continue to
increase in fiscal 2023, as we complete the development of our pump product candidate, engage third parties to test our product
and develop a low-volume manufacturing process.</span></p>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; white-space: nowrap; font-weight: bold; text-align: center">Years ended March 31,</td><td style="white-space: nowrap; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; white-space: nowrap; font-weight: bold; text-align: center">Year-over-Year Change</td><td style="white-space: nowrap; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; white-space: nowrap; font-weight: bold; text-align: center">2022&#160;to&#160;2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 48%; text-align: left">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">7,197,162</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,253,412</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,943,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">121.2</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">General and administrative
expenses consist primarily of personnel and related overhead costs for marketing, finance, human resources and general management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">General and administrative
expenses, or G&amp;A, increased in fiscal 2022 compared with fiscal 2021 primarily as a result of increased personnel and consulting
costs, stock-based compensation expenses and professional services fees, primarily related to our financing activities, including our
public offering that was completed in February 2022. G&amp;A expenses included stock-based compensation expenses of $3,272,964 and $837,533
for fiscal 2022 and fiscal 2021, respectively. We expect G&amp;A expenses to continue to increase in fiscal 2023, as we will increase
headcount as we expand our organization to support our anticipated growth and prepare for the expected commencement of the commercialization
of our product in late fiscal 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Expense</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; white-space: nowrap; font-weight: bold; text-align: center">Years ended March 31,</td><td style="white-space: nowrap; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; white-space: nowrap; font-weight: bold; text-align: center">Year-over-Year Change</td><td style="white-space: nowrap; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; white-space: nowrap; font-weight: bold; text-align: center">2022&#160;to&#160;2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 48%; text-align: left">Interest expense</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,752,229</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">39,791</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,712,438</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">6,816.7</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Interest
expense consisted of interest expense incurred from our convertible promissory notes, including amortization of debt issuance costs,
and our promissory (bridge) note. We retired our outstanding debt in February 2022. See Notes 5 and 6 to the consolidated financial statements
included in Item 8 of this Report for additional disclosure.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a development-stage
enterprise, we do not currently have revenues to generate cash flows to cover operating expenses. Since our inception, we have incurred
operating losses and negative cash flows in each year due to costs incurred in connection with R&amp;D activities and G&amp;A expenses
associated with our operations. For the years ended March 31, 2022 and 2021, we incurred net losses of approximately $18.6 million and
$7.4 million, respectively. At March 31, 2022, we had a cash balance of $9.1 million and an accumulated deficit of approximately $34.6
million. In May 2022, we completed a registered direct offering of securities for net proceeds of approximately $7.4 million. Our operating
needs include the planned costs to operate our business, including amounts required to fund research and development activities, including
clinical studies, working capital and capital expenditures. Our future capital requirements and the adequacy of our available funds will
depend on many factors, including, without limitation, our ability to successfully commercialize our product, competing technological
and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to
enhance or complement our product offerings. If we are unable to secure additional capital timely, we will be required to curtail our
research and development initiatives and take additional measures to reduce costs in order to conserve our cash. <span style="font-family: Times New Roman, Times, Serif; background-color: white">We
believe that our cash will be sufficient to meet our working capital and capital expenditure needs for at least the next twelve months.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In fiscal 2022, we
used $10,259,528 in operating activities, which primarily resulted from our net loss of $18,632,761 less changes to operating assets
and liabilities of $420,600, as adjusted for non-cash charges and gains, which included stock-based compensation expenses of $4,031,902,
amortization of debt issuance costs of $1,833,618, a loss on debt extinguishment of $1,321,450, accrued interest of $666,338, $395,950
for issuances of shares of common stock in exchange for services, and depreciation and amortization expenses of $117,490, partially offset
by a gain on PPP note forgiveness of $368,780 and net changes in lease assets and liabilities of $45,610 and other immaterial adjustments.
The changes in operating assets and liabilities primarily related to the timing of payments to vendors. In fiscal 2021, we used $5,908,662
in operating activities, which primarily resulted from our net loss of $7,377,976 and changes to operating assets and liabilities of
$61,147, as adjusted for non-cash charges and gains, which included stock-based compensation expenses of $1,227,578, $68,880 for issuance
of shares of common stock in exchange for services, $109,731 related to the lease right-of-use asset and liability and depreciation and
amortization expenses of $111,015. Such changes in assets and liabilities primarily related to the timing of payments to vendors. Increased
cash usage during fiscal 2022 was due to increased operating activities related to the development and eventual commercialization of
our product.<span style="font-family: Times New Roman, Times, Serif; color: red">&#160;</span></span></p>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; color: red"></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In fiscal 2022, cash
used in investing activities of $54,764 was for the purchase of property and equipment. We used $109,669 of cash to purchase property
and equipment in fiscal 2021.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Cash provided by financing
activities for fiscal 2022 totaled $17,922,199 and was attributable to $13,535,000 of net proceeds from a public offering of our common
stock in February 2022, $4,137,199 of net proceeds from the issuance of convertible notes, $2,100,000 of net proceeds from issuance of
a bridge promissory note, and $250,000 of proceeds from a private placement of common stock to officers, which were partially offset
by the $2,100,00 repayment of the bridge promissory note. Our financing activities for fiscal 2021 totaled $4,364,662 and were attributable
to $1,785,882 of net proceeds from the sale of shares of common stock in a private placement, $368,760 of proceeds from the PPP Note
and $2,210,00 of gross proceeds from the issuance of our convertible notes in the quarter ended March 31, 2021.&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our consolidated financial
statements are prepared in conformity with accounting principles generally accepted in the United States of America (GAAP). Note&#160;1
to the consolidated financial statements in Item&#160;8 of this Report describes the significant accounting policies and methods used
in the preparation of our consolidated financial statements. We have identified the accounting policies below&#160;as some of the more
critical to our business and the understanding of our results of operations. These policies may involve estimates and judgments that
affect the reported amounts of assets, liabilities, revenues and expenses. Although we believe our judgments and estimates are appropriate,
actual future results may differ from our estimates, and if different assumptions or conditions were to prevail, the results could be
materially different from our reported results.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of estimates</i></span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The preparation of
financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting periods. Estimates may include those pertaining to accruals, stock-based compensation and
income taxes. Actual results could materially differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based
compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We recognize stock-based
compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite service period, usually
the vesting period, based on the grant-date fair value. We estimate the value of stock options on the date of grant using the Black-Scholes
pricing model. The determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected
by the option price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but
are not limited to, the expected stock price&#160;volatility over the term of the awards, and projected stock option exercise behaviors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We determine deferred
tax assets and liabilities based upon the differences between the financial statement and tax bases of our assets and liabilities using
tax rates in effect for the year in which we expect the differences to affect taxable income. A valuation allowance is established for
any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized. Based
on the available information and other factors, management believes it is more likely than not that our federal and state net deferred
tax assets will not be fully realized, and we have recorded a full valuation allowance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We account for uncertain
tax positions in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) Topic 740,&#160;<span style="font-family: Times New Roman, Times, Serif"><i>Income
Taxes</i></span>. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would
be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period during which,
based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination,
including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.
Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more
than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated
with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits
in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing
authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are
classified in general and administrative expenses in the consolidated statements of operations.</span></p>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We account for our
leases under Accounting Standards Update (ASU) No. 2016-02,&#160;<span style="font-family: Times New Roman, Times, Serif"><i>Leases&#160;</i></span>(ASC
842),<span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span>and related ASUs, which provide supplementary guidance
and clarifications.&#160;Under ASC 842, all significant lease arrangements are generally recognized at lease commencement. Operating
lease right-of-use (ROU) assets and lease liabilities are recognized at the commencement date. A ROU asset and corresponding lease liability
are not recorded for leases with an initial term of 12 months or less (short-term leases), and we recognize lease expense for these leases
as incurred over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">ROU assets represent
our right to use an underlying asset during the reasonably certain lease terms, and lease liabilities represent our obligation to make
lease payments arising from the lease. Our lease terms may include options to extend or terminate the lease when it is reasonably certain
that we will exercise that option. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on
the present value of lease payments over the lease term. We use our incremental borrowing rate, based on the information available at
commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments
related to initial direct cost and prepayments and excludes lease incentives. Lease expense is recognized on a straight-line basis over
the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We do not maintain
any off-balance sheet arrangements or obligations that are reasonably likely to have a material current or future effect on our financial
condition, results of operations, liquidity or capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
Obligations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a &#8220;smaller
reporting company,&#8221; as defined by Item 10 of Regulation S-K, we are not required to provide the information requested by paragraph
(a)(5) of this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">See
Note&#160;1 to the consolidated financial statements in Item&#160;8 of this Report for a full description of recent accounting pronouncements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara010"></span>ITEM
7A: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Not required.&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara011"></span>ITEM
8: FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 96%"><a href="#modularb001"><span style="font-size: 10pt">Report of Independent Registered Accounting Firm &#8211; Farber Hass Hurley LLP</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right">45</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modularb002"><span style="font-size: 10pt">Consolidated Balance Sheets</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">47</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modularb003"><span style="font-size: 10pt">Consolidated Statements of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">48</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modularb004"><span style="font-size: 10pt">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">49</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modularb005"><span style="font-size: 10pt">Consolidated Statements of Cash Flows</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">50</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#modularb006"><span style="font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">51</td></tr>
</table>



<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><span style="font-size: 10pt"><span id="modularb001"></span>REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: left"><span style="font-size: 10pt">To the Audit Committee and<br />
Stockholders of Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Opinion on
the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">We have audited
the accompanying consolidated balance sheets of Modular Medical, Inc. (the &#8220;Company&#8221;) as of March 31, 2022 and 2021, and
the related consolidated statements of operations, stockholders&#8217; equity (deficit), and cash flows for the years then ended, and
the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2022 and 2021, and
the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted
in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Basis for
Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">These consolidated
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">We conducted
our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable
assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Our audits included
performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Critical Audit
Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The
critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements
that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are
material to the consolidated financial statements and (ii) involved especially challenging, subjective, or complex judgments. The communication
of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are
not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts
or disclosures to which they relate.</span></p>
<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt"><i>Going
Concern</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">As described
further in Note 1 to the financial statements, the Company has incurred losses since inception, and expects to continue to incur operating
losses for the foreseeable future and incur cash outflows from operations as it continues to invest in the development and subsequent
commercialization of its product. The Company expects that its research and development and general and administrative expenses will
continue to increase, and, as a result, it will eventually need to generate significant product revenues to achieve profitability. As
of March 31, 2022, the Company had cash balances of approximately $9,076,000, as a result of the capital raised in the public offering
in February 2022. In addition, subsequent to March 31, 2022, the Company raised net proceeds from an equity offering of approximately
$7,372,000. The Company has concluded that these plans alleviate the doubt related to its ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">We identified
management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern as a critical audit matter due to inherent
complexities and uncertainties related to the Company&#8217;s projections of operations. Auditing management&#8217;s going concern assessment
involved a high degree of auditor judgment and audit effort due to the impact of these assumptions on the determination of the degree
of doubt regarding the ability of the entity to continue as a going concern. The primary procedures we performed to address this critical
audit matter included:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            evaluated the reasonableness of key assumptions underlying management&#8217;s conclusion.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            evaluated that the disclosures included in the Form 10-K were complete and accurate and in
                                            accordance with accounting principles generally accepted in the United States of America.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            evaluated the impact of the Company&#8217;s existing financing arrangements and future capital
                                            needs over the next 12 months on its ability to continue as a going concern.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt"><i>Stock
Based Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">As discussed
in Note 8, during the year ended March 31, 2022, the Company granted 827,427 options to purchase shares of its common stock with 10-year
terms and a grant-date fair value of $8,507,311 to employees, directors and consultants. Management is required to analyze the fair value
of each option granted and amortize it over its vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">We identified
the grant of stock options as a&#160;critical&#160;audit&#160;matter. Management&#8217;s estimates regarding fair value of options result
in the application of a high degree of auditor judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The primary procedures
we performed to address this&#160;critical&#160;audit&#160;matter included the following:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We
                                            gained an understanding of Company&#8217;s processes and controls in place for determining
                                            the fair value of each granted option.&#160;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We
                                            evaluated the option price model the management selected to determine the fair value, and
                                            analyzed the underlying data used in the calculations. </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt"><span style="font: 10pt Symbol">&#183;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We
                                            also recalculated the fair value of each option granted. </span></td></tr></table>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/&#160;<span id="xdx_909_edei--AuditorName_c20210401__20220331_z7QzmMM3KJP"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:AuditorName">Farber
    Hass Hurley LLP</ix:nonNumeric></span></i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 83%"><span style="font-size: 10pt">&#160;Firm Id <span id="xdx_90D_edei--AuditorFirmId_c20210401__20220331_zf2Glc8o5dkg"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:AuditorFirmId">223</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 17%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have served as the Company&#8217;s auditor since 2018.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--AuditorLocation_c20210401__20220331_zEnBJhsKnn2k"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:AuditorLocation">Chatsworth,
    California</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    28, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>







<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Modular
Medical, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modularb002"></span>Consolidated
Balance Sheets</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_111_zpzgUSkD9DW2" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220331_z93wRU3pt5Gi" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20210331_zdXmQzkVJin6" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB_zc83QceySKX8" style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left">ASSETS</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsCurrentAbstract_i01B_zVtf9nEqRKyd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzJ3x_zQd0aKLyTlfg" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; padding-left: 8.65pt">Cash and cash equivalents</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,076,372</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,468,465</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseCurrent_i02I_maCzJ3x_zQnbaoqnE8Fl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">312,464</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,158</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherAssetsCurrent_i02I_maCzJ3x_zgXquO470suk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">958</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,466</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrent_i02TI_mtCzJ3x_maCzdrA_zFNON3r8cEU4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 25.95pt">TOTAL CURRENT ASSETS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,389,794</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,649,089</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maCzIUO_z8S1hux9HE45" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Property and equipment,&#160;net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,959</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">298,958</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzIUO_zKPH41xlliy9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Right of use asset, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,693</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,124</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DepositsAssets_i02I_maCzIUO_z6fwdEWnINng" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Security deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsNoncurrent_i02TI_mtCzIUO_maCzdrA_zBpjsl720mvc" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 25.95pt">TOTAL NON-CURRENT ASSETS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">456,652</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">599,082</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Assets_i01TI_mtCzdrA_z3HwggEHMF2h" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,846,446</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,248,171</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z5uTQBXP80N3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesCurrentAbstract_i01B_zfeyA4kPMPod" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maCzwUE_z9HBlF9X42Ae" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">299,951</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,284</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_i02I_maCzwUE_zWVvs2NmkSP3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">524,891</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,948</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzwUE_zkek0Zq3NK09" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Short-term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,857</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--UnsecuredDebtCurrent_i02I_maCzwUE_zvVRGv8wQih3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">PPP note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0093">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnsecuredDebtCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,780</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShortTermBankLoansAndNotesPayable_i02I_maCzwUE_zAABcZil2rN7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Convertible notes payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0096">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,133,453</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrent_i02TI_mtCzwUE_maCzVMt_zF8LMAKPizyi" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">TOTAL CURRENT LIABILITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">969,699</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,296,965</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maCzVMt_zqHqq9QHflf2" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Long-term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,957</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,355</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherLiabilitiesNoncurrent_i02I_maCzVMt_zFhyba1xGKs6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Bonus payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0105">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Liabilities_i01TI_mtCzVMt_maCzvCw_zWTRcZSyOa1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">TOTAL&#160; LIABILITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,009,656</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,523,320</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CommitmentsAndContingencies_i01I_zijWsVSzjX6f" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt">Commitments and Contingencies (Note 11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B_zAp9rNQTgquh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockValue_i02I_maCzn8T_zm6UwaD9CdW1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Preferred Stock, $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220331_zvGgFMbINwPf"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210331_zDVddJr2tX9b"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20220331_z6Liyz7f2DIk"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20210331_zPFo01plDzwk"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_dn_c20220331_zQqjydg9Hl5i"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20220331_zvNGqwIIxEu9"><span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_dn_c20210331_zDB4QImxzv0d"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20210331_zXpIOiFRste1"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0117">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0118">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CommonStockValue_i02I_maCzn8T_zHUyYHZrtsWk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">Common Stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220331_zuegq9ybN2R6"><span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210331_zWiW42MHCqGh"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20220331_z7iQUQ3IwGcb"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20210331_zcm9JMHYRCK7"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20220331_zY3ReKaUJiZ9"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20220331_zkGyeQ7hlpdc"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,461,898</ix:nonFraction></ix:nonFraction></span></span> shares and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20210331_zGVSbBdGpStf"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20210331_z19WHBToqvd"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,302,050</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of March 31, 2022 and 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,462</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,302</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdditionalPaidInCapital_i02I_maCzn8T_zdymwWb9KvBh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,406,099</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,665,559</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzn8T_ztmhZ1AY6FPe" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">34,579,771</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,947,010</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--StockholdersEquity_i02TI_mtCzn8T_maCzvCw_zsxN12PxJiTe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 25.95pt">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,836,790</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,275,149</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtCzvCw_zKRQIK2ILUCf" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,846,446</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,248,171</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 17.3pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">The accompanying notes
are an integral part of these audited consolidated financial statements</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Modular
Medical, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modularb003"></span>Consolidated
Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_113_zhwpOgNb5hV3" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="padding-bottom: 1pt"></td>
    <td style="white-space: nowrap; text-align: center"></td>
    <td id="xdx_491_20210401__20220331_zEUWzJ08Df4d" style="white-space: nowrap; text-align: center"></td>
    <td style="white-space: nowrap; text-align: center"></td>
    <td style="white-space: nowrap; text-align: center"></td>
    <td style="white-space: nowrap; text-align: center"></td>
    <td id="xdx_493_20200401__20210331_zMhFm6tMfhCg" style="white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Twelve Months Ended<br /> March 31,</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zZcSwezyXiU1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzK50_zkGyeQ7hlpdc" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; padding-left: 8.65pt">Research and development</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,729,240</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,083,303</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzK50_zY3ReKaUJiZ9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,197,162</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,253,412</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_i01T_mtCzK50_msCzKuI_z7iQUQ3IwGcb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,926,402</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,336,715</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_i01T_mtCzKuI_maCzcy8_zuegq9ybN2R6" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,926,402</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,336,715</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestIncomeExpenseNet_maCzcy8_zvNGqwIIxEu9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,920</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestExpense_iN_di_msCzcy8_zQqjydg9Hl5i" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,752,229</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,791</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_maCzcy8_z6Liyz7f2DIk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Loss on debt extinguishment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,321,450</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0173">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzcy8_maCz6Aa_zvGgFMbINwPf" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,631,161</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,376,376</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_msCz6Aa_zJUUawAyCJM1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Provision for income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_mtCz6Aa_zluTbyYAbpA6" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,632,761</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,377,976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--EarningsPerShareBasicAndDiluted1Abstract_iB_zNpWT2jNNoxl" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--EarningsPerShareBasicAndDiluted1_i01_zqXIzrzVkYde" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="modd:EarningsPerShareBasicAndDiluted1" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.74</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="modd:EarningsPerShareBasicAndDiluted1" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.20</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract_iB_zAugFQAQRo8c" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Shares used in computing net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--WeightedAverageNumberOfShareOutstandingBasicAndDiluted1_i01_z4WRjKY980X4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:WeightedAverageNumberOfShareOutstandingBasicAndDiluted1" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,807,710</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:WeightedAverageNumberOfShareOutstandingBasicAndDiluted1" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,211,562</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">The accompanying notes
are an integral part of these audited consolidated financial statements</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Modular
Medical, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modularb004"></span>Consolidated
Statements of Stockholders&#8217; Equity (Deficit)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_114_zVIYfz7X53Wb" summary="xdx: Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z1sRaI8bh1h1" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zGZFeMSXtoQ1" style="white-space: nowrap; padding-bottom: 1pt; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"></td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_custom--CommonStockIssuableMember_zyF4HHcQGgSf" style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z4R1Ajoxmva8" style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"></td>
    <td colspan="2" id="xdx_4BB_zwy2Tx2FzQlg" style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Common Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional<br /> Paid-In</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">Common Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Capital</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Issuable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Equity (Deficit)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43A_c20200401__20210331_eus-gaap--StockholdersEquity_iS_zne9W3WE2EKi" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 40%; font-weight: bold; text-indent: -8.65pt; padding-left: 8.65pt">Balance as of&#160;March 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXBbKbdf9xwa" title="Beginning balance, Shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,956,754</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,957</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,517,505</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">923,994</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,569,034</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,878,422</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20200401__20210331_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zlVBssH2tse" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Placement of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCB2Z6jtt4S7" title="Placement of common stock, Shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">320,796</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">321</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,709,555</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0207">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,785,882</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20200401__20210331_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zghhcM3G4YZ6" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRZ0GUtDckI2" title="Shares issued for services, Shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,921</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0214">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0215">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,945</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20200401__20210331_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zLngUsdrCnb7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0220">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,227,578</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0222">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0223">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,227,578</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20200401__20210331_eus-gaap--NetIncomeLoss_zMdYkkJF0mHh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0226">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0227">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0228">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,377,976</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,377,976</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20200401__20210331_eus-gaap--StockholdersEquity_iE_zvc92Nv6cPJe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -8.65pt; padding-left: 8.65pt">Balance as of March 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx4q6vQzEHP1" title="Ending balance, Shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,302,050</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,302</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,665,559</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0234">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,947,010</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,275,149</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_433_c20210401__20220331_eus-gaap--StockIssuedDuringPeriodValueOther_zDQjYjRsiqLa" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Issuance of common stock upon public offering, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDdlTYP27n14" title="Issuance of common stock upon public offering, net of issuance costs, Shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,657,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0242">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0243">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,660,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_431_c20210401__20220331_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zxQgTEmomJSl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.4pt; padding-left: 8.65pt">Issuance of common stock in settlement of convertible notes and accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpkYxgiMElck" title="Issuance of common stock in settlement of convertible notes and accrued interest, Shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,511,276</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,511</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,506,254</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0250">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0251">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,507,765</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20210401__20220331_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z0U1H3VTbeI5" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Placement of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zReBPyZ5L8H6" title="Placement of common stock, Shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,864</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">249,969</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0258">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0259">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20210401__20220331_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_zw65lH54W06g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Warrants issued with convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,700,632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,700,632</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20210401__20220331_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zxGfMZeH6dz1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgzutbK65VBj" title="Shares issued for services, Shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">594,310</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">594,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20210401__20220331_ecustom--SharesIssuedForReverseStockSplit_zsFCuDLqxPF8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">Shares issued for reverse stock split</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxgqZhY4Fux6" title="Shares issued for reverse stock split, Shares" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,211</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="modd:SharesIssuedForReverseStockSplit" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">(<ix:nonFraction name="modd:SharesIssuedForReverseStockSplit" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20210401__20220331_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_zIJL2nNMmnRe" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.4pt; padding-left: 8.65pt">Issuance of common stock under equity incentive plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk6QDIUkjVLd" title="Issuance of common stock under equity incentive plan, Shares" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,497</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,091</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,118</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20210401__20220331_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zsY3BS85TLcb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">Stock-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,859,785</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,859,785</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20210401__20220331_eus-gaap--NetIncomeLoss_zmjIBEoMOJ8l" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,632,761</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,632,761</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43A_c20210401__20220331_eus-gaap--StockholdersEquity_iE_zEPPocySasGa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">Balance as of March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNeHwM9IewFk" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,461,898</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,462</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,406,099</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">34,579,771</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,836,790</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">The accompanying notes
are an integral part of these audited consolidated financial statements</span></p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Modular
Medical, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modularb005"></span>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_112_zt00bAZA7CQd" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49F_20210401__20220331_zYB27mhgKC4h" style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_492_20200401__20210331_zcVJ8Pf0pTul" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zBhIsSe85wRk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Cash Flows from operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_i01_zsaHo0uLQfhe" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left">Net loss</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,632,761</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,377,976</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zEiYNoZJ56Z6" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--GainOnPPPNoteForgiveness_i02_zmgO9KJBVH81" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 8.65pt; padding-left: -17.3pt; text-align: left">Gain on PPP note forgiveness</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="modd:GainOnPPPNoteForgiveness" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">368,780</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_z9VVVOD5Xnt3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt; text-align: left">Loss on debt extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,321,450</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_i02_zBER1rIvYGaa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,031,902</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,227,578</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DepreciationAndAmortization_i02_zb3U0lVVxY51" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,490</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,015</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedInterest_i02_zxOLobCUs65g" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt; text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:AccruedInterest" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">666,338</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_zBbPCPrX2fM7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt; text-align: left">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">395,950</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,880</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_zosD7LAHLl76" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt; text-align: left">Amortization of lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,431</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,826</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncreaseDecreaseInLeaseLiability_i02_zau9Vud7UoG" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt; text-align: left">Change in lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="modd:IncreaseDecreaseInLeaseLiability" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">125,040</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:IncreaseDecreaseInLeaseLiability" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,905</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AmortizationOfDebtDiscountPremium_i02_zgiUXS5cPAi9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt; text-align: left">Amortization of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,833,618</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,253</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherNoncashIncomeExpense_i02_zUL8lX4sQ4Wg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,004</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_i01B_zeL2Dj1ETtu" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02_zW4JtJEvxrri" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Other assets and prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,652</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_zEtZc74efnR8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Accounts payable and accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">354,948</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">86,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01_maCzhhX_zbMM3kVPR2jd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,259,528</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,908,662</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z0Ewdr3WpXBg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCz2UY_zyHMsfiMwKF7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Purchases of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,764</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,669</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCz2UY_maCzhhX_zJPYg9wSqZj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">54,764</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">109,669</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zzzshdWeW4B7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_maNCPBUzXBv_zAoUN3pBCbX2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from private placements, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,785,882</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromConvertibleDebt_i01_maNCPBUzXBv_zihjPVa9F3lh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from issuance of convertible notes, net of placement fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,137,199</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,210,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ProceedsFromIssuanceOfPromissoryNote_i01_maNCPBUzXBv_zm7ZzP5HTBpj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from issuance of promissory note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:ProceedsFromIssuanceOfPromissoryNote" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--RepaymentOfPromissoryNote_i01_maNCPBUzXBv_zv5aWGg0Z7Ea" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Repayment of promissory note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="modd:RepaymentOfPromissoryNote" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,100,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromNotesPayable_i01_maNCPBUzXBv_zmJiVGcYVxdd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from issuance of PPP note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,780</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts_i01_maNCPBUzXBv_zwvR1qvHLnKb" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Proceeds from issuance of common stock upon public offering, net of issuance costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="modd:ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,535,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCzhhX_mtNCPBUzXBv_ztZh0fJbsTme" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,922,199</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,364,662</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzhhX_zT5d8NaRj2Ua" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Net increase (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,607,907</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,653,669</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zZmUpYOdOdo6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cash and cash equivalents, at beginning of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,468,465</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,122,134</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zDUMfkbZk2n8" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, at end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,076,372</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,468,465</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_iB_zSFtKJkbhxw6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_i01B_ztyMFwQhelY3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Noncash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_i02_zFuYAGeBEoW1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Fair value of detachable warrants issued with convertible notes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,700,632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_i02_z9XHVjaV0oh4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 9pt">Conversion of convertible notes and accrued interest into common stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="modd:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,253,876</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SupplementalCashFlowInformationAbstract_i01B_zOlhQLFgzWQ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash paid for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxesPaidNet_i02_zROmdypsGl47" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt">Income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InterestPaidNet_i02_zFywCR536aeh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt">Interest paid</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">The accompanying notes
are an integral part of these audited consolidated financial statements</span></p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MODULAR
MEDICAL, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modularb006"></span>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zYqNaSThYyA4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note&#160;1
&#8211; <span id="xdx_826_zadDPzMXkLk7">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Modular Medical, Inc.
(the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material business
operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a Delaware
corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was
accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the merger, at
their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the Company was a shell company, as
defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act). In June 2017, the Company changed its
name from Bear Lake Recreation, Inc. to Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative insulin
pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps for insulin-dependent
people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent diabetes to receive their
daily insulin in two ways, through a continuous &#8220;basal&#8221; delivery allowing a small amount of insulin to be in the blood at
all times and a &#8220;bolus&#8221; delivery to address meal time glucose input and to address when the blood glucose level becomes excessively
high. By addressing the time and effort required to effectively treat their condition, the Company believes it can address the less technically
savvy, less motivated part of the market.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
discussed in Note 7, in February 2022, the Company completed a public offering of its equity securities, and its common stock was approved
to list on the Nasdaq Capital Market under the symbol &#8220;MODD&#8221; and began trading there on February 10, 2022.</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:LiquidityPolicyTextBlock"><p id="xdx_842_ecustom--LiquidityPolicyTextBlock_zmtWXrgDJMli" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zH6oyktWLVp9">Going
Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The accompanying financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal
course of business. The realization of assets and the satisfaction of liabilities in the normal course of business are dependent on,
among other things, the Company&#8217;s ability to operate profitably, to generate cash flows from operations, and to pursue financing
arrangements to support its working capital requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">At issuance of the Company&#8217;s
financial statements for the year ended March 31, 2021, management had determined that there was significant doubt as to the ability
of the Company to meet its obligations and continue as a going concern. As a result of the Offering (see Note 7), which was completed
in February 2022, and the Registered Offering (see Note 13), which was completed in May 2022, and resulting improved financial position,
the Company believes it has sufficient liquidity to meet its obligations as they come due and conduct its business for a period of at
least 12 months from the date of issuance of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures.
The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&#8217;s
ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations
with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable
to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to
reduce costs in order to conserve its cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zRiJQCGBV25a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zjI0fxvkL60h">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America. The Company&#8217;s fiscal year ends on March 31 of each calendar year.<span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span>Each
reference to a fiscal year in these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar
year indicated (for example, fiscal 2022 refers to the fiscal year ending March 31, 2022). The consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been
eliminated in consolidation.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23A_zCeaondmKl48" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:ReverseStockSplitPolicyTextBlock"><p id="xdx_844_ecustom--ReverseStockSplitPolicyTextBlock_z04VSWRoT4g5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86F_zQBYomsOyt86"><span id="xdx_861_zwJZiczLUZTf">Reverse
Stock Split</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#8217;s shares of common stock.&#160;Such amendment
and ratio were previously approved by a majority of the Company&#8217;s stockholders and the board of directors. As a result of the reverse
stock split, which was effective November 29, 2021, every three shares of the Company&#8217;s pre-reverse split outstanding common stock
were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stock holders were
not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split were rounded up to the
nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company&#8217;s equity incentive
plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of
common stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split.</span><span style="font-size: 10pt">&#160;All
share numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3
reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84E_eus-gaap--UseOfEstimates_zQAMqRgArPf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zzdD9Zq4p7o1">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The preparation of
the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting
period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from
those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zo1ec0Mysvw" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zHVPNIpnofm">Reportable
Segment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The Company operates in one business segment
and uses one measurement of profitability for its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvIlXmwh0fD" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86C_zs0zYacJravk">Research
and Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company expenses research and development expenditures as incurred.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p id="xdx_84B_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zroIoQNwqFh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_866_zIUjRSyGNGN7">General
and Administrative</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees,
and office and other administrative expenses.</span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_ziJ2ewPFUZMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zUWOtBR5IV6k">Concentration
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Financial instruments
that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash at high
quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to
limits of approximately $250,000. <span style="font-family: Times New Roman, Times, Serif; background-color: white">No reserve has been
made in the financial statements for any possible loss due to financial institution failure.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:RisksAndUncertaintiesPolicyTextBlock"><p id="xdx_849_ecustom--RisksAndUncertaintiesPolicyTextBlock_zi0JfTofpvM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zqS2p0oVCk06">Risks
and Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company is subject
to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity
requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>COVID-19</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The global outbreak
of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S.
government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221; and created significant
disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#8217;s operational and financial performance
will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government
agencies to prevent disease spread, all of which are uncertain, out of the Company&#8217;s control, and cannot be predicted.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23C_zVhXi7a8P08a" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zxMnukNIy9E4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zgsqPjuzR3Q7">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Cash and cash equivalents
include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities
of three months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zttWp1WUggSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zjT4PvFPcfEc">Property
and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Property and equipment
are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets,
generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold
improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the lease term,
and amortization is recorded in operating expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zta5pBtur4x2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zu6Y5hpixDek">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company measures
the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value into three broad levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 inputs to the valuation methodology are quoted prices for identical assets or liabilities
                                            in active markets.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 inputs to the valuation methodology include quoted prices for similar assets and liabilities
                                            in active markets, and inputs that are observable for the asset or liability, either directly
                                            or indirectly, for substantially the full term of the financial instrument.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 inputs to the valuation methodology are unobservable and significant to the fair value
                                            measurement.</span></td></tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:DebtModificationsAndExtinguishmentsPolicyTextBlock"><p id="xdx_84A_ecustom--DebtModificationsAndExtinguishmentsPolicyTextBlock_z2qhNiR0tcA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zLW3oqwXW8mi">Debt
Modifications and Extinguishments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">When the Company modifies
or extinguishes debt, it does so in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC)
Topic 470-50, <span style="font-family: Times New Roman, Times, Serif"><i>Debt&#8212; Modifications and Extinguishments,</i></span> which
requires modification to debt instruments to be evaluated to assess whether the modifications are considered &#8220;substantial modifications.&#8221;
A substantial modification of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis
performed, if the Company believes the embedded conversion feature has no fair value on the date of issuance (measurement date) and the
embedded conversion feature has no beneficial conversion feature, the embedded conversion feature does not meet the criteria in ASC 470-50-40-10
or 470-20-25 and the issuance of the convertible note payable is considered a modification, and not an extinguishment that would require
the recognition of a gain or loss. If the Company determines the change in terms meet the criteria for substantial modification under
ASC 470 it will treat the modification as extinguishment and recognize a loss from debt extinguishment.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zZW1vseIs6U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zvU0gedkoKIf">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">Effective&#160;April&#160;1, 2019,
the Company adopted ASC No. 842,&#160;<span style="font-family: Times New Roman, Times, Serif"><i>Leases&#160;</i></span>(ASC 842). ASC
842 requires an entity to recognize a&#160;right-of-use&#160;asset and a lease liability for all leases with terms longer than 12 months.
The Company adopted ASC 842 utilizing the modified retrospective transition method. The Company elected the practical expedient afforded
in ASC 842 in which the Company did not reassess whether any contracts that existed prior to adoption have or contain leases or the classification
of its existing leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_znFDT9AfXlJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zOo0oLCtxyjh">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company recognizes
stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite service
period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options on the date
of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date of grant using
an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and subjective variables.
These variables include, but are not limited to, the expected stock price&#160;volatility over the term of the awards, and projected
stock option exercise behaviors.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zODhXhNVxva8" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zBWbC6sUp8wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zDSzZkLxl919">Per-Share
Amounts</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Basic net loss per
share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during the period.
Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive
common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zi6ge9YgSP21" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive: &#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract"><table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_zH619xBoQBl2" summary="xdx: Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49E_20220331_z5uGeYjdGb5g" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_495_20210331_zgovGgjVcjK6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_zczFTBzbQV3c" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Options to purchase common stock</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,650,705</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197,252</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_zj3b2oY6U1Fd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,779,072</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20220331_zvecWQIznBTi" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,429,777</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_zaRsOzR3gPNj" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197,252</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8AD_zhn1aY3xhyMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zpNroTjz06ie" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_862_zm3mQRzHAlL1">Reclassification</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zrhjoDfokqXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zzuDKj6X6Ldg">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company determines
deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company&#8217;s assets
and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation
allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets
will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal
and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company accounts
for uncertain tax positions in accordance with FASB ASC Topic 740,&#160;<span style="font-family: Times New Roman, Times, Serif"><i>Income
Taxes</i></span>. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would
be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period during which,
based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination,
including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.
Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more
than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated
with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits
in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing
authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are
classified in general and administrative expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company files U.S.
federal and state income tax returns in jurisdictions with varying statutes of limitations.&#160;&#160;All tax returns from 2016 to 2021
may be subject to examination by the U.S. federal and state tax authorities.&#160; As of March 31, 2022 and 2021, the Company had not
recorded any liability for unrecognized tax benefits related to uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zmRNsprJq3ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zk5hp2qYq0Ue">Comprehensive&#160;Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Comprehensive loss
represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2022 and 2021, the Company&#8217;s
comprehensive loss was the same as its net loss.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_232_zyu44hfZ2Mf3" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z64GYbkpeqQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86F_zImLuBeHUQvc">Recently
Issued Accounting Pronouncement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13,&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financial
Instruments&#8212;Credit Losses</i><span style="background-color: white">. This ASU added a new impairment model (known as the current
expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes
an allowance for its estimate of expected credit losses and applies to most debt instruments, trade receivables, lease receivables, financial
guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses
and entities will need to measure expected credit losses on assets that have a low risk of loss. This update is effective for fiscal
years beginning after December 15, 2022, including interim periods within those fiscal years for smaller reporting companies. The Company
is still evaluating the impact of this accounting guidance on its results of operations and financial position.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock"><p id="xdx_80F_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_zXMfyGTwGhx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;2
&#8211; <span id="xdx_82A_zdJfObx04A4i">CONSOLIDATED BALANCE SHEET DETAIL</span></b></span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock"><p id="xdx_89B_ecustom--DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock_zF4TfzlRybll" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:DisclosureConsolidatedBalanceSheetDetailDetailsAbstract"><table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureConsolidatedBalanceSheetDetailDetailsAbstract_zRU6V5vlbfXi" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_499_20220331_z4zq7k3BvC44" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_497_20210331_zFusOQa6llY4" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left">Property and equipment, net:</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zhgQfGDFDPs" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Leasehold improvements</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-03-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z8iLANmUwVub" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-03-31_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,298</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,476</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTw6M0iBZQEl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Computer equipment and software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-03-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,114</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,383</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherMachineryAndEquipmentMember_ztaCoDaSQzk6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Machinery and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-03-31_us-gaap_OtherMachineryAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,947</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31_us-gaap_OtherMachineryAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,993</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz4h6_zh3xNxmzW1th" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt"><span style="display: none">Property and equipment,&#160;gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">485,556</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">451,049</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz4h6_zhRPsukekoji" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">249,597</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,091</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_mtPPAENz4h6_zzcoOCxnSwoi" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt"><span style="display: none">Property and equipment,&#160;net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,959</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">298,958</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">Accrued expenses:</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedWagesAndBonus_iI_maALAOLz5T1_z0JhbMur571f" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Accrued wages and bonus</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="modd:AccruedWagesAndBonus" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">457,891</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="modd:AccruedWagesAndBonus" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,563</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AccruedPlacementFees_iI_maALAOLz5T1_zOkWAxDrX7qb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued placement fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:AccruedPlacementFees" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedInterests_iI_maALAOLz5T1_zJ1nXO47gpz7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:AccruedInterests" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,538</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALAOLz5T1_z1yiFJnzCMjf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,047</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_mtALAOLz5T1_zUcNbV9KXDyg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt"><span style="display: none">Accrued expenses</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">524,891</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,948</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8AE_z8ZxQBlNO71" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock"><p id="xdx_80F_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zmHx31Dpbln8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
3 &#8211;&#160;<span><span id="xdx_829_zqB3LaWTbQEd">LEASES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for the lease for its corporate facility in San Diego, California in accordance with ASC 842. The&#160;<span id="xdx_906_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxH_c20200402_zsO8A3aKgOzf" title="::XDX::P39M">39-month</span> lease
term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $12,400&#160;annual rent increases
of approximately&#160;3%.&#160;In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and
certain other operating costs. The right-to-use asset and corresponding liability for the facility lease have been measured at the present
value of the future minimum lease payments. A discount rate of 11%, which approximated the Company&#8217;s incremental borrowing rate,
was used to measure the lease asset and liability. Lease expense is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company obtained a right-of-use asset of $<span id="xdx_906_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210401__20220331_zuy8Mlso2Hzh"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">270,950</ix:nonFraction></span>&#160;in exchange for its obligations under the operating lease. The landlord also provided
a lease incentive of approximately $<span id="xdx_904_ecustom--LeaseIncentiveReceived_iI_c20200630_zz6lwak7y1Je"><ix:nonFraction name="modd:LeaseIncentiveReceived" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,000</ix:nonFraction></span>, which was paid to the Company in June 2020, for the Company to make improvements to the
leased space. In addition, the Company paid a $100,000 security deposit.</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zjd3UPUssYT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B3_zPODvyMmIpik">Future
minimum payments under the facility operating lease</span>, as of March 31, 2022, are listed in the table below.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:DisclosureLeasesDetailsAbstract"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureLeasesDetailsAbstract_zEfGkyRYw1Y1" summary="xdx: Disclosure - Leases (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Annual Fiscal Years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220331_zKyWa3i8HGR3" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating<br /> lease</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_maOLFMPz3Dp_zJgm0y6XYiIf" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 87%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_maOLFMPz3Dp_zn4AfYlqTTgi" style="vertical-align: bottom; background-color: White">
    <td>2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,692</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--OperatingLeasesImputedInterest_iI_maOLFMPz3Dp_zUwbalcxHbP2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="modd:OperatingLeasesImputedInterest" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,906</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_mtOLFMPz3Dp_zpDxDQUAJu15" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,814</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A0_zetWfTG4eLw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Cash
paid for amounts included in the measurement of lease liabilities was $<span id="xdx_903_ecustom--CashPaidforLeaseLiabilities_iI_c20220331_zdmyIRf8Z9r7"><ix:nonFraction name="modd:CashPaidforLeaseLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,432</ix:nonFraction></span>&#160;for the year ended March 31, 2022. Rent expense was
$<span id="xdx_90D_eus-gaap--LeaseAndRentalExpense_c20210401__20220331_zZZ4yLuV0FP4"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,820</ix:nonFraction></span>&#160;and $<span id="xdx_90A_eus-gaap--LeaseAndRentalExpense_c20200401__20210331_zuMwVUTJfLy7"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,540</ix:nonFraction></span>&#160;for the years ended March 31, 2022 and 2021, respectively.</span></p>

</ix:nonNumeric><p id="xdx_81D_zvvqfKBIomv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>
<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:PPPNotesPayableTextBlock"><p id="xdx_802_ecustom--PPPNotesPayableTextBlock_zwLyzNrqwDae" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_82F_zGsdHjLIWy79">PPP NOTE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In April 2020, the
Company received a $<span id="xdx_902_eus-gaap--UnsecuredDebtCurrent_iI_c20200424_zlKQ23LIqb54"><ix:nonFraction name="us-gaap:UnsecuredDebtCurrent" contextRef="AsOf2020-04-24" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,780</ix:nonFraction></span> unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was established under
the U.S. government&#8217;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note to the Company was made
through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration Paycheck Protection Program
Note with the Lender evidencing the PPP Note. <span style="font-family: Times New Roman, Times, Serif; background-color: white">The full
amount of the PPP Note was due in April 2022 and interest accrued on the outstanding principal balance of the PPP Note at a fixed rate
of 1.0% per annum, which was deferred for 10 months after the covered period during which the Company used the proceeds.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
May 2021, the Lender and the U.S. Small Business Administration notified the Company that the outstanding principal and accrued interest
for the PPP Note was forgiven in full. The Company accounted for the forgiveness of the PPP Note in accordance with ASC Topic 470: <i>Debt
</i>(ASC 470), and the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the consolidated
statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_z8WfRWXbDZbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
5 &#8211;&#160;<span id="xdx_82B_zVcXpCpmCKS8">CONVERTIBLE PROMISSORY NOTES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">From
February through April 2021, the Company sold $2,310,000 of convertible promissory notes (each an Original Note and, collectively, the
Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements under
the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between each holder
of an Original Note and the Company (the Revocation Agreement), the $2,310,000 of Original Notes and accrued interest thereon as of April
30, 2021 were replaced with $2,360,550 aggregate principal amount of new Notes (as defined below). The Company accounted for the replacement
of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $<span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20210401__20220331_zcYCamrqWUTl"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,321,450</ix:nonFraction></span> and interest expense of $<span id="xdx_90D_eus-gaap--AmortizationOfFinancingCosts_c20210401__20220331_zQUOtbO3j6Kj"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,647</ix:nonFraction></span>
for unamortized debt issuance costs as of April 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
April and May 2021, pursuant to a securities purchase agreement by and between the Company and each investor (the SPA), the Company sold
to investors $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20210531__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z2v5iu1F4zA7"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2021-05-31_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,250,000</ix:nonFraction></span>&#160;aggregate principal amount of convertible promissory notes (the Notes) and warrants to purchase shares of
its common stock (the Warrants). The Notes are unsecured obligations of the Company with each Note having a stated maturity date of 12
months from its issue date (the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity, provided that,
if the Company fails to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the maximum amount
permitted by law. Each Note may be prepaid at the Company&#8217;s option during the first 270 calendar days following its Issue Date
(the 270<sup>th</sup>&#160;day, the Trigger Date), subject to a 110% prepayment penalty on outstanding principal and accrued interest
then outstanding. No Note may be prepaid in whole or in part after the Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Notes
outstanding after the Trigger Date may be converted into shares of the Company&#8217;s common stock at an initial conversion price of
$8.61 per share; provided that a Note holder may not convert any portion of its Note that would cause it to beneficially own in excess
of 4.99% of the Company&#8217;s outstanding common stock. The conversion price and number of shares of Company common stock issuable
upon conversion of the Notes are subject to adjustment from time to time for subdivisions and consolidations of shares and other standard
dilutive and corporate events, as provided in the Notes. Subject to certain Exempt Issuances (as defined in the Notes), if while a Note
is outstanding, the Company sells, issues or grants any shares of its common stock or other securities to acquire shares of common stock
at a price per share less than the then conversion price, such conversion price shall be reduced to such lesser price, and the number
of conversion shares issuable upon conversion of the Notes shall be increased, as provided in the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
the Company completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital
Raise, as defined in the Notes), each Note holder will be required to convert its Adjusted Note Amount (as defined below) into the securities
of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued interest
on a Note, multiplied by (ii) 1.25.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23E_ziDzyMdZ2Bei" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Notes contained a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal
or interest thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements
under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v) material
restatements of the Company&#8217;s consolidated financial statements filed with the SEC, (vi) a holder&#8217;s inability to rely on
Rule 144 for sales of shares underlying the Notes, (vii) the Company&#8217;s common stock is suspended or halted from trading and/or
fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New York Stock Exchange, or
the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement covering the resale of shares
of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date, (ix) failure to cause such registration
statement to become effective within 120 calendar days following the Issue Date, or (x) certain mergers consolidations, business combinations
and sales of all or substantially all of the Company&#8217;s assets in the event the Company is not the survivor of such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Upon
an Event of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required
to pay such Note holder the sum of (i) the product of (a) all then outstanding principal amount and accrued interest thereon, multiplied
by (b) 125%; and (ii) all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder,
in the event the Company receives cash proceeds as a result of certain events, including, but not limited to, payments from customers,
issuances of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay
all or any lesser outstanding amounts due under such holder&#8217;s Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Notes include covenants, representations, warranties, other payment obligations and agreements by the Company including, without limitation,
most-favored nation rights, rights of participation and first refusal and exchange rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
connection with the issuance of the Notes, the Company issued Warrants to purchase in the aggregate 767,796 shares of its common stock
at an initial exercise price of $24.00 per share. The Warrants may be exercised for a period of five years from the Trigger Date, provided
that, if prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall be cancelled
or (ii) prepays a holder&#8217;s Note(s) in whole or in part, such holder&#8217;s pro-rata number of Warrants shall be cancelled. The
fair value of the Warrants was $3,700,632, of which $2,379,182 was recorded as a debt discount, which is being amortized to interest
expense over the term of the Warrants, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated the fair
value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of&#160;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_c20210401__20220331_zvrFaqBfupHe"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">88.98</ix:nonFraction>%</span>, risk-free
interest rate of&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20220331_zkcBlEDetFLf"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.86</ix:nonFraction>%</span>, a term of&#160;<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20220331_zvgVggjNhFKi" title="::XDX::P5Y9M">5.75</span>&#160;years and a dividend yield of&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dcpxH_c20210401__20220331_zhdUmAMSitU" title="::XDX::0">zero</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
connection with the April and May 2021 sales of the $4,250,000 aggregate principal amount of the Notes, the Company incurred debt issuance
costs of $116,000, which were recorded as a debt discount and were amortized to interest expense over the term of the Notes using the
effective interest rate method. The interest expense attributable to the debt discount, comprising the debt issuance costs and Warrants,
during the year ended March 31, 2022 was $1,833,618.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Upon
the closing of the Offering (see Note 7), which was a Qualified Capital Raise, in accordance with their terms, the Notes converted into
1,511,276 shares of common stock and the holders of the Notes received 1,511,276 Offering Warrants (as defined in Note 7). </span><span style="font-size: 10pt">As
a result of the Offering, the exercise price of the 767,796 outstanding Warrants was reduced to $6.00 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:PromissoryNoteTextBlock"><p id="xdx_80E_ecustom--PromissoryNoteTextBlock_z2u9bXbvv04k" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
6 &#8211;&#160;<span id="xdx_82F_zDckORpOa8We">PROMISSORY NOTE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
October 2021, the Company issued a secured promissory note (the Bridge Note) to Manchester Explorer, L.P. (Manchester) that provided
the Company with a $<span id="xdx_90E_eus-gaap--LineOfCredit_iI_c20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zCFnQVE0RhFh"><ix:nonFraction name="us-gaap:LineOfCredit" contextRef="AsOf2021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span>&#160;revolving credit facility with all amounts being drawn down by the Company thereunder being due and
payable, subject to acceleration in the event of a default, on&#160;<span id="xdx_90A_eus-gaap--LineOfCreditFacilityExpirationDate1_c20211027__20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zx4aXHUKrJBk"><ix:nonNumeric contextRef="From2021-10-272021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember" format="ixt:datemonthdayyearen" name="us-gaap:LineOfCreditFacilityExpirationDate1">March 15, 2022</ix:nonNumeric></span>&#160;(the Maturity Date). Interest at the rate of&#160;<span id="xdx_90E_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_c20211027__20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zzQUYBlJthaa"><ix:nonFraction name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" contextRef="From2021-10-272021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction>%</span>&#160;was
payable on each drawn down without regard to the draw down date or the date when interest is paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
principal amount of the Bridge Note and interest due thereon is payable to Manchester no later than the earlier of: (i) the Maturity
Date and (ii) the date on which the Company has received proceeds in excess of $12,000,000 from a transaction or series of related transactions
occurring prior to the Maturity Date, which such transactions constitute equity financings or other issuances of the Company&#8217;s
equity securities. Provided that no Event of Default (as such term is defined in the Bridge Note) has occurred, on any date prior to
the Maturity Date, upon no less than three days written notice by the Company specifying the draw amount, Manchester will advance the
draw amount to the Company. No draw amount can be in an amount less than $100,000 or exceed an amount equal to $3,000,000 minus the aggregate
principal amount outstanding under the Bridge Note at the time of such draw request. If an Event of Default occurs and is continuing,
Manchester may declare all of the Bridge Note, including any interest and other amounts due, to be due and payable immediately.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_235_zlwUE4iy0xtl" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
connection with the issuance of the Note, on October 28, 2021, the Company entered into a security agreement with Manchester (the Security
Agreement) under which the Company granted Manchester a continuing and unconditional first priority security interest in and to any and
all of the Company&#8217;s property of any kind or description, tangible or intangible, wheresoever located and whether now existing
or hereafter arising or acquired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
fiscal 2022, the Company made draws on the Bridge Note of $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_c20220101__20220331__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zoGTIywCOln1"><ix:nonFraction name="us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet" contextRef="From2022-01-012022-03-31_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,100,000</ix:nonFraction></span>&#160;and incurred interest charges of $<span id="xdx_908_eus-gaap--LineOfCreditFacilityIncreaseAccruedInterest_c20220101__20220331__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z2aYPdruvJt9"><ix:nonFraction name="us-gaap:LineOfCreditFacilityIncreaseAccruedInterest" contextRef="From2022-01-012022-03-31_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">252,000</ix:nonFraction></span>. In February 2022,
subsequent to the completion of the Offering (see Note 7), the Bridge Note and accrued interest was paid in full, and the Security Agreement
was terminated.</span></p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zbpO896vtM7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
7 &#8211;&#160;<span id="xdx_82C_zkLTR6nQIPoj">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Public
Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
February 9, 2022, the Company entered into an underwriting agreement (the Underwriting Agreement) with Oppenheimer &amp; Co. Inc., who
acted as the representative of the several underwriters (the Underwriters), in a firm commitment underwritten public
offering (the Offering) pursuant to which, on February 14, 2022, the Company sold to the Underwriters an aggregate of 2,500,000 shares
of the Company&#8217;s common stock and 2,500,000 warrants (the Offering Warrants and, collectively with the shares of common stock,
the Units), each to purchase one share of common stock. The price to the public in the Offering was $6.00 per Unit, before underwriting
discounts and commissions. The common stock and the Offering Warrants comprising the Units were immediately separable upon issuance and
were issued separately. The Offering Warrants were exercisable immediately, have an exercise price of $6.60 per share and expire on February
14, 2027. </span><span style="font-size: 10pt">The gross proceeds from the Offering were $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220209__20220210__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvyyeihuZKHi"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-02-092022-02-10_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction></span>, before deducting underwriting discounts
and commissions and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Placements
of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Between March and December
2020, the Company completed a private placement of shares of its common stock (the 2020 Placement). The Company sold 962,387 shares of
common stock, at a purchase price of $2.87 per share, for gross proceeds of $2,762,054. The Company paid placement agent fees on the
2020 Placement of $52,256 during fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
October 2021, the Company sold <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20220331_zyY1Sh2OYWl2"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,864</ix:nonFraction></span> shares of common stock to two officers, its i) chief executive officer and ii) the chairman of
the Company&#8217;s board of directors (the Board), president, chief financial officer and treasurer, </span><span style="font-size: 10pt">at
a purchase price of $8.10 per share, for gross proceeds of approximately $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210401__20220331_zbyGWlJw4h8f"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">During
the year ended March 31, 2022, the Company issued to service providers <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210401__20220331_z7MrwBD4GZif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,000</ix:nonFraction></span> shares of common stock with a fair value of approximately $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210401__20220331_zaBE538NoP95"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">594,400</ix:nonFraction></span>. </span></p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock"><p id="xdx_806_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zwvR1qvHLnKb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
8 &#8211;&#160;<span id="xdx_82C_zmJiVGcYVxdd">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Amended
2017 Equity Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
October 2017, the Company&#8217;s Board approved the 2017 Equity Incentive Plan (the Plan) with&#160;<span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20171031_zm7ZzP5HTBpj"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2017-10-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>&#160;shares of common
stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance
under the Plan by&#160;<span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200131_zihjPVa9F3lh"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-01-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">333,334</ix:nonFraction></span>&#160;and&#160;<span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200831_zAoUN3pBCbX2"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,333,334</ix:nonFraction></span>&#160;shares, respectively. Under the Plan, eligible employees, directors and consultants
may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards
and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation Expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The expense relating
to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant
date fair value. The unamortized compensation cost, as of March 31, 2022 was $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220331_zT5d8NaRj2Ua"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,286,370</ix:nonFraction></span> related to stock options and is expected to be
recognized as expense over a weighted-average period of approximately <span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxH_c20210401__20220331_zGbmL7WHQRu7" title="::XDX::P2Y">two years</span>.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">During the year
ended March 31, 2022, the Company granted options to purchase <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zZmUpYOdOdo6"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">827,427</ix:nonFraction></span> shares of its common stock to employees, directors and consultants.
The options had 10-year terms and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zDUMfkbZk2n8"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">137,292</ix:nonFraction></span> options vested immediately when granted. The grant-date fair value was determined to be $<span id="xdx_90F_ecustom--FairValueofOptionGranted_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuP6k2wHq4q7"><ix:nonFraction name="modd:FairValueofOptionGranted" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,507,311</ix:nonFraction></span>
of which $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOlhQLFgzWQ2"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,739,490</ix:nonFraction></span> was recorded as stock-based compensation expense and included in the consolidated statements of operations for the
year ended March 31, 2022.&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zROmdypsGl47" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following assumptions were used in the
fair-value method calculations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8BC_zoHpYNToBpPe" style="display: none">Schedule of Fair Value Assumptions</span></span></p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:DisclosureStockBasedCompensationDetailsAbstract"><table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureStockBasedCompensationDetailsAbstract_z9XHVjaV0oh4" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Year
    Ended<br /> March 31,</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; width: 74%; text-align: left"><span style="font-size: 10pt">Risk-free interest rates</span></td><td style="white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_zBER1rIvYGaa"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-04-012022-03-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.8</ix:nonFraction>%</span>&#160;-&#160;<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_zFywCR536aeh"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-04-012022-03-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.42</ix:nonFraction>%</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 10pt">&#8239;</span></td><td style="white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zbmJFTQM1Rjd"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-04-012021-03-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.28</ix:nonFraction>%</span>
                                            - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zQ3CtwjxJLh2"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-04-012021-03-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.71</ix:nonFraction>%</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 10pt">&#8239;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap"><span style="font-size: 10pt">Volatility</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_z9JNunmYOGRc"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-04-012022-03-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">89</ix:nonFraction>%</span>&#160;-&#160;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_z1lvZBdoBnpg"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-04-012022-03-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">370</ix:nonFraction>%</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#8239;</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z9R3QblRW8l3"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-04-012021-03-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">87</ix:nonFraction>%</span>&#160;-&#160;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zi56RSdNQjjl"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-04-012021-03-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">127</ix:nonFraction>%</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#8239;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">Expected life (years)</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_z1dk0fEmLUBk" title="::XDX::P5Y">5.0</span>&#160;-&#160;<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_z2xQrlUIAvzb" title="::XDX::P6Y2M12D">6.2</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zDWRWGadWDW6" title="::XDX::P5Y">5.0</span>&#160;-&#160;<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z7rTiSgV3EG4" title="::XDX::P6Y">6.0</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">Dividend yield</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20210401__20220331_zA0sD2YLEeqj"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331_zxUElb8g3KA1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-04-012021-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table></ix:nonNumeric>


<p id="xdx_8A0_zuoUO200IQz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair values of
options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish
the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate was derived from
the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the
expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention
to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zRu6BcKE8fBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">A summary of stock option activity under
the 2017 Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><span id="xdx_8BF_zMfIkSaPKpo3" style="display: none">Schedule of Stock Option activity</span></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:DisclosureStockBasedCompensationDetails2Abstract"><table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zyA2icRZIRid" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2020</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zN07dgH8qnc" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2020-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">274,019</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zh6taN8bcdI5" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,059,315</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zStOdBzaNOTl" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.74</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zj1FMd9UL4Z6" style="text-align: right">(<ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">163,492</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zilPlEWvwY4a" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">163,492</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zugRVMRUlLq" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.64</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEaifwfdaMf3" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,555</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgZa1obxL5Ab" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,555</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmXrsPDd3A56" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.75</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9DbbhhUZSPb" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">136,082</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zznrrwwjWBpc" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197,252</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zppeuIunqCx8" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 9pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8ZnEI11tJT9" style="text-align: right"><ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,333,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT1z72Cazb36" style="text-align: right">(<ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">827,427</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdt5hAYptlh9" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">827,427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1xTpXcxfi9g" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.39</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 9pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFNMAhir2QMi" style="text-align: right">(<ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">26,497</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkt1VGnVC8uc" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">373,974</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1GS5esT6EK4" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">373,974</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zycqAr4T4nz4" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.73</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt">Balance at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7uZY99nQfX" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">989,466</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPUkXXw3Bfj6" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,650,705</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLM2ww6i68j7" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.58</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8AE_zihANFXSOMBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There were no
stock options exercised during the years ended March 31, 2022 and 2021. <span style="font-family: Times New Roman, Times, Serif; background-color: white">The
Company issued 26,497 shares to its non-employee directors under the Company&#8217;s outside director compensation plan and approximately
$172,100 was recorded as stock-based compensation expense for these share awards during the year ended March 31, 2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z03c6lvyxSt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table summarizes the range of outstanding and exercisable options as of March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zjWp49Tt5yt7" style="display: none">Schedule of
Outstanding and Exercisable Option, Range</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:DisclosureStockBasedCompensationDetails3Abstract"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zoodrM9W77v9" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number<br /> Outstanding</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br /> Average<br /> Remaining<br /> Contractual<br /> Life<br /> (in Years)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br /> Average<br /> Exercise<br /> Price</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number<br /> Exercisable</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br /> Average<br /> Exercise<br /> Price</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br /> Intrinsic<br /> value</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z4Zx8uZq6t04"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.98</ix:nonFraction></span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zScc5IPzvlq8"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.70</ix:nonFraction></span></td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztv9LizGFHuk" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,650,705</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmFalTPkxkqd" title="::XDX::P8Y4D" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">8.01</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx2rQfGQCbbf" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.58</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIbn9Ff9oPKe" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,193,680</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDIs0MZ8bVVa" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.69</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWcFYBds9FM9" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,090,966</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8AA_zv2bwlGHVr26" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt">The intrinsic value per share is calculated
as the excess of the closing price of the common stock on the Company&#8217;s principal trading market over the exercise price of the
option at March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company is required
to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise of stock options
as financing cash flows in the consolidated statements of cash flows. For the years ended March 31, 2022 and 2021, there were no such
tax benefits associated with the exercise of stock options.<span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></span></p>

</ix:nonNumeric><p id="xdx_813_zv5aWGg0Z7Ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><b></b></span></span></p>
<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zHCNuOA94Mk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_82D_zjD666zGVw2a">INCOME TAXES</span></b></span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zRZ0GUtDckI2" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt">The income tax provision consisted
of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_8B3_zx4q6vQzEHP1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify; text-indent: 0.5in">Schedule of Income tax provision</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:DisclosureIncomeTaxesDetailsAbstract"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIncomeTaxesDetailsAbstract_z5Xj5wj9Bbij" summary="xdx: Disclosure - INCOME TAXES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_493_20210401__20220331_zkeOSngFHGFa" style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49B_20200401__20210331_zNeHwM9IewFk" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zpkYxgiMElck" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Current portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzDQj_z0U1H3VTbeI5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzDQj_zxQgTEmomJSl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; padding-bottom: 1pt; padding-left: 8.65pt">State</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_mtCITEBzDQj_maITEBzk6Q_zcVJ8Pf0pTul" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none">Current</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zxGfMZeH6dz1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Deferred portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzmjI_zDdlTYP27n14" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,109,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,931,390</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzmjI_zEPPocySasGa" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 1pt; padding-left: 8.65pt">State</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,300,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">576,868</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBzmjI_maITEBzk6Q_zYB27mhgKC4h" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none">Deferred</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">( <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,409,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,508,258</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzk6Q_zt00bAZA7CQd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,409,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,508,258</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzk6Q_z2UYVmXh0Qif" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8AF_zXBbKbdf9xwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">At March&#160;31, 2022,
the Company had net operating loss carryforwards (NOLs) of approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zMM0IF9WiNJc"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-03-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,600,000</ix:nonFraction></span> for federal income tax purposes and $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zKmerP3981I3"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,800,000</ix:nonFraction></span>
for state income tax purposes. These NOLs are available to reduce future taxable income and will expire at various times from 2037 through
2042, except federal NOLs from fiscal 2018, 2019, 2020, 2021 and 2022, which will never expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The Company
also had federal research and development tax credit carryforwards of approximately $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z2dZO8XYRaT6"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-03-31_us-gaap_DomesticCountryMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,000</ix:nonFraction></span>, which will begin expiring at various times
from 2038 through 2041, and state research and development credits of approximately $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zXBvfmMV5YP6"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>, which do not have an expiration date.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbmw0zaVahpb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">A reconciliation of
income taxes provided at the federal statutory rate (21% for each of fiscal 2022 and 2021) to the actual income tax provision is as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_8B4_z7Y3El0yR9Zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify; text-indent: 0.5in">Schedule of Income Tax Provisions</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:DisclosureIncomeTaxesDetails2Abstract"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIncomeTaxesDetails2Abstract_zCxDEnXAR8J7" summary="xdx: Disclosure - INCOME TAXES (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_498_20210401__20220331_zkjZav6vPWtf" style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49E_20200401__20210331_zEUQkS5ZM2xi" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi0_zPXVMzzIMfY9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Federal statutory rate</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp0_zr2EbQ66OVi1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax rate, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">7</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">7</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_dp0_zzzshdWeW4B7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:EffectiveIncomeTaxRateReconciliationPermanentDifferences" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:EffectiveIncomeTaxRateReconciliationPermanentDifferences" contextRef="From2020-04-012021-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_dp0_zJPYg9wSqZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">6</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_dp0_z0Ewdr3WpXBg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Section 179 assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="From2020-04-012021-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp0_zCezYLuSSlKj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">34</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zyMqlhqEfP6" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-04-01to2022-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2020-04-012021-03-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A6_zhhXqJeN7zul" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt">The losses before income tax provision for the years ended March 31, 2022 and 2021 were solely attributable to US operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z2wHiUpXVpYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt">Significant components of the Company&#8217;s
deferred tax assets and liabilities were:&#160;</span></p>

<p id="xdx_8BF_zSFtKJkbhxw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none">Schedule of Deferred Tax Assets</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:DisclosureIncomeTaxesDetails3Abstract"><table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--DisclosureIncomeTaxesDetails3Abstract_ztyMFwQhelY3" summary="xdx: Disclosure - INCOME TAXES (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49B_20220331_zLXdyv8xcKVg" style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49C_20210331_zG7GYfOP7f46" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzv9B_zgiUXS5cPAi9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Net operating loss carryforwards</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,731,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,909,434</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzv9B_zUL8lX4sQ4Wg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,824,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">554,892</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzv9B_zISj5piaI9R3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,039</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_iNI_di_maDTAGzv9B_znDSjqxtLEHf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reserves, accruals &amp; other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,878</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_msDTAGzv9B_z210jsTZQd4l" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Research and development tax credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">988,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">646,296</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzv9B_maDTANzyHM_zDKlltF9ReTl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,519,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,012,705</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesRegulatoryAssets_iNI_di_maDITLzKZ6_zYnHFMpZWCya" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.35pt; padding-left: 8.65pt">Section 179 assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesRegulatoryAssets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0725">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzKZ6_msDTANzyHM_zkSGwJWr1jPh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0728">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzyHM_zB8LJ6Krveze" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,422,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,012,705</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzyHM_zSRhUBbR1NMl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0733">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0734">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8A3_zFEWMznONjc" style="margin-top: 0; margin-bottom: 0"></p>
<ix:exclude><!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Based on the available
information and other factors, management believes it is more likely than not that the net deferred tax assets at March 31, 2022 and
2021, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred tax assets
at March 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Management has evaluated
and concluded that there were no material uncertain tax positions requiring recognition in the Company&#8217;s consolidated financial
statements at March 31, 2022 and 2021. The Company does not expect any significant changes in its unrecognized tax benefits within twelve
months of the reporting date.</span></p>

</ix:nonNumeric><p id="xdx_810_zCB2Z6jtt4S7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>
<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="modd:RoyaltyAgreementDisclosureTextBlock"><p id="xdx_80B_ecustom--RoyaltyAgreementDisclosureTextBlock_zf11PgarAcmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_829_zhjZLtsxknH8">ROYALTY AGREEMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In July 2017, the Company
entered into a royalty agreement with its founder, then-chief executive officer, president and major shareholder (the Founder). Pursuant
to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras in return for future
royalty payments on the Company&#8217;s product. The Company is obligated to make royalty payments under the agreement to the Founder
on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each sale of a royalty product
or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will cease, and the agreement will
terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant to the agreement, reaches $10,000,000.
The Company has the option to terminate the agreement at any time upon payment, to the Founder, of the difference between total royalty
payments actually made to him to date and the sum of $10,000,000. All payments of the royalties, if due, for the preceding quarter, will
be made by the Company to the Founder within thirty days after the end of each calendar quarter.&#160;</span></p>

</ix:nonNumeric><p id="xdx_817_z2O1bwcg5yS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zLLitPwtFoDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8211; <span id="xdx_828_z40w8AJWAJ25">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Litigations,
Claims and Assessments&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the normal course
of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The
Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the ordinary course
of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses
incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from
certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating
to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification
agreements with its officers and directors. No amounts were reflected in the Company&#8217;s consolidated financial statements for the
years ended March&#160;31, 2022 and 2021 related to these indemnifications. The Company has not estimated the maximum potential amount
of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances
applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements.</span></p>

</ix:nonNumeric><p id="xdx_813_zmFfgZjGpJ3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zT2nsXj2zSZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;12
&#8211; <span id="xdx_82A_zne9W3WE2EKi">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">In
February 2021, the Company&#8217;s chairman of the Board and president and Manchester, which is represented by a member of the Company&#8217;s
board of directors, purchased $100,000 and $1,000,000, aggregate principal amount of the Original Notes, respectively. Effective April
30, 2021, the related party holders entered into revocation agreements with the Company pursuant to which their aggregate principal amount
of Original Notes and accrued interest were replaced with Notes. On February 14, 2022, Manchester and the executive officer held Notes
in an aggregate principal amount of $<span id="xdx_906_eus-gaap--NotesPayable_iI_c20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zghhcM3G4YZ6"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,026,630</ix:nonFraction></span> <span style="font-family: Times New Roman, Times, Serif; background-color: white">and
$<span id="xdx_902_eus-gaap--NotesPayable_iI_c20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zMdYkkJF0mHh"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,663</ix:nonFraction></span>, respectively, with $<span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zhpgQV7iVpyd"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,881</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zzrFRkXJV053"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,788</ix:nonFraction></span> of interest payable thereon. In connection with the Offering, Manchester and
the executive officer received <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziTege4Yrw6i"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">234,274</ix:nonFraction></span> and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziffD998r629"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,429</ix:nonFraction></span> shares of common stock, respectively, and <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zED644BLlVQ4"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">234,274</ix:nonFraction></span> and <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgWrcJIVTM77"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,429</ix:nonFraction></span> Offering Warrants, respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">In
May 2021, a member of the Board purchased $<span id="xdx_901_eus-gaap--NotesPayable_iI_c20210531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_ztX6t42rW3f"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-05-31_custom_MemberOfBoardMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>&#160;aggregate principal amount of Notes (the Director Note). On February 14, 2022,
in connection with the Offering, the Director Note and $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_zGQo3AgyGFq6"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2022-02-14_custom_MemberOfBoardMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,805</ix:nonFraction></span> of accrued interest thereon were converted into <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHbyq67fUuHd"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-02-142022-02-14_custom_MemberOfBoardMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,586</ix:nonFraction></span> shares of common
stock <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhin0K09JOw1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-02-142022-02-14_custom_MemberOfBoardMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,586</ix:nonFraction></span> Offering Warrants<span style="font-family: Times New Roman, Times, Serif; background-color: white">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The daughter of the
Company&#8217;s president, chief financial officer, treasurer and chairman of the Board is an employee of the Company. During fiscal
2022, the Company paid her $<span id="xdx_901_eus-gaap--SalariesAndWages_c20210401__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DaughterOfPresidentCFOTreasurerAndChairmanMember_zNX5dbQpjRHl"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2021-04-012022-03-31_custom_DaughterOfPresidentCFOTreasurerAndChairmanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,589</ix:nonFraction></span>, which includes the aggregate grant date fair value, as determined pursuant to FASB ASC Topic 718,
of a stock option granted in November 2021.</span></p>

</ix:nonNumeric><p id="xdx_816_zlVBssH2tse" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>
<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zQ6K9HhHbPO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 &#8211; <span><span id="xdx_828_zd1eppOUMQz2">SUBSEQUENT EVENT</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On May 2, 2022, the
Company entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor (the Investor) pursuant
to which the Company sold, in a registered direct offering (the Registered Offering), for gross proceeds of $8,000,000 an aggregate
of 449,438 shares (the Shares) of the Company&#8217;s common stock, at a purchase price per Share of $4.45 and pre-funded warrants (the
Pre-Funded Warrants) to purchase an aggregate of 1,348,314 shares of common stock at a purchase price per Pre-Funded Warrant of $4.44.
The Pre-Funded Warrants were exercisable immediately on the date of issuance at an exercise price of $0.01 per share and may be exercised
at any time until all of the Pre-Funded Warrants are exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
a concurrent private placement under the Purchase Agreement, the Company issued warrants (the Private Placement Warrants) to the Investor
to purchase an aggregate of 1,438,202 shares of common stock at an exercise price of $6.60 per share. The Private Placement Warrants
will be exercisable commencing November 5, 2022 and have a five-year term.</span></p>

</ix:nonNumeric><p id="xdx_812_zyntYRKYGqg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara012"></span>ITEM
9: CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara013"></span>ITEM
9A: CONTROLS AND PROCEDURES</span></b></span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Evaluation
of Disclosure Controls and Procedures</i></span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Disclosure controls
and procedures are designed to ensure that information required to be disclosed in the reports filed with or furnished to the Securities
and Exchange Commission, or the SEC, under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed,
summarized and reported within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include,
without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports filed under the
Exchange Act is accumulated and communicated to our management, including our chief executive officer and chief financial officer, to
allow timely decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Under the supervision
and with the participation of our management, including our chief executive officer and our chief financial officer, we conducted an
evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules&#160;13a-15(e)
and 15d-15(e) under the Securities Exchange Act of 1934 (the Exchange Act). Based on this evaluation, our management concluded that as
of March&#160;31, 2022, our disclosure controls and procedures were effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Management&#8217;s
Annual Report on Internal Control over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules&#160;13a-15(f)
and 15d-15(f) under the Exchange Act. In designing and evaluating the disclosure controls and procedures, management recognizes that
any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired
control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible
controls. Internal control over financial reporting is the process designed by, or under the supervision of, our chief executive officer
and chief financial officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance
with generally accepted accounting principles, and includes those policies and procedures that: (i)&#160;pertain to the maintenance of
records that in reasonable detail accurately and fairly reflect our transactions and dispositions of assets; (ii)&#160;provide reasonable
assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally
accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management
and directors; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use
or disposition of our assets that could have a material effect on the financial statements.</span></p>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Because of its inherent
limitations, cost-effective internal controls over financial reporting may not prevent or detect misstatements. All internal control
systems, no matter how well designed, have inherent limitations, including the possibility of human error and the circumvention of overriding
controls. Accordingly, even effective internal control over financial reporting can provide only reasonable assurance with respect to
consolidated financial statement preparation. Also, projections of any evaluation of effectiveness to future periods are subject to the
risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures
may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Under the supervision
and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an assessment
of the effectiveness of our internal control over financial reporting as of the end of the period covered by this Annual Report on Form
10-K. In making this assessment, we used the criteria based on the framework in&#160;<span style="font-family: Times New Roman, Times, Serif"><i>Internal
Control&#8212;Integrated Framework (2013 Framework)</i></span>&#160;issued by the Committee of Sponsoring Organizations of the Treadway
Commission. Based on the assessment, our management concluded that our internal control over financial reporting was effective as of
March&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Changes
in Internal Control over Financial Reporting&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">There were no changes in our internal controls
over financial reporting during the fourth fiscal quarter of 2022 that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara014"></span>ITEM
9B: OTHER INFORMATION</span></b></span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara015"></span>ITEM
9C: DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Not applicable</span></p>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara016"></span>ITEM
10: DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The names of our directors, executive officers
and certain information about each of them at March 31, 2022 are set forth below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 66%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Besser</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    DiPerna</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Financial Officer, Treasurer and Chairman of the Board of Directors</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="margin: 0">William J. Febbo(1)</p>


</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">53</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Felsher(2)(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">73</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan
    C. Frank</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="margin: 0">Philip Sheibley(2)(3)</p>


</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">63</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="margin: 0">Carmen Volkart(1)(2)</p>


</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="margin: 0">Ellen O&#8217;Connor Vos</p>


</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">66</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 5%; padding-top: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 95%; padding-top: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of Compensation Committee </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of &#160;Audit Committee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of Nominating and Governance Committee</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The principal occupations
and positions for at least the past five years of our directors and executive officers are described below. There are no family relationships
among any of our directors or executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>James
&#8220;Jeb&#8221; Besser</i>. Mr. Besser has served as our chief executive officer since February 23, 2022 and combines over 25 years
of experience in alternative investments, strategic advisory, corporate strategy and corporate governance. Since 1999, he has been a
Managing Member at Manchester Management Company, LLC (Manchester), an investment management firm. Mr. Besser is also currently a director
of River Stone Biotech, a development stage specialty bioprocessing company. He holds a B.A. in history from Brown University. We believe
that Mr. Besser is qualified to serve as member of our board of directors due to his extensive prior experience conducting financial
analysis of public companies (certain of which were in the development stage), including such public companies&#8217; management teams,
products, including products in the development stage, the potential markets for such products and other factors that could affect the
likelihood and timing of success and market penetration of such entities&#8217; products as well as his capital raising activities. We
believe this provides us with valuable insights into the financial markets and investment criteria of institutional and other investors
as well as capital raising activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Paul
DiPerna.&#160;</i></span><span style="font-size: 10pt">Mr. DiPerna has been our chairman, chief financial officer, president and treasurer
since we acquired Quasuras, Inc. (Quasuras) in July 2017. He also served as our chief executive officer from July 2017 until August 2021.
In 2015, he founded Quasuras, an early-stage medical device company developing an insulin pump product, and, until its acquisition by
us, he served as its chief executive officer and chairman. Prior to that, Mr. DiPerna founded Fuel Source Partners, LLC to incubate early
stage medical device products and accumulate technical talent. Our current pump product was one of such proposed products and was spun-out
to Quasuras in 2015. From 2012 to 2015, he served as a co-inventor at a private company with property rights in a medical device used
for blood borne infection control called the Curos Cap, which was acquired by 3M Corporation. In 2003, Mr. DiPerna founded Tandem Diabetes
Care, Inc. (Tandem) and held various positions, including as director, chief executive officer and chief technology officer and was primarily
responsible for the design concept and development of Tandem&#8217;s initial insulin pump. Prior to that, he held executive and management
positions at Baxter Healthcare Corporation (Baxter) where he was tasked with identifying synergistic opportunities in the diabetes industry.
As a result, Mr. DiPerna developed substantial expertise and knowledge in the diabetes industry and led attempts by Baxter to acquire
three insulin pump manufacturers. Previously, he held mechanical design engineering positions in the automated test equipment and blood
separation sciences industries. Mr. DiPerna holds 70 patents in medical device and microfluidic technology and has achieved numerous
product clearances with the FDA. He has also achieved multiple successful exits with previous companies. Mr. DiPerna received a Masters
in Engineering Management from Northeastern University and a B.S. in Mechanical Engineering from the University of Massachusetts and
has spent over 35 years in the medical-device industry. We believe that Mr. DiPerna is qualified to serve as the chairman of our board
of directors due to his extensive knowledge and experience in the medical-device industry generally, and, in particular, with regard
to insulin pumps and the diabetes industry, as well as his management and leadership experience from holding director and senior executive
positions in other public and private companies and leading project development teams of medical device companies.</span></p>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>William
J. Febbo.</i><b>&#160;</b></span><span style="font-size: 10pt">Mr. Febbo was appointed to our board of directors in January 2020. He
is currently the Chief Executive Officer and a director of OptimizeRx Corporation, a digital health company focused on bringing life
sciences support to patients and providers, having joined the company in 2016. Since April 2022, he has served as member of the board
of directors of Augmedix, Inc., a Nasdaq-listed provider of automated medical documentation and data services. Mr. Febbo founded Plexuus,
LLC, a payment processing business for medical professionals in September 2015 and remained its Chairman from September 2015 to December
2020. From April 2007 to September 2015, he served as Chief Operating Officer of Merriman Holdings, Inc., an investment banking firm,
where he assisted with capital raises in the technology, biotechnology, clean technology, consumer and resources industries. Mr. Febbo
was a co-founder of, and from September 2013 to September 2015 served as Chief Executive Officer of, Digital Capital Network, Inc. a
transaction platform for institutional and accredited investors. He was a co-founder of, and from January 1999 to September 2015 was
Chief Executive Officer of, MedPanel, LLC, a provider of market intelligence and communications for the pharmaceutical, biomedical, and
medical device industries. Since 2017, Mr. Febbo has been a faculty member of the Massachusetts Institute of Technology&#8217;s linQ
program, which is a collaborative initiative focused on increasing the potential of innovative research to benefit society and the economy.
Since 2004, he has been a board member of the United Nations Association of Greater Boston, a resource for the citizens of Greater Boston
on the broad agenda of critical global issues addressed by the United Nations and its agencies. He holds a B.A. in international studies
and Spanish from Dickinson College. We believe that Mr. Febbo is qualified to serve on our board of directors because of his wealth of
experience in building and managing health services and financial businesses. Mr. Febbo brings more than 20 years of experience in building
and managing health services and financial businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On January 29, 2018,
the Financial Industry Regulatory Authority (FINRA) accepted a Letter of Acceptance, Waiver and Consent (the Consent) submitted by Mr.
Febbo. Without admitting or denying the findings, Mr. Febbo consented to the sanctions and to the entry of findings that he permitted
Merriman Capital, Inc. to conduct a securities business while below its net capital requirement. From August 2012 to October 2015, he
was the Financial and Operations Principal (FinOp) for a registered broker-dealer, Merriman Capital, Inc. (Merriman). During certain
months, while Mr. Febbo was FinOp, FINRA found that certain of Merriman&#8217;s net capital filings with FINRA were inaccurate because
of the method by which Merriman calculated net capital and that, when corrected, it was retroactively determined that Merriman had operated
below its minimum net capital requirements. Mr. Febbo, as FinOp, signed certain of these reports and was thus held responsible. Based
on the Consent, in settlement, Mr. Febbo, who was then no longer registered with any broker-dealer, accepted a fine of $5,000, a 10-business
day suspension from acting as FinOp for any FINRA member and required to requalify by examination for the Series 27 license before again
acting in a FinOp capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Steven
Felsher. </i></span><span style="font-size: 10pt">Mr. Felsher was appointed to our board of directors in November 2021. Mr. Felsher is
an experienced executive with respect to finance, administration, governance and other aspects of public and private company management.
He has served as a member of the board of directors of Signal Hill Acquisition Corp., a special purpose acquisition company, since March
2021. From August 2018 to July 2020, he served as a member of the board of directors of Sito Mobile, Inc., a publicly-traded company
that provided customized, data-driven solutions for brands spanning all forms of media. From January 2011 to June 2019, Mr. Felsher was
a senior advisor at Quadrangle Group LLC, a private investment firm focused on the information and communications technology sectors.
He spent a substantial portion of his career with Grey Global Group Inc., a global marketing services company, where he served as a senior
executive from 1979 until 2007, most recently as vice chairman and chief financial officer. He holds a BA in classical Greek from Dickinson
College and a J.D. from Yale University School of Law. We believe that Mr. Felsher is qualified to serve on our board of directors because
of his extensive business experience with administration, governance, capital allocation and other aspects of public and private company
management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Morgan
C. Frank.&#160;</i></span><span style="font-size: 10pt">Mr. Frank was appointed to our board of directors in April 2017. Mr. Frank has
worked with Manchester, LP since May 2002, and, prior to such time, he was a founder and managing director at First Principles Group,
a boutique consultancy and principal investor specializing in corporate restructuring, restarts, intellectual property assessment and
salvage, and spin outs. Prior to such time, Mr. Frank spent approximately five years as an analyst and portfolio manager at Hollis Capital,
a San Francisco based hedge fund and prior thereto, Mr. Frank worked for an independent private client group at Paine Webber specializing
in primary research to develop investment ideas (particularly short sale ideas) for institutional clients. Prior to his employment at
Paine Webber, Mr. Frank was a currency trader for Eastern Vanguard. Mr. Frank holds a BA in Economics and in Political Science from Brown
University. We believe that Mr. Frank is qualified to serve as member of our board of directors due to his extensive prior experience
conducting financial analysis of public companies (certain of which were in the development stage), including such public companies&#8217;
management teams, products, including products in the development stage, the potential markets for such products and other factors that
could affect the likelihood and timing of success and market penetration of such entities&#8217; products as well as his capital raising
activities. We believe this provides us with valuable insights into the financial markets and investment criteria of institutional and
other investors as well as capital raising activities.</span></p>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Philip
Sheibley. </i></span><span style="font-size: 10pt">Mr. Sheibley was appointed to our board of directors in November 2021. Mr. Sheibley
is an experienced executive and venture capitalist. Since 2011, he has served as a principal at Alumni Investment Partners, a private
equity firm. From 1981 to 2010, Mr. Sheibley served as a management and technology consultant with Accenture, where he focused on the
life sciences area, holding a variety of leadership positions, including North American industry director for life sciences and global
lead for management consulting. Mr. Sheibley holds a B.S. in industrial and systems engineering with a business minor from Lehigh University.
We believe that Mr. Sheibley is qualified to serve on our board of directors because of his extensive business experience in the life
sciences area and experience with venture capital investment and consulting, including financing transactions for early-stage and scale-up
stage companies, assisting with scale-up strategy/execution, and participating as a board member in the medical products industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Carmen
Volkart.&#160;</i></span><span style="font-size: 10pt">Ms. Volkart<span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span>was
appointed to our board of directors in December 2019. She has served as chief financial officer of Natureworks LLC, an advanced materials
company offering a portfolio of renewably-sourced polymers, since October 2018. Ms. Volkart served as a member of the board of directors,
including as a member of the audit committee of Antares Pharma, Inc., a Nasdaq-listed, specialty pharmaceutical company, from October
2021 to May 2022, when it was acquired by another Nasdaq-listed company. From October 2012 to July 2018, she served as chief financial
officer and, for a portion of that time, as senior vice president of commercialization for NxThera, Inc., a medical device company pioneering
the application of convective radiofrequency thermotherapy to treat endurological conditions. Ms. Volkart served as global chief financial
officer of Tornier N.V. from 2010 to 2012, and was chief operating and financial officer, corporate secretary, compliance officer and
treasurer of Spine Wave, Inc. from 2006 to 2010. Prior to 2006, she held various executive and financial positions at American Medical
Systems, Inc., Medtronic, Inc. and Honeywell, Inc. Ms. Volkart holds a B.S. in accounting from the University of North Dakota
and an MBA with a concentration in strategic management from the University of Minnesota. We believe that Ms. Volkart is qualified to
serve on our board of directors because of her substantial financial and public-company experience, as she has served as chief financial
officer at multiple medical device and other companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Ellen
O&#8217;Connor Vos. </i></span><span style="font-size: 10pt">Ms. Vos was appointed to our board of directors in May 2021 and served as
our chief executive officer from August 2021 until February 23, 2022. Ms. Vos has served as a member of VosHealth LLC since November
2020. Prior to that, she served as the president and chief executive officer of the Muscular Dystrophy Association from October 2017
to November 2020. Previously, Ms. Vos had been chief executive officer of ghg | greyhealth group from 1996 to 2017, and she has been
a champion of using digital capabilities to improve the public health. Ms. Vos also serves on the board of OptimizeRX Corporation, a
publicly-traded digital health company, and the Jed Foundation, a leading nonprofit dedicated to protecting the emotional health of college
students, and was a founding board member of MMRF, a pioneering cancer research foundation. Ms. Vos holds a B.S. in nursing from Alfred
University. We believe that Ms. Vos is qualified to serve on our board of directors because of her executive experience and extensive
executive skills in digital marketing, commercialization and communications in the healthcare industry.<span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Involvement
in Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Except with regard
to Mr. Febbo, to our knowledge, none of our executive officers or our directors has, during the last ten years:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">had
                                            any bankruptcy petition filed by or against the business or property of the person, or of
                                            any partnership, corporation or business association of which he was a general partner or
                                            executive officer, either at the time of the bankruptcy filing or within two years prior
                                            to that time;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
                                            subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated,
                                            of any court of competent jurisdiction or federal or state authority, permanently or temporarily
                                            enjoining, barring, suspending or otherwise limiting, his or her involvement in any type
                                            of business, securities, futures, commodities, investment, banking, savings and loan, or
                                            insurance activities, or to be associated with persons engaged in any such activity;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
                                            found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity
                                            Futures Trading Commission to have violated a federal or state securities or commodities
                                            law, and the judgment has not been reversed, suspended, or vacated;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
                                            the subject of, or a party to, any federal or state judicial or administrative order, judgment,
                                            decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement
                                            of a civil proceeding among private litigants), relating to an alleged violation of any federal
                                            or state securities or commodities law or regulation, any law or regulation respecting financial
                                            institutions or insurance companies including, but not limited to, a temporary or permanent
                                            injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent
                                            cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting
                                            mail or wire fraud or fraud in connection with any business entity; or</span></td></tr></table>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">been
                                            the subject of, or a party to, any sanction or order, not subsequently reversed, suspended
                                            or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange
                                            Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act),
                                            or any equivalent exchange, association, entity or organization that has disciplinary authority
                                            over its members or persons associated with a member.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To our knowledge, there
are no material proceedings to which any director, officer or affiliate of ours, any owner of record or beneficially of more than 5%
of any class of voting securities of us, or any associate of any such director, officer, affiliate of ours, or security holder is a party
adverse to us or any of our subsidiaries or has a material interest adverse to us or any of our subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Arrangements
for Appointment of Directors and Officers&#160;</b></span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Pursuant to the Reorganization
and Share Exchange Agreement dated as of July 24, 2017, by and among us, Quasuras, Mr. DiPerna and the other stockholders of Quasuras
(the Share Agreement), until July 24, 2022, our board of directors shall consist of no more than five and no less than two directors
of which (i) Manchester has the right to appoint two directors, pursuant to which Manchester appointed Mr. Frank and Ms. Volkart and
(ii) Mr. DiPerna, in addition to being our chairman of the board, has the right to appoint two additional directors, pursuant to which
he appointed Messrs. Burns and Febbo. In May 2021, the parties amended the Share Agreement and removed Manchester&#8217;s and Mr. DiPerna&#8217;s
rights to appoint directors. In addition, the parties agreed that Mr. DiPerna shall remain chairman of our board of directors until July
2022; provided, that in the event Mr. DiPerna resigns or is otherwise replaced as our chief executive officer, Mr. DiPerna shall remain
as chairman of our board of directors for an additional period of three years. Following such amendment, our board of directors increased
the size of the board to six members and, on May 18, 2021, appointed Ellen O&#8217;Connor Vos to our board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
DiPerna Employment and Related Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We entered into an
employment agreement dated August 1, 2018, with Mr. DiPerna pursuant to which Mr. DiPerna was employed by us as our chief executive officer
and president for an initial 2-year term with automatic one-year renewals. Pursuant to such agreement, we agreed to pay Mr. DiPerna:
i) an annual salary of $200,000 in cash, ii) $100,000 per year in fully-vested stock options granted monthly at an exercise price determined
by our board of directors in its sole discretion and iii) an annual bonus of $300,000, payable at the discretion of our board of directors,
either in shares or in cash. If the board chooses to pay the bonus in shares, such shares will be valued at a price determined by our
board of directors. Pursuant to such employment agreement (i) if (a) we terminate Mr. DiPerna&#8217;s employment without cause or he
resigns with good reason, we will pay Mr. DiPerna a lump sum of $200,000, and (b) we terminate Mr. DiPerna&#8217;s employment for cause,
we are not obligated to make any severance payment and Mr. DiPerna will receive only his base compensation through the last day of his
employment, (ii) upon Mr. DiPerna&#8217;s death or disability, he will receive his base compensation through the last day of his employment
and will remain eligible for all applicable benefits relative to death or disability pursuant to any plans that we have in place at such
time, and (iii) upon a change of control (as defined in the employment agreement), Mr. DiPerna will be paid a lump sum of $100,000 within
sixty days of the time at which such change of control takes place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In May 2020,
we amended our employment agreement with Mr. DiPerna to provide that in the event of a change in control:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">within
                                            60 days of the date the change in control occurs, Mr. DiPerna shall be paid by us or our
                                            successor in interest a lump sum cash payment equal to 12 months of Mr. DiPerna&#8217;s then
                                            annual Base Compensation (as defined in the employment agreement); and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">immediately
                                            prior to such change of control, any unvested stock options or other unvested securities
                                            of ours issued to Mr. DiPerna shall automatically accelerate and immediately become fully
                                            vested and exercisable.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In June 2020, our board
of directors approved an amendment to the employment agreement to provide that Mr. DiPerna&#8217;s base salary would be paid entirely
in cash commencing July 1, 2020. The payment of the additional cash component of Mr. DiPerna&#8217;s annual base salary ($8,333.33 per
month) was initially be deferred (the Deferred Salary) and accrue for Mr. DiPerna&#8217;s benefit until the Company has received $5,000,000
of cumulative gross proceeds of financing, at which time the Deferred Salary shall be paid to Mr. DiPerna and the salary deferrals will
cease. The salary deferrals ceased and the Deferred Salary was paid to Mr. DiPerna in May 2021. In August 2021, Mr. DiPerna resigned
as our chief executive officer, and he continues to serve as our president, chief financial officer, treasurer and chairman of our board
of directors.</span></p>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If a change of control
occurred on March 31, 2022, under his employment agreement, Mr. DiPerna would be entitled to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
                                            of a lump sum of $300,000 within 60 days of the time at which such change of control takes
                                            place; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accelerated
                                            vesting of 27,778 shares of common stock under an unvested stock option. The value of the
                                            shares subject to accelerated vesting is calculated as the intrinsic value per share multiplied
                                            by the number of shares that would become fully vested upon a change of control. The intrinsic
                                            value per share would be calculated as the excess of the closing price of the common stock
                                            of $4.40 on the Nasdaq Capital Market on March 31, 2022 over the exercise price of the option.
                                            As of March 31, 2022, the intrinsic value was zero.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In connection with
our acquisition of Quasuras, we entered into an Intellectual Property Transfer Agreement dated as of July 24, 2017, with Quasuras and
Mr. DiPerna, pursuant to which Mr. DiPerna transferred to us all intellectual property rights owned directly and/or indirectly by him
related to our business. Separately, we agreed to pay Mr. DiPerna, as part of his compensation for services to be performed for us, pursuant
to a royalty agreement, certain fees based upon future sales, if any, of our potential product subject to a maximum $10,000,000 cap on
the aggregate amount of fees that Mr. DiPerna could earn from such arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Vos Employment Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On August 11, 2021,
we entered into a two-year employment agreement (the Agreement) with Ms. Vos for her service as our chief executive officer, and the
Agreement renews for one-year terms, unless either party provides the other with 90-day prior written notice of termination. The Agreement
provided that Ms. Vos was entitled to total base compensation of $300,000 annually, as follows: a cash salary of $250,000 per year (the
Cash Salary), plus deferred salary of $50,000 per year (the Deferred Salary and, together with the Cash Salary, the Base Compensation).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">On
February 23, 2022, Ms. Vos informed our board of directors that she was resigning from her position as our chief executive officer,
effective immediately (the Resignation). In connection with the Resignation, we and Ms. Vos entered into a Severance and Release
Agreement dated February 23, 2022 (the Separation Agreement). Pursuant to the Separation Agreement, Ms. Vos is entitled to receive
separation payments in an aggregate gross amount of $375,000. Under the terms of the Separation Agreement, the vesting of an option
to purchase 362,452 shares of the Company&#8217;s common stock, which was granted to Ms. Vos on August 11, 2021, ceased
on May 24, 2022 and the remaining unvested shares were forfeited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Communications
with our Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Stockholders who desire
to communicate with the board of directors, or a specific director, may do so by sending the communication addressed to either the corporate
secretary, the board of directors or any individual director, c/o Modular Medical, Inc., 16772 West Bernardo Drive, San Diego, California
92127. These communications will be delivered to the board of directors, or any individual director, as specified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Board
Leadership Structure and Role in Risk Oversight</i></b></span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">Due to the small size
and early stage of the Company, we have not adopted a formal policy on whether the chairman and chief executive officer positions should
be separate or combined. Since 2017, Mr. DiPerna has been serving as our chairman, and, since February 23, 2022, Mr. Besser has been
serving as our chief executive officer. Our board of directors has oversight responsibility for our risk management processes. Our board
of directors receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate, regarding
our assessment of risks. Our board of directors will focus on the most significant risks facing us and our general risk management strategy,
and also ensure that risks undertaken by us are consistent with our appetite for risk. While our board of directors oversees our risk
management processes, management is responsible for day-to-day risk management processes. We believe this division of responsibilities
is the most effective approach for addressing the risks facing us and that the leadership structure of our board of directors supports
this approach.<span style="font-family: Times New Roman, Times, Serif"><b>&#160;<i>&#160;</i></b></span></span></p>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have established
an audit committee, a compensation committee, and a nominating and governance committee. Each committee&#8217;s members and functions
are described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">Our board of
directors established the audit committee (the Audit Committee) for the purpose of overseeing the accounting and financial reporting
processes and audits of our financial statements. The Audit Committee also is charged with reviewing any internal control violations
under our whistleblower policy. The responsibilities of our audit committee are described in the Audit Committee Charter adopted by our
board of directors, a current copy of which can be found on the investors section of our website, www.modular-medical.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Ms. Volkart, Mr. Felsher
and Mr. Sheibley are the current members of the Audit Committee. Mr. Felsher serves as the chairperson and has been designated by the
board of directors as the &#8220;audit committee financial expert,&#8221; as defined by Item 407(d)(5) of Regulation S-K under the Securities
Act of 1933, as amended, and the Exchange Act. That status does not impose duties, liabilities or obligations that are greater than the
duties, liabilities or obligations otherwise imposed on her as a member of the audit committee and the board of directors, however. Our
board of directors has determined that each of our Audit Committee members satisfies the &#8220;independence&#8221; requirements of the
Nasdaq listing rules and meets the independence standards under Rule 10A-3 under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our board of directors
established a compensation committee for the purpose of&#160;<span style="font-family: Times New Roman, Times, Serif">reviewing, recommending
and approving our compensation policies and benefits, including the compensation of all of our executive officers and directors</span>.&#160;<span style="font-family: Times New Roman, Times, Serif; background-color: white">Mr.
Febbo and Ms. Volkart are the current members of the compensation committee, and Mr. Febbo serves as the chairperson.</span> Each of
our compensation committee members satisfies the &#8220;independence&#8221; requirements of the Nasdaq listing rules and meets the independence
standards under Rule 10A-3 under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
compensation committee is responsible for reviewing, recommending and approving our compensation policies and benefits, including the
compensation of all of our executive officers and directors, and it also has the principal responsibility for the administration of our
equity incentive plan. The responsibilities of our compensation committee are more fully described in the Compensation Committee Charter
adopted by our board of directors, a current copy of which can be found on the investors section of our website,&#160;www.modular-medical.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
and Corporate Governance Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Nominating and
Governance Committee consists of Mr. Sheibley and Mr. Felsher, and Mr. Sheibley serves as the chairperson. Each of the members of our
Nominating and Governance Committee satisfies the &#8220;independence&#8221; requirements of the Nasdaq listing rules and meets the independence
standards under Rule 10A-3 under the Exchange Act. The Nominating and Governance Committee will consider persons recommended by stockholders
for inclusion as nominees for election to our board of directors if the information required by our bylaws is submitted in writing in
a timely manner addressed and delivered to our secretary at the address of our executive offices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Nominating and
Governance Committee will identify and evaluate nominees for our board of directors, including nominees recommended by stockholders,
based on numerous factors it considers appropriate, some of which may include strength of character, mature judgment, career specialization,
relevant technical skills, diversity, and the extent to which the nominee would fill a present need on our board of directors. The responsibilities
of our Nominating and Governance committee are more fully described in the Nominating and Governance Committee Charter adopted by our
board of directors, a current copy of which can be found on the investors section of our website, www.modular-medical.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Business Conduct and Ethics for Employees, Executive Officers and Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have adopted a Code
of Business Conduct and Ethics, or the Code of Conduct, applicable to all of our employees, executive officers and members of our board
of directors. The Code of Conduct is available on our website at www.modular-medical.com. Our Nominating and Governance Committee is
responsible for overseeing the Code of Conduct, and our board of directors must approve any waivers of the Code of Conduct. In addition,
we intend to post on our website all disclosures that are required by law concerning any amendments to, or waivers from, any provision
of the Code of Conduct.</span></p>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Board
Diversity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We seek diversity in
experience, viewpoint, education, skill, and other individual qualities and attributes to be represented on our board of directors. We
believe directors should have various qualifications, including individual character and integrity; business experience; leadership ability;
strategic planning skills, ability, and experience; requisite knowledge of our industry and finance, accounting, and legal matters; communications
and interpersonal skills; and the ability and willingness to devote time to our company. We also believe the skill sets, backgrounds,
and qualifications of our directors, taken as a whole, should provide a significant mix of diversity in personal and professional experience,
background, viewpoints, perspectives, knowledge, and abilities. Nominees are not to be discriminated against on the basis of race, religion,
national origin, sex, sexual orientation, disability, or any other basis proscribed by law. The assessment of prospective directors is
made in the context of the perceived needs of our board of directors from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All of our directors
have held high-level positions in business or professional service firms and have experience in dealing with complex issues. We believe
that all of our directors are individuals of high character and integrity, are able to work well with others, and have committed to devote
sufficient time to the business and affairs of our company. In addition to these attributes, the description of each director&#8217;s
background set forth above indicates the specific qualifications, skills, perspectives, and experience necessary to conclude that each
individual should continue to serve as a director of ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delinquent
Section&#160;16(a)&#160;Reports</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">Section&#160;16(a)&#160;of
the Exchange Act requires our directors, executive officers and persons who own more than 10% of a registered class of our equity securities
to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other equity securities of
ours. Directors, executive officers and greater than 10% holders are required by SEC regulation to furnish us with copies of all Section&#160;16(a)&#160;reports
they file. Based on our review of Forms&#160;3 and 4 filed during fiscal 2022 (and any written representations to us by such persons),
we believe that all directors, executive officers and 10% stockholders complied with all applicable Section&#160;16(a)&#160;filing requirements
during fiscal 2022, except that:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                            DiPerna failed to timely file&#160;a Form 4; </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                            Felsher failed to timely file a Form 3 and a Form 4; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                            Febbo failed to timely file&#160;a Form 4.</span></td></tr></table>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara017"></span>ITEM
11. EXECUTIVE COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
COMPENSATION TABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following table sets forth compensation
information for fiscal 2022 and 2021 for each of our named executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name and Principal<br /> Position</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary<br /> ($)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock<br /> Awards<br /> ($)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br /> Awards<br /> ($)(1)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Equity<br /> Incentive<br /> Plan<br /> Compensation<br /> ($)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All<br /> Other<br /> Compensation<br /> ($)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br /> ($)</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 31%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Paul DiPerna, President, Chief Financial Officer,</td><td style="width: 2%">&#160;</td>
    <td style="width: 6%; text-align: center">2022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">370,833</td><td style="width: 1%; text-align: left">(3)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">370,833</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">&#160;&#160;&#160;Treasurer and Chairman (2)</td><td>&#160;</td>
    <td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">(4)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">275,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">James E. Besser, Chief Executive Officer (5)</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Ellen O&#8217;Connor Vos, Chief Executive Officer (6)</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,654</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,414,645</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">409,662</td><td style="text-align: left">(7)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,957,961</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Stephen Daly, Chief Commercial Officer (8)</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,046</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,441</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-top: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 97%; padding-top: 2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Award
    amounts reflect the aggregate grant date fair value with respect to awards granted, as determined pursuant to FASB ASC &#160;Topic
    718. The assumptions used to calculate the aggregate grant date fair value of option awards are set forth in the notes to the consolidated
    financial statements included in item 8 of this Report. These amounts do not reflect actual compensation earned or to be earned by
    our named executive officers.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
    August 2018 until June 30, 2020, Mr. DiPerna&#8217;s $300,000 annual salary was paid $200,000 in cash and $100,000 in fully-vested
    stock options granted monthly. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    payment of $70,833 of deferred salary.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earned
    as a bonus of which $22,000 was paid on April 30, 2021, and the remainder was paid in quarterly installments commencing on July 15,
    2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
    Besser was appointed our chief executive officer in February 2022 and <span style="background-color: white">is paid <i>de minimis
    </i>compensation of $1.00 per year</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
    Vos was appointed our chief executive officer in August 2021 at an annual cash salary of $250,000 per year plus deferred salary of
    $50,000 per year. She resigned as our chief executive officer in February 2022. The compensation amounts disclosed in the table above
    exclude amounts paid to Ms. Vos for her service as a non-employee director.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">(7)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Represents
                                            payment during fiscal 2022 of i) accrued holiday and vacation pay, ii) deferred salary and
                                            iii) three months of salary for the notice period and accrued severance of $300,000 that
                                            will be paid in fiscal 2023.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Mr. Daly became our chief commercial officer in
    March 2020 at an annual base salary of $250,000. In February 2021, Mr. Daly converted to part time, and his annual base salary was
    reduced to $125,000. Mr. Daly resigned as our Chief Commercial Officer in September 2021, and we and Mr. Daly entered into a consulting
    arrangement pursuant to which Mr. Daly provides services to us on a part-time basis.</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The following
table shows certain information regarding outstanding equity awards held by our named executive officers as of March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Name</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br /> Securities<br /> Underlying<br /> Unexercised<br /> Options (#)<br /> Exercisable</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: left">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br /> Securities<br /> Underlying<br /> Unexercised<br /> Options (#)<br /> Unexercisable</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br /> Exercise<br /> Price($)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br /> Expiration<br /> Date(1)</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 49%; text-align: left">Paul DiPerna</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,155</td>
    <td style="vertical-align: bottom; width: 2%; text-align: left">(2)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">9.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 8%; text-align: right">6/1/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,169</td>
    <td style="vertical-align: bottom; text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/1/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,170</td>
    <td style="vertical-align: bottom; text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">4/1/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,660</td>
    <td style="vertical-align: bottom; text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/2/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,745</td>
    <td style="vertical-align: bottom; text-align: left">(6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">2/1/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,727</td>
    <td style="vertical-align: bottom; text-align: left">(7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/1/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,809</td>
    <td style="vertical-align: bottom; text-align: left">(8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/1/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,811</td>
    <td style="vertical-align: bottom; text-align: left">(9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/1/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,721</td>
    <td style="vertical-align: bottom; text-align: left">(10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">10/1/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,662</td>
    <td style="vertical-align: bottom; text-align: left">(11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">9/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,666</td>
    <td style="vertical-align: bottom; text-align: left">(12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">8/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,660</td>
    <td style="vertical-align: bottom; text-align: left">(13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">7/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,650</td>
    <td style="vertical-align: bottom; text-align: left">(14)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">6/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,677</td>
    <td style="vertical-align: bottom; text-align: left">(15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,624</td>
    <td style="vertical-align: bottom; text-align: left">(16)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">4/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,694</td>
    <td style="vertical-align: bottom; text-align: left">(17)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,641</td>
    <td style="vertical-align: bottom; text-align: left">(18)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">2/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,603</td>
    <td style="vertical-align: bottom; text-align: left">(19)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,775</td>
    <td style="vertical-align: bottom; text-align: left">(20)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/15/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,775</td>
    <td style="vertical-align: bottom; text-align: left">(21)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/15/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,005</td>
    <td style="vertical-align: bottom; text-align: left">(22)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">10/15/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,005</td>
    <td style="vertical-align: bottom; text-align: left">(23)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">09/15/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,005</td>
    <td style="vertical-align: bottom; text-align: left">(24)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">08/15/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,222</td>
    <td style="vertical-align: bottom; text-align: left">(25)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,778</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/25/2029</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    standard option term is ten years, but all of the options expire automatically unless exercised within 90&#160;days after the cessation
    of service as an employee, director or consultant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    option was granted on June 1, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    option was granted on May 1, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    option was granted on April 1, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    option was granted on March 2, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    option was granted on February 1,2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    option was granted on January 1, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    option was granted on December 1, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    option was granted on November 1, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on October 1, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on September 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on August 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on July 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on June 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on May 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on April 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on March 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on February 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on January 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on December 15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on November 15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
</table>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on October 15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on September 15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on August 15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
option was granted on November 25, 2019, and the shares subject to this option vest monthly over three years commencing January 1, 2020,
subject to continued service as an employee, director or consultant.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have entered into
our standard form of employment, confidential information and invention assignment agreement with each of our named executive officers.
We also have entered into agreements to indemnify our directors and executive officers, in addition to the indemnification provided for
in our certificate of incorporation and bylaws. These agreements, among other things, provide for indemnification of our directors and
certain executive officers for many expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by any
such person in any action or proceeding, including any action by or in the right of the Company, arising out of such person&#8217;s services
as a director or executive officer of ours, any subsidiary of ours or any other company or enterprise to which such person provided services
at our request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective April 1,
2021, our board of directors approved our outside (non-employee) director compensation plan (the Director Plan). Pursuant to the Director
Plan, outside directors are paid the following annual retainers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 24px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ 25,000
    for service as a member of the board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$5,000
    for service as chair of the audit committee; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$5,000
    for service as chair of the compensation committee.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The annual retainers
will be paid in quarterly installments in either cash, options to purchase shares of our common stock or in shares of our common stock,
as directed by each director based on an annual election. In addition, under the Director Plan, each director will also receive an annual
service equity award of $100,000 paid in quarterly installments in either options to purchase shares of our common stock or shares of
our common stock, as directed by each director based on an annual election.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In addition,
upon appointment to our board of directors, we award our non-employee directors a stock option grant under our Amended 2017 Equity Incentive
Plan (the 2017 Plan). During fiscal 2022, we awarded each of the new non-employee directors a stock option to purchase 16,667 shares
of our common stock. These options vest annually over three years from the date of appointment to our board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following table summarizes the compensation earned by our non-employee directors in fiscal 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fee</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Restricted&#160;Stock</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Option</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Compensation</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Awards</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Awards</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">All Other</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Name</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">($)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">($)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">($)(1)(2)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Compensation(3)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 35%">Liam Burns(4)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">18,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">222,291</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">241,041</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">William Febbo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Steven Felsher(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,981</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,657</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203,638</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Morgan Frank</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375,105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375,105</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Philip Sheibley(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,588</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,696</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">211,078</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Carmen Volkart</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">296,423</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,671</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">326,094</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Ellen O&#8217;Connor Vos(6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,953</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281,339</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">284,292</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 17.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Award
    amounts reflect the aggregate grant date fair value with respect to awards granted, as determined pursuant to FASB ASC Topic 718.
    The assumptions used to calculate the aggregate grant date fair value of option awards are set forth in the notes to the consolidated
    financial statements included in Item 8 of this Annual Report on Form 10-K. These amounts do not reflect actual compensation earned
    or to be earned by our directors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of March&#160;31, 2022, our non-employee directors each held outstanding options to purchase the following number of shares of our
    common stock: William Febbo, 66,667; Steven Felsher, 38,084; Morgan Frank, 100,699 ; Philip Sheibley, 16,667; Carmen Volkart;
    90,558 and Ellen O&#8217;Connor Vos, 111,873 .</span></td></tr>
  </table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 17.3pt; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Represents stock awards; we
calculated the estimated fair value of the stock awards issued to our non-employee directors using the closing price per share of our
common stock on the day prior to the grant date in accordance with the Director Plan.</span></td>
</tr></table>
<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 17.3pt; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Mr. Burns resigned as a director
on December 31, 2021.</span></td>
</tr></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 17.3pt; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Messrs. Felsher and Sheibley
were appointed to our board of directors on November 29, 2021.</span></td>
</tr></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 17.3pt; text-align: left"><span style="font-size: 10pt">(6)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Ms. Vos was appointed to our
board of directors in May 2021 and as our chief executive officer in August 2021. In February 2022, Ms. Vos resigned as our chief executive
officer.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara018"></span>ITEM
12: SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0; text-align: justify"><span style="font-size: 10pt">The following
table sets forth certain information as of May 31, 2022 concerning the ownership of our common stock by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            shareholder known by us to be the beneficial owner of more than 5% of the outstanding shares
                                            of our common stock (currently our only class of voting securities);</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of our directors;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of our executive officers; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.05pt; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            directors and executive officers as a group.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Beneficial ownership
is determined in accordance with Rule 13d-3 of the Exchange Act, and includes all shares over which the beneficial owner exercises voting
or investment power. Shares that are issuable upon the exercise of options, warrants and other rights to acquire common stock that are
presently exercisable or exercisable within 60 days of May 31, 2022 are reflected in a separate column in the table below. These shares
are taken into account in the calculation of the total number of shares beneficially owned by a particular holder and the total number
of shares outstanding for the purpose of calculating percentage ownership of the particular holder. We have relied on information supplied
by our officers, directors and certain stockholders and on information contained in filings with the SEC. Except as otherwise indicated,
and subject to community property laws where applicable, we believe, based on information provided by these persons, that the persons
named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them.
The percentage of beneficial ownership is based on 10,911,684 shares of common stock outstanding as of May 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Unless otherwise stated,
the business address of each of our directors and executive officers listed in the table is 16772 West Bernardo Drive, San Diego, California
92127.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Name and principal position</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Shares<br /> Beneficially Owned<br /> (Excluding<br /> Outstanding<br /> Options and<br />
 Warrants)(1)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br /> Shares Issuable<br /> on Exercise of<br /> Outstanding<br /> Options and<br />
 Warrants(2)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percent of<br /> Class</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%; text-align: left">JEB Partners, L.P.</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">2,720,577</td><td style="width: 1%; text-align: left">(3)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">653,511</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">29.17</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Manchester Explorer, L.P.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,720,577</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">653,511</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29.17</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Manchester Management LLC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,720,577</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">653,511</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29.17</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sio Capital Management, LLC</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">449,438</td><td style="text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">712,000</td><td style="text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.99</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Directors and Officers:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">James E. Besser</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,720,577</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">653,511</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29.17</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Paul DiPerna</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,553,586</td><td style="text-align: left">(6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186,682</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.69</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">William Febbo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">113,260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.74</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Steven Felsher</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,174</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,417</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Morgan C. Frank</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,720,577</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">737,554</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29.69</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Philip Sheibley</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,139</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Carmen Volkart</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,999</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,892</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Ellen O&#8217;Connor Vos(5)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,519</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">95,206</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1.03</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">All current directors and executive officers as a group (8 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,386,099</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">928,131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58.16</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 17.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    less than 1%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 3.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 3.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excludes
shares subject to outstanding options and warrants to acquire common stock that are exercisable within 60 days of May 31, 2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0.05pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0.05pt; padding-left: 1.35pt; text-align: justify; text-indent: -1.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
the number of shares subject to outstanding options and warrants to acquire common stock that are exercisable within 60 days of May 31,
2022.</span></td></tr>
</table>

<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 17.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
(i) 124,750 shares directly held by Mr. Besser, of which: (a) 60,277 shares were received in exchange for Mr. Besser&#8217;s shares as
a result of our acquisition of Quasuras; (b) 29,630 shares purchased in a private placement in 2018 (the 2018 Placement) and (c) 34,843
shares were purchased in a private placement in 2020 (the 2020 placement); (ii) 2,218,077 held by Manchester Explorer, L.P. of which:
(a) 1,515,152 shares were purchased in a private placement in 2017 (the 2017 Placement), (b) 157,037 shares were purchased in the 2018
Placement, (c) 11,614 were purchased in the 2020 Placement, (d) 300,000 shares were purchased in a public offering in February 2022,
and (e) 234,274 shares were acquired upon the conversion of a convertible note in February 2022; (iii) 317,473 shares held by JEB Partners,
L.P. of which (a) 252,526 shares were purchased in the 2017 Placement, (b) 53,333 shares were purchased in the 2018 Placement and (c)
11,614 shares were purchased in the 2020 Placement; and (iv) 60,277 shares held by Mr. Frank, which shares were received in our acquisition
of Quasuras in exchange for Mr. Frank&#8217;s shares of Quasuras. Mr. Besser, as the managing member, and Mr. Frank, as the portfolio
manager and consultant of Manchester Management, LLC, (MMC) the general partner of Manchester Explorer, L.P. and JEB Partners, L. P.,
have shared voting and dispositive power over shares held by Manchester Explorer, L.P. and JEB Partners, L.P. The address for Manchester
Explorer, L.P is c/o MMC, 2 Calle Candina, No. 1701, San Juan, Puerto Rico 00907.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Consists
of the following shares of Common Stock acquired in the Offering: (i) 144,438 shares of Common Stock held by Sio Partners LP (&#8220;Partners&#8221;),
(ii) 85,000 shares of Common Stock held by Sio Partners Offshore LTD (Offshore), (iii) 81,000 shares of Common Stock held by Compass
MAV LLC (Compass), (iv) 49,000 shares of Common Stock held by Compass Offshore MAV LTD (Compass Offshore), (v) 27,000 shares of Common
Stock held by Walleye Manager Opportunities LLC (Walleye Manager) and (vi) 63,000 shares of Common Stock held by Walleye Opportunities
Master Fund Ltd. (Walleye Master). Sio Capital Management, LLC&#160;(Sio Management) is the investment manager of Partners, Offshore,
Compass, Compass Offshore, Walleye Manager and Walleye Master, and Michael Castor is the sole owner and Managing Member of Sio Management.
Sio Management and Mr. Castor may be deemed to beneficially own the securities held by Partners, Offshore, Compass, Compass Offshore,
Walleye Manager, and Walleye Master. Each of Sio Management and Mr. Castor disclaim beneficial ownership of any of the shares of our
Common Stock they may be deemed to beneficially own except to the extent of their respective pecuniary interest therein. The address
for Sio Management, Mr. Castor, Partners, Offshore, Compass, Compass Offshore, Walleye Manager and Walleye Master is 600 Third Avenue,
New York, New York 10016.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -2.9pt"><span style="font-size: 10pt">(5)</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -2.9pt"><span style="font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
shares are issuable upon exercise of outstanding pre-funded warrants to purchase shares of our Common Stock. As of May 31, 2022, Sio
Management held 1,348,314 pre-funded warrants to purchase shares of Common Stock.&#160;&#160;Pursuant to the terms of the pre-funded
warrants, Sio Management cannot exercise such pre-funded warrants if Sio Management would beneficially own, after such exercise, more
than 9.99% of the outstanding shares of our Common Stock. Accordingly, pre-funded warrants to purchase 636,314 shares of our Common Stock
have been excluded from the table above.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Includes
(i) 2,000,000 shares directly held by the Paul DiPerna Irrevocable Trust, (ii) 333,334 shares directly held by Mr. DiPerna&#8217;s adult
daughters, Kelsie DiPerna and Alaria DiPerna, which shares Mr. DiPerna has sole voting power over; (iii) 207,906 shares directly held
by the Paul DiPerna Trust, of which 101,010 shares were purchased in the 2017 Placement and 23,429 shares were acquired upon the conversion
off a convertible note in February 2022 and (iv) 12,346 shares held by Mr. DiPerna. The 2,000,000 shares held by the Paul DiPerna Irrevocable
Trust, 333,334 shares held by Mr. DiPerna&#8217;s adult daughters and 73,480 shares held by the Paul DiPerna Trust that were issued in
2017 to Mr. DiPerna in the Control Block Acquisition and transferred to such persons in December 2020 by Mr. DiPerna. Mr. DiPerna is
the chairman of our board of directors, and also serves as our president, chief financial officer and treasurer. Mr. DiPerna is the trustee
of both the Paul DiPerna Irrevocable Trust and the Paul DiPerna Trust.</span></p></td></tr>
  </table>
<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara019"></span>ITEM
13: CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transactions
with Related Persons</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">As
disclosed elsewhere in this Annual Report on Form 10-K, Mr. DiPerna, is a party to related party transactions with us,
see&#160;<span style="font-family: Times New Roman, Times, Serif"><i>Item&#160;10. </i></span>Mr. DiPerna&#8217;s daughter is
an employee of ours, and, during fiscal 2022, we paid her $169,589, which includes the aggregate grant date fair value, as
determined pursuant to FASB ASC Topic 718, of a stock option granted in November 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">In
February 2021, Mr. DiPerna and Manchester Explorer, L.P. (the Related Party Holders), which is represented by Mr. Frank on our board
of directors, purchased $100,000 and $1,000,000, aggregate principal amount of our convertible notes and received warrants to purchase
119,237 and 11,924 shares of our common stock (the Note Warrants), respectively. Effective April 30, 2021, the Related Party Holders
entered into revocation agreements with the Company pursuant to which their collective $1,100,000&#160;aggregate principal amount of
convertible notes and accrued interest of $50,091&#160;were replaced with new convertible notes. In connection with a public offering
of our equity securities in February 2022, the convertible notes and accrued interest held by the Related Party Holders were converted
into our equity securities and Mr. DiPerna received 23,429 shares of our common stock and a warrant to purchase 23,429 shares of our
common stock at an exercise price of $6.60 per share and Manchester Explorer, L. P. received 234,274 shares of our common stock and a
warrant to purchase 234, 274 shares of our common stock at an exercise price of $6.60 per share. In addition, the exercise prices of
the Note Warrants were reduced to $6.00 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">In
May 2021, Mr. Febbo purchased $200,000&#160;aggregate principal amount of our convertible notes and received a warrant to purchase 23,229
shares of our common stock (the Director Warrant). In connection with a public offering of our equity securities in February 2022, the
convertible note held by Mr. Febbo was converted into our equity securities. Upon conversion, Mr. Febbo received 45,586 shares of our
common stock and a warrant to purchase 45,586 shares of our common stock at an exercise price of $6.60 per share. In addition, the exercise
price of the Director Warrant was reduced to $6.00 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In
October 2021, we sold 12,346 shares of common stock to Mr. DiPerna and 18,519 shares to Ms. Vos at a price per share
of $8.10 in a private placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 10pt; margin-bottom: 0; background-color: white; text-align: justify"><span style="font-size: 10pt">Our board
of directors has determined that each of the current directors, with the exception of Mr. DiPerna, Mr. Frank and Ms. Vos, is &#8220;independent,&#8221;
as defined by the listing rules of the NASDAQ Stock Market, or Nasdaq, and the rules and regulations of the SEC. Our board of directors
has standing Audit, Compensation and Nominating and Governance Committees, each of which is comprised solely of independent directors
in accordance with the Nasdaq listing rules. No director qualifies as independent unless the board of directors affirmatively determines
that he has no direct or indirect relationship with us that would impair his independence. We independently review the relationship of
the Company to any entity employing a director or on whose board of directors he is serving currently<span style="font-family: Times New Roman, Times, Serif; color: blue">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara020"></span>ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following table
shows the fees billed to us by Farber Hass Hurley LLP, or Farber, our independent registered public accounting firm, for the audit of
our consolidated financial statements and other services provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: justify">Audit fees(1)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">43,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">34,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Audit-related fees(2)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,200</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,700</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total(3)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">53,200</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38,200</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 17.3pt">(1)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Audit fees consisted of fees for professional services rendered for the audit of our annual consolidated financial statements and reviews of our quarterly consolidated financial statements</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">(2)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Audit-related fees consisted of fees for services related to our issuance of SEC registration statements and sales of common stock under registration statements.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">(3)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Farber did not provide any non-audit or other services other than those reported under &#8220;Audit fees&#8221; and &#8220;Audit-related fees.&#8221;</td></tr>
  </table>

<!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="modulara021"></span>ITEM
15: EXHIBITS</span></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(a)(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Consolidated financial statements</i>.
    See the audited consolidated financial statements for the year ended March 31, 2022 contained in Item 8 of this Report which
    are incorporated herein by this reference. </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Financial statement schedul</i>es.&#160;&#160;Omitted
    because they are not required, not applicable or because the required information is shown in the consolidated financial statements
    or notes thereto.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><i>Exhibits</i>. Required exhibits are
    incorporated by reference or are filed with this Report.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><span style="text-decoration: underline">No.</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Description</span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">1.1(18)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000180/ex1_1.htm">Form of Underwriting Agreement</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">2.1(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex2_1.htm">Reorganization and Share Exchange Agreement
    dated as of July 24, 2017, by and among the Registrant, Quasuras, Inc., Paul DiPerna and the other stockholders of Quasuras, Inc.</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">2.2(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex2_2.htm">Addendum No. 1 to Reorganization and Share Exchange Agreement dated as of July 24, 2017, by and among the Registrant, Quasuras, Inc., Paul DiPerna and the other Stockholders of Quasuras, Inc. dated May 3, 2021</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">3.1(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000593/ex3_1.htm">Third Amended and Restated Articles of Incorporation, as filed with the Secretary of State of Nevada on June 27, 2017</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">3.2(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000620/ex3_1.htm">Certificate of Amendment to the Amended and Restated Articles of Incorporation of Modular Medical, Inc., filed with the Secretary of State of the State of Nevada on November 24, 2021</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">3.3(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101041209000212/ex32amendedbylaws.htm">Amended Bylaws</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">4.1(6) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000551/ex4_1.htm">2017 Equity Incentive Plan, as amended</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">4.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="ex4_2.htm">Description
    of Securities</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">4.3(20)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000371/ex4_1.htm">Form of Pre-Funded Warrant dated May 2, 2022</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">4.4(20)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000371/ex4_2.htm">Form of Private Placement Warrant dated May 2, 2022</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">4.5(18)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000180/ex4_1.htm">Form
    of Warrant to Purchase Common Stock dated May 2, 2022</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.1(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101041217000014/stockpurchaseagreementbearla.htm">Common Stock Purchase Agreement, dated
    as of April 5, 2017, by and among Bear Lake Recreation, Inc., Manchester Explorer, LP, a Delaware limited partnership, and
    certain persons named therein&#160;</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.2(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_2.htm">Form of Common Stock Purchase Agreement,
    dated as of July 24, 2017, by and between the Registrant and the purchaser named therein&#160;</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.3(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905618001091/ex99_1.htm">Form
    of Common Stock Purchase Agreement dated as of November 19, 2018 among the Registrant and the Investors named
    therein</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.4(9) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905619000388/ex10_4.htm">Employment Agreement dated August 1, 2018,
    by and between the Registrant and Paul DiPerna</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.5(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_3.htm">Intellectual Property Assignment Agreement
    dated July 24, 2017, by and between the Registrant, Quasuras, Inc. and Paul DiPerna</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.6(1) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_4.htm">Technology Royalty Agreement dated as of
    July 24, 2017, by and between the Registrant, Quasuras, Inc. and Paul DiPerna</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.7(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905619000388/ex10_7.htm">Service Agreement effective January 16,
    2019 between the Registrant and Liam Burns</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.8(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905619000388/ex10_8.htm">Standard Sublease Agreement, dated August
    21, 2017, between the Registrant and Western Education Corporation</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.9(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_9.htm">Lease between MCP Socal Industrial &#8211;
    Bernardo, LLC and the Registrant dated January 10, 2020</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.10(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_10.htm">Consulting Agreement between the Registrant
    and Liam Burns dated April 15, 2019</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.11(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_11.htm">Consulting Agreement between the Registrant
    and Liam Burns dated July 15, 2019</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.12(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_12.htm">Consulting Agreement between the Registrant
    and Liam Burns dated September 3, 2019</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.13(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_13.htm">Service Agreement effective December 31,
    2019 between the Registrant and Carmen Volkart</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.14(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_14.htm">Service Agreement effective January 23,
    2020 between the Registrant and William Febbo</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.15(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_15.htm">Form of Indemnification Agreement between
    the Registrant and each of its directors and officers used from January 23, 2020</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.16(10) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_16.htm">Form of Notice of Stock Option Grant and
    Stock Option Agreement under the Amended 2017 Equity Incentive Plan</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.17(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000268/ex10_17.htm">Form of Common Stock Purchase Agreement dated March 2020 by and between the Registrant and the Investors named therein</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.18(12) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000364/ex10_18.htm">First Amendment to Employment Agreement
    between the Registrant and Paul DiPerna effective as of May 12, 2020</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000470/ex10_20.htm">Second Amendment to Employment Agreement between the Registrant and Paul DiPerna effective as of July 1, 2020</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.19(13)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000315/ex10_1.htm">U.S. Small Business Administration Paycheck
    Protection Program Note dated April 23, 2020</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.20(14)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000102/ex10_21.htm">Form of Promissory Note dated February 8, 2021</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.21(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_21.htm">Form of Convertible Promissory Note issued in the 2021 Private Placement</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.22(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_22.htm">Form of Common Stock Purchase Warrant issued in the 2021 Private Placement</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.23(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_23.htm">Form of Securities Purchase Agreement for the 2021 Private Placement</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.24(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_24.htm">Form of Registration Rights Agreement for the 2021 Private Placement</a></span></td></tr>
</table>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-size: 10pt">10.25(15) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000387/ex10_26.htm">Service Agreement effective May 18, 2021 between the Registrant and Ellen O&#8217;Connor Vos</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.26(16) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000475/ex10_27.htm">Employment Agreement between the Registrant and Ellen O&#8217;Connor Vos dated August 11, 2021</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.27(17)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_27.htm">Promissory Note dated October 28, 2021 between the Registrant and Manchester Explorer, L.P.</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.28(17)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_28.htm">Security Agreement dated October 28, 2021 between the Registrant and Manchester Explorer, L.P.</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.29(17)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_29.htm">Form of Common Stock Purchase Agreement dated October 28, 2021 between the Registrant and Investors</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.30(18)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000180/ex10_1.htm">Form of Warrant Agency Agreement</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.31(19)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000142/ex10_31.htm">Form of Warrant Omnibus Amendment Agreement</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.32(20)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000371/ex10_1.htm">Form of Securities Purchase Agreement dated May 2, 2022</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10.33(21) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000444/ex10_33.htm">Severance and Release Agreement between the Registrant and Ellen O&#8217;Connor Vos dated February 23, 2022</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Sole Subsidiary of the Registrant (as disclosed
    in the Notes to Consolidated Financial Statements as of March 31, 2022 in Item 8 of this Report)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">24.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Power of Attorney (see signature page of this Report)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="ex31_1.htm">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="ex31_2.htm">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">32.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="ex32_1.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">XBRL Instance Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">XBRL Taxonomy Extension Schema</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As
                                         filed with the Registrant&#8217;s Current Report on Form 8-K filed July 28, 2017, and
                                         incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Current Report on Form 8-K filed May 12, 2021, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Current Report on Form 8-K filed June 29, 2017, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Current Report on Form 8-K filed December 1, 2021, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Annual Report on Form 10-K/A for the year ended June 30, 2008, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(6)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Quarterly Report on Form 10-Q filed
November 12, 2018, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(7)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Current Report on Form 8-K filed April 5, 2017, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(8)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Current Report on Form 8-K filed November 20, 2018 and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(9)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Registration Statement on Form S-1, as amended, originally filed June 27, 2019, declared effective October 22, 2019 (Commission File No. 333-232377), and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(10)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended December 31, 2019, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(11)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Registration Statement on Form S-1, as amended, originally filed April 9, 2020, declared effective May 11, 2020 (Commission File No. 333-237615), and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(12)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Current Report on Form 8-K filed May 27, 2020, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(13)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Current Report on Form 8-K filed May 12, 2020, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(14)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(15)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Annual Report on Form 10-K filed June 29, 2021, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(16)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Current Report on Form 8-K filed August 16, 2021, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(17)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Current Report on Form 8-K filed October 29, 2021, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(18)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Current Report on Form 8-K filed February 14, 2022, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(19)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Registration Statement on Form S-1 filed February 9, 2022, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(20)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Current Report on Form 8-K filed May 5, 2022, and incorporated herein by reference.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-size: 10pt">(21)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s Registration Statement on Form S-1 filed June 6, 2022 (Commission File No. 333-265444), and incorporated herein by reference.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 33px; padding-top: 0"><span style="font-size: 10pt">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0"><span style="font-size: 10pt">Management contract,
    compensatory plan or arrangement.</span></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 33px; padding-top: 0"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0"><span style="font-size: 10pt">* Filed herewith</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara022"></span>Item&#160;16.&#160;&#160;Form
10-K Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-indent: 32.05pt; background-color: white"><span style="font-size: 10pt">Not
applicable.</span></p>
<!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara023"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Pursuant to the requirements of Section&#160;13
or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized, on the <span style="font-family: Times New Roman, Times, Serif">28th day of June, 2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MODULAR
MEDICAL, INC.</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    James E. Besser</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    E. Besser</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">KNOW ALL PERSONS
BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints James E. Besser and Paul DiPerna as her/his
true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for her and him and in her or his name,
place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K, and to file the same,
with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done
in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all
that said attorney-in- fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in
the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: justify"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: justify"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">/s/
    James E. Besser</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td rowspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">Chief Executive
    Officer (Principal Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">June 28, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">James E. Besser</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Paul DiPerna</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td rowspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Chairman, President
    and Chief Financial Officer (Principal Financial and Accounting Officer)&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">June 28, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Paul DiPerna</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">/s/ William
    Febbo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">June 28, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">William Febbo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">/s/
    Steven Felsher</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td rowspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">June 28, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Steven Felsher</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">/s/
    Morgan C. Frank</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">June 28, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Morgan C. Frank</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">/s/
    Philip Sheibley</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">June 28, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Philip Sheibley</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">/s/
    Carmen Volkart</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td rowspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">June 28, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Carmen Volkart</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">/s/
    Ellen O&#8217;Connor Vos</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td rowspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"><span style="font-size: 10pt">June 28, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Ellen O&#8217;Connor Vos</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--   -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>ex4_2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<HTML STYLE="font: 10pt Times New Roman, Times, Serif">
<HEAD STYLE="font: 10pt Times New Roman, Times, Serif">
     <TITLE STYLE="font: 10pt Times New Roman, Times, Serif"></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF THE REGISTRANTS&rsquo; SECURITIES REGISTERED PURSUANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The
following description of the common stock and preferred stock of Modular Medical, Inc. (&ldquo;we&rdquo; or &ldquo;us&rdquo;) is a summary
and does not purport to be complete. It is subject to and qualified in its entirety by reference to our second amended and restated articles
of incorporation, and our bylaws, as amended, each of which is incorporated herein by reference and are exhibits to our Annual Report
on Form 10-K filed with the Securities and Exchange Commission, of which this Exhibit 4.2 is a part. We encourage you to read our articles
of incorporation, our bylaws and the applicable provisions of the Nevada Revised Statutes for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Description
of Capital Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Each
holder of our common stock is entitled to a pro rata share of any cash distributions made to shareholders, including any dividend payments.
The holders of our common stock are entitled to one vote for each share on all matters to be voted on by our shareholders. There is no
cumulative voting with respect to the election of our directors or any other matter. Therefore, under our charter documents, the holders
of more than 50% of the shares voted for the election of those directors can elect all of the directors. Our board of directors currently
are elected as a single class. Our board of directors may from time to time declare dividends on our outstanding shares. In the event
of our liquidation, dissolution or winding up, the holders of common stock are entitled to share ratably in all assets remaining available
for distribution to them after payment of our liabilities and after provision has been made for each class of stock, if any, having any
preference in relation to our common stock. Holders of shares of our common stock have no conversion, preemptive or other subscription
rights, and there are no redemption provisions applicable to our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Anti-Takeover
Effects of Nevada Law and our Articles of Incorporation and Bylaws</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our articles
of incorporation, our bylaws and the Nevada Revised Statutes (the &ldquo;NRS&rdquo;) contain certain provisions that could delay or make
more difficult an acquisition of control of us not approved by our board of directors, whether by means of a tender offer, open market
purchases, proxy contests or otherwise. These provisions have been implemented to enable us to develop our business in a manner that
will foster our long-term growth without disruption caused by the threat of a takeover not deemed by our board of directors to be in
the best interest of our company and our shareholders. These provisions could have the effect of discouraging third parties from making
proposals involving an acquisition or change of control of our company even if such a proposal, if made, might be considered desirable
by a majority of our shareholders. These provisions may also have the effect of making it more difficult for third parties to cause the
replacement of our current management without the concurrence of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Set forth below
is a description of the provisions contained in our articles of incorporation, bylaws and NRS that could impede or delay an acquisition
of control of our company that our board of directors has not approved. This description is a summary only and is qualified in its entirety
by reference to our articles of incorporation and bylaws, forms of each are included as exhibits to our Annual Report on Form 10-K for
the year ended March 31, 2022.</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Authorized
But Unissued Preferred Stock</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We are
currently authorized to issue a total of 5,000,000 shares of preferred stock. Our articles of incorporation provide that our board of
directors has the right in its discretion to issue preferred stock without approval of our shareholders and to set the series, classes,
rights, privileges and preferences of our preferred stock or any classes, or series thereof without approval. In the event of a hostile
takeover, the board of directors could potentially use this preferred stock to preserve control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Filling
Vacancies and Increases in Director</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Any vacancies
on our board occurring by reason of death, resignation or otherwise, or if the number of our directors is increased, the directors then
in office shall continue to act and such vacancies or newly created directorships shall be filled by a vote of such then directors, though
less than a quorum, in any way approved by the meeting. Any directorship to be filled by reason of removal of one or more directors by
the shareholders may be filled by election by the shareholders at the meeting at which the director or directors are removed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Removal
of Director</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our bylaws
provide that, at a meeting of our shareholders expressly called for that purpose, one or more of our directors may be removed by a vote
of a majority of our outstanding shares of common stock entitled to vote at an election of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Board
Action Without Meeting</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Our bylaws provide
that any action required to be taken at a meeting of our directors or any other action which may be taken at a meeting of our directors
or of a committee, may be taken without a meeting, if a consent in writing, setting forth the action so taken, shall be signed by all
of the directors, or all of the members of the committee, as the case may be, which such consent shall have the same legal effect as
a unanimous vote of all the directors or members of the committee. Board action through written consent allows our board to make swift
decisions, including in the event of a hostile takeover attempt by current management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
Cumulative Voting</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Our bylaws
and articles of incorporation do not provide the right to cumulate votes in the election of directors. This provision means that the
holders of a plurality of the shares voting for the election of directors can elect all of the directors. Non-cumulative voting makes
it more difficult for an insurgent minority stockholder to elect a person to the board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Re-Capitalization</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our articles
of incorporation provide that our board of directors, without the approval of our shareholders, may adopt any re-capitalization affecting
our outstanding securities by effecting a forward or reverse split of all of our outstanding securities.</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stockholder
Proposals</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Except
to the extent required under applicable laws, we are not required to include on our proxy card, or describe in our proxy statement, any
information relating to any shareholder proposal and disseminated in connection with any meeting of shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amendments
to Articles of Incorporation and Bylaws</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Our by-laws
give both our board of directors and shareholders the right to amend, alter, repeal and adopt new bylaws, except that (i) bylaws adopted
or amended by our shareholders may not be altered or repealed by our board of directors; and (ii) no bylaws shall be adopted by our board
of directors that require more than a majority of our outstanding voting shares for a quorum at a meeting of our shareholders, or more
than a majority of the votes cast to constitute action by our shareholders, except where higher percentages are required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nevada
Statutory Provisions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Although
pursuant to our articles of incorporation and bylaws we elected that the Nevada Control Share Acquisition Act, Sections 78.378 to 78.3793,
inclusive, of the NRS, does not apply to us, we are subject to the provisions of NRS 78.411 to 78.444, inclusive, which generally prohibit
a publicly held Nevada corporation from engaging in a &ldquo;combination&rdquo; with an &ldquo;interested stockholder&rdquo; (each as
defined) that is the beneficial owner, directly or indirectly, of at least ten percent of the voting power of the outstanding voting
shares of the corporation or is an affiliate or associate of the corporation that previously held such voting power within the past three
years, for a period of three years after the date the person first became an &ldquo;interested stockholder,&rdquo; subject to certain
exceptions for authorized combinations, as provided therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Pursuant
to NRS 78.195, our articles of incorporation provide for the authority of our board of directors to, without shareholder approval, issue
shares of our preferred stock in series or classes by filing an amendment thereto and to establish from time to time the number of shares
to be included in such series or class and to fix the designation, powers, preferences and rights of the shares of each such series or
class and the qualifications, limitations or restrictions thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Classification
of Directors</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">Although
to date our board of directors has not elected to do so, our bylaws authorize our board to divide our directors into either two or three
classes, with each class to be as nearly equal in number as possible and the term of office of the directors of the first class to expire
at the first annual meeting of shareholders after their election, that of the second class to expire at the second annual meeting after
their election, and that of the third class, if any, to expire at the third annual meeting after their election. At each annual meeting
after such classification, the number of directors equal to the number of the class whose term expires at the time of such meeting shall
be elected to hold office until the second succeeding annual meeting, if there be two classes, or until the third succeeding annual meeting,
if there be three classes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">Transfer Agent and Registrar</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">The transfer agent and registrar
for our common stock is Colonial Stock Transfer Co., Inc.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><FONT STYLE="font-size: 10pt">Listing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-size: 10pt">Our common stock is currently
traded on the Nasdaq Stock Market under the symbol &ldquo;MODD.&rdquo;</FONT></P>


<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex31_1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">I, James E. Besser, certify
that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;I
have reviewed this Annual Report on Form 10-K of Modular Medical, Inc. for the period ended March 31, 2022;</FONT></P>



<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36.75pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under our supervision, to ensure that material information relating to the
                                            registrant, including its consolidated subsidiaries, is made known to us by others within
                                            those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36.75pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such internal controls over financial reporting, or caused such internal control over financial
                                            reporting to be designed under our supervision, to provide reasonable assurance regarding
                                            the reliability of financial reporting and the preparation of financial statements for external
                                            purposes in accordance with generally accepted accounting principles;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36.75pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
                                            in this report our conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36.75pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                            in this report any change in the registrant&rsquo;s internal controls over financial reporting
                                            that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
                                            reporting; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;
The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36.75pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            significant deficiencies and material weaknesses in the design or operation of internal controls
                                            over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36.75pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    James E. Besser</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;
    June 28, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    E. Besser</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex31_2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">I, Paul M. DiPerna, certify
that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;I have reviewed this Annual Report on Form 10-K of Modular Medical, Inc. for the period ended March 31, 2022;</FONT></P>



<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;
&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;
&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this
report;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;&nbsp;
The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36.75pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under our supervision, to ensure that material information relating to the
                                            registrant, including its consolidated subsidiaries, is made known to us by others within
                                            those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36.75pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such internal controls over financial reporting, or caused such internal control over financial
                                            reporting to be designed under our supervision, to provide reasonable assurance regarding
                                            the reliability of financial reporting and the preparation of financial statements for external
                                            purposes in accordance with generally accepted accounting principles;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36.75pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
                                            in this report our conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36.75pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                            in this report any change in the registrant&rsquo;s internal controls over financial reporting
                                            that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
                                            reporting; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&nbsp;&nbsp;The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36.75pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            significant deficiencies and material weaknesses in the design or operation of internal controls
                                            over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36.75pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Paul M. DiPerna</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;
    June 28, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    M. DiPerna</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    President, Chief Financial Officer and Treasurer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex32_1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 0 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">In
connection with the Annual Report on Form 10-K of Modular Medical, Inc. (the &ldquo;Company&rdquo;) for the twelve months ended March
31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), each of James E. Besser,
Chief Executive Officer of the Company, and Paul M. DiPerna, Chairman, President, Chief Financial Officer and Treasurer, hereby certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge,
that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities and
                                            Exchange Act of 1934, as amended; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.4pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            information contained in the Report fairly presents, in all material respects, the financial
                                            condition and the results of operations of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.2pt 0 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    /s/ James E. Besser</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 10%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    &nbsp;June 28, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    E. Besser</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    /s/ Paul M. DiPerna</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    &nbsp;June 28, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    M. DiPerna</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    President, Chief Financial Officer and Treasurer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-size: 10pt">This certification accompanies
this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley
Act of 2002, or otherwise required, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended.</FONT></P>

<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>modular001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ E "( P$1  (1 0,1 ?_$ +(    ' 0$
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M2#X1/0.-6B6D5YAE866]F)[N&CJQ+&-;DR6$+5(4\]%ER!=M:[(<0LPD+2H
M%9\(]5:MX&-<1O(W#M"'ZM6<+&<>5%G/A$*8IUM"742'W!KTH;=2ZIEQ*SQT
M*X5=Q;1/,B=B9B)E<]'VK.PJ4>81TO)L\7&4*7'+82@*0CF-EIY2"OB+FQJF
MFU&H4D><@Y+9\]B/$5MY*VG'G(HY,M;Q;8?"G'DNN?\ F?LO":)X)Z.'"M8V
MW0HYJI.SYV.3LW%SYN#/)RDI,A$6/(=U,S9X4IE8<"4J27'G@VLBVE2R>(O6
M48OF-)25" ;W)MA1S4CU#RN2M33:3.>&I;DI(<;T-@B&774A7@\%VX\*T<&1
M.2H>U[/)./D(EKQ>+3CL<D1FT*YI4IQ28;*A=L#0GEMK2WJ2HZM-8R3+6VJ'
MI,_["R/HSWDS5$683;WLF/\ '^6JD@LQ#=_V6S'H4GR*JF)EU.1C$]-=YX>1
MVA5 H&+PO\VQ_B(Z?^85$LC7I_N1^*-G9#&PLGCG(4]A$B*Z@!QI8X&XMTUP
MUHSVUM8'B()RFPWDQI*W)VT7'+1I3AU/0]1X)=_],'H_X=%:3=5^I6*HRP(\
MF/*CH?94'674ZDK3T$&L)5BC:-),-I2E("1:PM^84A)M$RBJC9+^,3,\TU-)
MEMM\SDW2'$MJ.G5I'0DD5(Y1R>3<KX:@FQ/]F@Y1GCXV(@16XT0-LQVQS6T#
MJ"R?"_.2:#E%9N.A3$L><-)6(SJ9#(O8)<2"$J_\1H*"PCQB%GEH_:$!SP>!
M*3W.NA(JE"4V  3;H %J 8[@]AY'T9[R9J4587;WLF/\?Y:J2"S$-W_9;,>A
M2?(JJ8F74Y&,3TUWGAY'+]^A5!J!B\'_ #C'^(CY0J'D:]/]R/Q1MM'P0/R?
MHKYMQXGN;61R0PT\PMIY(6VM)2M"A=)218@CN5?FIB3RU*VR4G(;-S#$3'H<
M.WY3J7I 4VKELA9*%MMK'@C^M:NN*5R-3ADW"5"Q]86VE:#<. $* XV/6*XV
MZ.AVI5Q*4WKV3;ESO:#N7)1H<7U9FL"J"94ETNK7*0D!CD  *CA#B$J5U&U"
MW,/&-D;X<9WAB\LTW/A[LER)#4AB0A/(6VAPL%Y190I3"D,QF-&E8%E7!!H.
M8@LKV#9D064PVXT]PX*/BIPE.)L7@ZUSUQM31#0;8:5R!<(2X4K"01<AS%[8
MAKE0F&B"DMM)3H*BX186^&;%71Q5U]-!4?4)!0$=N#V'D?1GO)FI15A-O>R(
M_P ?Y:J2)68CN_[*YCT*3Y%53$QZG(QFNNQGBFO^RV',QA?4ZWA#GV\R\XY?
MG474AE;?]YRM6OE_$K)GW'U/_%"O-O0,--EJ8RTMV$URU.-N--\P%21<I/A=
M.GX-:.1\JS;<Y-C5IMI.4;Y"U.,!Y*6UN)TJ*0H<=.KA4\V#*VZQO)?J;6;^
M G^757%(]G:R#FB+H*JUN/$=RH9$O0JSM^GS\=M2 _ D.Q'C-;:+C#BFCIY+
MJM/@D'JK:WF?*[O+EC4H7^+]V?OJ?]:>^=6YY[\E@_B_=G[ZG_6GOG4'Y+._
MQ?NRQ_\ NI_UI[YU"/R66%V'9_/9#?"8\W(RI3'FSJBV^\XZFXM8V62+\>FL
MKN1]/MM[FN4_0T4FW78*-_TUSGI?0..J@61'[@]AY'T9[R9J40PFWO9$?X_R
MU4D2LQ'=_P!E<QZ%)\BJIB8]3D9(V^AI62<6\VAY+$>3(;;<3J;6XAAQ36I/
M]+PZ[&>/MJI*XS [@R'+S[.491*=U*YCG.Y@2CP-/@-N(T_V:R9VV[=27P>;
M3MV?E,C':C(6Y%QY4PO4A&J2T'5I;"$K.HK"K G34M'18:C)GFLZG3O3()%D
M@9%:@E/0+N&X]VK4P.!R3O\ ^38K?P$_RZJY)'K;60<T1='.NC(EZ%2_B.^Q
MV/\ ]P1Y%ZM;69\CO7T&=3T5TT/,8!=5NFE J'02?R4H,"R.P'[?M^BO_H%9
M7LCZW:ON?X-.]0_+7*>I] PZJ!9$?N#V'D?1GO)FI1#"[>]DQ_C_ "U4D%F(
M;O\ LMF/0I/D55,3+J<C)6V6EOY-]EM)6Z[$EH:;2+J4I4=:4I2!Q))-@*ZY
M(\=95&>_VEOE.&VW#Q4G$9);S#:PXIM@Z;K4I0T^%U5A*)]WI^K44>;3/=QV
M=DPGHC;R),",U*;>6ZWI6Q#2HH5H4TK@I-B%5JU4X+=U1NR9YQR<YD,Z9[P2
MEZ5)+[@ /@J<7JTBZK_TJGT9RVIUOUWLVDW\!/\ +JKDD>PM9!ST41?T84]
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M '#O^[3  X=_W:8 '#O^[3  X=_W:8 '#O\ NTP .'?]VF !P[_NTP .'?\
7=J, 1^X;^HLA;Z.Y>_<TF_3WJLJ _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>modular002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular002.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!# "_ P$1  (1 0,1 ?_$ *D  0 " P$!
M       %!@$"! ,' 0$! 0$! 0               @$#! 40  $# P,!! 0'
M"@H'!P4   $" P0 $04A$@8Q05$3!V%Q(A2!D3)TM!4UH=%"4B.35187"+'!
MX6*",[,D=3?P<I)38S2DTD.#1)0E5J+R12<8$0$!  (" @$$ @(#
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MYI7 ,"]EI.1=\3<^XE\,7'A(>'AE;K:;7"E^[H2KT5N4VO"7Y68*5*E3''Y
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MFWA@[=_7H#I0>S<J*Z\ZRVXE2V2$O)!%TW%Q?UT'300.?2GZZX_H/:ENA7I
MAO\ 6N>\34\GH*N>%%:%AW4"P[J".SB#]43_ )N];T?DS6QD\50?(V:\UQ.#
MB9*CXC$&'(9W&]VG6$*[>ZJKP_K6S:ROIXZ5#WE H% H% H%!\I\S.&>9F;Y
M B5QO,B#CDL);4Q>QWA9)/Q5UUVCS[^V>(J?[+_//_Y*D^G=_)5>\<Y[_#/[
M+O//_P"2H_V_Y*7LGPW\6WG-?5N"8CD>(XHW"Y!*&0RC1=4MP:[DJ42A/IKG
MMM';3,5)6"RST5]]>/>2J3%DR5M(!]@J1+!CHM;JX\VH#T7J'5-8G'YIK,/R
MQ&6VCPRIT+!(>0X$.!L$]5(V*3002^/9AS'/GZO?0Z]!??#0"@4K>;4/=P!T
MM(7O">Z@NV'#RLMFYKD-QE)2PTRDIVAP--E94.\E3I%_1066D$%G_MKCOSQ[
MZ&_7/=*='05<\**T:*=2G0]1V4&2XGKV=_KH.#-*)P\_LO&=-O\ PS6QEO,?
M.N+?^VP>!9,#:U.P\*')_P#3-E)-:\7=/7ME?50=*E[F:!0*!0*!0*#Q*T!1
M!4+W[>ZGJ4\5%OECXQ6X3/Y8\9O\<?&*SUJ;V3PR%I"2JX( O?X:>JM>48CE
M&!L@^^HL6G'K:_U;2BA:NG80;^JBG:F9&4M;:70MQE"5N =0E:20>[7;0<*N
M48$I#HG-[ R9*5:ZMI)05'3\:@[HV0A2)4B,RZE;T500^@=4E0N+T'92""S_
M -M<=^>/?0WZY[I3HZ"KGA16B YO(R4?BF4?QVX3&V5>'LU4!?VU)MVA%R*"
ME8_.3Y?&A"C9!Y2).=^JH^34"E\1DV=/4"R]%H&E!VCFT'&\(9;STI:I<CWZ
M T\&W'"ZN*\Y'"E% (!5LN2=*5DF>?AY,1%O^3/'7T?U\/%XZ0@]HV,-A7W"
M:K5Y?V9G7V^'T'%3$3<=%E(^2^TA?PJ2#65WZKG27_#K'05CH4"@4"@4"@JO
M(>*Y#)Y 28^05&;"=I;':?BJYL\?9^K[6U%?L]S'Z7<MZ_Y*KV<I^F?L]S'Z
M8<^/^2L]G2=%BSX;&RL9B?=5O&2\WO4E:NJE*N0#479Z>OA2/U5SKT9Q:X*0
MY)COON,W%A)4W*0&NOR5&6%#U:UCHE,/A>0Q\GD)EG&6'DM/^[%22'%(:2E+
M0MTL$[57]%!#GB>=5"?#D(>._%>==&Y-O?'6E->&-?D[G/$]7IH+)QS#9&%G
M,_D'F;(GEM;3-QT2E?LC7O-CZ?106^D$%G_MKCOSQ[Z&_7/=*<'05<\-9K1X
M26W7&'$-K#2EI4 OM!/0T:I[G G!BF(3,Y2%QR)2'"#N.0]X]X4^I5]0HW3;
MN/6@D6^/1,9Q!4!X"2N-&>6MU2?E.+"EN+ -[;EDJH:N;A,5,KRMX_&(T?PD
M-!O_ #XJ!_'6QR[M<S'T>GEY(6[QIAM1.Z,XMA5_^&K3_P"DBJKG^E>++]*M
M.MC41WGAL.@HV>"C2@4"@4 @'J*!0+4#:.ZC,&T=WHHTL-=.O6@P4I(((N#U
M^&@S0*006?\ MKCOSQ[Z&_7/=*;"A8?%5SPIG</BK0M<>N@T\-6Z]^W4=A'^
M@O0<>:2?J>?<Z^[.W^!!HF>45Y=;CY=\8(ZG$P3_ -,BBMIEQ\,/NF7S^,Z)
M9EAUM/\ -=!.GQ"NE\/#T[>NVT_RN%<H]V&:T*!0*!0*!0*!0*!0*!0*!2""
MS_VUQWYX]]#?KGNE(3\A#@1E29CJ68Z"/$<7< ?%5SPS*/Q'+^/Y9XQX,M#K
MX&[P]02.MQ<"M,IU/R1VZ=:+*#AS?V//^;O?V9H817EO_EWQ?_"('T9N@CWC
M[AYC(4=&\I&"1W;V_P#[:Z?1\[MX[5P2=->M<WT=JWH% H% H% H% H% H%
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M<]TNG/*FIPN1,).^8(SIC)3J5+"#M%CVD]*Z=9OX5/@;>4C9K,P)+SDI$=*
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M) Z=/%]%<[Y>O6<++61:"S_VUQWYX]]#?KGNE.CH*N3A13 \WG5MM+6E!<*
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MA.FFE;MX)5R$AHJV!:=_2UQ>_JK,8+6%264:*6D7UU(&GPUDT,L+>:2+N*"
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B77[E!X8GW#ZO9^K[>Y;/[OMZ;?A^&A'>.E%4H% H%!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>modular003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular003.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ R '[ P$1  (1 0,1 ?_$ ,4  0 " P$! 0
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MO3]X<']22_6U ^CN]/WAP?U)+];4#Z.[T_>'!_4DOUM0/H[O3]X<']22_6U
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M?@_JZ)^CH/*^ZGNM%K;/P?U=$_1T'G[)>Z[W1PO+3_N^+S_*_D^?CYT%OH%
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M'R<WCLG!88EP&6%(9#/IRELIFI02[V:R I-B3J-C3D=VX>ZS)RMW(5&ARH^
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M+*1^*WI'_5K6)KQ]/8E-_P"<#S)5_@JX:>T.)OP>/F2K_!4L2]/:<[BB+^D
M7\((^^*B>Z.MJ5'=%VG$K\A%%E<67W!B<0TA_)24Q6G"0@KOQ(Y\K^&BMT'*
MX_(LI?@R$2&E<E-FXH1T:P.=7$]T>@XGCQIA[I_$#@/('[E9M7P!85RXCPTT
M9!JC6H665#IMX;^ >&@]H4%("DDV/$'P@]-!Z\YH'G-!CSF@><TT/.:#/G-
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MK(G73C <400"X?#S^_6HQK>UCWW""NZ$=)Z?)5IKI3!83QL56Z55E&XV2K2
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MLC;N4;1CXNW)N4C"1CW$6?BNM!#VM\M=LVI.L(4@:#X34T7;;N_]N3("BY.
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MAGS*?:=Q4\$2YK2&66V$H47HK79@]GVG4<-E&W'G21ONM>4VMW@N[AR,N N
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MUA5KH4/Q56OI-ZU.G.QID.=0D&QYCA?EY*U:D<&(W$[BT38DL!33;:Y$!1X
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M5-*:67$A:NST*UV2KJDK0GB#;AQJB0%"%%* :"J]VG]G9G]>;@_]<FT%JH%
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MZYKE.(B-_P"C;LMS^,>J/NU+TU(FX6VL7$7V@;[9[_3/'6H>3H3YA6=:Q)A
MMX*BLA-!F@5,"J% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% (H//9@D$GB/)^&@: .7#[GWJ#&BU^
M//S?>M33&2@'AQ^&I3#LQ:QX_=^_>@R$@<.CP4@S5"@4"@4"@4"@4"@4"@4"
E@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>modd-20220331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /6Ips7xRiXgen8uHZH0sSaeBObPtzpN2aekhtWp6fVm67yAhhbHBViD0eHKWYcIA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:modd="http://modular-medical.com/20220331" elementFormDefault="qualified" targetNamespace="http://modular-medical.com/20220331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://modular-medical.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" id="StatementsOfStockholdersEquityDeficit">
	  <link:definition>00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" id="CompanyAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" id="ConsolidatedBalanceSheetDetail">
	  <link:definition>00000008 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Leases" id="Leases">
	  <link:definition>00000009 - Disclosure - LEASES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/PppNote" id="PppNote">
	  <link:definition>00000010 - Disclosure - PPP NOTE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotes" id="ConvertiblePromissoryNotes">
	  <link:definition>00000011 - Disclosure - CONVERTIBLE PROMISSORY NOTES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/PromissoryNote" id="PromissoryNote">
	  <link:definition>00000012 - Disclosure - PROMISSORY NOTE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDeficit" id="StockholdersEquityDeficit">
	  <link:definition>00000013 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000014 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000015 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/RoyaltyAgreement" id="RoyaltyAgreement">
	  <link:definition>00000016 - Disclosure - ROYALTY AGREEMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000018 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/SubsequentEvent" id="SubsequentEvent">
	  <link:definition>00000019 - Disclosure - SUBSEQUENT EVENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" id="CompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000020 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" id="CompanyAndSummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000021 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" id="ConsolidatedBalanceSheetDetailTables">
	  <link:definition>00000022 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000023 - Disclosure - LEASES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000024 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000025 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" id="CompanyAndSummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>00000026 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" id="ConsolidatedBalanceSheetDetailDetails">
	  <link:definition>00000027 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/LeasesDetails" id="LeasesDetails">
	  <link:definition>00000028 - Disclosure - Leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000029 - Disclosure - LEASES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/PppNoteDetailsNarrative" id="PppNoteDetailsNarrative">
	  <link:definition>00000030 - Disclosure - PPP NOTE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" id="ConvertiblePromissoryNotesDetailsNarrative">
	  <link:definition>00000031 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/PromissoryNoteDetailsNarrative" id="PromissoryNoteDetailsNarrative">
	  <link:definition>00000032 - Disclosure - PROMISSORY NOTE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative" id="StockholdersEquityDeficitDetailsNarrative">
	  <link:definition>00000033 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails" id="Stock-basedCompensationDetails">
	  <link:definition>00000034 - Disclosure - STOCK-BASED COMPENSATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails2" id="Stock-basedCompensationDetails2">
	  <link:definition>00000035 - Disclosure - STOCK-BASED COMPENSATION (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails3" id="Stock-basedCompensationDetails3">
	  <link:definition>00000036 - Disclosure - STOCK-BASED COMPENSATION (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
	  <link:definition>00000037 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000038 - Disclosure - INCOME TAXES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
	  <link:definition>00000039 - Disclosure - INCOME TAXES (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxesDetails3" id="IncomeTaxesDetails3">
	  <link:definition>00000040 - Disclosure - INCOME TAXES (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000041 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="modd_CommonStockIssuableMember" name="CommonStockIssuableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_SecuredPromissoryNotesMember" name="SecuredPromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_CEOAndInvestorMember" name="CEOAndInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_NotesPayableOtherPayables1Member" name="NotesPayableOtherPayables1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_NotesPayableOtherPayables2Member" name="NotesPayableOtherPayables2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_MemberOfBoardMember" name="MemberOfBoardMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DaughterOfPresidentCFOTreasurerAndChairmanMember" name="DaughterOfPresidentCFOTreasurerAndChairmanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_EarningsPerShareBasicAndDiluted1Abstract" name="EarningsPerShareBasicAndDiluted1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="modd_EarningsPerShareBasicAndDiluted1" name="EarningsPerShareBasicAndDiluted1" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="modd_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" name="EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1" name="WeightedAverageNumberOfShareOutstandingBasicAndDiluted1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_SharesIssuedForReverseStockSplit" name="SharesIssuedForReverseStockSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_GainOnPPPNoteForgiveness" name="GainOnPPPNoteForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_AccruedInterest" name="AccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_IncreaseDecreaseInLeaseLiability" name="IncreaseDecreaseInLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ProceedsFromIssuanceOfPromissoryNote" name="ProceedsFromIssuanceOfPromissoryNote" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_RepaymentOfPromissoryNote" name="RepaymentOfPromissoryNote" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts" name="ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" name="ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosurePppNoteAbstract" name="DisclosurePppNoteAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="modd_PPPNotesPayableTextBlock" name="PPPNotesPayableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosurePromissoryNoteAbstract" name="DisclosurePromissoryNoteAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="modd_PromissoryNoteTextBlock" name="PromissoryNoteTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureRoyaltyAgreementAbstract" name="DisclosureRoyaltyAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="modd_RoyaltyAgreementDisclosureTextBlock" name="RoyaltyAgreementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock" name="DebtModificationsAndExtinguishmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" name="TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock" name="DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureConsolidatedBalanceSheetDetailDetailsAbstract" name="DisclosureConsolidatedBalanceSheetDetailDetailsAbstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureLeasesDetailsAbstract" name="DisclosureLeasesDetailsAbstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureStockBasedCompensationDetailsAbstract" name="DisclosureStockBasedCompensationDetailsAbstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureStockBasedCompensationDetails2Abstract" name="DisclosureStockBasedCompensationDetails2Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureStockBasedCompensationDetails3Abstract" name="DisclosureStockBasedCompensationDetails3Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureIncomeTaxesDetailsAbstract" name="DisclosureIncomeTaxesDetailsAbstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureIncomeTaxesDetails2Abstract" name="DisclosureIncomeTaxesDetails2Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureIncomeTaxesDetails3Abstract" name="DisclosureIncomeTaxesDetails3Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_AccruedWagesAndBonus" name="AccruedWagesAndBonus" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_AccruedPlacementFees" name="AccruedPlacementFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_AccruedInterests" name="AccruedInterests" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_OperatingLeasesImputedInterest" name="OperatingLeasesImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_LeaseIncentiveReceived" name="LeaseIncentiveReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_CashPaidforLeaseLiabilities" name="CashPaidforLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_FairValueofOptionGranted" name="FairValueofOptionGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>modd-20220331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modular-medical.com/role/Cover" xlink:href="modd-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheets" xlink:href="modd-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:href="modd-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfOperations" xlink:href="modd-20220331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="modd-20220331.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfCashFlows" xlink:href="modd-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="modd-20220331.xsd#CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:href="modd-20220331.xsd#ConsolidatedBalanceSheetDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Leases" xlink:href="modd-20220331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNote" xlink:href="modd-20220331.xsd#PppNote" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:href="modd-20220331.xsd#ConvertiblePromissoryNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PromissoryNote" xlink:href="modd-20220331.xsd#PromissoryNote" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficit" xlink:href="modd-20220331.xsd#StockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensation" xlink:href="modd-20220331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxes" xlink:href="modd-20220331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RoyaltyAgreement" xlink:href="modd-20220331.xsd#RoyaltyAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:href="modd-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactions" xlink:href="modd-20220331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEvent" xlink:href="modd-20220331.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="modd-20220331.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="modd-20220331.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:href="modd-20220331.xsd#ConsolidatedBalanceSheetDetailTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesTables" xlink:href="modd-20220331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:href="modd-20220331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesTables" xlink:href="modd-20220331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="modd-20220331.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:href="modd-20220331.xsd#ConsolidatedBalanceSheetDetailDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetails" xlink:href="modd-20220331.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:href="modd-20220331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:href="modd-20220331.xsd#PppNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:href="modd-20220331.xsd#ConvertiblePromissoryNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PromissoryNoteDetailsNarrative" xlink:href="modd-20220331.xsd#PromissoryNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:href="modd-20220331.xsd#StockholdersEquityDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:href="modd-20220331.xsd#Stock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:href="modd-20220331.xsd#Stock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:href="modd-20220331.xsd#Stock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="modd-20220331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails" xlink:href="modd-20220331.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails2" xlink:href="modd-20220331.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails3" xlink:href="modd-20220331.xsd#IncomeTaxesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:href="modd-20220331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="modd-20220331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaapUnsecuredDebtCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapUnsecuredDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaapShortTermBankLoansAndNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapShortTermBankLoansAndNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ProceedsFromIssuanceOfPromissoryNote" xlink:label="loc_moddProceedsFromIssuanceOfPromissoryNote" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_moddProceedsFromIssuanceOfPromissoryNote" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_RepaymentOfPromissoryNote" xlink:label="loc_moddRepaymentOfPromissoryNote" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_moddRepaymentOfPromissoryNote" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts" xlink:label="loc_moddProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_moddProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:title="00000008 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Leases" xlink:title="00000009 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNote" xlink:title="00000010 - Disclosure - PPP NOTE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:title="00000011 - Disclosure - CONVERTIBLE PROMISSORY NOTES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PromissoryNote" xlink:title="00000012 - Disclosure - PROMISSORY NOTE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficit" xlink:title="00000013 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensation" xlink:title="00000014 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RoyaltyAgreement" xlink:title="00000016 - Disclosure - ROYALTY AGREEMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEvent" xlink:title="00000019 - Disclosure - SUBSEQUENT EVENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:title="00000022 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesTables" xlink:title="00000023 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:title="00000024 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesTables" xlink:title="00000025 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000026 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:title="00000027 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_AccruedWagesAndBonus" xlink:label="loc_moddAccruedWagesAndBonus" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_moddAccruedWagesAndBonus" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_AccruedPlacementFees" xlink:label="loc_moddAccruedPlacementFees" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_moddAccruedPlacementFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_AccruedInterests" xlink:label="loc_moddAccruedInterests" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_moddAccruedInterests" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetails" xlink:title="00000028 - Disclosure - Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_OperatingLeasesImputedInterest" xlink:label="loc_moddOperatingLeasesImputedInterest" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_moddOperatingLeasesImputedInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:title="00000029 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:title="00000030 - Disclosure - PPP NOTE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:title="00000031 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PromissoryNoteDetailsNarrative" xlink:title="00000032 - Disclosure - PROMISSORY NOTE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="00000033 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:title="00000034 - Disclosure - STOCK-BASED COMPENSATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:title="00000035 - Disclosure - STOCK-BASED COMPENSATION (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:title="00000036 - Disclosure - STOCK-BASED COMPENSATION (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000037 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails" xlink:title="00000038 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails2" xlink:title="00000039 - Disclosure - INCOME TAXES (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails3" xlink:title="00000040 - Disclosure - INCOME TAXES (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesRegulatoryAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesRegulatoryAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000041 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>modd-20220331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modular-medical.com/role/Cover" xlink:href="modd-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheets" xlink:href="modd-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:href="modd-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfOperations" xlink:href="modd-20220331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="modd-20220331.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfCashFlows" xlink:href="modd-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="modd-20220331.xsd#CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:href="modd-20220331.xsd#ConsolidatedBalanceSheetDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Leases" xlink:href="modd-20220331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNote" xlink:href="modd-20220331.xsd#PppNote" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:href="modd-20220331.xsd#ConvertiblePromissoryNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PromissoryNote" xlink:href="modd-20220331.xsd#PromissoryNote" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficit" xlink:href="modd-20220331.xsd#StockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensation" xlink:href="modd-20220331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxes" xlink:href="modd-20220331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RoyaltyAgreement" xlink:href="modd-20220331.xsd#RoyaltyAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:href="modd-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactions" xlink:href="modd-20220331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEvent" xlink:href="modd-20220331.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="modd-20220331.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="modd-20220331.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:href="modd-20220331.xsd#ConsolidatedBalanceSheetDetailTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesTables" xlink:href="modd-20220331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:href="modd-20220331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesTables" xlink:href="modd-20220331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="modd-20220331.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:href="modd-20220331.xsd#ConsolidatedBalanceSheetDetailDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetails" xlink:href="modd-20220331.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:href="modd-20220331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:href="modd-20220331.xsd#PppNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:href="modd-20220331.xsd#ConvertiblePromissoryNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PromissoryNoteDetailsNarrative" xlink:href="modd-20220331.xsd#PromissoryNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:href="modd-20220331.xsd#StockholdersEquityDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:href="modd-20220331.xsd#Stock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:href="modd-20220331.xsd#Stock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:href="modd-20220331.xsd#Stock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="modd-20220331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails" xlink:href="modd-20220331.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails2" xlink:href="modd-20220331.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails3" xlink:href="modd-20220331.xsd#IncomeTaxesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:href="modd-20220331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="modd-20220331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_CommonStockIssuableMember" xlink:label="loc_moddCommonStockIssuableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_moddCommonStockIssuableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_SharesIssuedForReverseStockSplit" xlink:label="loc_moddSharesIssuedForReverseStockSplit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_moddSharesIssuedForReverseStockSplit_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_60" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:title="00000008 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Leases" xlink:title="00000009 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNote" xlink:title="00000010 - Disclosure - PPP NOTE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:title="00000011 - Disclosure - CONVERTIBLE PROMISSORY NOTES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PromissoryNote" xlink:title="00000012 - Disclosure - PROMISSORY NOTE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficit" xlink:title="00000013 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensation" xlink:title="00000014 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RoyaltyAgreement" xlink:title="00000016 - Disclosure - ROYALTY AGREEMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEvent" xlink:title="00000019 - Disclosure - SUBSEQUENT EVENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:title="00000022 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesTables" xlink:title="00000023 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:title="00000024 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesTables" xlink:title="00000025 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000026 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:title="00000027 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMachineryAndEquipmentMember" xlink:label="loc_us-gaapOtherMachineryAndEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOtherMachineryAndEquipmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_AccruedWagesAndBonus" xlink:label="loc_moddAccruedWagesAndBonus_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_moddAccruedWagesAndBonus_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_AccruedPlacementFees" xlink:label="loc_moddAccruedPlacementFees_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_moddAccruedPlacementFees_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_AccruedInterests" xlink:label="loc_moddAccruedInterests_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_moddAccruedInterests_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_110" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetails" xlink:title="00000028 - Disclosure - Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:title="00000029 - Disclosure - LEASES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:title="00000030 - Disclosure - PPP NOTE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:title="00000031 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PromissoryNoteDetailsNarrative" xlink:title="00000032 - Disclosure - PROMISSORY NOTE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_SecuredPromissoryNotesMember" xlink:label="loc_moddSecuredPromissoryNotesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_moddSecuredPromissoryNotesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCredit_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaapLineOfCreditFacilityExpirationDate1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityExpirationDate1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapLineOfCreditFacilityIncreaseDecreaseForPeriodNet_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityIncreaseDecreaseForPeriodNet_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:label="loc_us-gaapLineOfCreditFacilityIncreaseAccruedInterest_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityIncreaseAccruedInterest_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="00000033 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:title="00000034 - Disclosure - STOCK-BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:title="00000035 - Disclosure - STOCK-BASED COMPENSATION (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:title="00000036 - Disclosure - STOCK-BASED COMPENSATION (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000037 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_FairValueofOptionGranted" xlink:label="loc_moddFairValueofOptionGranted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_moddFairValueofOptionGranted_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_90" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails" xlink:title="00000038 - Disclosure - INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails2" xlink:title="00000039 - Disclosure - INCOME TAXES (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails3" xlink:title="00000040 - Disclosure - INCOME TAXES (Details 3)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000041 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_CEOAndInvestorMember" xlink:label="loc_moddCEOAndInvestorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_moddCEOAndInvestorMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_MemberOfBoardMember" xlink:label="loc_moddMemberOfBoardMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_moddMemberOfBoardMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DaughterOfPresidentCFOTreasurerAndChairmanMember" xlink:label="loc_moddDaughterOfPresidentCFOTreasurerAndChairmanMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_moddDaughterOfPresidentCFOTreasurerAndChairmanMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_NotesPayableOtherPayables1Member" xlink:label="loc_moddNotesPayableOtherPayables1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_moddNotesPayableOtherPayables1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_NotesPayableOtherPayables2Member" xlink:label="loc_moddNotesPayableOtherPayables2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_moddNotesPayableOtherPayables2Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesPayable_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesAndWages_120" xlink:type="arc" order="4" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>modd-20220331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_CommonStockIssuableMember" xlink:label="modd_CommonStockIssuableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockIssuableMember" xlink:to="modd_CommonStockIssuableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockIssuableMember_lbl" xml:lang="en-US">Common Stock Issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMachineryAndEquipmentMember" xlink:label="us-gaap_OtherMachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherMachineryAndEquipmentMember" xlink:to="us-gaap_OtherMachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherMachineryAndEquipmentMember_lbl" xml:lang="en-US">Other Machinery and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_SecuredPromissoryNotesMember" xlink:label="modd_SecuredPromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_SecuredPromissoryNotesMember" xlink:to="modd_SecuredPromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_SecuredPromissoryNotesMember_lbl" xml:lang="en-US">Secured Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employee Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_CEOAndInvestorMember" xlink:label="modd_CEOAndInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CEOAndInvestorMember" xlink:to="modd_CEOAndInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CEOAndInvestorMember_lbl" xml:lang="en-US">C E O And Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_NotesPayableOtherPayables1Member" xlink:label="modd_NotesPayableOtherPayables1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NotesPayableOtherPayables1Member" xlink:to="modd_NotesPayableOtherPayables1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_NotesPayableOtherPayables1Member_lbl" xml:lang="en-US">Notes Payable Other Payables 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_NotesPayableOtherPayables2Member" xlink:label="modd_NotesPayableOtherPayables2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NotesPayableOtherPayables2Member" xlink:to="modd_NotesPayableOtherPayables2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_NotesPayableOtherPayables2Member_lbl" xml:lang="en-US">Notes Payable Other Payables 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_MemberOfBoardMember" xlink:label="modd_MemberOfBoardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_MemberOfBoardMember" xlink:to="modd_MemberOfBoardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_MemberOfBoardMember_lbl" xml:lang="en-US">Member Of Board [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DaughterOfPresidentCFOTreasurerAndChairmanMember" xlink:label="modd_DaughterOfPresidentCFOTreasurerAndChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DaughterOfPresidentCFOTreasurerAndChairmanMember" xlink:to="modd_DaughterOfPresidentCFOTreasurerAndChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DaughterOfPresidentCFOTreasurerAndChairmanMember_lbl" xml:lang="en-US">Daughter of President, CFO, Treasurer and Chairman of Board [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment,&#160;net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssets_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">TOTAL NON-CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Short-term lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="us-gaap_UnsecuredDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtCurrent" xlink:to="us-gaap_UnsecuredDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebtCurrent_lbl" xml:lang="en-US">PPP note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Bonus payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL&#160; LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 11)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001 par value, 50,000,000 shares authorized, 10,461,898 shares and 6,302,050 shares issued and outstanding as of March 31, 2022 and 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_EarningsPerShareBasicAndDiluted1Abstract" xlink:label="modd_EarningsPerShareBasicAndDiluted1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_EarningsPerShareBasicAndDiluted1Abstract" xlink:to="modd_EarningsPerShareBasicAndDiluted1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_EarningsPerShareBasicAndDiluted1Abstract_lbl" xml:lang="en-US">Net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_EarningsPerShareBasicAndDiluted1" xlink:label="modd_EarningsPerShareBasicAndDiluted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_EarningsPerShareBasicAndDiluted1" xlink:to="modd_EarningsPerShareBasicAndDiluted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_EarningsPerShareBasicAndDiluted1_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" xlink:label="modd_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" xlink:to="modd_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract_lbl" xml:lang="en-US">Shares used in computing net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1" xlink:label="modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1" xlink:to="modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance as of&#160;March 31, 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Placement of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Placement of common stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Shares issued for services, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock upon public offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock upon public offering, net of issuance costs, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common stock in settlement of convertible notes and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common stock in settlement of convertible notes and accrued interest, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Warrants issued with convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_SharesIssuedForReverseStockSplit" xlink:label="modd_SharesIssuedForReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_SharesIssuedForReverseStockSplit" xlink:to="modd_SharesIssuedForReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_SharesIssuedForReverseStockSplit_lbl" xml:lang="en-US">Shares issued for reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Shares issued for reverse stock split, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Issuance of common stock under equity incentive plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Issuance of common stock under equity incentive plan, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_GainOnPPPNoteForgiveness" xlink:label="modd_GainOnPPPNoteForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_GainOnPPPNoteForgiveness" xlink:to="modd_GainOnPPPNoteForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_GainOnPPPNoteForgiveness_lbl" xml:lang="en-US">Gain on PPP note forgiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_AccruedInterest" xlink:label="modd_AccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedInterest" xlink:to="modd_AccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AccruedInterest_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_IncreaseDecreaseInLeaseLiability" xlink:label="modd_IncreaseDecreaseInLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncreaseDecreaseInLeaseLiability" xlink:to="modd_IncreaseDecreaseInLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IncreaseDecreaseInLeaseLiability_lbl" xml:lang="en-US">Change in lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Other assets and prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placements, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible notes, net of placement fees</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ProceedsFromIssuanceOfPromissoryNote" xlink:label="modd_ProceedsFromIssuanceOfPromissoryNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ProceedsFromIssuanceOfPromissoryNote" xlink:to="modd_ProceedsFromIssuanceOfPromissoryNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ProceedsFromIssuanceOfPromissoryNote_lbl" xml:lang="en-US">Proceeds from issuance of promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_RepaymentOfPromissoryNote" xlink:label="modd_RepaymentOfPromissoryNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RepaymentOfPromissoryNote" xlink:to="modd_RepaymentOfPromissoryNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RepaymentOfPromissoryNote_lbl" xml:lang="en-US">Repayment of promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from issuance of PPP note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts" xlink:label="modd_ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts" xlink:to="modd_ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from issuance of common stock upon public offering, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents, at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash and cash equivalents, at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash investing and financing activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_2_lbl" xml:lang="en-US">Fair value of detachable warrants issued with convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:label="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:to="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock_lbl" xml:lang="en-US">Conversion of convertible notes and accrued interest into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Cash paid for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEET DETAIL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosurePppNoteAbstract" xlink:label="modd_DisclosurePppNoteAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosurePppNoteAbstract" xlink:to="modd_DisclosurePppNoteAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosurePppNoteAbstract_lbl" xml:lang="en-US">Ppp Note</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_PPPNotesPayableTextBlock" xlink:label="modd_PPPNotesPayableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PPPNotesPayableTextBlock" xlink:to="modd_PPPNotesPayableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PPPNotesPayableTextBlock_lbl" xml:lang="en-US">PPP NOTE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE PROMISSORY NOTES</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosurePromissoryNoteAbstract" xlink:label="modd_DisclosurePromissoryNoteAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosurePromissoryNoteAbstract" xlink:to="modd_DisclosurePromissoryNoteAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosurePromissoryNoteAbstract_lbl" xml:lang="en-US">Promissory Note</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_PromissoryNoteTextBlock" xlink:label="modd_PromissoryNoteTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PromissoryNoteTextBlock" xlink:to="modd_PromissoryNoteTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PromissoryNoteTextBlock_lbl" xml:lang="en-US">PROMISSORY NOTE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureRoyaltyAgreementAbstract" xlink:label="modd_DisclosureRoyaltyAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureRoyaltyAgreementAbstract" xlink:to="modd_DisclosureRoyaltyAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureRoyaltyAgreementAbstract_lbl" xml:lang="en-US">Royalty Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_RoyaltyAgreementDisclosureTextBlock" xlink:label="modd_RoyaltyAgreementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RoyaltyAgreementDisclosureTextBlock" xlink:to="modd_RoyaltyAgreementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RoyaltyAgreementDisclosureTextBlock_lbl" xml:lang="en-US">ROYALTY AGREEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENT</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_LiquidityPolicyTextBlock" xlink:label="modd_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_LiquidityPolicyTextBlock" xlink:to="modd_LiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ReverseStockSplitPolicyTextBlock" xlink:label="modd_ReverseStockSplitPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ReverseStockSplitPolicyTextBlock" xlink:to="modd_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US">Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Reportable Segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and Administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_RisksAndUncertaintiesPolicyTextBlock" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RisksAndUncertaintiesPolicyTextBlock" xlink:to="modd_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:label="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:to="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DebtModificationsAndExtinguishmentsPolicyTextBlock_lbl" xml:lang="en-US">Debt Modifications and Extinguishments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Per-Share Amounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive:</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:label="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:to="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_lbl" xml:lang="en-US">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock" xlink:label="modd_DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock" xlink:to="modd_DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock_lbl" xml:lang="en-US">[custom:DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureConsolidatedBalanceSheetDetailDetailsAbstract" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetailDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureConsolidatedBalanceSheetDetailDetailsAbstract" xlink:to="modd_DisclosureConsolidatedBalanceSheetDetailDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetailDetailsAbstract_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEET DETAIL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Future minimum payments under the facility operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureLeasesDetailsAbstract" xlink:label="modd_DisclosureLeasesDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureLeasesDetailsAbstract" xlink:to="modd_DisclosureLeasesDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureLeasesDetailsAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureStockBasedCompensationDetailsAbstract" xlink:label="modd_DisclosureStockBasedCompensationDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetailsAbstract" xlink:to="modd_DisclosureStockBasedCompensationDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureStockBasedCompensationDetailsAbstract_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureStockBasedCompensationDetails2Abstract" xlink:label="modd_DisclosureStockBasedCompensationDetails2Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetails2Abstract" xlink:to="modd_DisclosureStockBasedCompensationDetails2Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureStockBasedCompensationDetails2Abstract_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION (Details 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Outstanding and Exercisable Option, Range</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureStockBasedCompensationDetails3Abstract" xlink:label="modd_DisclosureStockBasedCompensationDetails3Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetails3Abstract" xlink:to="modd_DisclosureStockBasedCompensationDetails3Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureStockBasedCompensationDetails3Abstract_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION (Details 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Income tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureIncomeTaxesDetailsAbstract" xlink:label="modd_DisclosureIncomeTaxesDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureIncomeTaxesDetailsAbstract" xlink:to="modd_DisclosureIncomeTaxesDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureIncomeTaxesDetailsAbstract_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Provisions</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureIncomeTaxesDetails2Abstract" xlink:label="modd_DisclosureIncomeTaxesDetails2Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureIncomeTaxesDetails2Abstract" xlink:to="modd_DisclosureIncomeTaxesDetails2Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureIncomeTaxesDetails2Abstract_lbl" xml:lang="en-US">INCOME TAXES (Details 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureIncomeTaxesDetails3Abstract" xlink:label="modd_DisclosureIncomeTaxesDetails3Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureIncomeTaxesDetails3Abstract" xlink:to="modd_DisclosureIncomeTaxesDetails3Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureIncomeTaxesDetails3Abstract_lbl" xml:lang="en-US">INCOME TAXES (Details 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment,&#160;gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_AccruedWagesAndBonus" xlink:label="modd_AccruedWagesAndBonus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedWagesAndBonus" xlink:to="modd_AccruedWagesAndBonus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AccruedWagesAndBonus_lbl" xml:lang="en-US">Accrued wages and bonus</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_AccruedPlacementFees" xlink:label="modd_AccruedPlacementFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedPlacementFees" xlink:to="modd_AccruedPlacementFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AccruedPlacementFees_lbl" xml:lang="en-US">Accrued placement fees</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_AccruedInterests" xlink:label="modd_AccruedInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedInterests" xlink:to="modd_AccruedInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_AccruedInterests_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_OperatingLeasesImputedInterest" xlink:label="modd_OperatingLeasesImputedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OperatingLeasesImputedInterest" xlink:to="modd_OperatingLeasesImputedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_OperatingLeasesImputedInterest_lbl" xml:lang="en-US">Imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_LeaseIncentiveReceived" xlink:label="modd_LeaseIncentiveReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_LeaseIncentiveReceived" xlink:to="modd_LeaseIncentiveReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_LeaseIncentiveReceived_lbl" xml:lang="en-US">Lease Incentive Received</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_CashPaidforLeaseLiabilities" xlink:label="modd_CashPaidforLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CashPaidforLeaseLiabilities" xlink:to="modd_CashPaidforLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CashPaidforLeaseLiabilities_lbl" xml:lang="en-US">Cash Paid for Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtCurrent" xlink:to="us-gaap_UnsecuredDebtCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnsecuredDebtCurrent_2_lbl" xml:lang="en-US">Unsecured Debt, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Long-Term Line of Credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xml:lang="en-US">Line of Credit Facility, Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US">Line of Credit Facility, Increase (Decrease), Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl" xml:lang="en-US">Line of Credit Facility, Increase, Accrued Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_lbl" xml:lang="en-US">Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_FairValueofOptionGranted" xlink:label="modd_FairValueofOptionGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_FairValueofOptionGranted" xlink:to="modd_FairValueofOptionGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_FairValueofOptionGranted_lbl" xml:lang="en-US">Fair Value of Options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2_lbl" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Current portion:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Deferred portion:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xml:lang="en-US">Section 179 assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_lbl" xml:lang="en-US">Reserves, accruals &amp; other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_lbl" xml:lang="en-US">Section 179 assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Interest Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_EarningsPerShareBasicAndDiluted1" xlink:to="modd_EarningsPerShareBasicAndDiluted1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_EarningsPerShareBasicAndDiluted1_doc" xml:lang="en-US">The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1" xlink:to="modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1_doc" xml:lang="en-US">Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1" xlink:to="modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1_3_lbl" xml:lang="en-US">WeightedAverageNumberOfShareOutstandingBasicAndDiluted1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2_lbl" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:to="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_2_lbl" xml:lang="en-US">TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureConsolidatedBalanceSheetDetailDetailsAbstract" xlink:to="modd_DisclosureConsolidatedBalanceSheetDetailDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetailDetailsAbstract_2_lbl" xml:lang="en-US">DisclosureConsolidatedBalanceSheetDetailDetailsAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureLeasesDetailsAbstract" xlink:to="modd_DisclosureLeasesDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureLeasesDetailsAbstract_2_lbl" xml:lang="en-US">DisclosureLeasesDetailsAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetailsAbstract" xlink:to="modd_DisclosureStockBasedCompensationDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureStockBasedCompensationDetailsAbstract_2_lbl" xml:lang="en-US">DisclosureStockBasedCompensationDetailsAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureIncomeTaxesDetailsAbstract" xlink:to="modd_DisclosureIncomeTaxesDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureIncomeTaxesDetailsAbstract_2_lbl" xml:lang="en-US">DisclosureIncomeTaxesDetailsAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedInterests" xlink:to="modd_AccruedInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AccruedInterests_2_lbl" xml:lang="en-US">Accrued Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Regulatory Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>modd-20220331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modular-medical.com/role/Cover" xlink:href="modd-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheets" xlink:href="modd-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:href="modd-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfOperations" xlink:href="modd-20220331.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="modd-20220331.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfCashFlows" xlink:href="modd-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="modd-20220331.xsd#CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:href="modd-20220331.xsd#ConsolidatedBalanceSheetDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Leases" xlink:href="modd-20220331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNote" xlink:href="modd-20220331.xsd#PppNote" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:href="modd-20220331.xsd#ConvertiblePromissoryNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PromissoryNote" xlink:href="modd-20220331.xsd#PromissoryNote" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficit" xlink:href="modd-20220331.xsd#StockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensation" xlink:href="modd-20220331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxes" xlink:href="modd-20220331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RoyaltyAgreement" xlink:href="modd-20220331.xsd#RoyaltyAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:href="modd-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactions" xlink:href="modd-20220331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEvent" xlink:href="modd-20220331.xsd#SubsequentEvent" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="modd-20220331.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="modd-20220331.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:href="modd-20220331.xsd#ConsolidatedBalanceSheetDetailTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesTables" xlink:href="modd-20220331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:href="modd-20220331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesTables" xlink:href="modd-20220331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="modd-20220331.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:href="modd-20220331.xsd#ConsolidatedBalanceSheetDetailDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetails" xlink:href="modd-20220331.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:href="modd-20220331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:href="modd-20220331.xsd#PppNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:href="modd-20220331.xsd#ConvertiblePromissoryNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PromissoryNoteDetailsNarrative" xlink:href="modd-20220331.xsd#PromissoryNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:href="modd-20220331.xsd#StockholdersEquityDeficitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:href="modd-20220331.xsd#Stock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:href="modd-20220331.xsd#Stock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:href="modd-20220331.xsd#Stock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="modd-20220331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails" xlink:href="modd-20220331.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails2" xlink:href="modd-20220331.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetails3" xlink:href="modd-20220331.xsd#IncomeTaxesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:href="modd-20220331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="modd-20220331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaapUnsecuredDebtCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapUnsecuredDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaapShortTermBankLoansAndNotesPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapShortTermBankLoansAndNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_EarningsPerShareBasicAndDiluted1Abstract" xlink:label="loc_moddEarningsPerShareBasicAndDiluted1Abstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_moddEarningsPerShareBasicAndDiluted1Abstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_EarningsPerShareBasicAndDiluted1" xlink:label="loc_moddEarningsPerShareBasicAndDiluted1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddEarningsPerShareBasicAndDiluted1Abstract" xlink:to="loc_moddEarningsPerShareBasicAndDiluted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" xlink:label="loc_moddEarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_moddEarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1" xlink:label="loc_moddWeightedAverageNumberOfShareOutstandingBasicAndDiluted1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddEarningsPerShareBasicAndDilutedOtherDisclosures1Abstract" xlink:to="loc_moddWeightedAverageNumberOfShareOutstandingBasicAndDiluted1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_CommonStockIssuableMember" xlink:label="loc_moddCommonStockIssuableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_moddCommonStockIssuableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_SharesIssuedForReverseStockSplit" xlink:label="loc_moddSharesIssuedForReverseStockSplit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_moddSharesIssuedForReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_GainOnPPPNoteForgiveness" xlink:label="loc_moddGainOnPPPNoteForgiveness" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_moddGainOnPPPNoteForgiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_AccruedInterest" xlink:label="loc_moddAccruedInterest" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_moddAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_IncreaseDecreaseInLeaseLiability" xlink:label="loc_moddIncreaseDecreaseInLeaseLiability" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_moddIncreaseDecreaseInLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaapOtherNoncashIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherNoncashIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ProceedsFromIssuanceOfPromissoryNote" xlink:label="loc_moddProceedsFromIssuanceOfPromissoryNote" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_moddProceedsFromIssuanceOfPromissoryNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_RepaymentOfPromissoryNote" xlink:label="loc_moddRepaymentOfPromissoryNote" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_moddRepaymentOfPromissoryNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts" xlink:label="loc_moddProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_moddProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:label="loc_moddConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_moddConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:title="00000008 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaapSupplementalBalanceSheetDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Leases" xlink:title="00000009 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNote" xlink:title="00000010 - Disclosure - PPP NOTE">
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosurePppNoteAbstract" xlink:label="loc_moddDisclosurePppNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_PPPNotesPayableTextBlock" xlink:label="loc_moddPPPNotesPayableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosurePppNoteAbstract" xlink:to="loc_moddPPPNotesPayableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:title="00000011 - Disclosure - CONVERTIBLE PROMISSORY NOTES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PromissoryNote" xlink:title="00000012 - Disclosure - PROMISSORY NOTE">
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosurePromissoryNoteAbstract" xlink:label="loc_moddDisclosurePromissoryNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_PromissoryNoteTextBlock" xlink:label="loc_moddPromissoryNoteTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosurePromissoryNoteAbstract" xlink:to="loc_moddPromissoryNoteTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficit" xlink:title="00000013 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensation" xlink:title="00000014 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RoyaltyAgreement" xlink:title="00000016 - Disclosure - ROYALTY AGREEMENT">
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureRoyaltyAgreementAbstract" xlink:label="loc_moddDisclosureRoyaltyAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_RoyaltyAgreementDisclosureTextBlock" xlink:label="loc_moddRoyaltyAgreementDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureRoyaltyAgreementAbstract" xlink:to="loc_moddRoyaltyAgreementDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEvent" xlink:title="00000019 - Disclosure - SUBSEQUENT EVENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_LiquidityPolicyTextBlock" xlink:label="loc_moddLiquidityPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_moddLiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ReverseStockSplitPolicyTextBlock" xlink:label="loc_moddReverseStockSplitPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_moddReverseStockSplitPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_moddRisksAndUncertaintiesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_moddRisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:label="loc_moddDebtModificationsAndExtinguishmentsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_moddDebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:label="loc_moddTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_moddTheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:title="00000022 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock" xlink:label="loc_moddDisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_moddDisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureConsolidatedBalanceSheetDetailDetailsAbstract" xlink:label="loc_moddDisclosureConsolidatedBalanceSheetDetailDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_moddDisclosureConsolidatedBalanceSheetDetailDetailsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesTables" xlink:title="00000023 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureLeasesDetailsAbstract" xlink:label="loc_moddDisclosureLeasesDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddDisclosureLeasesDetailsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:title="00000024 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureStockBasedCompensationDetailsAbstract" xlink:label="loc_moddDisclosureStockBasedCompensationDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_moddDisclosureStockBasedCompensationDetailsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureStockBasedCompensationDetails2Abstract" xlink:label="loc_moddDisclosureStockBasedCompensationDetails2Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_moddDisclosureStockBasedCompensationDetails2Abstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureStockBasedCompensationDetails3Abstract" xlink:label="loc_moddDisclosureStockBasedCompensationDetails3Abstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_moddDisclosureStockBasedCompensationDetails3Abstract" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesTables" xlink:title="00000025 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureIncomeTaxesDetailsAbstract" xlink:label="loc_moddDisclosureIncomeTaxesDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_moddDisclosureIncomeTaxesDetailsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureIncomeTaxesDetails2Abstract" xlink:label="loc_moddDisclosureIncomeTaxesDetails2Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_moddDisclosureIncomeTaxesDetails2Abstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosureIncomeTaxesDetails3Abstract" xlink:label="loc_moddDisclosureIncomeTaxesDetails3Abstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_moddDisclosureIncomeTaxesDetails3Abstract" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000026 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:title="00000027 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMachineryAndEquipmentMember" xlink:label="loc_us-gaapOtherMachineryAndEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOtherMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_AccruedWagesAndBonus" xlink:label="loc_moddAccruedWagesAndBonus" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_moddAccruedWagesAndBonus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_AccruedPlacementFees" xlink:label="loc_moddAccruedPlacementFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_moddAccruedPlacementFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_AccruedInterests" xlink:label="loc_moddAccruedInterests" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_moddAccruedInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetails" xlink:title="00000028 - Disclosure - Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_OperatingLeasesImputedInterest" xlink:label="loc_moddOperatingLeasesImputedInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddOperatingLeasesImputedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:title="00000029 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_LeaseIncentiveReceived" xlink:label="loc_moddLeaseIncentiveReceived" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddLeaseIncentiveReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_CashPaidforLeaseLiabilities" xlink:label="loc_moddCashPaidforLeaseLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddCashPaidforLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:title="00000030 - Disclosure - PPP NOTE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosurePppNoteAbstract" xlink:label="loc_moddDisclosurePppNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaapUnsecuredDebtCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosurePppNoteAbstract" xlink:to="loc_us-gaapUnsecuredDebtCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:title="00000031 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PromissoryNoteDetailsNarrative" xlink:title="00000032 - Disclosure - PROMISSORY NOTE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DisclosurePromissoryNoteAbstract" xlink:label="loc_moddDisclosurePromissoryNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosurePromissoryNoteAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_SecuredPromissoryNotesMember" xlink:label="loc_moddSecuredPromissoryNotesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_moddSecuredPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaapLineOfCreditFacilityExpirationDate1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapLineOfCreditFacilityIncreaseDecreaseForPeriodNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:label="loc_us-gaapLineOfCreditFacilityIncreaseAccruedInterest" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityIncreaseAccruedInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative" xlink:title="00000033 - Disclosure - STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:title="00000034 - Disclosure - STOCK-BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:title="00000035 - Disclosure - STOCK-BASED COMPENSATION (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:title="00000036 - Disclosure - STOCK-BASED COMPENSATION (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000037 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_FairValueofOptionGranted" xlink:label="loc_moddFairValueofOptionGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_moddFairValueofOptionGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails" xlink:title="00000038 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails2" xlink:title="00000039 - Disclosure - INCOME TAXES (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="loc_moddEffectiveIncomeTaxRateReconciliationPermanentDifferences" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_moddEffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetails3" xlink:title="00000040 - Disclosure - INCOME TAXES (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesRegulatoryAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesRegulatoryAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000041 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_CEOAndInvestorMember" xlink:label="loc_moddCEOAndInvestorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_moddCEOAndInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_MemberOfBoardMember" xlink:label="loc_moddMemberOfBoardMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_moddMemberOfBoardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_DaughterOfPresidentCFOTreasurerAndChairmanMember" xlink:label="loc_moddDaughterOfPresidentCFOTreasurerAndChairmanMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_moddDaughterOfPresidentCFOTreasurerAndChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_NotesPayableOtherPayables1Member" xlink:label="loc_moddNotesPayableOtherPayables1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_moddNotesPayableOtherPayables1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20220331.xsd#modd_NotesPayableOtherPayables2Member" xlink:label="loc_moddNotesPayableOtherPayables2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_moddNotesPayableOtherPayables2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416970767376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 24, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MODULAR MEDICAL, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001074871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0620495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">16772 W. Bernardo Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">800-3500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MODD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,862,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,911,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Farber
    Hass Hurley LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Chatsworth,
    California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416969016832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,076,372<span></span>
</td>
<td class="nump">$ 1,468,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">312,464<span></span>
</td>
<td class="nump">178,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">2,466<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">9,389,794<span></span>
</td>
<td class="nump">1,649,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment,&#160;net</a></td>
<td class="nump">235,959<span></span>
</td>
<td class="nump">298,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">120,693<span></span>
</td>
<td class="nump">200,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Security deposit</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NON-CURRENT ASSETS</a></td>
<td class="nump">456,652<span></span>
</td>
<td class="nump">599,082<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">9,846,446<span></span>
</td>
<td class="nump">2,248,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable</a></td>
<td class="nump">299,951<span></span>
</td>
<td class="nump">169,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="nump">524,891<span></span>
</td>
<td class="nump">499,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term lease liability</a></td>
<td class="nump">144,857<span></span>
</td>
<td class="nump">125,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebtCurrent', window );">PPP note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">368,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Convertible notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,133,453<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">969,699<span></span>
</td>
<td class="nump">3,296,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liability</a></td>
<td class="nump">39,957<span></span>
</td>
<td class="nump">184,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Bonus payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">42,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL&#160; LIABILITIES</a></td>
<td class="nump">1,009,656<span></span>
</td>
<td class="nump">3,523,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value, 50,000,000 shares authorized, 10,461,898 shares and 6,302,050 shares issued and outstanding as of March 31, 2022 and 2021, respectively</a></td>
<td class="nump">10,462<span></span>
</td>
<td class="nump">6,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">43,406,099<span></span>
</td>
<td class="nump">14,665,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(34,579,771)<span></span>
</td>
<td class="num">(15,947,010)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="nump">8,836,790<span></span>
</td>
<td class="num">(1,275,149)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="nump">$ 9,846,446<span></span>
</td>
<td class="nump">$ 2,248,171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416970101712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">10,461,898<span></span>
</td>
<td class="nump">6,302,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">10,461,898<span></span>
</td>
<td class="nump">6,302,050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416968982736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 7,729,240<span></span>
</td>
<td class="nump">$ 4,083,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,197,162<span></span>
</td>
<td class="nump">3,253,412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">14,926,402<span></span>
</td>
<td class="nump">7,336,715<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(14,926,402)<span></span>
</td>
<td class="num">(7,336,715)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Other income</a></td>
<td class="nump">368,920<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,752,229)<span></span>
</td>
<td class="num">(39,791)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="num">(1,321,450)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(18,631,161)<span></span>
</td>
<td class="num">(7,376,376)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,632,761)<span></span>
</td>
<td class="num">$ (7,377,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_EarningsPerShareBasicAndDiluted1Abstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_EarningsPerShareBasicAndDiluted1', window );">Basic and diluted</a></td>
<td class="num">$ (2.74)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract', window );"><strong>Shares used in computing net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1', window );">Basic and diluted</a></td>
<td class="nump">6,807,710<span></span>
</td>
<td class="nump">6,211,562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_EarningsPerShareBasicAndDiluted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_EarningsPerShareBasicAndDiluted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_EarningsPerShareBasicAndDiluted1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_EarningsPerShareBasicAndDiluted1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416970892624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Common Stock Issuable</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of&#160;March 31, 2020 at Mar. 31, 2020</a></td>
<td class="nump">$ 5,957<span></span>
</td>
<td class="nump">$ 10,517,505<span></span>
</td>
<td class="nump">$ 923,994<span></span>
</td>
<td class="num">$ (8,569,034)<span></span>
</td>
<td class="nump">$ 2,878,422<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, Shares at Mar. 31, 2020</a></td>
<td class="nump">5,956,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Placement of common stock</a></td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">2,709,555<span></span>
</td>
<td class="num">(923,994)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,785,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Placement of common stock, Shares</a></td>
<td class="nump">320,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">210,921<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">210,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services, Shares</a></td>
<td class="nump">24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,227,578<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,227,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,377,976)<span></span>
</td>
<td class="num">(7,377,976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Warrants issued with convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 6,302<span></span>
</td>
<td class="nump">14,665,559<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,947,010)<span></span>
</td>
<td class="num">(1,275,149)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Mar. 31, 2021</a></td>
<td class="nump">6,302,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Placement of common stock</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">249,969<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Placement of common stock, Shares</a></td>
<td class="nump">30,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">594,310<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 594,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services, Shares</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,859,785<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,859,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,632,761)<span></span>
</td>
<td class="num">(18,632,761)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">13,657,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,660,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock upon public offering, net of issuance costs, Shares</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in settlement of convertible notes and accrued interest</a></td>
<td class="nump">$ 1,511<span></span>
</td>
<td class="nump">6,506,254<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,507,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock in settlement of convertible notes and accrued interest, Shares</a></td>
<td class="nump">1,511,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Warrants issued with convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,700,632<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,700,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_SharesIssuedForReverseStockSplit', window );">Shares issued for reverse stock split</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Shares issued for reverse stock split, Shares</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under equity incentive plan</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">172,091<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">172,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under equity incentive plan, Shares</a></td>
<td class="nump">26,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 10,462<span></span>
</td>
<td class="nump">$ 43,406,099<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (34,579,771)<span></span>
</td>
<td class="nump">$ 8,836,790<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Mar. 31, 2022</a></td>
<td class="nump">10,461,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_SharesIssuedForReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_SharesIssuedForReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416970771376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,632,761)<span></span>
</td>
<td class="num">$ (7,377,976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_GainOnPPPNoteForgiveness', window );">Gain on PPP note forgiveness</a></td>
<td class="num">(368,780)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">1,321,450<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">4,031,902<span></span>
</td>
<td class="nump">1,227,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">117,490<span></span>
</td>
<td class="nump">111,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_AccruedInterest', window );">Accrued interest</a></td>
<td class="nump">666,338<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Shares issued for services</a></td>
<td class="nump">395,950<span></span>
</td>
<td class="nump">68,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of lease right-of-use asset</a></td>
<td class="nump">79,431<span></span>
</td>
<td class="nump">70,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_IncreaseDecreaseInLeaseLiability', window );">Change in lease liability</a></td>
<td class="num">(125,040)<span></span>
</td>
<td class="nump">38,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1,833,618<span></span>
</td>
<td class="nump">12,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other assets and prepaid expenses</a></td>
<td class="nump">65,652<span></span>
</td>
<td class="nump">25,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">354,948<span></span>
</td>
<td class="num">(86,747)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(10,259,528)<span></span>
</td>
<td class="num">(5,908,662)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(54,764)<span></span>
</td>
<td class="num">(109,669)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(54,764)<span></span>
</td>
<td class="num">(109,669)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placements, net of issuance costs</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">1,785,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, net of placement fees</a></td>
<td class="nump">4,137,199<span></span>
</td>
<td class="nump">2,210,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ProceedsFromIssuanceOfPromissoryNote', window );">Proceeds from issuance of promissory note</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_RepaymentOfPromissoryNote', window );">Repayment of promissory note</a></td>
<td class="num">(2,100,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of PPP note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">368,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts', window );">Proceeds from issuance of common stock upon public offering, net of issuance costs</a></td>
<td class="nump">13,535,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">17,922,199<span></span>
</td>
<td class="nump">4,364,662<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">7,607,907<span></span>
</td>
<td class="num">(1,653,669)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at beginning of year</a></td>
<td class="nump">1,468,465<span></span>
</td>
<td class="nump">3,122,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at end of year</a></td>
<td class="nump">9,076,372<span></span>
</td>
<td class="nump">1,468,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Fair value of detachable warrants issued with convertible notes</a></td>
<td class="nump">3,700,632<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock', window );">Conversion of convertible notes and accrued interest into common stock</a></td>
<td class="nump">7,253,876<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_AccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_AccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_GainOnPPPNoteForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_GainOnPPPNoteForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ProceedsFromIssuanceOfPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ProceedsFromIssuanceOfPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RepaymentOfPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RepaymentOfPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416971861088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zYqNaSThYyA4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note&#160;1
&#8211; <span id="xdx_826_zadDPzMXkLk7">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Modular Medical, Inc.
(the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material business
operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a Delaware
corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was
accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the merger, at
their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the Company was a shell company, as
defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act). In June 2017, the Company changed its
name from Bear Lake Recreation, Inc. to Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative insulin
pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps for insulin-dependent
people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent diabetes to receive their
daily insulin in two ways, through a continuous &#8220;basal&#8221; delivery allowing a small amount of insulin to be in the blood at
all times and a &#8220;bolus&#8221; delivery to address meal time glucose input and to address when the blood glucose level becomes excessively
high. By addressing the time and effort required to effectively treat their condition, the Company believes it can address the less technically
savvy, less motivated part of the market.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
discussed in Note 7, in February 2022, the Company completed a public offering of its equity securities, and its common stock was approved
to list on the Nasdaq Capital Market under the symbol &#8220;MODD&#8221; and began trading there on February 10, 2022.</span></p>

<p id="xdx_842_ecustom--LiquidityPolicyTextBlock_zmtWXrgDJMli" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zH6oyktWLVp9">Going
Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The accompanying financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal
course of business. The realization of assets and the satisfaction of liabilities in the normal course of business are dependent on,
among other things, the Company&#8217;s ability to operate profitably, to generate cash flows from operations, and to pursue financing
arrangements to support its working capital requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">At issuance of the Company&#8217;s
financial statements for the year ended March 31, 2021, management had determined that there was significant doubt as to the ability
of the Company to meet its obligations and continue as a going concern. As a result of the Offering (see Note 7), which was completed
in February 2022, and the Registered Offering (see Note 13), which was completed in May 2022, and resulting improved financial position,
the Company believes it has sufficient liquidity to meet its obligations as they come due and conduct its business for a period of at
least 12 months from the date of issuance of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures.
The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&#8217;s
ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations
with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable
to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to
reduce costs in order to conserve its cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zRiJQCGBV25a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zjI0fxvkL60h">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America. The Company&#8217;s fiscal year ends on March 31 of each calendar year.<span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span>Each
reference to a fiscal year in these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar
year indicated (for example, fiscal 2022 refers to the fiscal year ending March 31, 2022). The consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been
eliminated in consolidation.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/></p>

<p id="xdx_844_ecustom--ReverseStockSplitPolicyTextBlock_z04VSWRoT4g5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86F_zQBYomsOyt86"><span id="xdx_861_zwJZiczLUZTf">Reverse
Stock Split</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#8217;s shares of common stock.&#160;Such amendment
and ratio were previously approved by a majority of the Company&#8217;s stockholders and the board of directors. As a result of the reverse
stock split, which was effective November 29, 2021, every three shares of the Company&#8217;s pre-reverse split outstanding common stock
were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stock holders were
not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split were rounded up to the
nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company&#8217;s equity incentive
plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of
common stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split.</span><span style="font-size: 10pt">&#160;All
share numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3
reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84E_eus-gaap--UseOfEstimates_zQAMqRgArPf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zzdD9Zq4p7o1">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The preparation of
the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting
period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from
those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zo1ec0Mysvw" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zHVPNIpnofm">Reportable
Segment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The Company operates in one business segment
and uses one measurement of profitability for its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvIlXmwh0fD" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86C_zs0zYacJravk">Research
and Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company expenses research and development expenditures as incurred.</span></p>

<p id="xdx_84B_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zroIoQNwqFh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_866_zIUjRSyGNGN7">General
and Administrative</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees,
and office and other administrative expenses.</span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_ziJ2ewPFUZMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zUWOtBR5IV6k">Concentration
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Financial instruments
that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash at high
quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to
limits of approximately $250,000. <span style="font-family: Times New Roman, Times, Serif; background-color: white">No reserve has been
made in the financial statements for any possible loss due to financial institution failure.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_849_ecustom--RisksAndUncertaintiesPolicyTextBlock_zi0JfTofpvM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zqS2p0oVCk06">Risks
and Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company is subject
to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity
requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>COVID-19</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The global outbreak
of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S.
government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221; and created significant
disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#8217;s operational and financial performance
will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government
agencies to prevent disease spread, all of which are uncertain, out of the Company&#8217;s control, and cannot be predicted.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/></p>

<p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zxMnukNIy9E4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zgsqPjuzR3Q7">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Cash and cash equivalents
include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities
of three months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zttWp1WUggSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zjT4PvFPcfEc">Property
and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Property and equipment
are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets,
generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold
improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the lease term,
and amortization is recorded in operating expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zta5pBtur4x2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zu6Y5hpixDek">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company measures
the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value into three broad levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 inputs to the valuation methodology are quoted prices for identical assets or liabilities
                                            in active markets.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 inputs to the valuation methodology include quoted prices for similar assets and liabilities
                                            in active markets, and inputs that are observable for the asset or liability, either directly
                                            or indirectly, for substantially the full term of the financial instrument.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 inputs to the valuation methodology are unobservable and significant to the fair value
                                            measurement.</span></td></tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_ecustom--DebtModificationsAndExtinguishmentsPolicyTextBlock_z2qhNiR0tcA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zLW3oqwXW8mi">Debt
Modifications and Extinguishments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">When the Company modifies
or extinguishes debt, it does so in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC)
Topic 470-50, <span style="font-family: Times New Roman, Times, Serif"><i>Debt&#8212; Modifications and Extinguishments,</i></span> which
requires modification to debt instruments to be evaluated to assess whether the modifications are considered &#8220;substantial modifications.&#8221;
A substantial modification of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis
performed, if the Company believes the embedded conversion feature has no fair value on the date of issuance (measurement date) and the
embedded conversion feature has no beneficial conversion feature, the embedded conversion feature does not meet the criteria in ASC 470-50-40-10
or 470-20-25 and the issuance of the convertible note payable is considered a modification, and not an extinguishment that would require
the recognition of a gain or loss. If the Company determines the change in terms meet the criteria for substantial modification under
ASC 470 it will treat the modification as extinguishment and recognize a loss from debt extinguishment.</span></p>

<p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zZW1vseIs6U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zvU0gedkoKIf">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">Effective&#160;April&#160;1, 2019,
the Company adopted ASC No. 842,&#160;<span style="font-family: Times New Roman, Times, Serif"><i>Leases&#160;</i></span>(ASC 842). ASC
842 requires an entity to recognize a&#160;right-of-use&#160;asset and a lease liability for all leases with terms longer than 12 months.
The Company adopted ASC 842 utilizing the modified retrospective transition method. The Company elected the practical expedient afforded
in ASC 842 in which the Company did not reassess whether any contracts that existed prior to adoption have or contain leases or the classification
of its existing leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_znFDT9AfXlJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zOo0oLCtxyjh">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company recognizes
stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite service
period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options on the date
of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date of grant using
an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and subjective variables.
These variables include, but are not limited to, the expected stock price&#160;volatility over the term of the awards, and projected
stock option exercise behaviors.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/></p>

<p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zBWbC6sUp8wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zDSzZkLxl919">Per-Share
Amounts</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Basic net loss per
share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during the period.
Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive
common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zi6ge9YgSP21" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive: &#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_zH619xBoQBl2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49E_20220331_z5uGeYjdGb5g" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_495_20210331_zgovGgjVcjK6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_zczFTBzbQV3c" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Options to purchase common stock</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,650,705</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,197,252</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_zj3b2oY6U1Fd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,779,072</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20220331_zvecWQIznBTi" style="border-bottom: Black 2.5pt double; text-align: right">6,429,777</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_zaRsOzR3gPNj" style="border-bottom: Black 2.5pt double; text-align: right">1,197,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zhn1aY3xhyMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zpNroTjz06ie" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_862_zm3mQRzHAlL1">Reclassification</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zrhjoDfokqXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zzuDKj6X6Ldg">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company determines
deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company&#8217;s assets
and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation
allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets
will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal
and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company accounts
for uncertain tax positions in accordance with FASB ASC Topic 740,&#160;<span style="font-family: Times New Roman, Times, Serif"><i>Income
Taxes</i></span>. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would
be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period during which,
based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination,
including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.
Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more
than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated
with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits
in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing
authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are
classified in general and administrative expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company files U.S.
federal and state income tax returns in jurisdictions with varying statutes of limitations.&#160;&#160;All tax returns from 2016 to 2021
may be subject to examination by the U.S. federal and state tax authorities.&#160; As of March 31, 2022 and 2021, the Company had not
recorded any liability for unrecognized tax benefits related to uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zmRNsprJq3ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zk5hp2qYq0Ue">Comprehensive&#160;Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Comprehensive loss
represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2022 and 2021, the Company&#8217;s
comprehensive loss was the same as its net loss.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/></p>

<p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z64GYbkpeqQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86F_zImLuBeHUQvc">Recently
Issued Accounting Pronouncement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13,&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financial
Instruments&#8212;Credit Losses</i><span style="background-color: white">. This ASU added a new impairment model (known as the current
expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes
an allowance for its estimate of expected credit losses and applies to most debt instruments, trade receivables, lease receivables, financial
guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses
and entities will need to measure expected credit losses on assets that have a low risk of loss. This update is effective for fiscal
years beginning after December 15, 2022, including interim periods within those fiscal years for smaller reporting companies. The Company
is still evaluating the impact of this accounting guidance on its results of operations and financial position.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416976214320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEET DETAIL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">CONSOLIDATED BALANCE SHEET DETAIL</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_zXMfyGTwGhx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;2
&#8211; <span id="xdx_82A_zdJfObx04A4i">CONSOLIDATED BALANCE SHEET DETAIL</span></b></span></p>

<p id="xdx_89B_ecustom--DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock_zF4TfzlRybll" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureConsolidatedBalanceSheetDetailDetailsAbstract_zRU6V5vlbfXi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_499_20220331_z4zq7k3BvC44" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_497_20210331_zFusOQa6llY4" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left">Property and equipment, net:</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zhgQfGDFDPs" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Leasehold improvements</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">139,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">139,197</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z8iLANmUwVub" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,298</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,476</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTw6M0iBZQEl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Computer equipment and software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,383</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherMachineryAndEquipmentMember_ztaCoDaSQzk6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Machinery and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">230,947</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">202,993</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz4h6_zh3xNxmzW1th" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt"><span style="display: none">Property and equipment,&#160;gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">485,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">451,049</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz4h6_zhRPsukekoji" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(249,597</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(152,091</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_mtPPAENz4h6_zzcoOCxnSwoi" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt"><span style="display: none">Property and equipment,&#160;net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">235,959</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">298,958</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">Accrued expenses:</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedWagesAndBonus_iI_maALAOLz5T1_z0JhbMur571f" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Accrued wages and bonus</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">457,891</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">372,563</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AccruedPlacementFees_iI_maALAOLz5T1_zOkWAxDrX7qb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued placement fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,800</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedInterests_iI_maALAOLz5T1_zJ1nXO47gpz7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,538</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALAOLz5T1_z1yiFJnzCMjf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">67,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,047</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_mtALAOLz5T1_zUcNbV9KXDyg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt"><span style="display: none">Accrued expenses</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">524,891</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">499,948</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_z8ZxQBlNO71" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140417059232944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zmHx31Dpbln8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
3 &#8211;&#160;<span><span id="xdx_829_zqB3LaWTbQEd">LEASES</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for the lease for its corporate facility in San Diego, California in accordance with ASC 842. The&#160;<span id="xdx_906_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxH_c20200402_zsO8A3aKgOzf" title="::XDX::P39M">39-month</span> lease
term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $12,400&#160;annual rent increases
of approximately&#160;3%.&#160;In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and
certain other operating costs. The right-to-use asset and corresponding liability for the facility lease have been measured at the present
value of the future minimum lease payments. A discount rate of 11%, which approximated the Company&#8217;s incremental borrowing rate,
was used to measure the lease asset and liability. Lease expense is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company obtained a right-of-use asset of $<span id="xdx_906_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210401__20220331_zuy8Mlso2Hzh">270,950</span>&#160;in exchange for its obligations under the operating lease. The landlord also provided
a lease incentive of approximately $<span id="xdx_904_ecustom--LeaseIncentiveReceived_iI_c20200630_zz6lwak7y1Je">139,000</span>, which was paid to the Company in June 2020, for the Company to make improvements to the
leased space. In addition, the Company paid a $100,000 security deposit.</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zjd3UPUssYT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B3_zPODvyMmIpik">Future
minimum payments under the facility operating lease</span>, as of March 31, 2022, are listed in the table below.</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureLeasesDetailsAbstract_zEfGkyRYw1Y1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Annual Fiscal Years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220331_zKyWa3i8HGR3" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating<br/> lease</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_maOLFMPz3Dp_zJgm0y6XYiIf" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 87%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">158,028</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_maOLFMPz3Dp_zn4AfYlqTTgi" style="vertical-align: bottom; background-color: White">
    <td>2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,692</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--OperatingLeasesImputedInterest_iI_maOLFMPz3Dp_zUwbalcxHbP2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(13,906</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_mtOLFMPz3Dp_zpDxDQUAJu15" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">184,814</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zetWfTG4eLw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Cash
paid for amounts included in the measurement of lease liabilities was $<span id="xdx_903_ecustom--CashPaidforLeaseLiabilities_iI_c20220331_zdmyIRf8Z9r7">153,432</span>&#160;for the year ended March 31, 2022. Rent expense was
$<span id="xdx_90D_eus-gaap--LeaseAndRentalExpense_c20210401__20220331_zZZ4yLuV0FP4">107,820</span>&#160;and $<span id="xdx_90A_eus-gaap--LeaseAndRentalExpense_c20200401__20210331_zuMwVUTJfLy7">107,540</span>&#160;for the years ended March 31, 2022 and 2021, respectively.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI https://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416971887200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP NOTE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosurePppNoteAbstract', window );"><strong>Ppp Note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_PPPNotesPayableTextBlock', window );">PPP NOTE</a></td>
<td class="text"><p id="xdx_802_ecustom--PPPNotesPayableTextBlock_zwLyzNrqwDae" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_82F_zGsdHjLIWy79">PPP NOTE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In April 2020, the
Company received a $<span id="xdx_902_eus-gaap--UnsecuredDebtCurrent_iI_c20200424_zlKQ23LIqb54">368,780</span> unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was established under
the U.S. government&#8217;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note to the Company was made
through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration Paycheck Protection Program
Note with the Lender evidencing the PPP Note. <span style="font-family: Times New Roman, Times, Serif; background-color: white">The full
amount of the PPP Note was due in April 2022 and interest accrued on the outstanding principal balance of the PPP Note at a fixed rate
of 1.0% per annum, which was deferred for 10 months after the covered period during which the Company used the proceeds.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
May 2021, the Lender and the U.S. Small Business Administration notified the Company that the outstanding principal and accrued interest
for the PPP Note was forgiven in full. The Company accounted for the forgiveness of the PPP Note in accordance with ASC Topic 470: <i>Debt
</i>(ASC 470), and the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the consolidated
statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosurePppNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosurePppNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PPPNotesPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PPPNotesPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416971815504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PROMISSORY NOTES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE PROMISSORY NOTES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_z8WfRWXbDZbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
5 &#8211;&#160;<span id="xdx_82B_zVcXpCpmCKS8">CONVERTIBLE PROMISSORY NOTES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">From
February through April 2021, the Company sold $2,310,000 of convertible promissory notes (each an Original Note and, collectively, the
Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements under
the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between each holder
of an Original Note and the Company (the Revocation Agreement), the $2,310,000 of Original Notes and accrued interest thereon as of April
30, 2021 were replaced with $2,360,550 aggregate principal amount of new Notes (as defined below). The Company accounted for the replacement
of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $<span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20210401__20220331_zcYCamrqWUTl">1,321,450</span> and interest expense of $<span id="xdx_90D_eus-gaap--AmortizationOfFinancingCosts_c20210401__20220331_zQUOtbO3j6Kj">70,647</span>
for unamortized debt issuance costs as of April 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
April and May 2021, pursuant to a securities purchase agreement by and between the Company and each investor (the SPA), the Company sold
to investors $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20210531__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z2v5iu1F4zA7">4,250,000</span>&#160;aggregate principal amount of convertible promissory notes (the Notes) and warrants to purchase shares of
its common stock (the Warrants). The Notes are unsecured obligations of the Company with each Note having a stated maturity date of 12
months from its issue date (the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity, provided that,
if the Company fails to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the maximum amount
permitted by law. Each Note may be prepaid at the Company&#8217;s option during the first 270 calendar days following its Issue Date
(the 270<sup>th</sup>&#160;day, the Trigger Date), subject to a 110% prepayment penalty on outstanding principal and accrued interest
then outstanding. No Note may be prepaid in whole or in part after the Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Notes
outstanding after the Trigger Date may be converted into shares of the Company&#8217;s common stock at an initial conversion price of
$8.61 per share; provided that a Note holder may not convert any portion of its Note that would cause it to beneficially own in excess
of 4.99% of the Company&#8217;s outstanding common stock. The conversion price and number of shares of Company common stock issuable
upon conversion of the Notes are subject to adjustment from time to time for subdivisions and consolidations of shares and other standard
dilutive and corporate events, as provided in the Notes. Subject to certain Exempt Issuances (as defined in the Notes), if while a Note
is outstanding, the Company sells, issues or grants any shares of its common stock or other securities to acquire shares of common stock
at a price per share less than the then conversion price, such conversion price shall be reduced to such lesser price, and the number
of conversion shares issuable upon conversion of the Notes shall be increased, as provided in the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
the Company completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital
Raise, as defined in the Notes), each Note holder will be required to convert its Adjusted Note Amount (as defined below) into the securities
of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued interest
on a Note, multiplied by (ii) 1.25.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Notes contained a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal
or interest thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements
under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v) material
restatements of the Company&#8217;s consolidated financial statements filed with the SEC, (vi) a holder&#8217;s inability to rely on
Rule 144 for sales of shares underlying the Notes, (vii) the Company&#8217;s common stock is suspended or halted from trading and/or
fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New York Stock Exchange, or
the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement covering the resale of shares
of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date, (ix) failure to cause such registration
statement to become effective within 120 calendar days following the Issue Date, or (x) certain mergers consolidations, business combinations
and sales of all or substantially all of the Company&#8217;s assets in the event the Company is not the survivor of such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Upon
an Event of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required
to pay such Note holder the sum of (i) the product of (a) all then outstanding principal amount and accrued interest thereon, multiplied
by (b) 125%; and (ii) all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder,
in the event the Company receives cash proceeds as a result of certain events, including, but not limited to, payments from customers,
issuances of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay
all or any lesser outstanding amounts due under such holder&#8217;s Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Notes include covenants, representations, warranties, other payment obligations and agreements by the Company including, without limitation,
most-favored nation rights, rights of participation and first refusal and exchange rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
connection with the issuance of the Notes, the Company issued Warrants to purchase in the aggregate 767,796 shares of its common stock
at an initial exercise price of $24.00 per share. The Warrants may be exercised for a period of five years from the Trigger Date, provided
that, if prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall be cancelled
or (ii) prepays a holder&#8217;s Note(s) in whole or in part, such holder&#8217;s pro-rata number of Warrants shall be cancelled. The
fair value of the Warrants was $3,700,632, of which $2,379,182 was recorded as a debt discount, which is being amortized to interest
expense over the term of the Warrants, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated the fair
value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of&#160;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_c20210401__20220331_zvrFaqBfupHe">88.98%</span>, risk-free
interest rate of&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20220331_zkcBlEDetFLf">0.86%</span>, a term of&#160;<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20220331_zvgVggjNhFKi" title="::XDX::P5Y9M">5.75</span>&#160;years and a dividend yield of&#160;<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dcpxH_c20210401__20220331_zhdUmAMSitU" title="::XDX::0">zero</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
connection with the April and May 2021 sales of the $4,250,000 aggregate principal amount of the Notes, the Company incurred debt issuance
costs of $116,000, which were recorded as a debt discount and were amortized to interest expense over the term of the Notes using the
effective interest rate method. The interest expense attributable to the debt discount, comprising the debt issuance costs and Warrants,
during the year ended March 31, 2022 was $1,833,618.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Upon
the closing of the Offering (see Note 7), which was a Qualified Capital Raise, in accordance with their terms, the Notes converted into
1,511,276 shares of common stock and the holders of the Notes received 1,511,276 Offering Warrants (as defined in Note 7). </span><span style="font-size: 10pt">As
a result of the Offering, the exercise price of the 767,796 outstanding Warrants was reduced to $6.00 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416971749936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosurePromissoryNoteAbstract', window );"><strong>Promissory Note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_PromissoryNoteTextBlock', window );">PROMISSORY NOTE</a></td>
<td class="text"><p id="xdx_80E_ecustom--PromissoryNoteTextBlock_z2u9bXbvv04k" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
6 &#8211;&#160;<span id="xdx_82F_zDckORpOa8We">PROMISSORY NOTE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
October 2021, the Company issued a secured promissory note (the Bridge Note) to Manchester Explorer, L.P. (Manchester) that provided
the Company with a $<span id="xdx_90E_eus-gaap--LineOfCredit_iI_c20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zCFnQVE0RhFh">3,000,000</span>&#160;revolving credit facility with all amounts being drawn down by the Company thereunder being due and
payable, subject to acceleration in the event of a default, on&#160;<span id="xdx_90A_eus-gaap--LineOfCreditFacilityExpirationDate1_c20211027__20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zx4aXHUKrJBk">March 15, 2022</span>&#160;(the Maturity Date). Interest at the rate of&#160;<span id="xdx_90E_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_c20211027__20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zzQUYBlJthaa">12%</span>&#160;was
payable on each drawn down without regard to the draw down date or the date when interest is paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
principal amount of the Bridge Note and interest due thereon is payable to Manchester no later than the earlier of: (i) the Maturity
Date and (ii) the date on which the Company has received proceeds in excess of $12,000,000 from a transaction or series of related transactions
occurring prior to the Maturity Date, which such transactions constitute equity financings or other issuances of the Company&#8217;s
equity securities. Provided that no Event of Default (as such term is defined in the Bridge Note) has occurred, on any date prior to
the Maturity Date, upon no less than three days written notice by the Company specifying the draw amount, Manchester will advance the
draw amount to the Company. No draw amount can be in an amount less than $100,000 or exceed an amount equal to $3,000,000 minus the aggregate
principal amount outstanding under the Bridge Note at the time of such draw request. If an Event of Default occurs and is continuing,
Manchester may declare all of the Bridge Note, including any interest and other amounts due, to be due and payable immediately.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
connection with the issuance of the Note, on October 28, 2021, the Company entered into a security agreement with Manchester (the Security
Agreement) under which the Company granted Manchester a continuing and unconditional first priority security interest in and to any and
all of the Company&#8217;s property of any kind or description, tangible or intangible, wheresoever located and whether now existing
or hereafter arising or acquired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
fiscal 2022, the Company made draws on the Bridge Note of $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_c20220101__20220331__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zoGTIywCOln1">2,100,000</span>&#160;and incurred interest charges of $<span id="xdx_908_eus-gaap--LineOfCreditFacilityIncreaseAccruedInterest_c20220101__20220331__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z2aYPdruvJt9">252,000</span>. In February 2022,
subsequent to the completion of the Offering (see Note 7), the Bridge Note and accrued interest was paid in full, and the Security Agreement
was terminated.</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosurePromissoryNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosurePromissoryNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PromissoryNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PromissoryNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416971869280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="text"><p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zbpO896vtM7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
7 &#8211;&#160;<span id="xdx_82C_zkLTR6nQIPoj">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Public
Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
February 9, 2022, the Company entered into an underwriting agreement (the Underwriting Agreement) with Oppenheimer &amp; Co. Inc., who
acted as the representative of the several underwriters (the Underwriters), in a firm commitment underwritten public
offering (the Offering) pursuant to which, on February 14, 2022, the Company sold to the Underwriters an aggregate of 2,500,000 shares
of the Company&#8217;s common stock and 2,500,000 warrants (the Offering Warrants and, collectively with the shares of common stock,
the Units), each to purchase one share of common stock. The price to the public in the Offering was $6.00 per Unit, before underwriting
discounts and commissions. The common stock and the Offering Warrants comprising the Units were immediately separable upon issuance and
were issued separately. The Offering Warrants were exercisable immediately, have an exercise price of $6.60 per share and expire on February
14, 2027. </span><span style="font-size: 10pt">The gross proceeds from the Offering were $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220209__20220210__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvyyeihuZKHi">15,000,000</span>, before deducting underwriting discounts
and commissions and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Placements
of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Between March and December
2020, the Company completed a private placement of shares of its common stock (the 2020 Placement). The Company sold 962,387 shares of
common stock, at a purchase price of $2.87 per share, for gross proceeds of $2,762,054. The Company paid placement agent fees on the
2020 Placement of $52,256 during fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
October 2021, the Company sold <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20220331_zyY1Sh2OYWl2">30,864</span> shares of common stock to two officers, its i) chief executive officer and ii) the chairman of
the Company&#8217;s board of directors (the Board), president, chief financial officer and treasurer, </span><span style="font-size: 10pt">at
a purchase price of $8.10 per share, for gross proceeds of approximately $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210401__20220331_zbyGWlJw4h8f">250,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">During
the year ended March 31, 2022, the Company issued to service providers <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210401__20220331_z7MrwBD4GZif">90,000</span> shares of common stock with a fair value of approximately $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210401__20220331_zaBE538NoP95">594,400</span>. </span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416971786512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_806_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zwvR1qvHLnKb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>NOTE
8 &#8211;&#160;<span id="xdx_82C_zmJiVGcYVxdd">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Amended
2017 Equity Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
October 2017, the Company&#8217;s Board approved the 2017 Equity Incentive Plan (the Plan) with&#160;<span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20171031_zm7ZzP5HTBpj">1,000,000</span>&#160;shares of common
stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance
under the Plan by&#160;<span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200131_zihjPVa9F3lh">333,334</span>&#160;and&#160;<span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200831_zAoUN3pBCbX2">1,333,334</span>&#160;shares, respectively. Under the Plan, eligible employees, directors and consultants
may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards
and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation Expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The expense relating
to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant
date fair value. The unamortized compensation cost, as of March 31, 2022 was $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220331_zT5d8NaRj2Ua">3,286,370</span> related to stock options and is expected to be
recognized as expense over a weighted-average period of approximately <span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxH_c20210401__20220331_zGbmL7WHQRu7" title="::XDX::P2Y">two years</span>.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">During the year
ended March 31, 2022, the Company granted options to purchase <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zZmUpYOdOdo6">827,427</span> shares of its common stock to employees, directors and consultants.
The options had 10-year terms and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zDUMfkbZk2n8">137,292</span> options vested immediately when granted. The grant-date fair value was determined to be $<span id="xdx_90F_ecustom--FairValueofOptionGranted_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuP6k2wHq4q7">8,507,311</span>
of which $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOlhQLFgzWQ2">2,739,490</span> was recorded as stock-based compensation expense and included in the consolidated statements of operations for the
year ended March 31, 2022.&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"/>

<p id="xdx_893_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zROmdypsGl47" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following assumptions were used in the
fair-value method calculations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8BC_zoHpYNToBpPe" style="display: none">Schedule of Fair Value Assumptions</span></span></p>
<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureStockBasedCompensationDetailsAbstract_z9XHVjaV0oh4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Year
    Ended<br/> March 31,</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; width: 74%; text-align: left"><span style="font-size: 10pt">Risk-free interest rates</span></td><td style="white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_zBER1rIvYGaa">0.8%</span>&#160;-&#160;<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_zFywCR536aeh">2.42%</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 10pt">&#8239;</span></td><td style="white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zbmJFTQM1Rjd">0.28%</span>
                                            - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zQ3CtwjxJLh2">0.71%</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 10pt">&#8239;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap"><span style="font-size: 10pt">Volatility</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_z9JNunmYOGRc">89%</span>&#160;-&#160;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_z1lvZBdoBnpg">370%</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#8239;</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z9R3QblRW8l3">87%</span>&#160;-&#160;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zi56RSdNQjjl">127%</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#8239;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">Expected life (years)</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_z1dk0fEmLUBk" title="::XDX::P5Y">5.0</span>&#160;-&#160;<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_z2xQrlUIAvzb" title="::XDX::P6Y2M12D">6.2</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zDWRWGadWDW6" title="::XDX::P5Y">5.0</span>&#160;-&#160;<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z7rTiSgV3EG4" title="::XDX::P6Y">6.0</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">Dividend yield</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20210401__20220331_zA0sD2YLEeqj">&#8212;</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331_zxUElb8g3KA1">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>


<p id="xdx_8A0_zuoUO200IQz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair values of
options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish
the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate was derived from
the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the
expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention
to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zRu6BcKE8fBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">A summary of stock option activity under
the 2017 Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><span id="xdx_8BF_zMfIkSaPKpo3" style="display: none">Schedule of Stock Option activity</span></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zyA2icRZIRid" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2020</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zN07dgH8qnc" style="width: 8%; text-align: right">274,019</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zh6taN8bcdI5" style="width: 8%; text-align: right">1,059,315</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zStOdBzaNOTl" style="width: 8%; text-align: right">4.74</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zj1FMd9UL4Z6" style="text-align: right">(163,492</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zilPlEWvwY4a" style="text-align: right">163,492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zugRVMRUlLq" style="text-align: right">8.64</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEaifwfdaMf3" style="border-bottom: Black 1pt solid; text-align: right">25,555</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgZa1obxL5Ab" style="border-bottom: Black 1pt solid; text-align: right">(25,555</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmXrsPDd3A56" style="border-bottom: Black 1pt solid; text-align: right">6.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9DbbhhUZSPb" style="text-align: right">136,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zznrrwwjWBpc" style="text-align: right">1,197,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zppeuIunqCx8" style="text-align: right">5.25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 9pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8ZnEI11tJT9" style="text-align: right">1,333,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT1z72Cazb36" style="text-align: right">(827,427</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdt5hAYptlh9" style="text-align: right">827,427</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1xTpXcxfi9g" style="text-align: right">10.39</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 9pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFNMAhir2QMi" style="text-align: right">(26,497</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkt1VGnVC8uc" style="border-bottom: Black 1pt solid; text-align: right">373,974</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1GS5esT6EK4" style="border-bottom: Black 1pt solid; text-align: right">(373,974</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zycqAr4T4nz4" style="border-bottom: Black 1pt solid; text-align: right">10.73</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt">Balance at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7uZY99nQfX" style="border-bottom: Black 2.5pt double; text-align: right">989,466</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPUkXXw3Bfj6" style="border-bottom: Black 2.5pt double; text-align: right">1,650,705</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLM2ww6i68j7" style="border-bottom: Black 2.5pt double; text-align: right">6.58</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zihANFXSOMBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There were no
stock options exercised during the years ended March 31, 2022 and 2021. <span style="font-family: Times New Roman, Times, Serif; background-color: white">The
Company issued 26,497 shares to its non-employee directors under the Company&#8217;s outside director compensation plan and approximately
$172,100 was recorded as stock-based compensation expense for these share awards during the year ended March 31, 2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z03c6lvyxSt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table summarizes the range of outstanding and exercisable options as of March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zjWp49Tt5yt7" style="display: none">Schedule of
Outstanding and Exercisable Option, Range</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zoodrM9W77v9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number<br/> Outstanding</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Exercise<br/> Price</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number<br/> Exercisable</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Exercise<br/> Price</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> value</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z4Zx8uZq6t04">1.98</span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zScc5IPzvlq8">17.70</span></td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztv9LizGFHuk" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1,650,705</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmFalTPkxkqd" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P8Y4D">8.01</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx2rQfGQCbbf" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">6.58</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIbn9Ff9oPKe" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1,193,680</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDIs0MZ8bVVa" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">5.69</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWcFYBds9FM9" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1,090,966</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zv2bwlGHVr26" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt">The intrinsic value per share is calculated
as the excess of the closing price of the common stock on the Company&#8217;s principal trading market over the exercise price of the
option at March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company is required
to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise of stock options
as financing cash flows in the consolidated statements of cash flows. For the years ended March 31, 2022 and 2021, there were no such
tax benefits associated with the exercise of stock options.<span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416971686384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zHCNuOA94Mk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_82D_zjD666zGVw2a">INCOME TAXES</span></b></span></p>

<p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zRZ0GUtDckI2" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt">The income tax provision consisted
of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_8B3_zx4q6vQzEHP1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify; text-indent: 0.5in">Schedule of Income tax provision</p>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIncomeTaxesDetailsAbstract_z5Xj5wj9Bbij" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_493_20210401__20220331_zkeOSngFHGFa" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49B_20200401__20210331_zNeHwM9IewFk" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zpkYxgiMElck" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Current portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzDQj_z0U1H3VTbeI5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzDQj_zxQgTEmomJSl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; padding-bottom: 1pt; padding-left: 8.65pt">State</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_mtCITEBzDQj_maITEBzk6Q_zcVJ8Pf0pTul" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none">Current</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zxGfMZeH6dz1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Deferred portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzmjI_zDdlTYP27n14" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,109,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,931,390</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzmjI_zEPPocySasGa" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 1pt; padding-left: 8.65pt">State</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,300,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(576,868</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBzmjI_maITEBzk6Q_zYB27mhgKC4h" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none">Deferred</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">( 5,409,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,508,258</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzk6Q_zt00bAZA7CQd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,409,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,508,258</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzk6Q_z2UYVmXh0Qif" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zXBbKbdf9xwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">At March&#160;31, 2022,
the Company had net operating loss carryforwards (NOLs) of approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zMM0IF9WiNJc">27,600,000</span> for federal income tax purposes and $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zKmerP3981I3">27,800,000</span>
for state income tax purposes. These NOLs are available to reduce future taxable income and will expire at various times from 2037 through
2042, except federal NOLs from fiscal 2018, 2019, 2020, 2021 and 2022, which will never expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The Company
also had federal research and development tax credit carryforwards of approximately $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z2dZO8XYRaT6">800,000</span>, which will begin expiring at various times
from 2038 through 2041, and state research and development credits of approximately $<span id="xdx_90F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zXBvfmMV5YP6">200,000</span>, which do not have an expiration date.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbmw0zaVahpb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">A reconciliation of
income taxes provided at the federal statutory rate (21% for each of fiscal 2022 and 2021) to the actual income tax provision is as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_8B4_z7Y3El0yR9Zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify; text-indent: 0.5in">Schedule of Income Tax Provisions</p>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIncomeTaxesDetails2Abstract_zCxDEnXAR8J7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_498_20210401__20220331_zkjZav6vPWtf" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49E_20200401__20210331_zEUQkS5ZM2xi" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi0_zPXVMzzIMfY9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Federal statutory rate</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp0_zr2EbQ66OVi1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax rate, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_dp0_zzzshdWeW4B7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_dp0_zJPYg9wSqZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_dp0_z0Ewdr3WpXBg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Section 179 assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp0_zCezYLuSSlKj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">30</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">34</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zyMqlhqEfP6" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A6_zhhXqJeN7zul" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt">The losses before income tax provision for the years ended March 31, 2022 and 2021 were solely attributable to US operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z2wHiUpXVpYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt">Significant components of the Company&#8217;s
deferred tax assets and liabilities were:&#160;</span></p>

<p id="xdx_8BF_zSFtKJkbhxw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none">Schedule of Deferred Tax Assets</p>

<table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--DisclosureIncomeTaxesDetails3Abstract_ztyMFwQhelY3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 3)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49B_20220331_zLXdyv8xcKVg" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49C_20210331_zG7GYfOP7f46" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzv9B_zgiUXS5cPAi9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Net operating loss carryforwards</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">7,731,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,909,434</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzv9B_zUL8lX4sQ4Wg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,824,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">554,892</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzv9B_zISj5piaI9R3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,039</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_iNI_di_maDTAGzv9B_znDSjqxtLEHf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reserves, accruals &amp; other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(104,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(79,878</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_msDTAGzv9B_z210jsTZQd4l" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Research and development tax credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">988,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">646,296</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzv9B_maDTANzyHM_zDKlltF9ReTl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,519,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,012,705</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesRegulatoryAssets_iNI_di_maDITLzKZ6_zYnHFMpZWCya" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.35pt; padding-left: 8.65pt">Section 179 assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(97,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0725">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzKZ6_msDTANzyHM_zkSGwJWr1jPh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(97,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0728">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzyHM_zB8LJ6Krveze" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,422,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,012,705</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzyHM_zSRhUBbR1NMl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0733">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0734">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zFEWMznONjc" style="margin-top: 0; margin-bottom: 0"/>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Based on the available
information and other factors, management believes it is more likely than not that the net deferred tax assets at March 31, 2022 and
2021, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred tax assets
at March 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Management has evaluated
and concluded that there were no material uncertain tax positions requiring recognition in the Company&#8217;s consolidated financial
statements at March 31, 2022 and 2021. The Company does not expect any significant changes in its unrecognized tax benefits within twelve
months of the reporting date.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416971809392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ROYALTY AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureRoyaltyAgreementAbstract', window );"><strong>Royalty Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_RoyaltyAgreementDisclosureTextBlock', window );">ROYALTY AGREEMENT</a></td>
<td class="text"><p id="xdx_80B_ecustom--RoyaltyAgreementDisclosureTextBlock_zf11PgarAcmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_829_zhjZLtsxknH8">ROYALTY AGREEMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In July 2017, the Company
entered into a royalty agreement with its founder, then-chief executive officer, president and major shareholder (the Founder). Pursuant
to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras in return for future
royalty payments on the Company&#8217;s product. The Company is obligated to make royalty payments under the agreement to the Founder
on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each sale of a royalty product
or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will cease, and the agreement will
terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant to the agreement, reaches $10,000,000.
The Company has the option to terminate the agreement at any time upon payment, to the Founder, of the difference between total royalty
payments actually made to him to date and the sum of $10,000,000. All payments of the royalties, if due, for the preceding quarter, will
be made by the Company to the Founder within thirty days after the end of each calendar quarter.&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureRoyaltyAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureRoyaltyAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RoyaltyAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RoyaltyAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416971753168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zLLitPwtFoDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8211; <span id="xdx_828_z40w8AJWAJ25">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Litigations,
Claims and Assessments&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the normal course
of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The
Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the ordinary course
of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses
incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from
certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating
to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification
agreements with its officers and directors. No amounts were reflected in the Company&#8217;s consolidated financial statements for the
years ended March&#160;31, 2022 and 2021 related to these indemnifications. The Company has not estimated the maximum potential amount
of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances
applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416971926512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zT2nsXj2zSZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE&#160;12
&#8211; <span id="xdx_82A_zne9W3WE2EKi">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">In
February 2021, the Company&#8217;s chairman of the Board and president and Manchester, which is represented by a member of the Company&#8217;s
board of directors, purchased $100,000 and $1,000,000, aggregate principal amount of the Original Notes, respectively. Effective April
30, 2021, the related party holders entered into revocation agreements with the Company pursuant to which their aggregate principal amount
of Original Notes and accrued interest were replaced with Notes. On February 14, 2022, Manchester and the executive officer held Notes
in an aggregate principal amount of $<span id="xdx_906_eus-gaap--NotesPayable_iI_c20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zghhcM3G4YZ6">1,026,630</span> <span style="font-family: Times New Roman, Times, Serif; background-color: white">and
$<span id="xdx_902_eus-gaap--NotesPayable_iI_c20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zMdYkkJF0mHh">102,663</span>, respectively, with $<span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zhpgQV7iVpyd">97,881</span> and $<span id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zzrFRkXJV053">9,788</span> of interest payable thereon. In connection with the Offering, Manchester and
the executive officer received <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziTege4Yrw6i">234,274</span> and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziffD998r629">23,429</span> shares of common stock, respectively, and <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zED644BLlVQ4">234,274</span> and <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgWrcJIVTM77">23,429</span> Offering Warrants, respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">In
May 2021, a member of the Board purchased $<span id="xdx_901_eus-gaap--NotesPayable_iI_c20210531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_ztX6t42rW3f">200,000</span>&#160;aggregate principal amount of Notes (the Director Note). On February 14, 2022,
in connection with the Offering, the Director Note and $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_zGQo3AgyGFq6">18,805</span> of accrued interest thereon were converted into <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHbyq67fUuHd">45,586</span> shares of common
stock <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhin0K09JOw1">45,586</span> Offering Warrants<span style="font-family: Times New Roman, Times, Serif; background-color: white">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The daughter of the
Company&#8217;s president, chief financial officer, treasurer and chairman of the Board is an employee of the Company. During fiscal
2022, the Company paid her $<span id="xdx_901_eus-gaap--SalariesAndWages_c20210401__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DaughterOfPresidentCFOTreasurerAndChairmanMember_zNX5dbQpjRHl">169,589</span>, which includes the aggregate grant date fair value, as determined pursuant to FASB ASC Topic 718,
of a stock option granted in November 2021.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416971724272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zQ6K9HhHbPO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 &#8211; <span><span id="xdx_828_zd1eppOUMQz2">SUBSEQUENT EVENT</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On May 2, 2022, the
Company entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor (the Investor) pursuant
to which the Company sold, in a registered direct offering (the Registered Offering), for gross proceeds of $8,000,000 an aggregate
of 449,438 shares (the Shares) of the Company&#8217;s common stock, at a purchase price per Share of $4.45 and pre-funded warrants (the
Pre-Funded Warrants) to purchase an aggregate of 1,348,314 shares of common stock at a purchase price per Pre-Funded Warrant of $4.44.
The Pre-Funded Warrants were exercisable immediately on the date of issuance at an exercise price of $0.01 per share and may be exercised
at any time until all of the Pre-Funded Warrants are exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
a concurrent private placement under the Purchase Agreement, the Company issued warrants (the Private Placement Warrants) to the Investor
to purchase an aggregate of 1,438,202 shares of common stock at an exercise price of $6.60 per share. The Private Placement Warrants
will be exercisable commencing November 5, 2022 and have a five-year term.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416969994240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_LiquidityPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><p id="xdx_842_ecustom--LiquidityPolicyTextBlock_zmtWXrgDJMli" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zH6oyktWLVp9">Going
Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The accompanying financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal
course of business. The realization of assets and the satisfaction of liabilities in the normal course of business are dependent on,
among other things, the Company&#8217;s ability to operate profitably, to generate cash flows from operations, and to pursue financing
arrangements to support its working capital requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">At issuance of the Company&#8217;s
financial statements for the year ended March 31, 2021, management had determined that there was significant doubt as to the ability
of the Company to meet its obligations and continue as a going concern. As a result of the Offering (see Note 7), which was completed
in February 2022, and the Registered Offering (see Note 13), which was completed in May 2022, and resulting improved financial position,
the Company believes it has sufficient liquidity to meet its obligations as they come due and conduct its business for a period of at
least 12 months from the date of issuance of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures.
The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&#8217;s
ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations
with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable
to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to
reduce costs in order to conserve its cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zRiJQCGBV25a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zjI0fxvkL60h">Basis
of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America. The Company&#8217;s fiscal year ends on March 31 of each calendar year.<span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span>Each
reference to a fiscal year in these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar
year indicated (for example, fiscal 2022 refers to the fiscal year ending March 31, 2022). The consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been
eliminated in consolidation.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p id="xdx_844_ecustom--ReverseStockSplitPolicyTextBlock_z04VSWRoT4g5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86F_zQBYomsOyt86"><span id="xdx_861_zwJZiczLUZTf">Reverse
Stock Split</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#8217;s shares of common stock.&#160;Such amendment
and ratio were previously approved by a majority of the Company&#8217;s stockholders and the board of directors. As a result of the reverse
stock split, which was effective November 29, 2021, every three shares of the Company&#8217;s pre-reverse split outstanding common stock
were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stock holders were
not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split were rounded up to the
nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company&#8217;s equity incentive
plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of
common stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split.</span><span style="font-size: 10pt">&#160;All
share numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3
reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--UseOfEstimates_zQAMqRgArPf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zzdD9Zq4p7o1">Use
of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The preparation of
the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting
period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from
those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segment</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zo1ec0Mysvw" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zHVPNIpnofm">Reportable
Segment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The Company operates in one business segment
and uses one measurement of profitability for its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvIlXmwh0fD" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86C_zs0zYacJravk">Research
and Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company expenses research and development expenditures as incurred.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zroIoQNwqFh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_866_zIUjRSyGNGN7">General
and Administrative</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees,
and office and other administrative expenses.</span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_ziJ2ewPFUZMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zUWOtBR5IV6k">Concentration
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Financial instruments
that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash at high
quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to
limits of approximately $250,000. <span style="font-family: Times New Roman, Times, Serif; background-color: white">No reserve has been
made in the financial statements for any possible loss due to financial institution failure.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p id="xdx_849_ecustom--RisksAndUncertaintiesPolicyTextBlock_zi0JfTofpvM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zqS2p0oVCk06">Risks
and Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company is subject
to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity
requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>COVID-19</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The global outbreak
of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S.
government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221; and created significant
disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#8217;s operational and financial performance
will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government
agencies to prevent disease spread, all of which are uncertain, out of the Company&#8217;s control, and cannot be predicted.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zxMnukNIy9E4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zgsqPjuzR3Q7">Cash
and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Cash and cash equivalents
include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities
of three months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zttWp1WUggSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zjT4PvFPcfEc">Property
and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Property and equipment
are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets,
generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold
improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the lease term,
and amortization is recorded in operating expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zta5pBtur4x2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zu6Y5hpixDek">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company measures
the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value into three broad levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 inputs to the valuation methodology are quoted prices for identical assets or liabilities
                                            in active markets.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 inputs to the valuation methodology include quoted prices for similar assets and liabilities
                                            in active markets, and inputs that are observable for the asset or liability, either directly
                                            or indirectly, for substantially the full term of the financial instrument.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 inputs to the valuation methodology are unobservable and significant to the fair value
                                            measurement.</span></td></tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DebtModificationsAndExtinguishmentsPolicyTextBlock', window );">Debt Modifications and Extinguishments</a></td>
<td class="text"><p id="xdx_84A_ecustom--DebtModificationsAndExtinguishmentsPolicyTextBlock_z2qhNiR0tcA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zLW3oqwXW8mi">Debt
Modifications and Extinguishments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">When the Company modifies
or extinguishes debt, it does so in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC)
Topic 470-50, <span style="font-family: Times New Roman, Times, Serif"><i>Debt&#8212; Modifications and Extinguishments,</i></span> which
requires modification to debt instruments to be evaluated to assess whether the modifications are considered &#8220;substantial modifications.&#8221;
A substantial modification of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis
performed, if the Company believes the embedded conversion feature has no fair value on the date of issuance (measurement date) and the
embedded conversion feature has no beneficial conversion feature, the embedded conversion feature does not meet the criteria in ASC 470-50-40-10
or 470-20-25 and the issuance of the convertible note payable is considered a modification, and not an extinguishment that would require
the recognition of a gain or loss. If the Company determines the change in terms meet the criteria for substantial modification under
ASC 470 it will treat the modification as extinguishment and recognize a loss from debt extinguishment.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zZW1vseIs6U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zvU0gedkoKIf">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">Effective&#160;April&#160;1, 2019,
the Company adopted ASC No. 842,&#160;<span style="font-family: Times New Roman, Times, Serif"><i>Leases&#160;</i></span>(ASC 842). ASC
842 requires an entity to recognize a&#160;right-of-use&#160;asset and a lease liability for all leases with terms longer than 12 months.
The Company adopted ASC 842 utilizing the modified retrospective transition method. The Company elected the practical expedient afforded
in ASC 842 in which the Company did not reassess whether any contracts that existed prior to adoption have or contain leases or the classification
of its existing leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_znFDT9AfXlJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zOo0oLCtxyjh">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company recognizes
stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite service
period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options on the date
of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date of grant using
an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and subjective variables.
These variables include, but are not limited to, the expected stock price&#160;volatility over the term of the awards, and projected
stock option exercise behaviors.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Per-Share Amounts</a></td>
<td class="text"><p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zBWbC6sUp8wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zDSzZkLxl919">Per-Share
Amounts</span>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Basic net loss per
share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during the period.
Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive
common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zi6ge9YgSP21" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive: &#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_zH619xBoQBl2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49E_20220331_z5uGeYjdGb5g" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_495_20210331_zgovGgjVcjK6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_zczFTBzbQV3c" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Options to purchase common stock</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,650,705</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,197,252</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_zj3b2oY6U1Fd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,779,072</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20220331_zvecWQIznBTi" style="border-bottom: Black 2.5pt double; text-align: right">6,429,777</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_zaRsOzR3gPNj" style="border-bottom: Black 2.5pt double; text-align: right">1,197,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zhn1aY3xhyMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zpNroTjz06ie" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_862_zm3mQRzHAlL1">Reclassification</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zrhjoDfokqXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zzuDKj6X6Ldg">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company determines
deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company&#8217;s assets
and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation
allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets
will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal
and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company accounts
for uncertain tax positions in accordance with FASB ASC Topic 740,&#160;<span style="font-family: Times New Roman, Times, Serif"><i>Income
Taxes</i></span>. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would
be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period during which,
based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination,
including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.
Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more
than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated
with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits
in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing
authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are
classified in general and administrative expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company files U.S.
federal and state income tax returns in jurisdictions with varying statutes of limitations.&#160;&#160;All tax returns from 2016 to 2021
may be subject to examination by the U.S. federal and state tax authorities.&#160; As of March 31, 2022 and 2021, the Company had not
recorded any liability for unrecognized tax benefits related to uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zmRNsprJq3ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zk5hp2qYq0Ue">Comprehensive&#160;Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Comprehensive loss
represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2022 and 2021, the Company&#8217;s
comprehensive loss was the same as its net loss.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"/></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncement</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z64GYbkpeqQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span id="xdx_86F_zImLuBeHUQvc">Recently
Issued Accounting Pronouncement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13,&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financial
Instruments&#8212;Credit Losses</i><span style="background-color: white">. This ASU added a new impairment model (known as the current
expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes
an allowance for its estimate of expected credit losses and applies to most debt instruments, trade receivables, lease receivables, financial
guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses
and entities will need to measure expected credit losses on assets that have a low risk of loss. This update is effective for fiscal
years beginning after December 15, 2022, including interim periods within those fiscal years for smaller reporting companies. The Company
is still evaluating the impact of this accounting guidance on its results of operations and financial position.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DebtModificationsAndExtinguishmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DebtModificationsAndExtinguishmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416975006496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive:</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zi6ge9YgSP21" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive: &#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract', window );">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_zH619xBoQBl2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49E_20220331_z5uGeYjdGb5g" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_495_20210331_zgovGgjVcjK6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_zczFTBzbQV3c" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Options to purchase common stock</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,650,705</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,197,252</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_zj3b2oY6U1Fd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,779,072</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20220331_zvecWQIznBTi" style="border-bottom: Black 2.5pt double; text-align: right">6,429,777</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_zaRsOzR3gPNj" style="border-bottom: Black 2.5pt double; text-align: right">1,197,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416971773824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEET DETAIL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock', window );">[custom:DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock]</a></td>
<td class="text"><p id="xdx_89B_ecustom--DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock_zF4TfzlRybll" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureConsolidatedBalanceSheetDetailDetailsAbstract', window );">CONSOLIDATED BALANCE SHEET DETAIL</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureConsolidatedBalanceSheetDetailDetailsAbstract_zRU6V5vlbfXi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_499_20220331_z4zq7k3BvC44" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_497_20210331_zFusOQa6llY4" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left">Property and equipment, net:</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zhgQfGDFDPs" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Leasehold improvements</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">139,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">139,197</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z8iLANmUwVub" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,298</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,476</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTw6M0iBZQEl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Computer equipment and software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,383</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherMachineryAndEquipmentMember_ztaCoDaSQzk6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Machinery and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">230,947</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">202,993</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz4h6_zh3xNxmzW1th" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt"><span style="display: none">Property and equipment,&#160;gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">485,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">451,049</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz4h6_zhRPsukekoji" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(249,597</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(152,091</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_mtPPAENz4h6_zzcoOCxnSwoi" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt"><span style="display: none">Property and equipment,&#160;net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">235,959</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">298,958</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">Accrued expenses:</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedWagesAndBonus_iI_maALAOLz5T1_z0JhbMur571f" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Accrued wages and bonus</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">457,891</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">372,563</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AccruedPlacementFees_iI_maALAOLz5T1_zOkWAxDrX7qb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued placement fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,800</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedInterests_iI_maALAOLz5T1_zJ1nXO47gpz7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,538</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALAOLz5T1_z1yiFJnzCMjf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">67,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,047</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_mtALAOLz5T1_zUcNbV9KXDyg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt"><span style="display: none">Accrued expenses</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">524,891</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">499,948</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureConsolidatedBalanceSheetDetailDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureConsolidatedBalanceSheetDetailDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416971701856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future minimum payments under the facility operating lease</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zjd3UPUssYT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_8B3_zPODvyMmIpik">Future
minimum payments under the facility operating lease</span>, as of March 31, 2022, are listed in the table below.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureLeasesDetailsAbstract', window );">Leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureLeasesDetailsAbstract_zEfGkyRYw1Y1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Annual Fiscal Years</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220331_zKyWa3i8HGR3" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating<br/> lease</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_maOLFMPz3Dp_zJgm0y6XYiIf" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 87%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">158,028</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_maOLFMPz3Dp_zn4AfYlqTTgi" style="vertical-align: bottom; background-color: White">
    <td>2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,692</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--OperatingLeasesImputedInterest_iI_maOLFMPz3Dp_zUwbalcxHbP2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(13,906</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_mtOLFMPz3Dp_zpDxDQUAJu15" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">184,814</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureLeasesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureLeasesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416968757664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zROmdypsGl47" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following assumptions were used in the
fair-value method calculations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8BC_zoHpYNToBpPe" style="display: none">Schedule of Fair Value Assumptions</span></span></p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureStockBasedCompensationDetailsAbstract', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureStockBasedCompensationDetailsAbstract_z9XHVjaV0oh4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Year
    Ended<br/> March 31,</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 10pt">2022</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; width: 74%; text-align: left"><span style="font-size: 10pt">Risk-free interest rates</span></td><td style="white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_zBER1rIvYGaa">0.8%</span>&#160;-&#160;<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_zFywCR536aeh">2.42%</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 10pt">&#8239;</span></td><td style="white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; width: 8%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zbmJFTQM1Rjd">0.28%</span>
                                            - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zQ3CtwjxJLh2">0.71%</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 10pt">&#8239;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap"><span style="font-size: 10pt">Volatility</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_z9JNunmYOGRc">89%</span>&#160;-&#160;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_z1lvZBdoBnpg">370%</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#8239;</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z9R3QblRW8l3">87%</span>&#160;-&#160;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zi56RSdNQjjl">127%</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#8239;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">Expected life (years)</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_z1dk0fEmLUBk" title="::XDX::P5Y">5.0</span>&#160;-&#160;<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_z2xQrlUIAvzb" title="::XDX::P6Y2M12D">6.2</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zDWRWGadWDW6" title="::XDX::P5Y">5.0</span>&#160;-&#160;<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z7rTiSgV3EG4" title="::XDX::P6Y">6.0</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">Dividend yield</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20210401__20220331_zA0sD2YLEeqj">&#8212;</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331_zxUElb8g3KA1">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option activity</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zRu6BcKE8fBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">A summary of stock option activity under
the 2017 Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><span id="xdx_8BF_zMfIkSaPKpo3" style="display: none">Schedule of Stock Option activity</span></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureStockBasedCompensationDetails2Abstract', window );">STOCK-BASED COMPENSATION (Details 2)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zyA2icRZIRid" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2020</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zN07dgH8qnc" style="width: 8%; text-align: right">274,019</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zh6taN8bcdI5" style="width: 8%; text-align: right">1,059,315</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zStOdBzaNOTl" style="width: 8%; text-align: right">4.74</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zj1FMd9UL4Z6" style="text-align: right">(163,492</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zilPlEWvwY4a" style="text-align: right">163,492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zugRVMRUlLq" style="text-align: right">8.64</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEaifwfdaMf3" style="border-bottom: Black 1pt solid; text-align: right">25,555</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgZa1obxL5Ab" style="border-bottom: Black 1pt solid; text-align: right">(25,555</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmXrsPDd3A56" style="border-bottom: Black 1pt solid; text-align: right">6.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9DbbhhUZSPb" style="text-align: right">136,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zznrrwwjWBpc" style="text-align: right">1,197,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zppeuIunqCx8" style="text-align: right">5.25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 9pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8ZnEI11tJT9" style="text-align: right">1,333,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT1z72Cazb36" style="text-align: right">(827,427</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdt5hAYptlh9" style="text-align: right">827,427</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1xTpXcxfi9g" style="text-align: right">10.39</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 9pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFNMAhir2QMi" style="text-align: right">(26,497</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkt1VGnVC8uc" style="border-bottom: Black 1pt solid; text-align: right">373,974</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1GS5esT6EK4" style="border-bottom: Black 1pt solid; text-align: right">(373,974</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zycqAr4T4nz4" style="border-bottom: Black 1pt solid; text-align: right">10.73</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt">Balance at March 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7uZY99nQfX" style="border-bottom: Black 2.5pt double; text-align: right">989,466</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPUkXXw3Bfj6" style="border-bottom: Black 2.5pt double; text-align: right">1,650,705</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLM2ww6i68j7" style="border-bottom: Black 2.5pt double; text-align: right">6.58</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of Outstanding and Exercisable Option, Range</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z03c6lvyxSt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table summarizes the range of outstanding and exercisable options as of March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zjWp49Tt5yt7" style="display: none">Schedule of
Outstanding and Exercisable Option, Range</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureStockBasedCompensationDetails3Abstract', window );">STOCK-BASED COMPENSATION (Details 3)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zoodrM9W77v9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number<br/> Outstanding</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Exercise<br/> Price</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number<br/> Exercisable</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Exercise<br/> Price</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> value</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z4Zx8uZq6t04">1.98</span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zScc5IPzvlq8">17.70</span></td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztv9LizGFHuk" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1,650,705</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmFalTPkxkqd" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P8Y4D">8.01</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx2rQfGQCbbf" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">6.58</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIbn9Ff9oPKe" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1,193,680</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDIs0MZ8bVVa" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">5.69</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWcFYBds9FM9" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1,090,966</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureStockBasedCompensationDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureStockBasedCompensationDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureStockBasedCompensationDetails3Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureStockBasedCompensationDetails3Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureStockBasedCompensationDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureStockBasedCompensationDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416968760160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income tax provision</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zRZ0GUtDckI2" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-size: 10pt">The income tax provision consisted
of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_8B3_zx4q6vQzEHP1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify; text-indent: 0.5in">Schedule of Income tax provision</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureIncomeTaxesDetailsAbstract', window );">INCOME TAXES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIncomeTaxesDetailsAbstract_z5Xj5wj9Bbij" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_493_20210401__20220331_zkeOSngFHGFa" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49B_20200401__20210331_zNeHwM9IewFk" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zpkYxgiMElck" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Current portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzDQj_z0U1H3VTbeI5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzDQj_zxQgTEmomJSl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; padding-bottom: 1pt; padding-left: 8.65pt">State</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_mtCITEBzDQj_maITEBzk6Q_zcVJ8Pf0pTul" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none">Current</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zxGfMZeH6dz1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Deferred portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzmjI_zDdlTYP27n14" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,109,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,931,390</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzmjI_zEPPocySasGa" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 1pt; padding-left: 8.65pt">State</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,300,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(576,868</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBzmjI_maITEBzk6Q_zYB27mhgKC4h" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none">Deferred</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">( 5,409,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,508,258</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzk6Q_zt00bAZA7CQd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,409,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,508,258</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzk6Q_z2UYVmXh0Qif" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Provisions</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbmw0zaVahpb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">A reconciliation of
income taxes provided at the federal statutory rate (21% for each of fiscal 2022 and 2021) to the actual income tax provision is as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_8B4_z7Y3El0yR9Zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify; text-indent: 0.5in">Schedule of Income Tax Provisions</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureIncomeTaxesDetails2Abstract', window );">INCOME TAXES (Details 2)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIncomeTaxesDetails2Abstract_zCxDEnXAR8J7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_498_20210401__20220331_zkjZav6vPWtf" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49E_20200401__20210331_zEUQkS5ZM2xi" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi0_zPXVMzzIMfY9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Federal statutory rate</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp0_zr2EbQ66OVi1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax rate, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_dp0_zzzshdWeW4B7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_dp0_zJPYg9wSqZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_dp0_z0Ewdr3WpXBg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Section 179 assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp0_zCezYLuSSlKj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">30</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">34</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zyMqlhqEfP6" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z2wHiUpXVpYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font-size: 10pt">Significant components of the Company&#8217;s
deferred tax assets and liabilities were:&#160;</span></p>

<p id="xdx_8BF_zSFtKJkbhxw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none">Schedule of Deferred Tax Assets</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureIncomeTaxesDetails3Abstract', window );">INCOME TAXES (Details 3)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--DisclosureIncomeTaxesDetails3Abstract_ztyMFwQhelY3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 3)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49B_20220331_zLXdyv8xcKVg" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49C_20210331_zG7GYfOP7f46" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzv9B_zgiUXS5cPAi9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Net operating loss carryforwards</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">7,731,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,909,434</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzv9B_zUL8lX4sQ4Wg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,824,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">554,892</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzv9B_zISj5piaI9R3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,039</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_iNI_di_maDTAGzv9B_znDSjqxtLEHf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reserves, accruals &amp; other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(104,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(79,878</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_msDTAGzv9B_z210jsTZQd4l" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Research and development tax credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">988,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">646,296</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzv9B_maDTANzyHM_zDKlltF9ReTl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,519,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,012,705</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesRegulatoryAssets_iNI_di_maDITLzKZ6_zYnHFMpZWCya" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.35pt; padding-left: 8.65pt">Section 179 assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(97,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0725">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzKZ6_msDTANzyHM_zkSGwJWr1jPh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(97,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0728">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzyHM_zB8LJ6Krveze" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,422,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,012,705</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzyHM_zSRhUBbR1NMl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0733">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0734">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureIncomeTaxesDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureIncomeTaxesDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureIncomeTaxesDetails3Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureIncomeTaxesDetails3Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureIncomeTaxesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureIncomeTaxesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416969027536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options to purchase common stock</a></td>
<td class="nump">1,650,705<span></span>
</td>
<td class="nump">1,197,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">4,779,072<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">6,429,777<span></span>
</td>
<td class="nump">1,197,252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416965506640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEET DETAIL (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment,&#160;gross</a></td>
<td class="nump">$ 485,556<span></span>
</td>
<td class="nump">$ 451,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(249,597)<span></span>
</td>
<td class="num">(152,091)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment,&#160;net</a></td>
<td class="nump">235,959<span></span>
</td>
<td class="nump">298,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_AccruedWagesAndBonus', window );">Accrued wages and bonus</a></td>
<td class="nump">457,891<span></span>
</td>
<td class="nump">372,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_AccruedPlacementFees', window );">Accrued placement fees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">88,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_AccruedInterests', window );">Accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">67,000<span></span>
</td>
<td class="nump">11,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="nump">524,891<span></span>
</td>
<td class="nump">499,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment,&#160;gross</a></td>
<td class="nump">139,197<span></span>
</td>
<td class="nump">139,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment,&#160;gross</a></td>
<td class="nump">63,298<span></span>
</td>
<td class="nump">56,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment,&#160;gross</a></td>
<td class="nump">52,114<span></span>
</td>
<td class="nump">52,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember', window );">Other Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment,&#160;gross</a></td>
<td class="nump">$ 230,947<span></span>
</td>
<td class="nump">$ 202,993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_AccruedInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_AccruedInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_AccruedPlacementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_AccruedPlacementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_AccruedWagesAndBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_AccruedWagesAndBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416975013216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">$ 158,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">40,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_OperatingLeasesImputedInterest', window );">Imputed interest</a></td>
<td class="num">(13,906)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 184,814<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_OperatingLeasesImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_OperatingLeasesImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416968982528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="nump">$ 270,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_LeaseIncentiveReceived', window );">Lease Incentive Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_CashPaidforLeaseLiabilities', window );">Cash Paid for Lease Liabilities</a></td>
<td class="nump">153,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="nump">$ 107,820<span></span>
</td>
<td class="nump">$ 107,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_CashPaidforLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_CashPaidforLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_LeaseIncentiveReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_LeaseIncentiveReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416970107776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PPP NOTE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosurePppNoteAbstract', window );"><strong>Ppp Note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebtCurrent', window );">Unsecured Debt, Current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 368,780<span></span>
</td>
<td class="nump">$ 368,780<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosurePppNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosurePppNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416969115216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PROMISSORY NOTES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="nump">$ 1,321,450<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="nump">$ 70,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</a></td>
<td class="nump">88.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">0.86%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416970027200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTE (Details Narrative) - Revolving Credit Facility [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet', window );">Line of Credit Facility, Increase (Decrease), Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest', window );">Line of Credit Facility, Increase, Accrued Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Secured Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-Term Line of Credit</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Line of Credit Facility, Expiration Date</a></td>
<td class="text">Mar. 15,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Line of Credit Facility, Interest Rate During Period</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the credit facility for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=modd_SecuredPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=modd_SecuredPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416969941584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT) (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 1,785,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 594,400<span></span>
</td>
<td class="nump">$ 210,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416968771856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">0.86%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.28%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">2.42%<span></span>
</td>
<td class="nump">0.71%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">370.00%<span></span>
</td>
<td class="nump">127.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416970795360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance</a></td>
<td class="nump">1,197,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance</a></td>
<td class="nump">1,650,705<span></span>
</td>
<td class="nump">1,197,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">136,082<span></span>
</td>
<td class="nump">274,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance</a></td>
<td class="nump">1,197,252<span></span>
</td>
<td class="nump">1,059,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant', window );">Granted</a></td>
<td class="num">(827,427)<span></span>
</td>
<td class="num">(163,492)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">827,427<span></span>
</td>
<td class="nump">163,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 10.39<span></span>
</td>
<td class="nump">$ 8.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant', window );">Cancelled</a></td>
<td class="nump">373,974<span></span>
</td>
<td class="nump">25,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</a></td>
<td class="num">(373,974)<span></span>
</td>
<td class="num">(25,555)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 10.73<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant]</a></td>
<td class="nump">1,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards]</a></td>
<td class="num">(26,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">989,466<span></span>
</td>
<td class="nump">136,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance</a></td>
<td class="nump">1,650,705<span></span>
</td>
<td class="nump">1,197,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 6.58<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416970776992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">1,650,705<span></span>
</td>
<td class="nump">1,197,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">1,650,705<span></span>
</td>
<td class="nump">1,197,252<span></span>
</td>
<td class="nump">1,059,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 6.58<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">1,193,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="nump">$ 1,090,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="nump">$ 17.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416970990800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,333,334<span></span>
</td>
<td class="nump">333,334<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 3,286,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">$ 3,859,785<span></span>
</td>
<td class="nump">$ 1,227,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">827,427<span></span>
</td>
<td class="nump">163,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_FairValueofOptionGranted', window );">Fair Value of Options</a></td>
<td class="nump">$ 8,507,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">$ 2,739,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">137,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">827,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_FairValueofOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_FairValueofOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416965463888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(4,109,000)<span></span>
</td>
<td class="num">(1,931,390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="num">(576,868)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">5,409,000<span></span>
</td>
<td class="num">(2,508,258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">5,409,000<span></span>
</td>
<td class="nump">2,508,258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416971147712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details 2)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal benefit</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Section 179 assets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416968744112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details 3) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 7,731,000<span></span>
</td>
<td class="nump">$ 3,909,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock-based compensation expense</a></td>
<td class="nump">1,824,000<span></span>
</td>
<td class="nump">554,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="num">(18,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves', window );">Reserves, accruals &amp; other</a></td>
<td class="num">(104,000)<span></span>
</td>
<td class="num">(79,878)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Research and development tax credits</a></td>
<td class="nump">988,000<span></span>
</td>
<td class="nump">646,296<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">10,519,000<span></span>
</td>
<td class="nump">5,012,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesRegulatoryAssets', window );">Section 179 assets</a></td>
<td class="num">(97,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(97,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(10,422,000)<span></span>
</td>
<td class="num">(5,012,705)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from loss reserves other than estimated credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesRegulatoryAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from regulatory assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesRegulatoryAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416970132288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 27,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Deferred Tax Assets, in Process Research and Development</a></td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">27,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Deferred Tax Assets, in Process Research and Development</a></td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140416965093536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,511,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember', window );">C E O And Investor [Member] | Notes Payable Other Payables 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">$ 1,026,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="nump">$ 97,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember', window );">C E O And Investor [Member] | Notes Payable Other Payables 1 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other</a></td>
<td class="nump">234,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember', window );">C E O And Investor [Member] | Notes Payable Other Payables 1 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other</a></td>
<td class="nump">234,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember', window );">C E O And Investor [Member] | Notes Payable Other Payables 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">$ 102,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="nump">$ 9,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember', window );">C E O And Investor [Member] | Notes Payable Other Payables 2 [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other</a></td>
<td class="nump">23,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember', window );">C E O And Investor [Member] | Notes Payable Other Payables 2 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other</a></td>
<td class="nump">23,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_MemberOfBoardMember', window );">Member Of Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="nump">$ 18,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_MemberOfBoardMember', window );">Member Of Board [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities</a></td>
<td class="nump">45,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_MemberOfBoardMember', window );">Member Of Board [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities</a></td>
<td class="nump">45,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_DaughterOfPresidentCFOTreasurerAndChairmanMember', window );">Daughter of President, CFO, Treasurer and Chairman of Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=modd_NotesPayableOtherPayables1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=modd_NotesPayableOtherPayables1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=modd_NotesPayableOtherPayables2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=modd_NotesPayableOtherPayables2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_MemberOfBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_MemberOfBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_DaughterOfPresidentCFOTreasurerAndChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_DaughterOfPresidentCFOTreasurerAndChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>modular_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:modd="http://modular-medical.com/20220331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="modd-20220331.xsd" xlink:type="simple"/>
    <context id="From2021-04-01to2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2022-06-24</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_OtherMachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_OtherMachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-04-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-04-02</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-04-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-04-24</instant>
        </period>
    </context>
    <context id="AsOf2021-05-31_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">modd:SecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-28</instant>
        </period>
    </context>
    <context id="From2021-10-272021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">modd:SecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-27</startDate>
            <endDate>2021-10-28</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-02-092022-02-10_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="AsOf2017-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="AsOf2020-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="AsOf2020-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_CommonStockMember_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_StockOptionMember_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_StockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_StockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="AsOf2022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-14</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-14</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-14</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-14</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-31_custom_MemberOfBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2022-02-14_custom_MemberOfBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="From2022-02-142022-02-14_custom_MemberOfBoardMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-14</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="From2022-02-142022-02-14_custom_MemberOfBoardMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-14</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_DaughterOfPresidentCFOTreasurerAndChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:DaughterOfPresidentCFOTreasurerAndChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-04-01to2022-03-31">0001074871</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-04-01to2022-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-04-01to2022-03-31">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2021-04-01to2022-03-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-04-01to2022-03-31">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:UnsecuredDebtCurrent
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0093"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0096"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0105"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0173"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0207"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0214"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0220"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0222"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0223"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0226"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0227"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0228"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0242"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0259"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:SharesIssuedForReverseStockSplit
      contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:SharesIssuedForReverseStockSplit
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:SharesIssuedForReverseStockSplit
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:GainOnPPPNoteForgiveness
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:AccruedInterest
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:ProceedsFromIssuanceOfPromissoryNote
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:RepaymentOfPromissoryNote
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0469"
      unitRef="Shares"
      xsi:nil="true"/>
    <modd:AccruedPlacementFees
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:AccruedInterests
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2020-04-02">P39M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-04-01to2022-03-31">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      id="xdx2ixbrl0553"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2021-04-01to2022-03-31">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-04-012022-03-31_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-04-012022-03-31_srt_MaximumMember">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-04-012021-03-31_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-04-012021-03-31_srt_MaximumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember">P8Y4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0646"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesRegulatoryAssets
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0725"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0728"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0733"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0734"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-04-01to2022-03-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2021-04-01to2022-03-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-04-01to2022-03-31">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2021-04-01to2022-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-04-01to2022-03-31">001-41277</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-04-01to2022-03-31">MODULAR MEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-04-01to2022-03-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-04-01to2022-03-31">87-0620495</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-04-01to2022-03-31">16772 W. Bernardo Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2021-04-01to2022-03-31">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-04-01to2022-03-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-04-01to2022-03-31">92127</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-04-01to2022-03-31">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-04-01to2022-03-31">800-3500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-04-01to2022-03-31">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-04-01to2022-03-31">MODD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-04-01to2022-03-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2021-04-01to2022-03-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2021-04-01to2022-03-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2021-04-01to2022-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-04-01to2022-03-31">No</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-04-01to2022-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-04-01to2022-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-04-01to2022-03-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2021-04-01to2022-03-31">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="From2021-04-01to2022-03-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">14862263</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-06-24" decimals="INF" unitRef="Shares">10911684</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="From2021-04-01to2022-03-31">Farber Hass Hurley LLP</dei:AuditorName>
    <dei:AuditorFirmId contextRef="From2021-04-01to2022-03-31">223</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="From2021-04-01to2022-03-31">Chatsworth, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">9076372</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1468465</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">312464</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">178158</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">958</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2466</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">9389794</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1649089</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">235959</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">298958</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">120693</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">200124</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssets contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">100000</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">100000</us-gaap:DepositsAssets>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">456652</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">599082</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">9846446</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2248171</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">299951</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">169284</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">524891</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">499948</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">144857</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">125500</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:UnsecuredDebtCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">368780</us-gaap:UnsecuredDebtCurrent>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2133453</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">969699</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">3296965</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">39957</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">184355</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">42000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1009656</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">3523320</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">10461898</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">10461898</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">6302050</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">6302050</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">10462</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">6302</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">43406099</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">14665559</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-34579771</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-15947010</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">8836790</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-1275149</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">9846446</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2248171</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">7729240</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">4083303</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">7197162</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">3253412</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">14926402</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">7336715</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-14926402</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-7336715</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">368920</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">130</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">2752229</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">39791</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-1321450</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-18631161</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-7376376</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-18632761</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-7377976</us-gaap:NetIncomeLoss>
    <modd:EarningsPerShareBasicAndDiluted1
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">-2.74</modd:EarningsPerShareBasicAndDiluted1>
    <modd:EarningsPerShareBasicAndDiluted1
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">-1.20</modd:EarningsPerShareBasicAndDiluted1>
    <modd:WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">6807710</modd:WeightedAverageNumberOfShareOutstandingBasicAndDiluted1>
    <modd:WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">6211562</modd:WeightedAverageNumberOfShareOutstandingBasicAndDiluted1>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5956754</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5957</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">10517505</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">923994</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-8569034</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">2878422</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">320796</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">321</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2709555</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">-923994</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1785882</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">24500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">24</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">210921</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">210945</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1227578</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1227578</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-7377976</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-7377976</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6302050</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6302</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">14665559</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-15947010</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-1275149</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2500000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2500</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">13657500</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">13660000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1511276</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1511</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6506254</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">6507765</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">30864</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">31</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">249969</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3700632</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">3700632</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">90000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">90</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">594310</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">594400</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1211</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <modd:SharesIssuedForReverseStockSplit
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</modd:SharesIssuedForReverseStockSplit>
    <modd:SharesIssuedForReverseStockSplit
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-1</modd:SharesIssuedForReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">26497</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">27</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">172091</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">172118</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3859785</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">3859785</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-18632761</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-18632761</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">10461898</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">10462</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">43406099</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-34579771</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">8836790</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-18632761</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-7377976</us-gaap:NetIncomeLoss>
    <modd:GainOnPPPNoteForgiveness
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-368780</modd:GainOnPPPNoteForgiveness>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-1321450</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">4031902</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1227578</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">117490</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">111015</us-gaap:DepreciationAndAmortization>
    <modd:AccruedInterest
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">666338</modd:AccruedInterest>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">395950</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">68880</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">79431</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">70826</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <modd:IncreaseDecreaseInLeaseLiability
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-125040</modd:IncreaseDecreaseInLeaseLiability>
    <modd:IncreaseDecreaseInLeaseLiability
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">38905</modd:IncreaseDecreaseInLeaseLiability>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1833618</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">12253</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">274</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1004</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">65652</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">25600</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">354948</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-86747</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-10259528</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-5908662</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">54764</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">109669</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-54764</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-109669</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">250000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1785882</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">4137199</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">2210000</us-gaap:ProceedsFromConvertibleDebt>
    <modd:ProceedsFromIssuanceOfPromissoryNote
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">2100000</modd:ProceedsFromIssuanceOfPromissoryNote>
    <modd:RepaymentOfPromissoryNote
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-2100000</modd:RepaymentOfPromissoryNote>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">368780</us-gaap:ProceedsFromNotesPayable>
    <modd:ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">13535000</modd:ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">17922199</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">4364662</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">7607907</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-1653669</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1468465</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3122134</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">9076372</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1468465</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">3700632</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <modd:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">7253876</modd:ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">252000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zYqNaSThYyA4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note&#160;1
&#x2013; &lt;span id="xdx_826_zadDPzMXkLk7"&gt;THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Modular Medical, Inc.
(the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material business
operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras, Inc., a Delaware
corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras, the share exchange was
accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras, acquired in the merger, at
their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the Company was a shell company, as
defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act). In June 2017, the Company changed its
name from Bear Lake Recreation, Inc. to Modular Medical, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative insulin
pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps for insulin-dependent
people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent diabetes to receive their
daily insulin in two ways, through a continuous &#x201c;basal&#x201d; delivery allowing a small amount of insulin to be in the blood at
all times and a &#x201c;bolus&#x201d; delivery to address meal time glucose input and to address when the blood glucose level becomes excessively
high. By addressing the time and effort required to effectively treat their condition, the Company believes it can address the less technically
savvy, less motivated part of the market.&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
discussed in Note 7, in February 2022, the Company completed a public offering of its equity securities, and its common stock was approved
to list on the Nasdaq Capital Market under the symbol &#x201c;MODD&#x201d; and began trading there on February 10, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--LiquidityPolicyTextBlock_zmtWXrgDJMli" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zH6oyktWLVp9"&gt;Going
Concern&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The accompanying financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal
course of business. The realization of assets and the satisfaction of liabilities in the normal course of business are dependent on,
among other things, the Company&#x2019;s ability to operate profitably, to generate cash flows from operations, and to pursue financing
arrangements to support its working capital requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;At issuance of the Company&#x2019;s
financial statements for the year ended March 31, 2021, management had determined that there was significant doubt as to the ability
of the Company to meet its obligations and continue as a going concern. As a result of the Offering (see Note 7), which was completed
in February 2022, and the Registered Offering (see Note 13), which was completed in May 2022, and resulting improved financial position,
the Company believes it has sufficient liquidity to meet its obligations as they come due and conduct its business for a period of at
least 12 months from the date of issuance of these financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures.
The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&#x2019;s
ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations
with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable
to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to
reduce costs in order to conserve its cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zRiJQCGBV25a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zjI0fxvkL60h"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America. The Company&#x2019;s fiscal year ends on March 31 of each calendar year.&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;Each
reference to a fiscal year in these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar
year indicated (for example, fiscal 2022 refers to the fiscal year ending March 31, 2022). The consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been
eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--ReverseStockSplitPolicyTextBlock_z04VSWRoT4g5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_86F_zQBYomsOyt86"&gt;&lt;span id="xdx_861_zwJZiczLUZTf"&gt;Reverse
Stock Split&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#x2019;s shares of common stock.&#160;Such amendment
and ratio were previously approved by a majority of the Company&#x2019;s stockholders and the board of directors. As a result of the reverse
stock split, which was effective November 29, 2021, every three shares of the Company&#x2019;s pre-reverse split outstanding common stock
were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stock holders were
not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split were rounded up to the
nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company&#x2019;s equity incentive
plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of
common stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split.&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;&#160;All
share numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3
reverse stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zQAMqRgArPf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zzdD9Zq4p7o1"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The preparation of
the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting
period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from
those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zo1ec0Mysvw" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zHVPNIpnofm"&gt;Reportable
Segment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;The Company operates in one business segment
and uses one measurement of profitability for its business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvIlXmwh0fD" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_86C_zs0zYacJravk"&gt;Research
and Development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company expenses research and development expenditures as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zroIoQNwqFh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_866_zIUjRSyGNGN7"&gt;General
and Administrative&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees,
and office and other administrative expenses.&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_ziJ2ewPFUZMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zUWOtBR5IV6k"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial instruments
that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash at high
quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to
limits of approximately $250,000. &lt;span style="font-family: Times New Roman, Times, Serif; background-color: white"&gt;No reserve has been
made in the financial statements for any possible loss due to financial institution failure.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--RisksAndUncertaintiesPolicyTextBlock_zi0JfTofpvM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zqS2p0oVCk06"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company is subject
to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity
requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The global outbreak
of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S.
government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#x201c;shelter-in-place&#x201d; and created significant
disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#x2019;s operational and financial performance
will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government
agencies to prevent disease spread, all of which are uncertain, out of the Company&#x2019;s control, and cannot be predicted.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zxMnukNIy9E4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zgsqPjuzR3Q7"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Cash and cash equivalents
include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities
of three months or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zttWp1WUggSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zjT4PvFPcfEc"&gt;Property
and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Property and equipment
are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets,
generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold
improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the lease term,
and amortization is recorded in operating expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zta5pBtur4x2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zu6Y5hpixDek"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company measures
the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value into three broad levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            1 inputs to the valuation methodology are quoted prices for identical assets or liabilities
                                            in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            2 inputs to the valuation methodology include quoted prices for similar assets and liabilities
                                            in active markets, and inputs that are observable for the asset or liability, either directly
                                            or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            3 inputs to the valuation methodology are unobservable and significant to the fair value
                                            measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--DebtModificationsAndExtinguishmentsPolicyTextBlock_z2qhNiR0tcA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zLW3oqwXW8mi"&gt;Debt
Modifications and Extinguishments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;When the Company modifies
or extinguishes debt, it does so in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC)
Topic 470-50, &lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Debt&#x2014; Modifications and Extinguishments,&lt;/i&gt;&lt;/span&gt; which
requires modification to debt instruments to be evaluated to assess whether the modifications are considered &#x201c;substantial modifications.&#x201d;
A substantial modification of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis
performed, if the Company believes the embedded conversion feature has no fair value on the date of issuance (measurement date) and the
embedded conversion feature has no beneficial conversion feature, the embedded conversion feature does not meet the criteria in ASC 470-50-40-10
or 470-20-25 and the issuance of the convertible note payable is considered a modification, and not an extinguishment that would require
the recognition of a gain or loss. If the Company determines the change in terms meet the criteria for substantial modification under
ASC 470 it will treat the modification as extinguishment and recognize a loss from debt extinguishment.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zZW1vseIs6U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zvU0gedkoKIf"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Effective&#160;April&#160;1, 2019,
the Company adopted ASC No. 842,&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Leases&#160;&lt;/i&gt;&lt;/span&gt;(ASC 842). ASC
842 requires an entity to recognize a&#160;right-of-use&#160;asset and a lease liability for all leases with terms longer than 12 months.
The Company adopted ASC 842 utilizing the modified retrospective transition method. The Company elected the practical expedient afforded
in ASC 842 in which the Company did not reassess whether any contracts that existed prior to adoption have or contain leases or the classification
of its existing leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_znFDT9AfXlJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zOo0oLCtxyjh"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company recognizes
stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite service
period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options on the date
of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date of grant using
an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and subjective variables.
These variables include, but are not limited to, the expected stock price&#160;volatility over the term of the awards, and projected
stock option exercise behaviors.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zBWbC6sUp8wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zDSzZkLxl919"&gt;Per-Share
Amounts&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Basic net loss per
share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during the period.
Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive
common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zi6ge9YgSP21" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive: &#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_zH619xBoQBl2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49E_20220331_z5uGeYjdGb5g" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_495_20210331_zgovGgjVcjK6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_zczFTBzbQV3c" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;1,650,705&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_zj3b2oY6U1Fd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,779,072&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0469"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20220331_zvecWQIznBTi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,429,777&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_zaRsOzR3gPNj" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zhn1aY3xhyMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zpNroTjz06ie" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_862_zm3mQRzHAlL1"&gt;Reclassification&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zrhjoDfokqXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zzuDKj6X6Ldg"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company determines
deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company&#x2019;s assets
and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation
allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets
will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal
and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company accounts
for uncertain tax positions in accordance with FASB ASC Topic 740,&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/span&gt;. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would
be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period during which,
based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination,
including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.
Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more
than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated
with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits
in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing
authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are
classified in general and administrative expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company files U.S.
federal and state income tax returns in jurisdictions with varying statutes of limitations.&#160;&#160;All tax returns from 2016 to 2021
may be subject to examination by the U.S. federal and state tax authorities.&#160; As of March 31, 2022 and 2021, the Company had not
recorded any liability for unrecognized tax benefits related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zmRNsprJq3ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zk5hp2qYq0Ue"&gt;Comprehensive&#160;Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Comprehensive loss
represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2022 and 2021, the Company&#x2019;s
comprehensive loss was the same as its net loss.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z64GYbkpeqQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_86F_zImLuBeHUQvc"&gt;Recently
Issued Accounting Pronouncement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13,&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Financial
Instruments&#x2014;Credit Losses&lt;/i&gt;&lt;span style="background-color: white"&gt;. This ASU added a new impairment model (known as the current
expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes
an allowance for its estimate of expected credit losses and applies to most debt instruments, trade receivables, lease receivables, financial
guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses
and entities will need to measure expected credit losses on assets that have a low risk of loss. This update is effective for fiscal
years beginning after December 15, 2022, including interim periods within those fiscal years for smaller reporting companies. The Company
is still evaluating the impact of this accounting guidance on its results of operations and financial position.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <modd:LiquidityPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_842_ecustom--LiquidityPolicyTextBlock_zmtWXrgDJMli" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zH6oyktWLVp9"&gt;Going
Concern&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The accompanying financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal
course of business. The realization of assets and the satisfaction of liabilities in the normal course of business are dependent on,
among other things, the Company&#x2019;s ability to operate profitably, to generate cash flows from operations, and to pursue financing
arrangements to support its working capital requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;At issuance of the Company&#x2019;s
financial statements for the year ended March 31, 2021, management had determined that there was significant doubt as to the ability
of the Company to meet its obligations and continue as a going concern. As a result of the Offering (see Note 7), which was completed
in February 2022, and the Registered Offering (see Note 13), which was completed in May 2022, and resulting improved financial position,
the Company believes it has sufficient liquidity to meet its obligations as they come due and conduct its business for a period of at
least 12 months from the date of issuance of these financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures.
The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&#x2019;s
ability to successfully commercialize its product, competing technological and market developments, and the need to enter into collaborations
with other companies or acquire other companies or technologies to enhance or complement its product offering. If the Company is unable
to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to
reduce costs in order to conserve its cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</modd:LiquidityPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zRiJQCGBV25a" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zjI0fxvkL60h"&gt;Basis
of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States
of America. The Company&#x2019;s fiscal year ends on March 31 of each calendar year.&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;Each
reference to a fiscal year in these notes to the consolidated financial statements refers to the fiscal year ended March 31 of the calendar
year indicated (for example, fiscal 2022 refers to the fiscal year ending March 31, 2022). The consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been
eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <modd:ReverseStockSplitPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_844_ecustom--ReverseStockSplitPolicyTextBlock_z04VSWRoT4g5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_86F_zQBYomsOyt86"&gt;&lt;span id="xdx_861_zwJZiczLUZTf"&gt;Reverse
Stock Split&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
November 24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#x2019;s shares of common stock.&#160;Such amendment
and ratio were previously approved by a majority of the Company&#x2019;s stockholders and the board of directors. As a result of the reverse
stock split, which was effective November 29, 2021, every three shares of the Company&#x2019;s pre-reverse split outstanding common stock
were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common stock holders were
not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split were rounded up to the
nearest whole share. All stock options outstanding and common stock reserved for issuance under the Company&#x2019;s equity incentive
plans and warrants outstanding immediately prior to the reverse stock split were adjusted by dividing the number of affected shares of
common stock by three and, as applicable, multiplying the exercise price by three, as a result of the reverse stock split.&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;&#160;All
share numbers, share prices, exercise prices and per share amounts have been adjusted, on a retroactive basis to reflect this 1-for-3
reverse stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</modd:ReverseStockSplitPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zQAMqRgArPf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zzdD9Zq4p7o1"&gt;Use
of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The preparation of
the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting
period. Estimates may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from
those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84A_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zo1ec0Mysvw" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zHVPNIpnofm"&gt;Reportable
Segment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;The Company operates in one business segment
and uses one measurement of profitability for its business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvIlXmwh0fD" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_86C_zs0zYacJravk"&gt;Research
and Development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company expenses research and development expenditures as incurred.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84B_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zroIoQNwqFh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_866_zIUjRSyGNGN7"&gt;General
and Administrative&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting fees,
and office and other administrative expenses.&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_ziJ2ewPFUZMl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zUWOtBR5IV6k"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial instruments
that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash at high
quality financial institutions within the United States, which are insured by the Federal Deposit Insurance Corporation (FDIC) up to
limits of approximately $250,000. &lt;span style="font-family: Times New Roman, Times, Serif; background-color: white"&gt;No reserve has been
made in the financial statements for any possible loss due to financial institution failure.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <modd:RisksAndUncertaintiesPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_849_ecustom--RisksAndUncertaintiesPolicyTextBlock_zi0JfTofpvM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zqS2p0oVCk06"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company is subject
to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity
requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The global outbreak
of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S.
government in March 2020.&#160;&#160;This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#x201c;shelter-in-place&#x201d; and created significant
disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#x2019;s operational and financial performance
will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government
agencies to prevent disease spread, all of which are uncertain, out of the Company&#x2019;s control, and cannot be predicted.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

</modd:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zxMnukNIy9E4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zgsqPjuzR3Q7"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Cash and cash equivalents
include cash on hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with original maturities
of three months or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zttWp1WUggSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zjT4PvFPcfEc"&gt;Property
and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Property and equipment
are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets,
generally three to five years. Depreciation is recorded in operating expenses in the consolidated statements of operations. Leasehold
improvements and assets acquired through capital leases are amortized over the shorter of their estimated useful life or the lease term,
and amortization is recorded in operating expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zta5pBtur4x2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zu6Y5hpixDek"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company measures
the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value into three broad levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            1 inputs to the valuation methodology are quoted prices for identical assets or liabilities
                                            in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            2 inputs to the valuation methodology include quoted prices for similar assets and liabilities
                                            in active markets, and inputs that are observable for the asset or liability, either directly
                                            or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            3 inputs to the valuation methodology are unobservable and significant to the fair value
                                            measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <modd:DebtModificationsAndExtinguishmentsPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84A_ecustom--DebtModificationsAndExtinguishmentsPolicyTextBlock_z2qhNiR0tcA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zLW3oqwXW8mi"&gt;Debt
Modifications and Extinguishments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;When the Company modifies
or extinguishes debt, it does so in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC)
Topic 470-50, &lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Debt&#x2014; Modifications and Extinguishments,&lt;/i&gt;&lt;/span&gt; which
requires modification to debt instruments to be evaluated to assess whether the modifications are considered &#x201c;substantial modifications.&#x201d;
A substantial modification of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis
performed, if the Company believes the embedded conversion feature has no fair value on the date of issuance (measurement date) and the
embedded conversion feature has no beneficial conversion feature, the embedded conversion feature does not meet the criteria in ASC 470-50-40-10
or 470-20-25 and the issuance of the convertible note payable is considered a modification, and not an extinguishment that would require
the recognition of a gain or loss. If the Company determines the change in terms meet the criteria for substantial modification under
ASC 470 it will treat the modification as extinguishment and recognize a loss from debt extinguishment.&lt;/span&gt;&lt;/p&gt;

</modd:DebtModificationsAndExtinguishmentsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zZW1vseIs6U1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zvU0gedkoKIf"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Effective&#160;April&#160;1, 2019,
the Company adopted ASC No. 842,&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Leases&#160;&lt;/i&gt;&lt;/span&gt;(ASC 842). ASC
842 requires an entity to recognize a&#160;right-of-use&#160;asset and a lease liability for all leases with terms longer than 12 months.
The Company adopted ASC 842 utilizing the modified retrospective transition method. The Company elected the practical expedient afforded
in ASC 842 in which the Company did not reassess whether any contracts that existed prior to adoption have or contain leases or the classification
of its existing leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_znFDT9AfXlJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zOo0oLCtxyjh"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company recognizes
stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the requisite service
period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock options on the date
of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards on the date of grant using
an option-pricing model is affected by the option price, as well as assumptions regarding a number of highly complex and subjective variables.
These variables include, but are not limited to, the expected stock price&#160;volatility over the term of the awards, and projected
stock option exercise behaviors.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zBWbC6sUp8wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zDSzZkLxl919"&gt;Per-Share
Amounts&lt;/span&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Basic net loss per
share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding during the period.
Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive
common shares consist of incremental shares of common stock issuable upon the exercise of stock options and exercise of warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zi6ge9YgSP21" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive: &#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_zH619xBoQBl2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49E_20220331_z5uGeYjdGb5g" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_495_20210331_zgovGgjVcjK6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_zczFTBzbQV3c" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;1,650,705&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_zj3b2oY6U1Fd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,779,072&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0469"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20220331_zvecWQIznBTi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,429,777&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_zaRsOzR3gPNj" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zhn1aY3xhyMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zi6ge9YgSP21" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The
following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion
would be anti-dilutive: &#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <modd:TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract_zH619xBoQBl2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49E_20220331_z5uGeYjdGb5g" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_495_20210331_zgovGgjVcjK6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_zczFTBzbQV3c" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;1,650,705&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_zj3b2oY6U1Fd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,779,072&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0469"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20220331_zvecWQIznBTi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,429,777&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_zaRsOzR3gPNj" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</modd:TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">1650705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">1197252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">4779072</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">6429777</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">1197252</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zpNroTjz06ie" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_862_zm3mQRzHAlL1"&gt;Reclassification&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect
on the reported results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zrhjoDfokqXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zzuDKj6X6Ldg"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company determines
deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company&#x2019;s assets
and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation
allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets
will not be realized. Based on the available information and other factors, management believes it is more likely than not that its federal
and state net deferred tax assets will not be fully realized, and the Company has recorded a full valuation allowance.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company accounts
for uncertain tax positions in accordance with FASB ASC Topic 740,&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/span&gt;. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would
be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period during which,
based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination,
including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.
Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more
than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated
with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits
in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing
authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are
classified in general and administrative expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company files U.S.
federal and state income tax returns in jurisdictions with varying statutes of limitations.&#160;&#160;All tax returns from 2016 to 2021
may be subject to examination by the U.S. federal and state tax authorities.&#160; As of March 31, 2022 and 2021, the Company had not
recorded any liability for unrecognized tax benefits related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zmRNsprJq3ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zk5hp2qYq0Ue"&gt;Comprehensive&#160;Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Comprehensive loss
represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive
loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2022 and 2021, the Company&#x2019;s
comprehensive loss was the same as its net loss.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z64GYbkpeqQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;span id="xdx_86F_zImLuBeHUQvc"&gt;Recently
Issued Accounting Pronouncement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13,&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Financial
Instruments&#x2014;Credit Losses&lt;/i&gt;&lt;span style="background-color: white"&gt;. This ASU added a new impairment model (known as the current
expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes
an allowance for its estimate of expected credit losses and applies to most debt instruments, trade receivables, lease receivables, financial
guarantee contracts, and other loan commitments. The CECL model does not have a minimum threshold for recognition of impairment losses
and entities will need to measure expected credit losses on assets that have a low risk of loss. This update is effective for fiscal
years beginning after December 15, 2022, including interim periods within those fiscal years for smaller reporting companies. The Company
is still evaluating the impact of this accounting guidance on its results of operations and financial position.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80F_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_zXMfyGTwGhx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;2
&#x2013; &lt;span id="xdx_82A_zdJfObx04A4i"&gt;CONSOLIDATED BALANCE SHEET DETAIL&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock_zF4TfzlRybll" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureConsolidatedBalanceSheetDetailDetailsAbstract_zRU6V5vlbfXi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_499_20220331_z4zq7k3BvC44" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_497_20210331_zFusOQa6llY4" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;Property and equipment, net:&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zhgQfGDFDPs" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;139,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;139,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z8iLANmUwVub" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;63,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTw6M0iBZQEl" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment and software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherMachineryAndEquipmentMember_ztaCoDaSQzk6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;230,947&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;202,993&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz4h6_zh3xNxmzW1th" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;&lt;span style="display: none"&gt;Property and equipment,&#160;gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;485,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;451,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz4h6_zhRPsukekoji" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"&gt;Less: accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(249,597&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(152,091&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_mtPPAENz4h6_zzcoOCxnSwoi" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none"&gt;Property and equipment,&#160;net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;235,959&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;298,958&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;Accrued expenses:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedWagesAndBonus_iI_maALAOLz5T1_z0JhbMur571f" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Accrued wages and bonus&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;457,891&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;372,563&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AccruedPlacementFees_iI_maALAOLz5T1_zOkWAxDrX7qb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued placement fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0511"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AccruedInterests_iI_maALAOLz5T1_zJ1nXO47gpz7" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0514"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALAOLz5T1_z1yiFJnzCMjf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;67,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,047&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_mtALAOLz5T1_zUcNbV9KXDyg" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;524,891&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;499,948&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_z8ZxQBlNO71" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <modd:DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_89B_ecustom--DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock_zF4TfzlRybll" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</modd:DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock>
    <modd:DisclosureConsolidatedBalanceSheetDetailDetailsAbstract contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--DisclosureConsolidatedBalanceSheetDetailDetailsAbstract_zRU6V5vlbfXi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_499_20220331_z4zq7k3BvC44" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_497_20210331_zFusOQa6llY4" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;Property and equipment, net:&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zhgQfGDFDPs" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;139,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;139,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z8iLANmUwVub" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;63,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTw6M0iBZQEl" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment and software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherMachineryAndEquipmentMember_ztaCoDaSQzk6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;230,947&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;202,993&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz4h6_zh3xNxmzW1th" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;&lt;span style="display: none"&gt;Property and equipment,&#160;gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;485,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;451,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz4h6_zhRPsukekoji" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"&gt;Less: accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(249,597&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(152,091&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iI_mtPPAENz4h6_zzcoOCxnSwoi" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none"&gt;Property and equipment,&#160;net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;235,959&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;298,958&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;Accrued expenses:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedWagesAndBonus_iI_maALAOLz5T1_z0JhbMur571f" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Accrued wages and bonus&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;457,891&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;372,563&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AccruedPlacementFees_iI_maALAOLz5T1_zOkWAxDrX7qb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued placement fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0511"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AccruedInterests_iI_maALAOLz5T1_zJ1nXO47gpz7" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0514"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALAOLz5T1_z1yiFJnzCMjf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;67,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,047&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_mtALAOLz5T1_zUcNbV9KXDyg" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;524,891&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;499,948&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</modd:DisclosureConsolidatedBalanceSheetDetailDetailsAbstract>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-03-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">139197</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-03-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">139197</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-03-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">63298</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-03-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">56476</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-03-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">52114</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-03-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">52383</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-03-31_us-gaap_OtherMachineryAndEquipmentMember"
      decimals="0"
      unitRef="USD">230947</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-03-31_us-gaap_OtherMachineryAndEquipmentMember"
      decimals="0"
      unitRef="USD">202993</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">485556</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">451049</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">249597</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">152091</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">235959</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">298958</us-gaap:PropertyPlantAndEquipmentNet>
    <modd:AccruedWagesAndBonus contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">457891</modd:AccruedWagesAndBonus>
    <modd:AccruedWagesAndBonus contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">372563</modd:AccruedWagesAndBonus>
    <modd:AccruedPlacementFees contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">88800</modd:AccruedPlacementFees>
    <modd:AccruedInterests contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">27538</modd:AccruedInterests>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">67000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">11047</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">524891</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">499948</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80F_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zmHx31Dpbln8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
3 &#x2013;&#160;&lt;span&gt;&lt;span id="xdx_829_zqB3LaWTbQEd"&gt;LEASES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company accounts for the lease for its corporate facility in San Diego, California in accordance with ASC 842. The&#160;&lt;span id="xdx_906_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxH_c20200402_zsO8A3aKgOzf" title="::XDX::P39M"&gt;39-month&lt;/span&gt; lease
term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $12,400&#160;annual rent increases
of approximately&#160;3%.&#160;In addition to the minimum lease payments, the Company is responsible for property taxes, insurance and
certain other operating costs. The right-to-use asset and corresponding liability for the facility lease have been measured at the present
value of the future minimum lease payments. A discount rate of 11%, which approximated the Company&#x2019;s incremental borrowing rate,
was used to measure the lease asset and liability. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company obtained a right-of-use asset of $&lt;span id="xdx_906_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210401__20220331_zuy8Mlso2Hzh"&gt;270,950&lt;/span&gt;&#160;in exchange for its obligations under the operating lease. The landlord also provided
a lease incentive of approximately $&lt;span id="xdx_904_ecustom--LeaseIncentiveReceived_iI_c20200630_zz6lwak7y1Je"&gt;139,000&lt;/span&gt;, which was paid to the Company in June 2020, for the Company to make improvements to the
leased space. In addition, the Company paid a $100,000 security deposit.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zjd3UPUssYT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span id="xdx_8B3_zPODvyMmIpik"&gt;Future
minimum payments under the facility operating lease&lt;/span&gt;, as of March 31, 2022, are listed in the table below.&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureLeasesDetailsAbstract_zEfGkyRYw1Y1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Annual Fiscal Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220331_zKyWa3i8HGR3" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Operating&lt;br/&gt; lease&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_maOLFMPz3Dp_zJgm0y6XYiIf" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 87%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;158,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_maOLFMPz3Dp_zn4AfYlqTTgi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,692&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;Less:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--OperatingLeasesImputedInterest_iI_maOLFMPz3Dp_zUwbalcxHbP2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"&gt;Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(13,906&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_mtOLFMPz3Dp_zpDxDQUAJu15" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;184,814&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zetWfTG4eLw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Cash
paid for amounts included in the measurement of lease liabilities was $&lt;span id="xdx_903_ecustom--CashPaidforLeaseLiabilities_iI_c20220331_zdmyIRf8Z9r7"&gt;153,432&lt;/span&gt;&#160;for the year ended March 31, 2022. Rent expense was
$&lt;span id="xdx_90D_eus-gaap--LeaseAndRentalExpense_c20210401__20220331_zZZ4yLuV0FP4"&gt;107,820&lt;/span&gt;&#160;and $&lt;span id="xdx_90A_eus-gaap--LeaseAndRentalExpense_c20200401__20210331_zuMwVUTJfLy7"&gt;107,540&lt;/span&gt;&#160;for the years ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">270950</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <modd:LeaseIncentiveReceived contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">139000</modd:LeaseIncentiveReceived>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zjd3UPUssYT4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;span id="xdx_8B3_zPODvyMmIpik"&gt;Future
minimum payments under the facility operating lease&lt;/span&gt;, as of March 31, 2022, are listed in the table below.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <modd:DisclosureLeasesDetailsAbstract contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureLeasesDetailsAbstract_zEfGkyRYw1Y1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Annual Fiscal Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220331_zKyWa3i8HGR3" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Operating&lt;br/&gt; lease&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_maOLFMPz3Dp_zJgm0y6XYiIf" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 87%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;158,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_maOLFMPz3Dp_zn4AfYlqTTgi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,692&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;Less:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--OperatingLeasesImputedInterest_iI_maOLFMPz3Dp_zUwbalcxHbP2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"&gt;Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(13,906&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_mtOLFMPz3Dp_zpDxDQUAJu15" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;184,814&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</modd:DisclosureLeasesDetailsAbstract>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">158028</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">40692</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <modd:OperatingLeasesImputedInterest contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-13906</modd:OperatingLeasesImputedInterest>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">184814</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <modd:CashPaidforLeaseLiabilities contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">153432</modd:CashPaidforLeaseLiabilities>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">107820</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">107540</us-gaap:LeaseAndRentalExpense>
    <modd:PPPNotesPayableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_802_ecustom--PPPNotesPayableTextBlock_zwLyzNrqwDae" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2013; &lt;span id="xdx_82F_zGsdHjLIWy79"&gt;PPP NOTE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In April 2020, the
Company received a $&lt;span id="xdx_902_eus-gaap--UnsecuredDebtCurrent_iI_c20200424_zlKQ23LIqb54"&gt;368,780&lt;/span&gt; unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was established under
the U.S. government&#x2019;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note to the Company was made
through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration Paycheck Protection Program
Note with the Lender evidencing the PPP Note. &lt;span style="font-family: Times New Roman, Times, Serif; background-color: white"&gt;The full
amount of the PPP Note was due in April 2022 and interest accrued on the outstanding principal balance of the PPP Note at a fixed rate
of 1.0% per annum, which was deferred for 10 months after the covered period during which the Company used the proceeds.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
May 2021, the Lender and the U.S. Small Business Administration notified the Company that the outstanding principal and accrued interest
for the PPP Note was forgiven in full. The Company accounted for the forgiveness of the PPP Note in accordance with ASC Topic 470: &lt;i&gt;Debt
&lt;/i&gt;(ASC 470), and the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the consolidated
statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
</modd:PPPNotesPayableTextBlock>
    <us-gaap:UnsecuredDebtCurrent contextRef="AsOf2020-04-24" decimals="0" unitRef="USD">368780</us-gaap:UnsecuredDebtCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_z8WfRWXbDZbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
5 &#x2013;&#160;&lt;span id="xdx_82B_zVcXpCpmCKS8"&gt;CONVERTIBLE PROMISSORY NOTES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;From
February through April 2021, the Company sold $2,310,000 of convertible promissory notes (each an Original Note and, collectively, the
Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements under
the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between each holder
of an Original Note and the Company (the Revocation Agreement), the $2,310,000 of Original Notes and accrued interest thereon as of April
30, 2021 were replaced with $2,360,550 aggregate principal amount of new Notes (as defined below). The Company accounted for the replacement
of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $&lt;span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20210401__20220331_zcYCamrqWUTl"&gt;1,321,450&lt;/span&gt; and interest expense of $&lt;span id="xdx_90D_eus-gaap--AmortizationOfFinancingCosts_c20210401__20220331_zQUOtbO3j6Kj"&gt;70,647&lt;/span&gt;
for unamortized debt issuance costs as of April 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
April and May 2021, pursuant to a securities purchase agreement by and between the Company and each investor (the SPA), the Company sold
to investors $&lt;span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20210531__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z2v5iu1F4zA7"&gt;4,250,000&lt;/span&gt;&#160;aggregate principal amount of convertible promissory notes (the Notes) and warrants to purchase shares of
its common stock (the Warrants). The Notes are unsecured obligations of the Company with each Note having a stated maturity date of 12
months from its issue date (the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity, provided that,
if the Company fails to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the maximum amount
permitted by law. Each Note may be prepaid at the Company&#x2019;s option during the first 270 calendar days following its Issue Date
(the 270&lt;sup&gt;th&lt;/sup&gt;&#160;day, the Trigger Date), subject to a 110% prepayment penalty on outstanding principal and accrued interest
then outstanding. No Note may be prepaid in whole or in part after the Trigger Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Notes
outstanding after the Trigger Date may be converted into shares of the Company&#x2019;s common stock at an initial conversion price of
$8.61 per share; provided that a Note holder may not convert any portion of its Note that would cause it to beneficially own in excess
of 4.99% of the Company&#x2019;s outstanding common stock. The conversion price and number of shares of Company common stock issuable
upon conversion of the Notes are subject to adjustment from time to time for subdivisions and consolidations of shares and other standard
dilutive and corporate events, as provided in the Notes. Subject to certain Exempt Issuances (as defined in the Notes), if while a Note
is outstanding, the Company sells, issues or grants any shares of its common stock or other securities to acquire shares of common stock
at a price per share less than the then conversion price, such conversion price shall be reduced to such lesser price, and the number
of conversion shares issuable upon conversion of the Notes shall be increased, as provided in the Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;If
the Company completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital
Raise, as defined in the Notes), each Note holder will be required to convert its Adjusted Note Amount (as defined below) into the securities
of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued interest
on a Note, multiplied by (ii) 1.25.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Notes contained a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal
or interest thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements
under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v) material
restatements of the Company&#x2019;s consolidated financial statements filed with the SEC, (vi) a holder&#x2019;s inability to rely on
Rule 144 for sales of shares underlying the Notes, (vii) the Company&#x2019;s common stock is suspended or halted from trading and/or
fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New York Stock Exchange, or
the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement covering the resale of shares
of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date, (ix) failure to cause such registration
statement to become effective within 120 calendar days following the Issue Date, or (x) certain mergers consolidations, business combinations
and sales of all or substantially all of the Company&#x2019;s assets in the event the Company is not the survivor of such transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Upon
an Event of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required
to pay such Note holder the sum of (i) the product of (a) all then outstanding principal amount and accrued interest thereon, multiplied
by (b) 125%; and (ii) all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder,
in the event the Company receives cash proceeds as a result of certain events, including, but not limited to, payments from customers,
issuances of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay
all or any lesser outstanding amounts due under such holder&#x2019;s Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Notes include covenants, representations, warranties, other payment obligations and agreements by the Company including, without limitation,
most-favored nation rights, rights of participation and first refusal and exchange rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
connection with the issuance of the Notes, the Company issued Warrants to purchase in the aggregate 767,796 shares of its common stock
at an initial exercise price of $24.00 per share. The Warrants may be exercised for a period of five years from the Trigger Date, provided
that, if prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall be cancelled
or (ii) prepays a holder&#x2019;s Note(s) in whole or in part, such holder&#x2019;s pro-rata number of Warrants shall be cancelled. The
fair value of the Warrants was $3,700,632, of which $2,379,182 was recorded as a debt discount, which is being amortized to interest
expense over the term of the Warrants, and $1,321,450 was recorded as a loss on debt extinguishment. The Company calculated the fair
value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions: volatility of&#160;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_c20210401__20220331_zvrFaqBfupHe"&gt;88.98%&lt;/span&gt;, risk-free
interest rate of&#160;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20220331_zkcBlEDetFLf"&gt;0.86%&lt;/span&gt;, a term of&#160;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20220331_zvgVggjNhFKi" title="::XDX::P5Y9M"&gt;5.75&lt;/span&gt;&#160;years and a dividend yield of&#160;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dcpxH_c20210401__20220331_zhdUmAMSitU" title="::XDX::0"&gt;zero&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
connection with the April and May 2021 sales of the $4,250,000 aggregate principal amount of the Notes, the Company incurred debt issuance
costs of $116,000, which were recorded as a debt discount and were amortized to interest expense over the term of the Notes using the
effective interest rate method. The interest expense attributable to the debt discount, comprising the debt issuance costs and Warrants,
during the year ended March 31, 2022 was $1,833,618.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Upon
the closing of the Offering (see Note 7), which was a Qualified Capital Raise, in accordance with their terms, the Notes converted into
1,511,276 shares of common stock and the holders of the Notes received 1,511,276 Offering Warrants (as defined in Note 7). &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;As
a result of the Offering, the exercise price of the 767,796 outstanding Warrants was reduced to $6.00 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-1321450</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">70647</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2021-05-31_us-gaap_ConvertibleNotesPayableMember"
      decimals="0"
      unitRef="USD">4250000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0.8898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0.0086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <modd:PromissoryNoteTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80E_ecustom--PromissoryNoteTextBlock_z2u9bXbvv04k" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
6 &#x2013;&#160;&lt;span id="xdx_82F_zDckORpOa8We"&gt;PROMISSORY NOTE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
October 2021, the Company issued a secured promissory note (the Bridge Note) to Manchester Explorer, L.P. (Manchester) that provided
the Company with a $&lt;span id="xdx_90E_eus-gaap--LineOfCredit_iI_c20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zCFnQVE0RhFh"&gt;3,000,000&lt;/span&gt;&#160;revolving credit facility with all amounts being drawn down by the Company thereunder being due and
payable, subject to acceleration in the event of a default, on&#160;&lt;span id="xdx_90A_eus-gaap--LineOfCreditFacilityExpirationDate1_c20211027__20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zx4aXHUKrJBk"&gt;March 15, 2022&lt;/span&gt;&#160;(the Maturity Date). Interest at the rate of&#160;&lt;span id="xdx_90E_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_c20211027__20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zzQUYBlJthaa"&gt;12%&lt;/span&gt;&#160;was
payable on each drawn down without regard to the draw down date or the date when interest is paid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
principal amount of the Bridge Note and interest due thereon is payable to Manchester no later than the earlier of: (i) the Maturity
Date and (ii) the date on which the Company has received proceeds in excess of $12,000,000 from a transaction or series of related transactions
occurring prior to the Maturity Date, which such transactions constitute equity financings or other issuances of the Company&#x2019;s
equity securities. Provided that no Event of Default (as such term is defined in the Bridge Note) has occurred, on any date prior to
the Maturity Date, upon no less than three days written notice by the Company specifying the draw amount, Manchester will advance the
draw amount to the Company. No draw amount can be in an amount less than $100,000 or exceed an amount equal to $3,000,000 minus the aggregate
principal amount outstanding under the Bridge Note at the time of such draw request. If an Event of Default occurs and is continuing,
Manchester may declare all of the Bridge Note, including any interest and other amounts due, to be due and payable immediately.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
connection with the issuance of the Note, on October 28, 2021, the Company entered into a security agreement with Manchester (the Security
Agreement) under which the Company granted Manchester a continuing and unconditional first priority security interest in and to any and
all of the Company&#x2019;s property of any kind or description, tangible or intangible, wheresoever located and whether now existing
or hereafter arising or acquired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;During
fiscal 2022, the Company made draws on the Bridge Note of $&lt;span id="xdx_90A_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_c20220101__20220331__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zoGTIywCOln1"&gt;2,100,000&lt;/span&gt;&#160;and incurred interest charges of $&lt;span id="xdx_908_eus-gaap--LineOfCreditFacilityIncreaseAccruedInterest_c20220101__20220331__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z2aYPdruvJt9"&gt;252,000&lt;/span&gt;. In February 2022,
subsequent to the completion of the Offering (see Note 7), the Bridge Note and accrued interest was paid in full, and the Security Agreement
was terminated.&lt;/span&gt;&lt;/p&gt;
</modd:PromissoryNoteTextBlock>
    <us-gaap:LineOfCredit
      contextRef="AsOf2021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember"
      decimals="0"
      unitRef="USD">3000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityExpirationDate1 contextRef="From2021-10-272021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember">2022-03-15</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="From2021-10-272021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember"
      decimals="INF"
      unitRef="Pure">0.12</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet
      contextRef="From2022-01-012022-03-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">2100000</us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet>
    <us-gaap:LineOfCreditFacilityIncreaseAccruedInterest
      contextRef="From2022-01-012022-03-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">252000</us-gaap:LineOfCreditFacilityIncreaseAccruedInterest>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zbpO896vtM7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
7 &#x2013;&#160;&lt;span id="xdx_82C_zkLTR6nQIPoj"&gt;STOCKHOLDERS&#x2019; EQUITY (DEFICIT)&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;Public
Offering&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
February 9, 2022, the Company entered into an underwriting agreement (the Underwriting Agreement) with Oppenheimer &amp;amp; Co. Inc., who
acted as the representative of the several underwriters (the Underwriters), in a firm commitment underwritten public
offering (the Offering) pursuant to which, on February 14, 2022, the Company sold to the Underwriters an aggregate of 2,500,000 shares
of the Company&#x2019;s common stock and 2,500,000 warrants (the Offering Warrants and, collectively with the shares of common stock,
the Units), each to purchase one share of common stock. The price to the public in the Offering was $6.00 per Unit, before underwriting
discounts and commissions. The common stock and the Offering Warrants comprising the Units were immediately separable upon issuance and
were issued separately. The Offering Warrants were exercisable immediately, have an exercise price of $6.60 per share and expire on February
14, 2027. &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;The gross proceeds from the Offering were $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220209__20220210__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvyyeihuZKHi"&gt;15,000,000&lt;/span&gt;, before deducting underwriting discounts
and commissions and other offering expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Placements
of Common Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Between March and December
2020, the Company completed a private placement of shares of its common stock (the 2020 Placement). The Company sold 962,387 shares of
common stock, at a purchase price of $2.87 per share, for gross proceeds of $2,762,054. The Company paid placement agent fees on the
2020 Placement of $52,256 during fiscal 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
October 2021, the Company sold &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20220331_zyY1Sh2OYWl2"&gt;30,864&lt;/span&gt; shares of common stock to two officers, its i) chief executive officer and ii) the chairman of
the Company&#x2019;s board of directors (the Board), president, chief financial officer and treasurer, &lt;/span&gt;&lt;span style="font-size: 10pt"&gt;at
a purchase price of $8.10 per share, for gross proceeds of approximately $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210401__20220331_zbyGWlJw4h8f"&gt;250,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;During
the year ended March 31, 2022, the Company issued to service providers &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210401__20220331_z7MrwBD4GZif"&gt;90,000&lt;/span&gt; shares of common stock with a fair value of approximately $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210401__20220331_zaBE538NoP95"&gt;594,400&lt;/span&gt;. &lt;/span&gt;&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-02-092022-02-10_us-gaap_IPOMember"
      decimals="0"
      unitRef="USD">15000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">30864</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">90000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">594400</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_806_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zwvR1qvHLnKb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;NOTE
8 &#x2013;&#160;&lt;span id="xdx_82C_zmJiVGcYVxdd"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;Amended
2017 Equity Incentive Plan&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;In
October 2017, the Company&#x2019;s Board approved the 2017 Equity Incentive Plan (the Plan) with&#160;&lt;span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20171031_zm7ZzP5HTBpj"&gt;1,000,000&lt;/span&gt;&#160;shares of common
stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved for issuance
under the Plan by&#160;&lt;span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200131_zihjPVa9F3lh"&gt;333,334&lt;/span&gt;&#160;and&#160;&lt;span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200831_zAoUN3pBCbX2"&gt;1,333,334&lt;/span&gt;&#160;shares, respectively. Under the Plan, eligible employees, directors and consultants
may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards
and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the Board.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock-Based
Compensation Expense&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The expense relating
to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant
date fair value. The unamortized compensation cost, as of March 31, 2022 was $&lt;span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20220331_zT5d8NaRj2Ua"&gt;3,286,370&lt;/span&gt; related to stock options and is expected to be
recognized as expense over a weighted-average period of approximately &lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxH_c20210401__20220331_zGbmL7WHQRu7" title="::XDX::P2Y"&gt;two years&lt;/span&gt;.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;During the year
ended March 31, 2022, the Company granted options to purchase &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zZmUpYOdOdo6"&gt;827,427&lt;/span&gt; shares of its common stock to employees, directors and consultants.
The options had 10-year terms and &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zDUMfkbZk2n8"&gt;137,292&lt;/span&gt; options vested immediately when granted. The grant-date fair value was determined to be $&lt;span id="xdx_90F_ecustom--FairValueofOptionGranted_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zuP6k2wHq4q7"&gt;8,507,311&lt;/span&gt;
of which $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOlhQLFgzWQ2"&gt;2,739,490&lt;/span&gt; was recorded as stock-based compensation expense and included in the consolidated statements of operations for the
year ended March 31, 2022.&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"/&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zROmdypsGl47" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;The following assumptions were used in the
fair-value method calculations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BC_zoHpYNToBpPe" style="display: none"&gt;Schedule of Fair Value Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureStockBasedCompensationDetailsAbstract_z9XHVjaV0oh4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year
    Ended&lt;br/&gt; March 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="white-space: nowrap; width: 74%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Risk-free interest rates&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_zBER1rIvYGaa"&gt;0.8%&lt;/span&gt;&#160;-&#160;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_zFywCR536aeh"&gt;2.42%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zbmJFTQM1Rjd"&gt;0.28%&lt;/span&gt;
                                            - &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zQ3CtwjxJLh2"&gt;0.71%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_z9JNunmYOGRc"&gt;89%&lt;/span&gt;&#160;-&#160;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_z1lvZBdoBnpg"&gt;370%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z9R3QblRW8l3"&gt;87%&lt;/span&gt;&#160;-&#160;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zi56RSdNQjjl"&gt;127%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_z1dk0fEmLUBk" title="::XDX::P5Y"&gt;5.0&lt;/span&gt;&#160;-&#160;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_z2xQrlUIAvzb" title="::XDX::P6Y2M12D"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zDWRWGadWDW6" title="::XDX::P5Y"&gt;5.0&lt;/span&gt;&#160;-&#160;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z7rTiSgV3EG4" title="::XDX::P6Y"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20210401__20220331_zA0sD2YLEeqj"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331_zxUElb8g3KA1"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A0_zuoUO200IQz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The fair values of
options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to establish
the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate was derived from
the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date for terms equal to the
expected terms of the options. A dividend yield of zero was applied because the Company has never paid dividends and has no intention
to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zRu6BcKE8fBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;A summary of stock option activity under
the 2017 Plan is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BF_zMfIkSaPKpo3" style="display: none"&gt;Schedule of Stock Option activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zyA2icRZIRid" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Available&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;for Grant&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 61%"&gt;Balance at March 31, 2020&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zN07dgH8qnc" style="width: 8%; text-align: right"&gt;274,019&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zh6taN8bcdI5" style="width: 8%; text-align: right"&gt;1,059,315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zStOdBzaNOTl" style="width: 8%; text-align: right"&gt;4.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zj1FMd9UL4Z6" style="text-align: right"&gt;(163,492&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zilPlEWvwY4a" style="text-align: right"&gt;163,492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zugRVMRUlLq" style="text-align: right"&gt;8.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEaifwfdaMf3" style="border-bottom: Black 1pt solid; text-align: right"&gt;25,555&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgZa1obxL5Ab" style="border-bottom: Black 1pt solid; text-align: right"&gt;(25,555&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmXrsPDd3A56" style="border-bottom: Black 1pt solid; text-align: right"&gt;6.75&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at March 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9DbbhhUZSPb" style="text-align: right"&gt;136,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zznrrwwjWBpc" style="text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zppeuIunqCx8" style="text-align: right"&gt;5.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Additional shares authorized under the Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8ZnEI11tJT9" style="text-align: right"&gt;1,333,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT1z72Cazb36" style="text-align: right"&gt;(827,427&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdt5hAYptlh9" style="text-align: right"&gt;827,427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1xTpXcxfi9g" style="text-align: right"&gt;10.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFNMAhir2QMi" style="text-align: right"&gt;(26,497&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkt1VGnVC8uc" style="border-bottom: Black 1pt solid; text-align: right"&gt;373,974&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1GS5esT6EK4" style="border-bottom: Black 1pt solid; text-align: right"&gt;(373,974&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zycqAr4T4nz4" style="border-bottom: Black 1pt solid; text-align: right"&gt;10.73&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7uZY99nQfX" style="border-bottom: Black 2.5pt double; text-align: right"&gt;989,466&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPUkXXw3Bfj6" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,650,705&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLM2ww6i68j7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;6.58&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zihANFXSOMBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;There were no
stock options exercised during the years ended March 31, 2022 and 2021. &lt;span style="font-family: Times New Roman, Times, Serif; background-color: white"&gt;The
Company issued 26,497 shares to its non-employee directors under the Company&#x2019;s outside director compensation plan and approximately
$172,100 was recorded as stock-based compensation expense for these share awards during the year ended March 31, 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z03c6lvyxSt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The following
table summarizes the range of outstanding and exercisable options as of March 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B0_zjWp49Tt5yt7" style="display: none"&gt;Schedule of
Outstanding and Exercisable Option, Range&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zoodrM9W77v9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"&gt;Range of Exercise Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;br/&gt; Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; (in Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;br/&gt; Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt"&gt;$&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z4Zx8uZq6t04"&gt;1.98&lt;/span&gt; - $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zScc5IPzvlq8"&gt;17.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztv9LizGFHuk" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;1,650,705&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmFalTPkxkqd" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P8Y4D"&gt;8.01&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx2rQfGQCbbf" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;6.58&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIbn9Ff9oPKe" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;1,193,680&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDIs0MZ8bVVa" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;5.69&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWcFYBds9FM9" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;1,090,966&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zv2bwlGHVr26" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"&gt;&lt;span style="font-size: 10pt"&gt;The intrinsic value per share is calculated
as the excess of the closing price of the common stock on the Company&#x2019;s principal trading market over the exercise price of the
option at March 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company is required
to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise of stock options
as financing cash flows in the consolidated statements of cash flows. For the years ended March 31, 2022 and 2021, there were no such
tax benefits associated with the exercise of stock options.&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2017-10-31" decimals="INF" unitRef="Shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2020-01-31" decimals="INF" unitRef="Shares">333334</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2020-08-31" decimals="INF" unitRef="Shares">1333334</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">3286370</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-04-012022-03-31_us-gaap_CommonStockMember_us-gaap_EmployeeStockMember"
      decimals="INF"
      unitRef="Shares">827427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember_us-gaap_EmployeeStockMember"
      decimals="INF"
      unitRef="Shares">137292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <modd:FairValueofOptionGranted
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">8507311</modd:FairValueofOptionGranted>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">2739490</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zROmdypsGl47" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;The following assumptions were used in the
fair-value method calculations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BC_zoHpYNToBpPe" style="display: none"&gt;Schedule of Fair Value Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <modd:DisclosureStockBasedCompensationDetailsAbstract contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureStockBasedCompensationDetailsAbstract_z9XHVjaV0oh4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year
    Ended&lt;br/&gt; March 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="white-space: nowrap; width: 74%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Risk-free interest rates&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_zBER1rIvYGaa"&gt;0.8%&lt;/span&gt;&#160;-&#160;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_zFywCR536aeh"&gt;2.42%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zbmJFTQM1Rjd"&gt;0.28%&lt;/span&gt;
                                            - &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zQ3CtwjxJLh2"&gt;0.71%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_z9JNunmYOGRc"&gt;89%&lt;/span&gt;&#160;-&#160;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_z1lvZBdoBnpg"&gt;370%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z9R3QblRW8l3"&gt;87%&lt;/span&gt;&#160;-&#160;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zi56RSdNQjjl"&gt;127%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20220331__srt--RangeAxis__srt--MinimumMember_z1dk0fEmLUBk" title="::XDX::P5Y"&gt;5.0&lt;/span&gt;&#160;-&#160;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20220331__srt--RangeAxis__srt--MaximumMember_z2xQrlUIAvzb" title="::XDX::P6Y2M12D"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zDWRWGadWDW6" title="::XDX::P5Y"&gt;5.0&lt;/span&gt;&#160;-&#160;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z7rTiSgV3EG4" title="::XDX::P6Y"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20210401__20220331_zA0sD2YLEeqj"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331_zxUElb8g3KA1"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</modd:DisclosureStockBasedCompensationDetailsAbstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-04-012022-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-04-012022-03-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-04-012021-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-04-012021-03-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-04-012022-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-04-012022-03-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">3.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-04-012021-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-04-012021-03-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">1.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zRu6BcKE8fBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;A summary of stock option activity under
the 2017 Plan is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BF_zMfIkSaPKpo3" style="display: none"&gt;Schedule of Stock Option activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <modd:DisclosureStockBasedCompensationDetails2Abstract contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zyA2icRZIRid" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Available&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;for Grant&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 61%"&gt;Balance at March 31, 2020&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zN07dgH8qnc" style="width: 8%; text-align: right"&gt;274,019&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zh6taN8bcdI5" style="width: 8%; text-align: right"&gt;1,059,315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zStOdBzaNOTl" style="width: 8%; text-align: right"&gt;4.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zj1FMd9UL4Z6" style="text-align: right"&gt;(163,492&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zilPlEWvwY4a" style="text-align: right"&gt;163,492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zugRVMRUlLq" style="text-align: right"&gt;8.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zEaifwfdaMf3" style="border-bottom: Black 1pt solid; text-align: right"&gt;25,555&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgZa1obxL5Ab" style="border-bottom: Black 1pt solid; text-align: right"&gt;(25,555&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmXrsPDd3A56" style="border-bottom: Black 1pt solid; text-align: right"&gt;6.75&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at March 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9DbbhhUZSPb" style="text-align: right"&gt;136,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zznrrwwjWBpc" style="text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zppeuIunqCx8" style="text-align: right"&gt;5.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Additional shares authorized under the Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8ZnEI11tJT9" style="text-align: right"&gt;1,333,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT1z72Cazb36" style="text-align: right"&gt;(827,427&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdt5hAYptlh9" style="text-align: right"&gt;827,427&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1xTpXcxfi9g" style="text-align: right"&gt;10.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFNMAhir2QMi" style="text-align: right"&gt;(26,497&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zkt1VGnVC8uc" style="border-bottom: Black 1pt solid; text-align: right"&gt;373,974&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1GS5esT6EK4" style="border-bottom: Black 1pt solid; text-align: right"&gt;(373,974&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zycqAr4T4nz4" style="border-bottom: Black 1pt solid; text-align: right"&gt;10.73&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7uZY99nQfX" style="border-bottom: Black 2.5pt double; text-align: right"&gt;989,466&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPUkXXw3Bfj6" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,650,705&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLM2ww6i68j7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;6.58&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</modd:DisclosureStockBasedCompensationDetails2Abstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2020-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">274019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1059315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">-163492</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">163492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">8.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">25555</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">25555</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">136082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1197252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1333334</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">-827427</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">827427</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">10.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">-26497</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">373974</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">373974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-04-012022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">10.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">989466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1650705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z03c6lvyxSt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The following
table summarizes the range of outstanding and exercisable options as of March 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B0_zjWp49Tt5yt7" style="display: none"&gt;Schedule of
Outstanding and Exercisable Option, Range&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <modd:DisclosureStockBasedCompensationDetails3Abstract contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zoodrM9W77v9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"&gt;Range of Exercise Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;br/&gt; Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; (in Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;br/&gt; Exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt"&gt;$&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z4Zx8uZq6t04"&gt;1.98&lt;/span&gt; - $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zScc5IPzvlq8"&gt;17.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztv9LizGFHuk" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;1,650,705&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmFalTPkxkqd" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P8Y4D"&gt;8.01&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx2rQfGQCbbf" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;6.58&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIbn9Ff9oPKe" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;1,193,680&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDIs0MZ8bVVa" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;5.69&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWcFYBds9FM9" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;1,090,966&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</modd:DisclosureStockBasedCompensationDetails3Abstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">1.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">17.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1650705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1193680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2022-03-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">1090966</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zHCNuOA94Mk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2013; &lt;span id="xdx_82D_zjD666zGVw2a"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zRZ0GUtDckI2" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"&gt;&lt;span style="font-size: 10pt"&gt;The income tax provision consisted
of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8B3_zx4q6vQzEHP1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify; text-indent: 0.5in"&gt;Schedule of Income tax provision&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIncomeTaxesDetailsAbstract_z5Xj5wj9Bbij" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_493_20210401__20220331_zkeOSngFHGFa" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49B_20200401__20210331_zNeHwM9IewFk" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zpkYxgiMElck" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Current portion:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzDQj_z0U1H3VTbeI5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzDQj_zxQgTEmomJSl" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; padding-bottom: 1pt; padding-left: 8.65pt"&gt;State&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_mtCITEBzDQj_maITEBzk6Q_zcVJ8Pf0pTul" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zxGfMZeH6dz1" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Deferred portion:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzmjI_zDdlTYP27n14" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,109,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,931,390&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzmjI_zEPPocySasGa" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 8.65pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,300,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(576,868&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBzmjI_maITEBzk6Q_zYB27mhgKC4h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;( 5,409,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,508,258&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzk6Q_zt00bAZA7CQd" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,409,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,508,258&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzk6Q_z2UYVmXh0Qif" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zXBbKbdf9xwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;At March&#160;31, 2022,
the Company had net operating loss carryforwards (NOLs) of approximately $&lt;span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zMM0IF9WiNJc"&gt;27,600,000&lt;/span&gt; for federal income tax purposes and $&lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zKmerP3981I3"&gt;27,800,000&lt;/span&gt;
for state income tax purposes. These NOLs are available to reduce future taxable income and will expire at various times from 2037 through
2042, except federal NOLs from fiscal 2018, 2019, 2020, 2021 and 2022, which will never expire.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
also had federal research and development tax credit carryforwards of approximately $&lt;span id="xdx_90C_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z2dZO8XYRaT6"&gt;800,000&lt;/span&gt;, which will begin expiring at various times
from 2038 through 2041, and state research and development credits of approximately $&lt;span id="xdx_90F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_c20220331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zXBvfmMV5YP6"&gt;200,000&lt;/span&gt;, which do not have an expiration date.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbmw0zaVahpb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A reconciliation of
income taxes provided at the federal statutory rate (21% for each of fiscal 2022 and 2021) to the actual income tax provision is as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8B4_z7Y3El0yR9Zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify; text-indent: 0.5in"&gt;Schedule of Income Tax Provisions&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIncomeTaxesDetails2Abstract_zCxDEnXAR8J7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_498_20210401__20220331_zkjZav6vPWtf" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49E_20200401__20210331_zEUQkS5ZM2xi" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi0_zPXVMzzIMfY9" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp0_zr2EbQ66OVi1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State tax rate, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_dp0_zzzshdWeW4B7" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_dp0_zJPYg9wSqZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_dp0_z0Ewdr3WpXBg" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Section 179 assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp0_zCezYLuSSlKj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;34&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zyMqlhqEfP6" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zhhXqJeN7zul" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"&gt;&lt;span style="font-size: 10pt"&gt;The losses before income tax provision for the years ended March 31, 2022 and 2021 were solely attributable to US operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z2wHiUpXVpYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Significant components of the Company&#x2019;s
deferred tax assets and liabilities were:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BF_zSFtKJkbhxw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none"&gt;Schedule of Deferred Tax Assets&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--DisclosureIncomeTaxesDetails3Abstract_ztyMFwQhelY3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49B_20220331_zLXdyv8xcKVg" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49C_20210331_zG7GYfOP7f46" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzv9B_zgiUXS5cPAi9" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;7,731,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;3,909,434&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzv9B_zUL8lX4sQ4Wg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,824,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;554,892&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzv9B_zISj5piaI9R3" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,039&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_iNI_di_maDTAGzv9B_znDSjqxtLEHf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reserves, accruals &amp;amp; other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(104,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(79,878&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_msDTAGzv9B_z210jsTZQd4l" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Research and development tax credits&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;988,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;646,296&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzv9B_maDTANzyHM_zDKlltF9ReTl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,519,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,012,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesRegulatoryAssets_iNI_di_maDITLzKZ6_zYnHFMpZWCya" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; text-indent: -8.35pt; padding-left: 8.65pt"&gt;Section 179 assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(97,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0725"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzKZ6_msDTANzyHM_zkSGwJWr1jPh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(97,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0728"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzyHM_zB8LJ6Krveze" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,422,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,012,705&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzyHM_zSRhUBbR1NMl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0733"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0734"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zFEWMznONjc" style="margin-top: 0; margin-bottom: 0"/&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Based on the available
information and other factors, management believes it is more likely than not that the net deferred tax assets at March 31, 2022 and
2021, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred tax assets
at March 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Management has evaluated
and concluded that there were no material uncertain tax positions requiring recognition in the Company&#x2019;s consolidated financial
statements at March 31, 2022 and 2021. The Company does not expect any significant changes in its unrecognized tax benefits within twelve
months of the reporting date.&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zRZ0GUtDckI2" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"&gt;&lt;span style="font-size: 10pt"&gt;The income tax provision consisted
of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8B3_zx4q6vQzEHP1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify; text-indent: 0.5in"&gt;Schedule of Income tax provision&lt;/p&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <modd:DisclosureIncomeTaxesDetailsAbstract contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIncomeTaxesDetailsAbstract_z5Xj5wj9Bbij" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_493_20210401__20220331_zkeOSngFHGFa" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49B_20200401__20210331_zNeHwM9IewFk" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zpkYxgiMElck" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Current portion:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCITEBzDQj_z0U1H3VTbeI5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCITEBzDQj_zxQgTEmomJSl" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; padding-bottom: 1pt; padding-left: 8.65pt"&gt;State&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_mtCITEBzDQj_maITEBzk6Q_zcVJ8Pf0pTul" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zxGfMZeH6dz1" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Deferred portion:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDITEBzmjI_zDdlTYP27n14" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,109,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,931,390&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDITEBzmjI_zEPPocySasGa" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 8.65pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,300,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(576,868&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_mtDITEBzmjI_maITEBzk6Q_zYB27mhgKC4h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;( 5,409,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,508,258&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzk6Q_zt00bAZA7CQd" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,409,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,508,258&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzk6Q_z2UYVmXh0Qif" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</modd:DisclosureIncomeTaxesDetailsAbstract>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-4109000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-1931390</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-1300000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-576868</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">5409000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-2508258</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">5409000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">2508258</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-03-31_us-gaap_DomesticCountryMember"
      decimals="0"
      unitRef="USD">27600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      unitRef="USD">27800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2022-03-31_us-gaap_DomesticCountryMember"
      decimals="0"
      unitRef="USD">800000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2022-03-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      unitRef="USD">200000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zbmw0zaVahpb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A reconciliation of
income taxes provided at the federal statutory rate (21% for each of fiscal 2022 and 2021) to the actual income tax provision is as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8B4_z7Y3El0yR9Zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none; text-align: justify; text-indent: 0.5in"&gt;Schedule of Income Tax Provisions&lt;/p&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <modd:DisclosureIncomeTaxesDetails2Abstract contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureIncomeTaxesDetails2Abstract_zCxDEnXAR8J7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_498_20210401__20220331_zkjZav6vPWtf" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49E_20200401__20210331_zEUQkS5ZM2xi" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi0_zPXVMzzIMfY9" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp0_zr2EbQ66OVi1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State tax rate, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_dp0_zzzshdWeW4B7" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_dp0_zJPYg9wSqZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsOther_dp0_z0Ewdr3WpXBg" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Section 179 assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp0_zCezYLuSSlKj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;34&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_zyMqlhqEfP6" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</modd:DisclosureIncomeTaxesDetails2Abstract>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">-0.07</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">-0.07</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <modd:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0</modd:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <modd:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0</modd:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">-0.06</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0.30</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_z2wHiUpXVpYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Significant components of the Company&#x2019;s
deferred tax assets and liabilities were:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8BF_zSFtKJkbhxw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; display: none"&gt;Schedule of Deferred Tax Assets&lt;/p&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <modd:DisclosureIncomeTaxesDetails3Abstract contextRef="From2021-04-01to2022-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--DisclosureIncomeTaxesDetails3Abstract_ztyMFwQhelY3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49B_20220331_zLXdyv8xcKVg" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49C_20210331_zG7GYfOP7f46" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzv9B_zgiUXS5cPAi9" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;7,731,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;3,909,434&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzv9B_zUL8lX4sQ4Wg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,824,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;554,892&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzv9B_zISj5piaI9R3" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,039&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_iNI_di_maDTAGzv9B_znDSjqxtLEHf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reserves, accruals &amp;amp; other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(104,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(79,878&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_msDTAGzv9B_z210jsTZQd4l" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Research and development tax credits&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;988,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;646,296&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzv9B_maDTANzyHM_zDKlltF9ReTl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,519,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,012,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesRegulatoryAssets_iNI_di_maDITLzKZ6_zYnHFMpZWCya" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; text-indent: -8.35pt; padding-left: 8.65pt"&gt;Section 179 assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(97,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0725"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzKZ6_msDTANzyHM_zkSGwJWr1jPh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(97,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0728"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzyHM_zB8LJ6Krveze" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,422,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,012,705&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzyHM_zSRhUBbR1NMl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0733"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0734"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</modd:DisclosureIncomeTaxesDetails3Abstract>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">7731000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">3909434</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1824000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">554892</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">80000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-18039</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">104000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">79878</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">988000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">646296</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">10519000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">5012705</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesRegulatoryAssets contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">97000</us-gaap:DeferredTaxLiabilitiesRegulatoryAssets>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">97000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">10422000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">5012705</us-gaap:DeferredTaxAssetsValuationAllowance>
    <modd:RoyaltyAgreementDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80B_ecustom--RoyaltyAgreementDisclosureTextBlock_zf11PgarAcmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 &#x2013; &lt;span id="xdx_829_zhjZLtsxknH8"&gt;ROYALTY AGREEMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In July 2017, the Company
entered into a royalty agreement with its founder, then-chief executive officer, president and major shareholder (the Founder). Pursuant
to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras in return for future
royalty payments on the Company&#x2019;s product. The Company is obligated to make royalty payments under the agreement to the Founder
on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each sale of a royalty product
or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will cease, and the agreement will
terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant to the agreement, reaches $10,000,000.
The Company has the option to terminate the agreement at any time upon payment, to the Founder, of the difference between total royalty
payments actually made to him to date and the sum of $10,000,000. All payments of the royalties, if due, for the preceding quarter, will
be made by the Company to the Founder within thirty days after the end of each calendar quarter.&#160;&lt;/span&gt;&lt;/p&gt;

</modd:RoyaltyAgreementDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zLLitPwtFoDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 &#x2013; &lt;span id="xdx_828_z40w8AJWAJ25"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Litigations,
Claims and Assessments&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the normal course
of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The
Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Indemnification&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the ordinary course
of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses
incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from
certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating
to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification
agreements with its officers and directors. No amounts were reflected in the Company&#x2019;s consolidated financial statements for the
years ended March&#160;31, 2022 and 2021 related to these indemnifications. The Company has not estimated the maximum potential amount
of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances
applicable to each particular agreement. To date, the Company has not made any payments related to these indemnification agreements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zT2nsXj2zSZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;12
&#x2013; &lt;span id="xdx_82A_zne9W3WE2EKi"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;In
February 2021, the Company&#x2019;s chairman of the Board and president and Manchester, which is represented by a member of the Company&#x2019;s
board of directors, purchased $100,000 and $1,000,000, aggregate principal amount of the Original Notes, respectively. Effective April
30, 2021, the related party holders entered into revocation agreements with the Company pursuant to which their aggregate principal amount
of Original Notes and accrued interest were replaced with Notes. On February 14, 2022, Manchester and the executive officer held Notes
in an aggregate principal amount of $&lt;span id="xdx_906_eus-gaap--NotesPayable_iI_c20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zghhcM3G4YZ6"&gt;1,026,630&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; background-color: white"&gt;and
$&lt;span id="xdx_902_eus-gaap--NotesPayable_iI_c20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zMdYkkJF0mHh"&gt;102,663&lt;/span&gt;, respectively, with $&lt;span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zhpgQV7iVpyd"&gt;97,881&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zzrFRkXJV053"&gt;9,788&lt;/span&gt; of interest payable thereon. In connection with the Offering, Manchester and
the executive officer received &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziTege4Yrw6i"&gt;234,274&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziffD998r629"&gt;23,429&lt;/span&gt; shares of common stock, respectively, and &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zED644BLlVQ4"&gt;234,274&lt;/span&gt; and &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesOther_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgWrcJIVTM77"&gt;23,429&lt;/span&gt; Offering Warrants, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;In
May 2021, a member of the Board purchased $&lt;span id="xdx_901_eus-gaap--NotesPayable_iI_c20210531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_ztX6t42rW3f"&gt;200,000&lt;/span&gt;&#160;aggregate principal amount of Notes (the Director Note). On February 14, 2022,
in connection with the Offering, the Director Note and $&lt;span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_zGQo3AgyGFq6"&gt;18,805&lt;/span&gt; of accrued interest thereon were converted into &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHbyq67fUuHd"&gt;45,586&lt;/span&gt; shares of common
stock &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20220214__20220214__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhin0K09JOw1"&gt;45,586&lt;/span&gt; Offering Warrants&lt;span style="font-family: Times New Roman, Times, Serif; background-color: white"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The daughter of the
Company&#x2019;s president, chief financial officer, treasurer and chairman of the Board is an employee of the Company. During fiscal
2022, the Company paid her $&lt;span id="xdx_901_eus-gaap--SalariesAndWages_c20210401__20220331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DaughterOfPresidentCFOTreasurerAndChairmanMember_zNX5dbQpjRHl"&gt;169,589&lt;/span&gt;, which includes the aggregate grant date fair value, as determined pursuant to FASB ASC Topic 718,
of a stock option granted in November 2021.&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:NotesPayable
      contextRef="AsOf2022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member"
      decimals="0"
      unitRef="USD">1026630</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member"
      decimals="0"
      unitRef="USD">102663</us-gaap:NotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member"
      decimals="0"
      unitRef="USD">97881</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member"
      decimals="0"
      unitRef="USD">9788</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">234274</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">23429</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">234274</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-02-142022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">23429</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-05-31_custom_MemberOfBoardMember"
      decimals="0"
      unitRef="USD">200000</us-gaap:NotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2022-02-14_custom_MemberOfBoardMember"
      decimals="0"
      unitRef="USD">18805</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-02-142022-02-14_custom_MemberOfBoardMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">45586</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-02-142022-02-14_custom_MemberOfBoardMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">45586</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:SalariesAndWages
      contextRef="From2021-04-012022-03-31_custom_DaughterOfPresidentCFOTreasurerAndChairmanMember"
      decimals="0"
      unitRef="USD">169589</us-gaap:SalariesAndWages>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zQ6K9HhHbPO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13 &#x2013; &lt;span&gt;&lt;span id="xdx_828_zd1eppOUMQz2"&gt;SUBSEQUENT EVENT&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On May 2, 2022, the
Company entered into a securities purchase agreement (the Purchase Agreement) with an institutional investor (the Investor) pursuant
to which the Company sold, in a registered direct offering (the Registered Offering), for gross proceeds of $8,000,000 an aggregate
of 449,438 shares (the Shares) of the Company&#x2019;s common stock, at a purchase price per Share of $4.45 and pre-funded warrants (the
Pre-Funded Warrants) to purchase an aggregate of 1,348,314 shares of common stock at a purchase price per Pre-Funded Warrant of $4.44.
The Pre-Funded Warrants were exercisable immediately on the date of issuance at an exercise price of $0.01 per share and may be exercised
at any time until all of the Pre-Funded Warrants are exercised in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;In
a concurrent private placement under the Purchase Agreement, the Company issued warrants (the Private Placement Warrants) to the Investor
to purchase an aggregate of 1,438,202 shares of common stock at an exercise price of $6.60 per share. The Private Placement Warrants
will be exercisable commencing November 5, 2022 and have a five-year term.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M+@GO+ND"@XK7A!\CQSY"V,)8<T$N7/YG$A\CW*TM'\/E,[I6WVYEY3;0&J<
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M9C0$F%*K;D H0X!S4 C(1B-R56Y:,JYU'7MT;EC<)IY'E8P2\;>"VBT(1J.
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M:9$\7""SYDA(Y*8G1?>$%8"F8#KLLK=-1>D_</[V3V,=XP[&9HG6VSD>BVK
M]VKXWLO@':1"UX7.A*1_(&T#+CVC+90^=I\=Y.-Q#>A^#=T_"_I6J:(=N/\,
M9!?U4$0#,JHAH[,@OQ9::<)3RI=MI-%1TD,1#=)!33HX2#H1>6ZVZ[G5.SBI
M>H]%-<B'-?GP!>0GE>YP7TGN3O,)@0WFRYKY\L7,%P=*]_(91X![43"\'.X
M/P^,NCC$_3V\ ?YWON$SB(_4<>5Y G=+9#NXOW5&VPN2.<^6E"O$8&&4N#,P
M>UB6=XZRH<7*'=MSH<TEP#UFYIX&T@:8]PLA]%/#W@3JFU_\%U!+ P04
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M ?]]5?&==W<CWID__MO&_']02P,$%     @ %G_<5! Q[&>)!P  1"(  !@
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MY^32\7!ZEUGO%E&$;('A'^<-Z;0Z>Q]?47%O/E-H@#E_:M]S]T_[3R$^F \
M)L\_PJM-^T'#8*;]ON(K$8KH&E#2G3(9O$\4.M%^LM#>2'XP;_VW7$I>F<L]
M)045NH'Z?<?5*NUN] #]AR/K_P-02P,$%     @ %G_<5,3G9.5X%P  (CX
M !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6RU6UMOW+B2?M>O(#R+00*T
M.^[.;3*Y (Z3S/A@<CEQ,H.#Q3ZP)78W)VJIAY3<]O[Z_:J*I"A;SADL=E\2
MM\1+L:Y?55$O#JW[YK?&=.IJ5S?^Y=&VZ_8_/WC@RZW9:3]O]Z;!FW7K=KK#
M3[=YX/?.Z(HG[>H'RY.3)P]VVC9'KU[PLT_NU8NV[VK;F$].^7ZWT^[ZM:G;
MP\NCQ5%\\-ENMAT]>/#JQ5YOS(7IONX_.?QZD%:I[,XTWK:-<F;]\NAT\?/K
M1S2>!_QNS<%G?RLZR:IMO]&/\^KET0D19&I3=K2"QG^7YLS4-2T$,OX*:QZE
M+6EB_G=<_1V?'6=9:6_.VOH/6W7;ET<_':G*K'5?=Y_;PZ\FG.<QK5>VM>=_
MU2&,/3E29>^[=A<F@X*=;>1_?17X\'<F+,.$)=,M&S&5;W2G7[UP[4$Y&HW5
MZ \^*L\&<;8AH5QT#F\MYG6OOOSZ5IU]?/_I],._U.F'-^KBZ_OWIY__I3Z^
M4Q?GOWPX?W=^=OKABSH]._OX]<.7\P^_J$\??SL_.W][\>)!A_UIE0=EV.NU
M[+6\8Z_%4KUOFV[KU=NF,M5X@0<@/%&_C-2_7GYWQ??:S=7#Q4PM3Y;+[ZSW
M,''C(:_W\([U/KJ-;NQ_:U*8F3IK&]_6MM*B/TVE/CGC3=/)@W:MWME&-Z75
MM;K 0P-E[;SZS].5[QS4[;^F6"0$/)HF@$SP9[_7I7EYM*>]W*4Y>O7C#XLG
M)\^_<[Q'Z7B/OK?Z_[&PO[O7]$D^M)U1B^+''WY:+A;/U?^>'BA2U=?:J?>F
MLJ6N9^J\*>?%O6YK(+;=7C?7]]5!>V6;LG7[UD$Z%7ZH#^925YK^^EAV[<HX
MM7CV["?50R&=HMF-WAGUVF#IW_0WHSZ;$KY.](&V4%^&'=165ZII88Z=<:0$
MJ]Z#"]X7\)F.)WFU=NT.ZGFRQ!Z=K97>[UU[96E.?8T7BZ?JL#6-LAT\U%^]
M=:!3US5I%Y%CO>_I"90/+M5W^,,V&^6W&DRE0?_LM>^=]D+>3&GUQM3Z@-=%
M/#DIZ[TX[OY<G7I>>J?_;)VLM&UK.G^V'!QN!Y>.K4N8K&N9H%7;;57&8B9K
M((#>\'+*7)5;W6P,B:#09=GB[%@*,41A:8W%+XWS(,&XC7%,D>_+[6RTN#-E
MNX$U8B(]UMX;6!=M65N]LK7M[$T6) Y"OGQ$7A_/NP(_K5-;"X_J2&-4J9V[
M)E[J'9'GY[!N"P*[5K:CI;R-EI[X@OUG"F(N,:13M=&^8_&.:3_P,>&6(<E2
MGH$*7R!>,%-!W^>^ABTL5\=+!8W8]?6&=730Q M3]DX.^3;R\[3LB)K%LX>/
M%"M[_@:B/6_4/_K&L%Z-*9)AV+GS!>LX*^9W%!U\F#2RW (*2\>L(,VZW9/W
M.X:&;HCO/('>6# J< #R1T0##:U(IS+>;K!=-I_%BY]-UVOF'"1(_C7X9#J[
MAJTT37NI*9SC3]_#]13[?K<GDG55P3"@3MO6=9@/ 8O.@,>KVNQ(L??BQ4'(
MZIH)<; 86@T&6=N=I3>Z:O=Q1XC!83S>ZDMM:XUU%.WG6:$#!<>5 5"J,*[8
MFW:/(0<+:ZF@JJ8S_J;C\/'4M!=^NXI,5G6FW#9MW6ZNR0FT!]+/?+E;FZ4-
MZ/"P&$-,85TO*M!Z'6>P11Q:*.8U6ZIK^\T6.Y-UVZ9O>Z_(*R]/G@/CZ)K_
MAH>N3(T%748-M'I'_DFLAM@3=P !*Q,M;U6W;45V1V,[P#B1@DZ[M'7O;^V2
M"7!GM$Q4F[HO6T\K[WM1D&P8^\YAPSBV)N:"'&@ =H8[PE@6<+$%3)NKU]=Q
M!3H3S>>M6/O6D&H'7@97@LWPR)1!03JR$N$P,:^R8C*YJ:UP'.SOR:>74-=(
M*XVI^0^2,AD(Z/'Z\A*^@9_O6FS"7F"O71=# ,#R-].1DRPJZV%!/H0R"J:P
M<OSYSJQ<#TS-..B&W>/_VK!*0VE7M2VQ[AKQ"N<FX<&ETDF[:^63OYDQ(^@5
M62", $ZS_"9.C<+7I:D*L*6&,XVV_$'[2O^ESO3>=A#<>Z8Y<V;^>@>11^F_
M__CF310^;;4RP%U@K:Z".& *;7:LQ8E O+GZI<6( LBL-*YAFZ+PPD>EJ>L$
MR'P"9,56PR96!HH"RP=GQ0-IM:&U2(B\%O3>XN2'K2VW;!8&C--L6>PBQDYH
M"$8>#_U:E_%5'IR",324/]2(QST%/0JD 2B(5[A[;>;<WUU?W5Y?D4\9? 44
MM8#=DN2)QYA+[G&D+PS-GC['3-Z$35+0C"$7NH9T5S7T%8\WII'GI?9;M89_
M"&AG0#^S:*Y[4-:;*!Y($,&7XI$@9@SP_7Y/9D=*1WD<2R8H4S!%'@LSZ!@4
M:8K P4)NT%Y,:0'[:AI\32&/&%*1ED+6(7_ OSO=:*&)H5T%LW$[CM?=5HS>
M,:11%+?L&A9,#KCM5QW!F@@<A''%F#9ZNZ,DFPZ(2&0W 1\2@X(3-@*.1FK)
MV(@ $WQL\@@?HP'?\\8$/W _JB[1EXR^N.T<HEY]-AO8KR%KF%AO\7!Z05*Y
M]SI?2TBCV78GOB&SPGTK$&I6W.4@*13Z?@UF6N)[;2'K*BC>-,/8(-FQ0;=[
M$SE8]:4,3LK/<!/A$["N8L/J"L%K2$1WDHBROC(6(44F?SA6+6\F7<HHFB>U
M"WH/3C3&5)Q[U'W%X5C!E32"IKTH?#2JG.)9F)*ATE$<6L.?WK(./G[XVUR1
MJ=NNAU#FQ02-6()>3II6T@Q=X:DNKV-\&% /$0#[M'4=O HYTAU#.SBHUHU.
M,&69F5<!X*>HO.X1!4=(3W@"52*)SECU#',U@2/&ED2MA,8<0/I!P4D('+WA
MR@FFX<^RK7&0D!/Y@B&5N$*)(9Q0N)A&3+T::!#(99JMJ(L+-L+>(SM BK8
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MABXE 7D.2@JI%G!J27GD\JKV33STA\,A.VB>AT"-\?!-W2) \,@/)S%TBZ8
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MVM$I[6\+^BQ"PP$TGFOM^@<NL/G0FOX$4$L#!!0    ( !9_W%20I4YUHP0
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M]3@M$'A+)>Q@!?4Z]8V1V](RH][!B;:Q[$XT)TRL55/^D$1::VE;9?J-"*P
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MT%+9^%)]:!UZ8%QC6M(^K^/+RR'<']19I\^N+?B%Z'\G=1^N<%H2L0](#(;
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M88'W-@AM@/LYY^HXT0'Z/X'9/U!+ P04    "  6?]Q4MB16I)("  #X!0
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M/ZZ?MUOS^D<")L$\P^AS-L.E>)3PYA?UP[L>*+ZJ'KM3KO#I7'47^%N%"6V
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M+,#[BZC_#>H/Q4MS'U]SA;=[,]SB[Q0(O0'74\[5_D,?T/Z@+?X#4$L#!!0
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M*P!^!'#ONQ7R+J<"15D8?6#&91.;&_A2/9K,R=H=RAP-K4K"8?D-J"3+KJ:
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MA49J1#_<TLL'QB70^EIK/ 6N&[NWM/P'4$L#!!0    ( !9_W%2"8SW>9 ,
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MQ!DYD.":;#-UQW=_8=6?ON&+>2;M$W9EVZ'G0+R5BN<56&>04U:^R5.EPQ[
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M$9SX* D-!=P3SHF>H%,XAV\C'TY^/6W94HVO5>Q).E8O&<L[,);KP1V+Y5S
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MORRU793>.TKO<VLSEV.AUM$<RU3S4[7MDV'5JSGJ+ZL%"2)[ZZ8:(9^9&[^
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M22#EA*:(P6Q@O+5/ ]M2#MKB,X$57VLCE<J4TGO5&44#PU(S@AA"H22PO#S
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M4('<@!-^>.?WO$]U=O\3V8'Y;F6^V\0>7D$,DF9$::K76LAG(JF&.LO-/*W
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MK]W'>B"+$T8QT6)EF_1":&SY=ICBJ0RD"<#GB1!Z-S$OJ,YYX5]02P,$%
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M0^!IQ!', 7C D"AJSL&]\RA<GU/AYM>C\2-02P,$%     @ %G_<5)>*NQS
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M#YOY)U!+ 0(4 Q0    ( !9_W%0'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ %G_<5,69+0+N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ %G_<5)E<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  6?]Q4KF7X)H$'  #!,   &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ %G_<5 :'O/+2!0  SQ<  !@              ("!Q \  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !9_W%000UX>[ (   4*
M   8              " @<P5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    "  6?]Q4:,3=V14$  #X#@  &               @('N&
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ %G_<5'U<>L5?
M!P  PC$  !@              ("!.1T  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( !9_W%00,>QGB0<  $0B   8              "
M@<XD  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  6?]Q4
MQ.=DY7@7   B/@  &               @(&-+   >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ %G_<5!^=B9IQ P  ; <  !@
M     ("!.T0  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M !9_W%0N/ [_(0,  &4&   8              " @>)'  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    "  6?]Q4K@/D,1X#  #+!@  &0
M            @($Y2P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( !9_W%3BD6^KY@L  -(>   9              " @8Y.  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ %G_<5"OP_#L=!0
MHPL  !D              ("!JUH  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    "  6?]Q4Z 3!C,L$   @"P  &0              @('_
M7P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !9_W%0!
MP(IH!P@  &H2   9              " @0%E  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ %G_<5&C*5#\C!@  J@X  !D
M     ("!/VT  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !9_W%29VT%S!Q8  &5!   9              "
M@06%  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ %G_<
M5+D=8B0J P  AP<  !D              ("!0YL  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    "  6?]Q4X% B%:0#   5"   &0
M        @(&DG@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( !9_W%2V)%:DD@(  /@%   9              " @7^B  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ %G_<5#@KQ)7C!   "0T
M !D              ("!2*4  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    "  6?]Q4)F:EZ?P$  "L#0  &0              @(%BJ@
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( !9_W%3>;(Y$
M% ,  )L'   9              " @96O  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ %G_<5),[Q,M?!   ^A0  !D
M ("!X+(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  6
M?]Q4E8@FFC@"  !7!0  &0              @(%VMP  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !9_W%2"8SW>9 ,  *0-   9
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M970S,RYX;6Q02P$"% ,4    "  6?]Q4A9^*77X#  "/#P  &0
M    @($WRP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M !9_W%3V%,1=W00  !<7   9              " @>S.  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ %G_<5&;7]>IV!   T1D  !D
M             ("! -0  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    "  6?]Q4E2_9PJD%   $*@  &0              @(&MV   >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( !9_W%1-JCY:$@,
M  (+   9              " @8W>  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ %G_<5"",!> D P  \PD  !D              ("!
MUN$  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  6?]Q4
M^-()6((#  "D"P  &0              @($QY0  >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( !9_W%2#7R="I (   \(   9
M      " @>KH  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ %G_<5)*0U<DP!@  ;30  !D              ("!Q>L  'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  6?]Q4PEAG+B<#  !*$@
M#0              @ $L\@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !9_
MW%27BKL<P    !,"   +              "  7[U  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( !9_W%28^B>FQP,   ,<   /              "  6?V  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  6?]Q4OLLS09D!  !U&0  &@
M            @ %;^@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  6?]Q4(]5N#:@!  "X&0  $P              @ $L_   6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     ,@ R )4-   %_@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>72</ContextCount>
  <ElementCount>250</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>24</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/ConsolidatedBalanceSheetDetail</Role>
      <ShortName>CONSOLIDATED BALANCE SHEET DETAIL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - PPP NOTE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/PppNote</Role>
      <ShortName>PPP NOTE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - CONVERTIBLE PROMISSORY NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://modular-medical.com/role/ConvertiblePromissoryNotes</Role>
      <ShortName>CONVERTIBLE PROMISSORY NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - PROMISSORY NOTE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/PromissoryNote</Role>
      <ShortName>PROMISSORY NOTE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDeficit</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - ROYALTY AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/RoyaltyAgreement</Role>
      <ShortName>ROYALTY AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/SubsequentEvent</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables</Role>
      <ShortName>CONSOLIDATED BALANCE SHEET DETAIL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/ConsolidatedBalanceSheetDetail</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Leases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Stock-basedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/IncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails</Role>
      <ShortName>CONSOLIDATED BALANCE SHEET DETAIL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/LeasesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - PPP NOTE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/PppNoteDetailsNarrative</Role>
      <ShortName>PPP NOTE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/PppNote</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative</Role>
      <ShortName>CONVERTIBLE PROMISSORY NOTES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/ConvertiblePromissoryNotes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - PROMISSORY NOTE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/PromissoryNoteDetailsNarrative</Role>
      <ShortName>PROMISSORY NOTE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/PromissoryNote</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (DEFICIT) (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - STOCK-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - STOCK-BASED COMPENSATION (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensationDetails2</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - STOCK-BASED COMPENSATION (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensationDetails3</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/IncomeTaxesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - INCOME TAXES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxesDetails2</Role>
      <ShortName>INCOME TAXES (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/IncomeTaxesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - INCOME TAXES (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxesDetails3</Role>
      <ShortName>INCOME TAXES (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/IncomeTaxesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/IncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="modular_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/RelatedPartyTransactions</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="modular_10k.htm">modular_10k.htm</File>
    <File>ex31_1.htm</File>
    <File>ex31_2.htm</File>
    <File>ex32_1.htm</File>
    <File>ex4_2.htm</File>
    <File>modd-20220331.xsd</File>
    <File>modd-20220331_cal.xml</File>
    <File>modd-20220331_def.xml</File>
    <File>modd-20220331_lab.xml</File>
    <File>modd-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>modular001.jpg</File>
    <File>modular002.jpg</File>
    <File>modular003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="411">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>63
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "modular_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 10,
   "contextCount": 72,
   "dts": {
    "calculationLink": {
     "local": [
      "modd-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "modd-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "modular_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "modd-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "modd-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "modd-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 372,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 56,
    "http://modular-medical.com/20220331": 11,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 72
   },
   "keyCustom": 39,
   "keyStandard": 211,
   "memberCustom": 7,
   "memberStandard": 17,
   "nsprefix": "modd",
   "nsuri": "http://modular-medical.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://modular-medical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:PPPNotesPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - PPP NOTE",
     "role": "http://modular-medical.com/role/PppNote",
     "shortName": "PPP NOTE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:PPPNotesPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - CONVERTIBLE PROMISSORY NOTES",
     "role": "http://modular-medical.com/role/ConvertiblePromissoryNotes",
     "shortName": "CONVERTIBLE PROMISSORY NOTES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:PromissoryNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - PROMISSORY NOTE",
     "role": "http://modular-medical.com/role/PromissoryNote",
     "shortName": "PROMISSORY NOTE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:PromissoryNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "role": "http://modular-medical.com/role/StockholdersEquityDeficit",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://modular-medical.com/role/Stock-basedCompensation",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - INCOME TAXES",
     "role": "http://modular-medical.com/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:RoyaltyAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - ROYALTY AGREEMENT",
     "role": "http://modular-medical.com/role/RoyaltyAgreement",
     "shortName": "ROYALTY AGREEMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:RoyaltyAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://modular-medical.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://modular-medical.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - SUBSEQUENT EVENT",
     "role": "http://modular-medical.com/role/SubsequentEvent",
     "shortName": "SUBSEQUENT EVENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "role": "http://modular-medical.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:LiquidityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:LiquidityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)",
     "role": "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables",
     "shortName": "CONSOLIDATED BALANCE SHEET DETAIL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - LEASES (Tables)",
     "role": "http://modular-medical.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://modular-medical.com/role/Stock-basedCompensationTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://modular-medical.com/role/IncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureConsolidatedBalanceSheetDetailDetailsAbstract",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)",
     "role": "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails",
     "shortName": "CONSOLIDATED BALANCE SHEET DETAIL (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureConsolidatedBalanceSheetDetailDetailsAbstract",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureLeasesDetailsAbstract",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Leases (Details)",
     "role": "http://modular-medical.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureLeasesDetailsAbstract",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - LEASES (Details Narrative)",
     "role": "http://modular-medical.com/role/LeasesDetailsNarrative",
     "shortName": "LEASES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://modular-medical.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnsecuredDebtCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - PPP NOTE (Details Narrative)",
     "role": "http://modular-medical.com/role/PppNoteDetailsNarrative",
     "shortName": "PPP NOTE (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "modd:PPPNotesPayableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2020-04-24",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:UnsecuredDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)",
     "role": "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
     "shortName": "CONVERTIBLE PROMISSORY NOTES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "modd:PromissoryNoteTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2022-01-012022-03-31_us-gaap_RevolvingCreditFacilityMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - PROMISSORY NOTE (Details Narrative)",
     "role": "http://modular-medical.com/role/PromissoryNoteDetailsNarrative",
     "shortName": "PROMISSORY NOTE (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "modd:PromissoryNoteTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2022-01-012022-03-31_us-gaap_RevolvingCreditFacilityMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details Narrative)",
     "role": "http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2022-02-092022-02-10_us-gaap_IPOMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - STOCK-BASED COMPENSATION (Details)",
     "role": "http://modular-medical.com/role/Stock-basedCompensationDetails",
     "shortName": "STOCK-BASED COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetailsAbstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-012022-03-31_srt_MinimumMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - STOCK-BASED COMPENSATION (Details 2)",
     "role": "http://modular-medical.com/role/Stock-basedCompensationDetails2",
     "shortName": "STOCK-BASED COMPENSATION (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails2Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2020-03-31_us-gaap_StockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - STOCK-BASED COMPENSATION (Details 3)",
     "role": "http://modular-medical.com/role/Stock-basedCompensationDetails3",
     "shortName": "STOCK-BASED COMPENSATION (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails3Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_StockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2020-08-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)",
     "role": "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative",
     "shortName": "STOCK-BASED COMPENSATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2020-08-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureIncomeTaxesDetailsAbstract",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - INCOME TAXES (Details)",
     "role": "http://modular-medical.com/role/IncomeTaxesDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureIncomeTaxesDetailsAbstract",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureIncomeTaxesDetails2Abstract",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - INCOME TAXES (Details 2)",
     "role": "http://modular-medical.com/role/IncomeTaxesDetails2",
     "shortName": "INCOME TAXES (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureIncomeTaxesDetails2Abstract",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "role": "http://modular-medical.com/role/StatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureIncomeTaxesDetails3Abstract",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - INCOME TAXES (Details 3)",
     "role": "http://modular-medical.com/role/IncomeTaxesDetails3",
     "shortName": "INCOME TAXES (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureIncomeTaxesDetails3Abstract",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_DomesticCountryMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - INCOME TAXES (Details Narrative)",
     "role": "http://modular-medical.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "INCOME TAXES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-03-31_us-gaap_DomesticCountryMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-012022-03-31_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesOther",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "role": "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2022-02-14_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2020-03-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)",
     "role": "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "AsOf2020-03-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://modular-medical.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "lang": null,
      "name": "modd:GainOnPPPNoteForgiveness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies",
     "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL",
     "role": "http://modular-medical.com/role/ConsolidatedBalanceSheetDetail",
     "shortName": "CONSOLIDATED BALANCE SHEET DETAIL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - LEASES",
     "role": "http://modular-medical.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_10k.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 24,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r386",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r386",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r386",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r386",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "modd_AccruedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest"
       }
      }
     },
     "localname": "AccruedInterest",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_AccruedInterests": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Interest",
        "verboseLabel": "Accrued interest"
       }
      }
     },
     "localname": "AccruedInterests",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_AccruedPlacementFees": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued placement fees"
       }
      }
     },
     "localname": "AccruedPlacementFees",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_AccruedWagesAndBonus": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued wages and bonus"
       }
      }
     },
     "localname": "AccruedWagesAndBonus",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_CEOAndInvestorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "C E O And Investor [Member]"
       }
      }
     },
     "localname": "CEOAndInvestorMember",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_CashPaidforLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid for Lease Liabilities"
       }
      }
     },
     "localname": "CashPaidforLeaseLiabilities",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_CommonStockIssuableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issuable"
       }
      }
     },
     "localname": "CommonStockIssuableMember",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible notes and accrued interest into common stock"
       }
      }
     },
     "localname": "ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_DaughterOfPresidentCFOTreasurerAndChairmanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Daughter of President, CFO, Treasurer and Chairman of Board [Member]"
       }
      }
     },
     "localname": "DaughterOfPresidentCFOTreasurerAndChairmanMember",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_DebtModificationsAndExtinguishmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Modifications and Extinguishments"
       }
      }
     },
     "localname": "DebtModificationsAndExtinguishmentsPolicyTextBlock",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureConsolidatedBalanceSheetDetailDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureConsolidatedBalanceSheetDetailDetailsAbstract",
        "verboseLabel": "CONSOLIDATED BALANCE SHEET DETAIL"
       }
      }
     },
     "localname": "DisclosureConsolidatedBalanceSheetDetailDetailsAbstract",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureIncomeTaxesDetails2Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES (Details 2)"
       }
      }
     },
     "localname": "DisclosureIncomeTaxesDetails2Abstract",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureIncomeTaxesDetails3Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES (Details 3)"
       }
      }
     },
     "localname": "DisclosureIncomeTaxesDetails3Abstract",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureIncomeTaxesDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureIncomeTaxesDetailsAbstract",
        "verboseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "DisclosureIncomeTaxesDetailsAbstract",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureLeasesDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureLeasesDetailsAbstract",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "DisclosureLeasesDetailsAbstract",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock]"
       }
      }
     },
     "localname": "DisclosureOfSupplementalBalanceSheetDisclosuresTableTextBlock",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosurePppNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ppp Note"
       }
      }
     },
     "localname": "DisclosurePppNoteAbstract",
     "nsuri": "http://modular-medical.com/20220331",
     "xbrltype": "stringItemType"
    },
    "modd_DisclosurePromissoryNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note"
       }
      }
     },
     "localname": "DisclosurePromissoryNoteAbstract",
     "nsuri": "http://modular-medical.com/20220331",
     "xbrltype": "stringItemType"
    },
    "modd_DisclosureRoyaltyAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Agreement"
       }
      }
     },
     "localname": "DisclosureRoyaltyAgreementAbstract",
     "nsuri": "http://modular-medical.com/20220331",
     "xbrltype": "stringItemType"
    },
    "modd_DisclosureStockBasedCompensationDetails2Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION (Details 2)"
       }
      }
     },
     "localname": "DisclosureStockBasedCompensationDetails2Abstract",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureStockBasedCompensationDetails3Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK-BASED COMPENSATION (Details 3)"
       }
      }
     },
     "localname": "DisclosureStockBasedCompensationDetails3Abstract",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureStockBasedCompensationDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureStockBasedCompensationDetailsAbstract",
        "verboseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureStockBasedCompensationDetailsAbstract",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_EarningsPerShareBasicAndDiluted1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted1",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "modd_EarningsPerShareBasicAndDiluted1Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted1Abstract",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares used in computing net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosures1Abstract",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "modd_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "modd_FairValueofOptionGranted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Options"
       }
      }
     },
     "localname": "FairValueofOptionGranted",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_GainOnPPPNoteForgiveness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on PPP note forgiveness"
       }
      }
     },
     "localname": "GainOnPPPNoteForgiveness",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_LeaseIncentiveReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Incentive Received"
       }
      }
     },
     "localname": "LeaseIncentiveReceived",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_MemberOfBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Member Of Board [Member]"
       }
      }
     },
     "localname": "MemberOfBoardMember",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_NotesPayableOtherPayables1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable Other Payables 1 [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayables1Member",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_NotesPayableOtherPayables2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable Other Payables 2 [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayables2Member",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_OperatingLeasesImputedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/LeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Imputed interest"
       }
      }
     },
     "localname": "OperatingLeasesImputedInterest",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_PPPNotesPayableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PPP NOTE"
       }
      }
     },
     "localname": "PPPNotesPayableTextBlock",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/PppNote"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock upon public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_ProceedsFromIssuanceOfPromissoryNote": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of promissory note"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPromissoryNote",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_PromissoryNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROMISSORY NOTE"
       }
      }
     },
     "localname": "PromissoryNoteTextBlock",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNote"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_RepaymentOfPromissoryNote": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of promissory note"
       }
      }
     },
     "localname": "RepaymentOfPromissoryNote",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_ReverseStockSplitPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Split"
       }
      }
     },
     "localname": "ReverseStockSplitPolicyTextBlock",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_RoyaltyAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ROYALTY AGREEMENT"
       }
      }
     },
     "localname": "RoyaltyAgreementDisclosureTextBlock",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/RoyaltyAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_SecuredPromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Promissory Notes [Member]"
       }
      }
     },
     "localname": "SecuredPromissoryNotesMember",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_SharesIssuedForReverseStockSplit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for reverse stock split"
       }
      }
     },
     "localname": "SharesIssuedForReverseStockSplit",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract",
        "verboseLabel": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "TheCompanyAndSummaryOfSignificantAccountingPoliciesDetailsAbstract",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_WeightedAverageNumberOfShareOutstandingBasicAndDiluted1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted1",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted1",
     "nsuri": "http://modular-medical.com/20220331",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r149",
      "r168",
      "r187",
      "r188",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r346",
      "r347",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r149",
      "r168",
      "r187",
      "r188",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r346",
      "r347",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r129",
      "r133",
      "r134",
      "r135",
      "r136",
      "r149",
      "r168",
      "r184",
      "r187",
      "r188",
      "r201",
      "r202",
      "r203",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r346",
      "r347",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r129",
      "r133",
      "r134",
      "r135",
      "r136",
      "r149",
      "r168",
      "r184",
      "r187",
      "r188",
      "r201",
      "r202",
      "r203",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r346",
      "r347",
      "r372",
      "r373"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets",
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r10",
      "r127"
     ],
     "calculation": {
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r47",
      "r48",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r292"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r78",
      "r79",
      "r80",
      "r206",
      "r207",
      "r208",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r56",
      "r65",
      "r159",
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r54",
      "r65",
      "r159",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r12",
      "r73",
      "r105",
      "r113",
      "r117",
      "r121",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r246",
      "r248",
      "r260",
      "r290",
      "r292",
      "r317",
      "r333"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r26",
      "r73",
      "r121",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r246",
      "r248",
      "r260",
      "r290",
      "r292"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r73",
      "r121",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r246",
      "r248",
      "r260",
      "r290"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "TOTAL NON-CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r8",
      "r67"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents, at end of year",
        "periodStartLabel": "Cash and cash equivalents, at beginning of year"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets",
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r61",
      "r261"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r323",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r137",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r78",
      "r79",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r292"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, $0.001 par value, 50,000,000 shares authorized, 10,461,898 shares and 6,302,050 shares issued and outstanding as of March 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r96",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r14",
      "r320",
      "r335",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r13",
      "r318",
      "r332",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r74",
      "r230",
      "r237"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r74",
      "r230",
      "r237",
      "r239"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r74",
      "r230",
      "r237"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r160",
      "r161",
      "r162",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "CONVERTIBLE PROMISSORY NOTES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r74",
      "r231",
      "r237"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred portion:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r65",
      "r74",
      "r231",
      "r237",
      "r238",
      "r239"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r15",
      "r16",
      "r220",
      "r319",
      "r331"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r74",
      "r231",
      "r237"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r228",
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r223"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r228",
      "r229"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r228",
      "r229"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves": {
     "auth_ref": [
      "r228",
      "r229"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from loss reserves other than estimated credit losses.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves",
        "negatedLabel": "Reserves, accruals &amp; other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [
      "r228",
      "r229"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "verboseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesRegulatoryAssets": {
     "auth_ref": [
      "r228",
      "r229"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails3": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from regulatory assets.",
        "label": "Deferred Tax Liabilities, Regulatory Assets",
        "negatedLabel": "Section 179 assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRegulatoryAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssets": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.",
        "label": "Security deposit"
       }
      }
     },
     "localname": "DepositsAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r65",
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r42",
      "r251",
      "r252",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Per-Share Amounts"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r75",
      "r215",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r215",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r215",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r215",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State tax rate, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "auth_ref": [
      "r215",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.",
        "label": "Section 179 assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r47",
      "r48",
      "r49",
      "r78",
      "r79",
      "r80",
      "r82",
      "r87",
      "r89",
      "r93",
      "r122",
      "r180",
      "r182",
      "r206",
      "r207",
      "r208",
      "r233",
      "r234",
      "r256",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r281",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r65",
      "r163",
      "r164"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Loss on debt extinguishment",
        "negatedLabel": "Loss on debt extinguishment",
        "negatedTerseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfCashFlows",
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r51",
      "r105",
      "r112",
      "r115",
      "r116",
      "r118",
      "r316",
      "r324",
      "r328",
      "r344"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r216",
      "r218",
      "r225",
      "r235",
      "r241",
      "r243",
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r76",
      "r88",
      "r89",
      "r104",
      "r214",
      "r236",
      "r242",
      "r345"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails",
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r212",
      "r213",
      "r218",
      "r219",
      "r224",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://modular-medical.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Other assets and prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r50",
      "r103",
      "r268",
      "r270",
      "r327"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Other income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r60",
      "r62",
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r322",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "verboseLabel": "Shares issued for services"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "LEASES"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32",
      "r73",
      "r114",
      "r121",
      "r138",
      "r139",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r247",
      "r248",
      "r249",
      "r260",
      "r290",
      "r291"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL\u00a0 LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r73",
      "r121",
      "r260",
      "r292",
      "r321",
      "r338"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r34",
      "r73",
      "r121",
      "r138",
      "r139",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r247",
      "r248",
      "r249",
      "r260",
      "r290",
      "r291",
      "r292"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r14",
      "r320",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.",
        "label": "Line of Credit Facility, Expiration Date"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LineOfCreditFacilityIncreaseAccruedInterest": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the credit facility for the period.",
        "label": "Line of Credit Facility, Increase, Accrued Interest"
       }
      }
     },
     "localname": "LineOfCreditFacilityIncreaseAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of the credit facility.",
        "label": "Line of Credit Facility, Increase (Decrease), Net"
       }
      }
     },
     "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate during the reporting period.",
        "label": "Line of Credit Facility, Interest Rate During Period"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r29",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r61",
      "r63",
      "r66"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r44",
      "r45",
      "r49",
      "r52",
      "r66",
      "r73",
      "r81",
      "r83",
      "r84",
      "r85",
      "r86",
      "r88",
      "r89",
      "r90",
      "r105",
      "r112",
      "r115",
      "r116",
      "r118",
      "r121",
      "r138",
      "r139",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r257",
      "r260",
      "r325",
      "r343"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows",
      "http://modular-medical.com/role/StatementsOfOperations",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Issued Accounting Pronouncement"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r14",
      "r320",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Offsetting Assets [Line Items]"
       }
      }
     },
     "localname": "OffsettingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsTable": {
     "auth_ref": [
      "r40",
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.",
        "label": "Offsetting Assets [Table]"
       }
      }
     },
     "localname": "OffsettingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r105",
      "r112",
      "r115",
      "r116",
      "r118"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Short-term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Long-term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use asset, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r271",
      "r272"
     ],
     "calculation": {
      "http://modular-medical.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r271",
      "r272"
     ],
     "calculation": {
      "http://modular-medical.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r271",
      "r272"
     ],
     "calculation": {
      "http://modular-medical.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r77",
      "r102",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r25",
      "r292"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Bonus payable"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherMachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.",
        "label": "Other Machinery and Equipment [Member]"
       }
      }
     },
     "localname": "OtherMachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17",
      "r292"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r24",
      "r123",
      "r124"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from issuance of convertible notes, net of placement fees"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from private placements, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from issuance of PPP note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r9",
      "r126"
     ],
     "calculation": {
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment,\u00a0gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r128",
      "r292",
      "r329",
      "r339"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment,\u00a0net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets",
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r128",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r186",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r186",
      "r284",
      "r287",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r282",
      "r283",
      "r285",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r211",
      "r302",
      "r374"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r182",
      "r292",
      "r337",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r78",
      "r79",
      "r80",
      "r82",
      "r87",
      "r89",
      "r122",
      "r206",
      "r207",
      "r208",
      "r233",
      "r234",
      "r256",
      "r348",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "The following table sets forth securities outstanding which were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive:"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Income tax provision"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Income Tax Provisions"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Future minimum payments under the facility operating lease"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r190",
      "r196",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Stock Option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.",
        "label": "Schedule of Outstanding and Exercisable Option, Range"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Reportable Segment"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "General and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r191",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Options to purchase common stock",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r191",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r183",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, Shares",
        "periodStartLabel": "Beginning balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBankLoansAndNotesPayable": {
     "auth_ref": [
      "r27",
      "r342"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.",
        "label": "Convertible notes payable"
       }
      }
     },
     "localname": "ShortTermBankLoansAndNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r39",
      "r47",
      "r48",
      "r49",
      "r78",
      "r79",
      "r80",
      "r82",
      "r87",
      "r89",
      "r93",
      "r122",
      "r180",
      "r182",
      "r206",
      "r207",
      "r208",
      "r233",
      "r234",
      "r256",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r281",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r78",
      "r79",
      "r80",
      "r93",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/Stock-basedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Warrants issued with convertible notes",
        "verboseLabel": "Fair value of detachable warrants issued with convertible notes"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r38",
      "r158",
      "r180",
      "r181",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Issuance of common stock in settlement of convertible notes and accrued interest, Shares",
        "verboseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r17",
      "r18",
      "r180",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Issuance of common stock under equity incentive plan, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Shares issued for services, Shares",
        "verboseLabel": "Stock Issued During Period, Shares, Issued for Services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r180",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Placement of common stock, Shares",
        "verboseLabel": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Issuance of common stock upon public offering, net of issuance costs, Shares",
        "verboseLabel": "Stock Issued During Period, Shares, Other"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.",
        "label": "Shares issued for reverse stock split, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r39",
      "r180",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Issuance of common stock in settlement of convertible notes and accrued interest"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r17",
      "r18",
      "r180",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Issuance of common stock under equity incentive plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Shares issued for services",
        "verboseLabel": "Stock Issued During Period, Value, Issued for Services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r180",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Placement of common stock",
        "verboseLabel": "Stock Issued During Period, Value, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Issuance of common stock upon public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r182",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock-based compensation",
        "verboseLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r21",
      "r22",
      "r73",
      "r120",
      "r121",
      "r260",
      "r292"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Balance as of\u00a0March 31, 2020",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r167",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r182",
      "r183",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENT"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "CONSOLIDATED BALANCE SHEET DETAIL"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnsecuredDebtCurrent": {
     "auth_ref": [
      "r13",
      "r318",
      "r334"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.",
        "label": "PPP note payable",
        "verboseLabel": "Unsecured Debt, Current"
       }
      }
     },
     "localname": "UnsecuredDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets",
      "http://modular-medical.com/role/PppNoteDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r94",
      "r95",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "https://asc.fasb.org/topic&trid=2208923"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r375": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r376": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r377": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r378": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r379": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r381": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r382": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r383": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r384": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r385": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r386": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r387": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r388": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r389": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r391": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r392": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r393": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r394": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001019056-22-000478-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001019056-22-000478-xbrl.zip
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M!U%*L %_R<V;!V>3.AJS(::;7)5<.(JFOEC:RMS /- -?P\E2?;(4=((%>"
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MZ6J2OCY<\P@7';UV::R*HC#BQZ58U,(\F"]WB*M6-NK)D8 (.XDK)E=5-,^
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ME-R"9+EY"8=/^36R<5N(&X70Z*!^=4CU%F'U=S!/<04H=^OX%_Z0)JLE]9=
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M;6AP^F7$;7A3>H]%8%R%1,YD.;:J#%4*X\>;J#NL(<TOKB)2V UO.Z?I$+J
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MI/KFXN1DV\>E2VR!L3]*$?GI>Q61F>4G]._NR#_$<_WF]>%_ 5!+ P04
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M<CAF896VLH#6W 0$@O8<(%ZQ&=363^K/8:/KF)3V[O3H:%:$1$1KM!(*4EU
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MTF-]N)O<WD\NZ4R?_TAYOWDL\#\VI#&8OE@<8U.+N]U%KP?=W3$OEP5#+P-
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M\4EIWPH5FVM!%R#\WYL"?X%;) E,"'7\!5O2*0#[0F,@ZN\Q41=PB(KWP%M
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M*--U3,<]^TLY[(*F4,!QKDC*V#LWU-'""<DB(>G>\2S/9B[5L9:K '5E+Z@
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MLEYH5:HKF34U_^C3:LQ(M'C$,GY:;^H\K=B6]%- 8D8EAD[>#:VJ=16;!T$
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M*W^1[,()F5EQ=G#\P/:VV'C?3'5_H-:OF.$;PIZ?KY5Q_$C_D<04Y05C)E.
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M9_U./XG@]4U6'6J[MAVMF>"8Q1J'*T*YB"A9,2G%)U=,BN3!#U0Y!GJCF'%
M 4H]T&,,/R,!2&_!/E46Z8-I^0M5%+J:T!],RG8X%/),U)J3['OLGX'B-55Y
MMXL1J8)/]#R('%FJ! A!<S/$!5+%G'P$#&'G/*1>G%3E/)0TQ=Z52I4J)P A
MI_B^R@6^$5V'15.^ 5US'H6.R%[?@"Z36 O>@!ZL-ZZ_)01D\DH;8QN]RN]"
M2UA'MX&7F\M:@R4$I;C>OJ:XOJ:X&I'BVEB5$?-37*OMO'O6Q@GW-^JG#%/Z
M'+_^>A_QJ@_[Y^%!.W/H4,CY4U6C..(]O1Z&Z-(_K,7) [_EQS,CWWLFP>&Z
M_-QG#*9_W_.#<.2'GTDX);;_Y/$R#(#-3/V?Q,Z>JDF=&A?*Y:I=4HF&S;?=
MCW@[R5'9N>G 3HLR74&EXD/7VC],G=/&$J!JTC^#RY\*J@0=\J?]94+#K@!-
MB?QY>W%S["2C4R4HY\Z4B<YW<GRO1A;]B#K>4Z(H,<WENJ?P7S3'PL[JJ6N:
M5H:QYNQOI(2,!*FY]4*"7<Y$>>[%]_G<B^&H-_XXZ,R[_QK,#OD62%D6!R:.
M%*I3+J2=D/S<B'+-OR=LZC#_C!^==;W% _N6R^CD#R5Z ;DC'EDZH9K!:J,A
M>[L 4>8=VQ- 0[?B6>(+]$*%6](1V\\\22PR"0M!,D68<EZ5(E5UQ_;/ZA<L
M##!3Q'NP4)IR%?;#=GCJ%Z@"HLH[IY#[YZBWYOH[<FM:HBL.A^U@Z2_2)^&&
M/O-SU&M; &A_;)_J-"E))=Z423#A*NV>U0Q>E94$-@IV9D43JJ*#WT4H3&4=
M.54M&CQVKE\M+G<W<>",'R5XMN,ZR:G#BL>(A]X> -8@N4G$HU*)*%W7_R(_
MZ*YC;.SG(_3W&?4ABK[IT#8.IQJ%QAY?.$&,9YCRQ@1>C]46,I'7]Z#(:^?F
M-?9ZVG'_<DGL\'!VP$T(6[NR9J2;=I(C1L,VTUARAE_'X*V+S-8(::O?IH+@
M4+[W)9+#]]-&Q0X/-Z--*A0;.CF'D#8A=&W%-V\<UIHA9)<*EX]7?3CLV+"&
M5$]CU) ]&H2!D<\W!Q%K]NB2W7Z&)UTRLE=,5?ODF;C^AJ=_G#;7=;Z#'7)N
M9O;K(]T*!6(_[+'ES@F#.-'A-"TI#-:^6/()F+5"WK6X_[5_"#LVW8R>G!88
M:%_DL1P3?D7$\2+'>QIOR.[%3%W5*A\#.TQ=E];($#*GNDXQIE#^',\W[V Q
M!:PG>"XEIE"P*COE\9YX:F+/HG2[]*GH.<U<&!PT2.MB!!4@0E_$"S1SAG<_
MVVT[,SG?WF(7O]21LL:8[?/E3T>PU:MP@?T)]9G:A]N):WDA?[GZ]\A1N(0Z
M8[0H+%"!N_98A=U=2_XV>=>V:62Y ;=R^Q^?9!V48[?/YZ\/T5:'CU,P/#C6
M(W-=0H=O\++F,KG3RR^HE8<\^%4VF(:=_I'VQ10:P/BR5BC%34!1^_9%#>2<
MMSC9I%S%I^2)7Z+RZ3;A5M="%/NWS^770^8BUI(#2"F&-=+.,KVP<\ZJ"UR&
MPJEBGILTX?7CQQ>:']9HG-? >7[@<T1T?,FX=?O2QF1<7V;.F+QB^C?7L#@O
M=I7T2XGWBF.7JF?951W-J/&F/R.5C.%721>3^ !XP1W2V0SA 943+, 'DRJ>
M'S2S&X4KG_):_M)JF*+V;1:5B"?T>N9%PE0%+\4]S!"07-V4<C&EQ"6C@P2A
M8_?\R OI5E7F4M#<F.,G@7KE-XDRIM%/$3(9K/\=42=@>T!8#5)%1V,.@6!B
M @*!+K J1_H&G^!K[(; .P5C9%7P#X?>A/HV20Z,=!)R]4?"MI+5!5L5-7/R
MHJ8DKA,VL6BX356 !SK1-WDG>CIXZ,X'_<ZD.YU_[LRGW=&LV^/OCAGD4HM8
M5OO5ZIY(*Z.](DR^9+P447BWS?Q&[G)7',Z,_2=4NODUM1K/^#ZZ@%R @Z[N
M:89$3]+NG)C5/.,[[# NY4Z\SAA_&"F7<H\> DB3I'+^R]J:(3Y]I97(K*8@
M@.!*8F\P9KNR85S>VJ="YY&W+6^*O5\5:TSZ!J&,S88N>R8?&2_O?+9YE@);
MVA+[M!R&JX3)AF#M6Q%_*IM]<\(0<18\G>I^/*?$XKMNRJ3<6UD.OPLJQ5Q_
M&*BB(VMZ57S0G>[9RJ?AG-!UGSS&C] HGNLK;V[& E#G^BU@%/^]OCQ=RD?Z
M1!T,D9E,_U0R:7:1'ODA"2;6EFM)?$]U]_?@6FKCU-VP%V^%#J7M&A2#AI8=
MX>=OJHG@QI1P>QTBN#%M*;G@=ZUK75I #USCO8+X^L#U'_>!Z\;N%UW& ]>_
M\',#+U3AGVN&?<U"!_M2#M%Q3Z^!8MBSK9"/:J%!\1S^99RBPS_TF&M+@G!'
MUZZ./'-J1[YG)_^090L!.F-OB2M*2P,8="$*WE)*WAE5U"Z"],7>4E<4(1R6
M5E\9E++9XP\MTH"A-5XF?X^+=,T(TV'%Y:-3Q\7>ES2A-6 XVZU1EFM1)[[<
M_8OU)-610DOL*\A5I2Y@62N79O<;_G^/5D#83_X?4$L#!!0    ( !9_W%0?
MX.23+AH  /P:   .    ;6]D=6QA<C P,2YJ<&>55@=05-V2O@,,(#DCDB0)
M0Y H20;)88@SY*22A!DD9Y"<<QH0)8<A@Y)!0!!0$)"<AR@(2E80D+C\_WO[
M]FWM5FUMW[I5?;_3Y^NNNM_IT]>SURL !4Q%704 X0" S<T#7.\ E$J>U@Z^
M  C  P! Y@;: \CD;9RM; &;KAL$=(T%P@%\/#P\,!X^&(Q_"__F)2;$QR<D
M)B$B(B8B(J$@^=LH2,C(*<C)2*BI:6BHJ9D8&1F96/]E( (" E(2TML4%+?O
MT%+2WF']_]IU%T!)"*"!:%P0)8!#"<*E!%WW G4W!1* 0,"_&0XN'IB $(1_
M@^*"_ML2Z&8)'TP!@'!Q<7!P;Q$3$.$1_!,&*,%4^&S4PO($<$OVM'H:#]H'
M!:LBH77C^FAQ>D+7D-HQ#@.Z@Q0%A)6HNYB-YP<WQ=N%>M9AG%S*-\7<$!#@
M@/%P0?^9AA*739CZ )Y"A0>FE?_I.B8B2F-9L(H(J67GN)X'2&X";T(H@4?
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MJ/9:P;MB=!.HU/-/@X5ZX&1N$>C\]GDXME0V%2.R6U>RS%$=R/B+I$P@IV_
MH&%1>#+,2>;^R[:CJ1@UKU;''>GST&%?M(_6GI+(D+=Y +@L@HS> H!H&'M
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MOSCBEO'G$1^FVDLI/ULKT-1@<1DWY)!^11(WR]4;2O7F0B4TM%O&BL[7_K(
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M5NX%A6G_)A\T+RT_(I$NHU,*_-=!I.B^&?WZ3J\! ?UDDVBG:Z!N+DDA;=U
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M]/!J5PA873Y!!A.070-MFH"D]^7\4U!/Y]X$0'9S)7AE B[[YPU=N%%!BR7
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M>OX&P$-#P )T(2'@ 1#Q$)#P$)[[ &5_V$9$0D  _(N * B(R$BH"'^G__$
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M48MY>5BU P$15WO5QEG$Q ,##\4S0(P%]6QFD./(]<V%C[<WK<-9,86:<(%
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M13IRF=@W]S^(NZ;#75+P-FE219>UY<7'=9:J:X [BB:V?>9DN=$Q;QH1T[Z
M1]O0Y1G\B(8[.@RL]!Z$9?Z)Q?^/Y7ZY<5-Y)>KUD(EP<Z!NB*X5DQJC7K<D
M9^$VU<MWN@:?HTPE^EZ7G7GB1.WN.,B!: Q>XE=U-K\W(=)2CNW4BLU,VM 3
M\6-"<K&0,V!/FMQ741Y%$[8UTAQJ5TR2[1ZT9)/->&-%6<E,:X-FGB_ET:?0
M4=DT _^TBPX]2MNZXC+!M:B6IFIQA>8;KK5AER;0@OU'H:OY*9*B6]U=:>V&
MU_#WE[?US$P1OS(OQ/MM98T%;OT,<'H$FG/)JL76YC]OJ_E?L:@,78<$4<D?
MMB",1>N\:V^SB6O>\EQSH?KXL"+,:)(:LNX<2M-C8:7H4_9!J+E_L.>0!Z C
M=,W]?ZE%CM;%S"_P%<QR<H+H-Y6$8;@(+R&%Q]RL$O8#ZXI)#7F7MZ&>ACE(
MWKI4:=7M<IK6PJBYPWA"U"Y?G0V[TK>MH=0-TT;4WXU2KS"NG"EG@@HNSF=-
M]]#\#. 4:+YY1U- %]1;QW-JQAG_=#I>*#&P+MA.2, =I0*Y!OO<?XU$=Z*1
MZ0D0VIL=2\,Y$=3E-OT>;78;ACC&S),2GU10"4-  E><_CZ9=K]_TK9G8AJP
MV. [U$G4K*N0[9:XUL_?/YJX)W# [^XMNKC0['@37R]7TAJSP*-9G-B%K<S
M6<=PH!<";UZ!N$*+60IK7EF^WH^D<&95=U-%QD>KZN$VSNM>X5Q^QT>1XGH-
M? VQFDA.,3!N#!F;KBU0LN[3]A6EP<9=,:?"F QA:I217="2WUJ</UBGA^>B
M]CTY'/B15!HVSW*"AQK^#5.SSHM+,!->)W6^C]Z+3M[7K UNT+U*FFQUS[S1
MO*'PEI^O_('.*0C"F_P8G@W!!N0W$\9G9TME@M0N9Y4F?G5% 5"=JAV*-U=F
MH?!1_[CXOP(D6BY[UT@G^Q,!ZNX0M-Y#-6)IFX[/C(R3C+UV4R\&E);H#E,=
M?R IGUG/M$OK%VG>)!#IVG2\M1M.L[<=[LS+6;_23+%;/SYN7IYL-?;V9H(T
MS]KT[F88HV-(5V1&)WY0,&E LAQ:<A<RSI!]Y'H&5,GQ#[LN029HN A>O>1[
MEWE!X])\MM5K,K]HS.9CZ3>_,13T%AUROS%HC2%.]UB<&V,0L'6C/<T="4KB
M9!Q9L*/SKT7*&5+[%1?;C!,8)W)O;*CX&P/]";X#BJ3'1*(/*!)KT_+)OWP&
M+'0$M*\=%N'"O7W%[K"'-=?KXQS]E8F$3D:5-[IT!<$.*WI%LM:^C"FZ9=+-
M$CQ%41<+C^ISAE<ZF G*%&(.X8%;13DA2.\YBUSK_$6;RQ]735*.,"7E:76(
MB3@+LGY?^)B 4V3Y,;B6F&N8+I,R4*JZR,);3.!5YSY^Q-6Y<F.91LU=PV=F
M7^NO;EAS3*0I33OH5?\-Y3I:,,QKT.,=Z!Y RG+N>&E.XBR%S*]FCZJS[0]/
MR[UM6)GWEQ5_=)!C>40!Y)E9#<H3SQ.5>]P59=!%LZ=]"\K\G!5/M0N97*[P
MDSV($$H&50\+8ETS[7"_I'&34Z3$)%'36TM2&'K(A:"W:.>0^O-#ZY2^-#J7
M&*4:?) >7U*?:%-:(<X3.I <VVJ^]>SOZGG_2$9(#,:RD6:Q2G\R?-]2S2:;
M[<'XNNKL5?.CF:WHH'Z+FL_E_/F?FC;[=A$T3Y-6]B;LLU3D-7)L\*:G]E9O
M0%M-V-#C/-=DHEC]YHE(3I.D^,"7/6%SI@-%[H#JW:[6&@K$\_HI2O[.4)HK
M&U^SP(IRM9KE\$_Y_8X*;E<II79JMZR!-536CXL/K?(S7&E[3+<VMV2/NA.K
MRVTC)0B(0A/^'$F3.4=/C;=:WK@)9"O,RKX?S3?1U="<O2Z9\>$:96 'O@?+
MG!]/';=Z-R8BO=X)X8%XJ?9F+91JCW"6ZA1@@533B3]B)_DLQ90P-^>#-H[@
MT"MXB;]T5BN&3-ZPCDP)%/FN@DU.SGTV4''=6T%! L1/)4G%FK3;A_MF#$L9
M9&?O^.49L%G (Y3"J?A -"F7V_85&Q:&!7<:;5I?!IT,#[DVP*J4+$H.W/T#
MM#&B1<FVOLA"OSX#(,ZK.:(7_ <Y>UZN?@:"'"+WG$K&HMBE(A9%I@B,'1):
M=X77.LJMHSLXN!ST2.%W_;)2)BF' C3::S7H,B!GNF^%;+8(%<NBSH[+3FY=
M!>T')4NEL>7D]%TTT3]BDOHH,X:\YD$_@ S UHNHO&S'"IM%QTMKWLQO">)!
M&P7;N?XML A;^F].3*K336SS.H@ST-SSM:2M$Q*FLKYN\8LA:-TX&_,/WM,I
M.Y^Q08-42+4N^\LH#PV6J:/3N9<(#MU%2J&;:/*[H##33(PI+ C5KUZE_.A>
M8$-.ZT1.W3DNGU])"I>M=SBN">P\W:I?3^[K1HBMI]M5)_E>]4_1#I=VF)5X
MKW=XS%V2R*?H+=4&YZ)[C)5L?OZ WS>BMH>]<8Y/7^Y^W0N*F0TJA-VC^#D_
M&A1HE"A/:1Q0,EDY),TH1.SW?G"9;V_E]BZ\8:NKE.\86"#0RQ*VF6VVNN=$
MEPV&N55K+W4L[.B%W;LU0ZI\IBBW&O_#UYHWV^UHAIPC!S9%5-S4)^&)DY'H
MZN[R?/LY9SIYS6$P:EX"',,WR_$[$<F%1=>:^Q*HI^I5!%J-EG6O$9H#K8D;
MJW2;^.(]XCXN%H?KXQB.=U+[^+ZS<G_Z!(TZ7WUHAZ^NOPZ(CL2D^H.#L(Y2
M$D+,V#LL!Y7 @F/C8'YRN]DBP L?<H27JMZ&*50\G9$G,XGU@R,//\Z521C\
M!=M9PTF^DUU-L.=^OXDDOS< NS.=5A3.#^P6<&_39/OQC7NC$&X5?#V\GP*]
M6A<R+&4T@FCN-,W=L0G@KN@@L?B^<$W?J0.>6' (H,OK%,9G:IOZ>*Y?47K(
M8MV4)F%(NY#J4AA!)!6$/".CJ+H8JMMB[U+_EUDJXP25>VGPYND34@K6U)W3
M\/O><TL2;77=>O\S, @!$8,3[<,^# 8H[B^,@#2J65M 2M]O *^"M^9^>O[@
MAOV@?_U VN(=]\[!8\.-J5?*V )Q3Z@L+5.4F:%.S$(Q>\BK789K\=T6;<HF
M 6RYQ8%$?5*CN*R=:;!?\FA(4.ZE8_R/%]DQ-!112?B8I8E5.;_II/#O%I$9
MWQ)R[8*:-8I0[5>Y7L?P$TNX*YCVE4N7OX2<2IE?K6XY1%>HRF[X+0R0.;Q)
M@<S%5KO69=HH(-B_3NPU58FZ%\[V0IBM0H&9\,)]"]]N3L*+A]G85X&T\A8X
MKUC J0K4@Y]!0HNGI6Q^GIGKWA2_20=!OGDAB82 ,PH]?74XF])X$9]]N:Y,
M%B:FISI7N[%%&D'CP&3#52AF7)M!:@!(ZZ?2U@[A)FR'UOS-$43K2F!!BC!I
MA3"3O,;<..(6N0;T,+%.@/E P%)6ZU@HB+(OSP252643WN^ >7=1I78.3655
M7"+#X!IWX\[EZFHW8G>D##C9(B8RKIW&'5:8[.;Z_U9 [NZR;*[+O!99<8<T
M-!8!>SXJ]ST4Z;J15!$1MP]@!(ONU+G0CP2#(D AVST;DPPAH(:713)"X:@:
MD@S1FWYC+WR9J!BQOT><1]DU;8*8U;5##4X3"^/M>%LJ76\=:6OFGP'$LILG
M=\5HB\Z^]_4\C4;3&;HI[(69(!L5AT)L5C;1#,UD^KL>O*HP./!1,W%J/LY+
M0AE>&++DJS-E)'2W1^_R>1,V5N/U)$TX]83!Q%5Z+)"(CN8JAR;TA,!3.YS-
M.J*3O_WNF$FPW06Q77.@11\I*N[XF)T?DY]92HSE!S?[QJW:Y]AA]<_4K\#<
M<Y=2J46^D'S$^/PH3-QA&L(*E5XM!XJT+I8U%Y<6A6KNI+>&'@;?7$%4)FP<
M F#\ R$:&R4HPVJM^D^RP^B$+?JX<FE7E]QEG"LH(Q^PR1$D=:UB--G_#)BF
M_F+'Y<M]SYI^<55_BQ7,^=U']K;:KI;/&/(KS!ZE+7/!TX/\_4@!S=8',HM-
M)OJN_M@EE[R&Y'DU34V>YB?%XRD4]7;4D#<#J^G)(E-5L)#7/08,%=T0!Q"+
MT3, XV?(7G%*FQ>C84A89!.P)%#1T/BI_,?[QE %"W*0#<FL.DHNMOGX"*9W
M810,^C% >>.]#:-%57PA2'A<*M[!01ABH,,ZL^!CAV+SKRV52]=ET,2XUA@&
MJ]R7SYW!QKVK=IFJ?M\OWYD1H=A'U&1@#.-(BKXD(AS@3)6R1REW$(X0ENT<
M1:V%M["%HT:>;ROT"<SG"LZ-LF$/I1[4JT\%#:R#G#!&_5*:4PU?81J:16\C
MI_VZJSM=/;W&Q2(:E*Q5:K4S<ABJ,_UQFJYG'][9]4K: 0+FXZLE.,SFJ3LI
M:49KG37VC>K_D1?2^?O'#<F"GJH"_X%OL))']X&N"4EDM=C*"[%S/4=K7$9M
MMY *C_)F?:66D<(PDFC9_HU-2=.=)0>EX25W244%U05[>U#3_.OSC0<A8GR#
MQ *QWY'N'9&*Y1@ 1%YB)"-6C@%J):<(YE%_NQ-\S$Z6[-/KF)#2TGB95NQI
MSP LOM'3(>_//7:3Y@UK\O+2=NB2@"5#W>M?]TX[%KX[ NWVO6P\OT]JZ0GJ
M[)D9XB%.%<$W#9GO+RN?*FLK$9V*KCN6 4R#+ ]-49@D6EV1S8MI"EA,)%$1
MH73T*D)PFEL9VQ;Y!8W#/3V/UZ??G.:\%&Q3J*6/V962"5NAA?N2G1\#V/D6
M7Y'CX (%I]*N,Z@%W3K60^.PJ \,BAR[4"BL8)J4/R8XWG[&9F.@MP,CB'V?
MJKV>,CJ-JB@1'*"WI'_=>](^;':A 497FUS(),]H9KNL7I)E)YW#EH;TPU)[
M@K2_NN,7!%K_6ARI/(WO3#NLM)%_^745XOPH_COV$7L_9DJC %K^MT,.Q.!P
MWBLQZ>V30$OK7RJISX"M5>)G 'KPA;D&J(*ZD;>X8:MR*I5P\_V,/;>6'Y:=
MWHB2S="HH*FR++9E+Z_.MX&&V5XE6]YS;B-2558@TQ<K\XU;$FI3-J]('_#C
MJCIB:G'JA,(EJN3-0>R]CK".IE_"/M&B"6;T3&/4'?-K0M_&/S5%TB6?1&SG
M\7'NC640YXCS,^#@)^=?A47EM[J%QG1V:2"Y*C,Q5#^ZVY:4>?*31"/B+TO2
M1BQNV61R@0.ECX;ZJCC!SHC/ "I4PB4W!2YZ>6\$N[#Z0_><_N12&IBM0T3=
M2B)?%$5DT8"U2(Y_$X7SK"9^V&01[.LXK5"2),8S@&V >U#6WZ"C7T;8[2H-
M+D NB335&ERLV3>ZH3(L!<9_X"?&KRYPU:F#KI\O/K3!9Q__7O;\^Z;JWQJW
M@5DQG1<_Q<FP[H?TLK1H^J3YF6-:6%?J\3&TIF8EM732LW(<@#<OEM&EG?2C
M7[7Y/['0<IVOJL&NM WU5;[9UILN$OP0TXK)R7+)<@@,?J5>V%*ZE.;BHJN\
MF'M?R#U9Z,\?]F[X!_QF?MZBJ:5^HYDQ  .LCG\NU>/.M'G<B!J>7C7L&6Q%
M%JF9MA+1%)1Y*\F!74&_IE[*<G-[>FZHPA@SK!0?\>.[0?IMF53PTW'OKH9B
MYR1'FE:MS;BJ[VCHJ&L6!0$7A\;^O$*$T= Q^),_8UN<53DXW!\Y+JT]+H[^
MHW/J=$)L*)8ALKW!:"BCE!"/:I>JS[ANE[[ VC/@W#E09'45.G8@1_D((OD]
M^GB'+:YWLRL<J\PQ]1XU=OEN/T +9;6*TO6BT&2,_WJ7UX1YHQ!")@\M7Z.A
MZD"?Z@PV'?9:)[F;Y.@ZR[R_('NTWL@MHGOR[NJ2W/:6HUR^*E0T*8F.VBM[
M8,%^!N@+[.S)=^4XGHQ;5ZL,X@2SDCCO*A[M^0OO\E.6Q.(%5L*?_/^,S)V)
M%;Q3Y]SY\T%JVRT1>R,3_;>UJ"ID)#!^T0:*IP;GL<F$O]B>NBR(36&9ET^C
M0O<F)K>YT:0^M*P]5S^+XPU7HQ)>G8-KOOA4QO)RK\0?E9\.+F L$4:0:-5_
M;0&"4,,;DEF>@I+,#!)^[*0]F-K%U[B!-5CX6P7& ?SKA]B&KQ98>^65[C]6
M(FT] \BN![;0H )3L2($Q=/LTT2)>1#[KS ?!=$&@CK3.F+6-[K* _10GDE4
MB>08J!] U:$XL3"YO)]!3^'PY27J!G1'FP,_XU11X?3J< '0M'C</#@9G/<N
MSUJ=&#&^KE%!%$T(;Q]Z6\)QGADB"_<N<9[3[KB,P$]#9X8P&K.0Z3G:2K0(
M?ZPEQ"<=8[[!/YL@HL<:BB\VX$0,V:V/UYI?E9RZIST_7C6K"SCZO'>FJC-_
M7A-![0D*-:40:(!OL*=XF5FUDW$6V714^7]"">H1R3T__!A08O88\KB/)@;9
M$L>(ZW.-W7"JH@SVVG.01K,G\OIN84SUD:3S7C](G239V"0]&O7UCYM.<OY[
M4!,\V[W9"WKUF.#MZ>O_;DS"L8YOYBE.!AC G[PD\7LI2K&7_U)W0)J-*M@Q
MUB0)_A%B=X@]KCN8M&*T>.@1.*>R OVT_:3A- ,+<_9J9V5B6")CB< /.>8(
MTUE?Z-5H#3+F3PXP3B7'Z.7N^@"N#KFD6_Y%W55/P_$,D*YS>"R[_T6T*Z9Q
M>ND:W?:WF3XXGQ(1)@.";CUTHA$::QK95]>@=7%,#VWTAQZX)1\"+H&^V;=*
MO8OK&?WPTZ/']^DJ]U I%/B:Y.)[X 4/<:4. MP+IF$0' ,),4_7]*[*>^D5
MP?PRV+0,="!I^X\H$50Q8K7])^OC'(A'9MKFQGE+MZ#@)I1/7/OUB*D7PNCC
MCA@D'N*"M2VKGCD,2Q.K'1P8>8N&0%N\!;)A7T)HZP6KE9U 89T+2S;64@^\
M92QHNB2@5VL4'G>E8CH4F2[?EYSQ/RC;[$$:4X;:SR#H&#&QSMA-PQ^1&>U6
M"*OW<2MZXS/>D";F)OZV<18K*J39@):[K.@^\2>LG;T!:Y;5=P\1Z=XX*RHC
MG);UQ706>:JZ.@5(9^4R-R:[LUX?NMFW\^31BA&X)->M6P.O(,HEG4&SJ?YS
M-RV)Y%V1(QSL^<##0FA""01U=(QKLU[@@7]-Q>86\BTC>4AT'6K8=^J(58B(
M#\Y6![=&J?J#Z7<3B#+0;G%I.9A^0=&>R#%R7--Y<3.ZNZNEU;ZPD7'QSU7U
MP%,7V6B9'M<AX"XCP!'T="TK6#@AOJF^FG&0<0-ND6\O+P]IR6%?&,=>H0G+
M5O$'MNH;&^IH4'V;ZF=!<_HHA?Z+JD1:\C>)MPFW(P6MT@^;O1>+PYM8<=@
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M*Q^IW3XVM_&EIIS'@7^DZ]W(,]&\6:]0Y]+(>A_LW#"DNR2*"MDWXM4#5I6
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M_*1#:Z3?$Q;] G#XJP7HNRWTL",C?@$,_!?<?YU8\I6L[_]WME@LO;>%X!<
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MXL/PG)-68R;9/6HXH1\M]$G$VP?(GLUO-&$#Z0GMNMB6?JL V:7M.7)AFZM
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MKW8GK0:OEG7E&4U7,0L 6Z.#,S=ZVJ#4&\?U!6= /%T*"(K)6J<MZ7D!O-)
M-X0(H\%$,T'8;J*Q>JE@?*DVS^(U>R+KXP(#<ZAH'0 .E=FW,G\D]1?*/4XM
MKDY[M.^[IZ+I;O\9YZ-I4J"9;YWQ/\YNG\W !CE3B%'P^.6\8X@.>3+>+,!
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M%7>0H3_-T;WZ>;=?1\5GOF*V)I0*!9GZ':IR_^8&0Y#U<[6.!IY)/R'X?=;
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M$0J#E.$U@1'S35+KXA==9-_RQJI?N7$R\?[RU:?FO&5);F#(*Y_0L):$E><
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M^)?OU:+,&)=P>[:"**IAU=))'_&2#?L'1$^-YD[D(#HY7++DFGLU8YH3Z('
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MY9(<9E\/23__!F,Z&<1)=JJ2X4<W.OL4@[6T$_E?XDREQ^[8[8:JV@"W%C[
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M=[VB["]UG6]^R^IIE1?[EZZ7T1PY<<])S-PX;NJD(^5AYMAW EC&+'6\@9O
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M7^+ADPV4L^-E[Y8W\$5/Z5-TWV]JM_!S%Y'YW&S/1,O<P/X\#;)0&>-$N=[
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MD50XY9 D',\ZG[ZZH=H7S NB)8+A4/G80C&LN&/<;GRNZAU0[X![-'2H87E
M*$WN6 [R#D(.5CT)6NA>P-.2/-10%]X*'&HJ8#(E \5&_%82?[B_P? B;W!
M6#:R8D[V=QLF9U";-/4N>3!WP,JWHBR"HN\J-&8X<C,*7;V30HSH))P^B!DI
MB*T]$<_JX &!B#*PD8*J&6-NA%W;2O4>N-,>Z*M()6[%H+KRXB@>!AZ"S;E_
M68.@D(*/1/!R3+D'3W- UU):2^E]:NI$B34C].,3:)E$43#G!7X5])Q(@>V>
MNLFX@:X &.QP@9?D02;&#JGSE]6CEK%0<S7@?!#F+KKCF1H["@RN>*S)/^ ,
M"4HCE'&P2T)'393!WP*>KGAL9;HTA^&?B)@F&VWX?DY[QWIOUGOS/JPH/GW
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ML3S?G ^;$YYJ8@G92OAB>W"I2PX1!:S%3)6:QI!_Y"M,"4LC"_7?\Y< RN;
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M*"MOHCB#H 8@"A9C,\<'/^M_U59#ZYFL]"8[ILV*RHT6[38N 83=YB/$9XH
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MC=V)!]#0SXT?F\R9WQNTD9:TP/OULH&]UVY5A3=*AF>9"Y31=S;Q53S9"Z9
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MS3$OWTH4%+I6]I;,7$I1^Y5"K)OM^&>P5*XI3E;Z0M-:T*F/B=I3GV/2#TL
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M:_MJ"?? **@F <*_G0'ATP#AW\R \!D0?IOL3*[<T'M8:?B/9K.A1@!%NV#
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M4Q2(EE@[>@ALB@5(;Q2]>0WZ:1;O^S"$91[/#@X@[OD1/,<9+Q5F/:!W?M;
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M,O7U"!2[)7$*];B,H/0[8_ZH(N$J=J%7K0:MGN[K:QF3'>1ZS).#SY6.3!)
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MHOX,0O:.+A-O@$@<^?;Z6B>+>J'P5/D1EGY@:=%5G X#F 8\;W@U3@,XO H
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MY?U#61+[2VZ\2V](;,%HW*GG@>679& 9A.018]P\CL""X^(FCYD*I'E&+X[
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M9N(]Z*=@V30RFY(*Q=P?6O94@!Q@8DVFA:XA15E2L0EX553-BJ:TB23T)'Y
MJ$UYBH/8\!>UJ(8F0G7S8N2JKXB0RK?8:G)M[;+%K%3.V$0PE8[/_ JF1EYM
MWN@F9BHDNJK@.1@@,:.F>Y;5!I5'1=2.F.<"<G10,N926>PQ\S'^F%B!4M9C
MLVH^U#K4-3# N"KQ#H)O@BMBN1=@"(9C">E/DDKD33J8/G-05A?8@RXP:=&
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M=VU_W#6)2.G-+2G&=HC9C<LKNU,4#MF\DCYOAH.W%6:=0-:0RHHL&O2>\WU
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MLQD6\$>7<$P9"L2S=*G5$)ECHM^I%(X:JB!^*PX9\FNFH-%)FTX[)8)3S31
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M@D6@7FX-M#Z<_?/F[[W=VE^MIP7.3+WV'Q=)1:K]GBNZC-NZA*Y^M[;C[LQ
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MUL^_KS)_:Y55 DJH0""QZBAB:7H-0#F^6.%S^D_V\6)8_G:>\&.%97KMQ *
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M8)B\N:L.!]].O89U^O3C,*:DG:4,&='XB\ ZNGQ69,V88DKO^&29?UWCMEW
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MABE4C[\@.Y'*J8DY.H)L_O:<AW2KRT=0DXE5R+6)]3ZBIF"2 '+:P.B..T"
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M*/W0=GJ$*FC(_@S<NP]F;X_)@E=45Q;3+Z,\X$_, U[$HP.4Z+[' ;51#55
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M8L!7-?)<LN6NV[KGP4*SHE0'U&&1)S)*:@6[_CHN&<2PLH\.Z>B4E\V(P[P
M_(M1V'=!11S#]A;HMHI.!) #V&/, (1%/N9U"J@T1G*!Y&?T779<)#%9Q-B
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M)U4HK+H',\Z-L9VVCB/*MN%D.6+J&,)7&6W0#Q#Y"(TZSL+>]#-K/W1F+?+
MZM!UCIV+LZ<_AZU%PBJ;PPH1VR-;'1[?W%]>#8[.CLYR.U\Y;=CN")/GM3W
M*R=':*YZ:*[!1D$5&5.P0>V'(6,) QY*^L!U;)NG57?,!B;68Q:)JF!QQF2=
M%=/JFSR91[(IL-^[RL;A8):<*?GA)@SL):Z6-[1<K^[*H'SL3H]9EI>6]W
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MY[D;!+CVO7'M-+J/ITOI?Z_DI?YSE>QJSL^#!T0)H0DS32,TYP_9O8;D><R
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MGPD#">_=3:34L&ZQ.L7+"MJHPPH%N'H\:XHWLD=-BWOYY%=/G#KZ(,#\A5F
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MQ/X@?VI[3O+;L#5+-5OBW2ON:ACA#M+40B;*>B<V8L($T6'Y2'WY[M1LWCH
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M]K.M/X'6YY.S#6.I4:4>JR[I11;5.4S]Y.X;LK$M%T:5!*VDKMN@2P+A#'V
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M9S:6]-O6HU BO-%3VZ/[PC?2D<7-Y:OR ?J:4?5%\!,I/@ ZI)\_(D N,#J
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M._CZ$QYK=U^[#%PO )&RO27;@,@W\T3%+U'WP(I1><&HOJO;GE!,H+M0GG1
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M2%)!'74M6A4H'W&ZNH\FBA^SI34#(+FLSH?3W3#0OM2 E5P?)\O; ]8HO7J
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MCQS;=EQ@;F_#TDDL_1H"H6FPM$BE6/FD,?/?T2G#K^5^E:*Z<QP:@G/<0QK
M_&SGP=5[L3L_00W. >)TG]0VB.)0J1Q],>'*HF?,"/0\4:=%")6&[>F4@!#5
M-BPNBKB W4YU0_.+B].DM&4L$:I!T_2C'?M]-VR!@;64-NS<Z9JV'D(JO,.2
M <8?F+!]Z6BI-<FZO>FHO<B<1B/@RCJ)/Q?"*2"ZA.YKEJ%SORH0E_ /Q)?5
M$%]V. M+0!(,)F))'+N&:]:QOHM2J32N4M&Y2(49((8Q@M/I.K25_>$W$?#%
MX(M>IA1D(3;'"L]\'-*S*7,DT$W(9__Y8-3I7[E_PHP)\]]][<S=%W]K'40!
M,MQ[!ML85[_IF7B2PYYX^8*"?=QPNG73-D2M=_Z &91*-Q$BPS4IUQG!,"PJ
M*Q*ET CZ3"7>&: +UBNVS8:F-^]-SW'[6%GN]JA<5W[;%R^3'[=#";.O7=/T
M<I5*):/!6<%UU0WPF'2L!K3U-DHEEE><;!CV#C^+"A$%C'5&^_CQ2-N)?K.;
M83Q\.5^U>+%ENMT81;$FU/(<3>!I8R56>'"((E<F$NG:=VQ#>VLZOM'H8&_(
MIG$/)[-'@WH^IC@3E")0K*_534= ]5!EN&QJ]![6Z5A8?ZV]W:_N(X$[)N)H
M][66ZW2UMZ[S8&N?;9/::/GPQ%<LM[9,>!7V2T="Q";^*P"N)?!&WV&V0*Z(
MNE8F8_9HS<# !PC5[=$',PNWMX>UUNKVBP)?;L,D[G]1YNE6WS-)FO6"ND6-
M.'!]6,6](]-'X4ON+4!E=0*@<8ABNVHM,F%;#8XHW&=U WU#[WJ9[2T@,$[/
M4\>0GXU\8T94G?N("0#B'(3 G2&0@7@"<H0(RZBE,]44#!6NO..Z>:K-,SN.
MPXA5OMFERNH6CD=@38PRA>_1P*0U_ @(A]Z(,_&5I48S\!@; ?X7=ZJA]TP?
M*_ETD[@* 7CNZ4EDD^TMP2=<Y2R "#PM\+@PG. !J&T [':[0R02P$-1D:"D
M!F,:A:<G+(U&8(E8DXF(2++=!*JA:-YCYOSB>GT=:[5,D1LD\H+VAQ7BV"6C
M\!"/1@*7=0BG;XSIZ1;V?6,NE]D?VUNL9QX,AB3"LOQ/ 7ZGPT).[<:^MB/_
MWL5C^2&PL+]NKDSBD"3O=/J,)&3XM&A(40W:0&9NZ[6]=6KC=P>D4%H.-Z>(
M)H/P(+IK]?=86F/W#"S.!1EADK3CE@A"9+!1C.P>6##K7M#MR9-) %,9,0$$
M6E&PF+1Z?WLK\&@&T;+P1^-A%IC\^]CD ,$S'!(V&4W=,+F@D\"PM&N@%$P:
MV]'9!N;SHP:$QV O@CJJ6EHIMKA,6&I,QD5@N!IJ-IM^"&<6=GI?0YC#L,^$
M0@*JXD=]*(48?-XC+-[8V/@KKQ?8>T[ _6;D9B CX$[AG2WL*OPSC[,/-R\B
M';:ZV$/A8OML7NMAPPNY8R3?< *@>\ FEM*-VC?'UAU05Q,4]74+Q77=<6T4
MB"V!L25+I^$12Z!"' 6NXVE'>D_VL,,EA8Q>[VN%,[!"V+XA# 5BP6PA>>MN
M@"A&%S[6ZX:/9M\1V//RE/"7N]R;P@ E<Z\#,X#\#CT,5=,A%JS0YYDI(#QH
M:\'V;/=C7^)J@)Q=PCQ$R+D0PY(TH@):BY@/1H\/OZI5@0%XXF%O'M,V2;6J
M1V>(L='BPS5&<XYC,8)Z#_TJV/2W.J+V@<  ZZK3T E=/22ZML-?[\(6H;4!
M8^.Z?-V[D_#=)+A &).=T8<3@YV+P,YP>E@5C\T,32,R&L3VP-]-$"YN'R1+
MU:.&2+"B@5,I: $O\H(ZG#8V*\B*\DV/EW5G.P_ 4&UCY!OH9\AS"(O41;0Z
M8"VQ:$2?9(9#$Q"Q=&)""6@6H(6"PMA#.@.O ]<@E)$D<M= 4 -Q$F@W#1LT
MEF$07$%$:#$[/?"=+F-A8^=E1,'LA?".=') KD2 ?EZ#S,5P,620Q#0-F;SE
M+/C#OD3W&SB9M/EFPW5:5F#"-RJ_<J\63^!ZPJQL[,4"2PQ-0*T!/C?!*WD1
M"L[)<94-;EW8]^'S(.U\1 J4!EHKP U#&2TD"5,P,D+CRR% 09).X(J@M\%8
M&S6%I(J+0EKK'&NB#/JQ:MZS_ 57X)I<@;-HF]3!: 1<D?(@H2M['BP)9)K/
MTG9[BWS#'IU*]%@*PJV3^RIHOB=H'G*WXF1HH8\A5SO2R2#,'"7K,W0UR&>:
MX&M$)T*B,D8NYYBI1B"00@?C(2"T(RPJS$APK3;-@K1A=%"\$!5LZ/1E!DWM
M;AS2%+BK"81'(%=EJK0OR-L$_2$[R./O/<,VU8"+*LS0-V*$5/9T&")456@2
M.!3?*GP:PNE2I2[Y0$CU1",FR;P>5QM^L*D-GZTVO+BI#=] -KZ$]R?2S;>W
M9+[Y/OE^21V_)CJ"]#S;LV %F;;2_"(A9(2>&U@:%$G,YK.H6D'M>4K4C,QE
M,C:'JGF$H@N%)(Q\T<- R9-Q]:B:<A17,]L4,^B0L1=:^2VG$0AXLCKJ112-
MH)9@%J$!X@5DSA'P, Q'MH: 8,9@"+I)'9V0P7\ZA)S.H-VB%1YY)"49F*R"
M4+9$SP(1GHR<DBC AB,D:3WX UQ3E,Z/;-_CRLYUKZG_VK.P:V8T*T)P#$VN
M4*##<E'4LXU%5K?NZS0'H*@P27@+I7=Q:1F/08"A,7 &\7T]O2\0),-09#WP
M3,+C0_->O@N^;QF$ 0>&$A+B&N&51;_LW('H(X/XU(@V#T0-JSU(!P[\&JA_
M#"82WS0QKY"3)RF:+>-/X@\-.'W,1A?<(P,Q[ 0;H=F# )[XZO>L>;V0O+&
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M 3%B:$P+H,G0W!(V/)&ST0HR6]J.OHM<P .C3Y:@FM4!'@18L:@N< FZ5VI
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M>_C@X58UEY0HS0?0\P5X!9E89L&"QU6KF;D\U:- 7*+"HA'_K+XD\[T+O[9
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M&MO@V^.BYI9I@!ZQF>@H[.\A'M\0%/"I$0BK@%>RF.+C*=E]O,NP0#'#[DZ
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M;D!.U)F)/3&QO-#3&)7SB[2EG$XQ;9E\_R2*!(J8[_%6T"&OZ_!#A>06I?Z
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M,2YH=&U02P$"% ,4    "  6?]Q48@UT JD(  #A-@  "@
M@ &R"   97@S,5\R+FAT;5!+ 0(4 Q0    ( !9_W%2^E_*IB 4  ,8@   *
M              "  8,1  !E>#,R7S$N:'1M4$L! A0#%     @ %G_<5,+"
M'FL,$0  24@   D              ( !,Q<  &5X-%\R+FAT;5!+ 0(4 Q0
M   ( !9_W%26#(\E&PP  !)[   1              "  68H  !M;V1D+3(P
M,C(P,S,Q+GAS9%!+ 0(4 Q0    ( !9_W%3U:7Z?NPX  !N\   5
M      "  ; T  !M;V1D+3(P,C(P,S,Q7V-A;"YX;6Q02P$"% ,4    "  6
M?]Q43ZU9,]$7   A@0$ %0              @ &>0P  ;6]D9"TR,#(R,#,S
M,5]D968N>&UL4$L! A0#%     @ %G_<5/ZW59>;20  42<$ !4
M     ( !HEL  &UO9&0M,C R,C S,S%?;&%B+GAM;%!+ 0(4 Q0    ( !9_
MW%3M>O=[_3$  '!& P 5              "  7"E  !M;V1D+3(P,C(P,S,Q
M7W!R92YX;6Q02P$"% ,4    "  6?]Q4'^#DDRX:  #\&@  #@
M    @ &@UP  ;6]D=6QA<C P,2YJ<&=02P$"% ,4    "  6?]Q4X2;0,RHH
M  ">*0  #@              @ 'Z\0  ;6]D=6QA<C P,BYJ<&=02P$"% ,4
M    "  6?]Q4)B^ (1%8   P7@  #@              @ %0&@$ ;6]D=6QA
M<C P,RYJ<&=02P$"% ,4    "  6?]Q41&YG3-MF @"A5A( #P
M    @ &-<@$ ;6]D=6QA<E\Q,&LN:'1M4$L%!@     -  T &P,  )79 P
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
